

---

## APPENDIX 12

# Antivirals publications, 2010–2011

1. 2009. [Black triangle down] Tamiflu – the wrong message? *Drug Ther.Bull.* 47:97. doi:47/9/97 [pii];10.1136/dtb.2009.08.0034 [doi].
2. 2009. A caution about giving Tamiflu to children. *Child Health Alert.* 27:4–5.
3. 2009. Antiviral drugs for influenza. *Med.Lett.Drugs Ther.* 51:89–92.
4. 2009. Campus response to novel influenza H1N1. *J.Am.Coll.Health* 58:281–289. doi:U6265414166J437M [pii];10.1080/07448480903482510 [doi].
5. 2009. Case management for influenza. *J.Indian Med.Assoc.* 107:528–530.
6. 2009. Epidemiology of seasonal, avian and pandemic influenza. *J.Indian Med.Assoc.* 107:506–507.
7. 2009. Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008. *Seton.Hall.Law Rev.* 39:1103–1109.
8. 2009. Pandemic preparedness. *Alta.RN.* 65:20–27.
9. 2009. Update on oseltamivir-resistant pandemic A (H1N1)
10. 2009 influenza virus: January 2010. *Wkly.Epidemiol.Rec.* 85:37–40.
11. 2010. [Technical report on the 2009 influenza A (H1N1) pandemic]. *An.Pediatr.(Barc.)* 72:81–35. doi:S1695-4033(09)00614-6 [pii];10.1016/j.anpedi.2009.11.002 [doi].
12. 2010. [Treatment with antiviral agents]. *An.Pediatr.(Barc.)* 72:81–85. doi:S1695-4033(09)00621-3 [pii];10.1016/j.anpedi.2009.11.009 [doi].
13. 2010. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care – New York City, 2009. *MMWR Morb.Mortal.Wkly.Rep.* 59:321–326. doi:mm5911a1 [pii].
14. 2010. A pandemic of hindsight? *Nature* 465:985. doi:465985a [pii];10.1038/465985a [doi].
15. 2010. Fatal H1N1 infection in an HIV positive woman. Negative flu tests, HIV infection delay treatment. *AIDS Alert.* 25:9–10.
16. 2010. Influenza activity – United States and worldwide, June 13–September 25, 2010. *MMWR Morb.Mortal.Wkly.Rep.* 59:1270–1273. doi:mm5939a3 [pii].
17. 2010. Outbreak of 2009 pandemic influenza A (H1N1) on a Peruvian Navy ship – June–July 2009. *MMWR Morb.Mortal.Wkly.Rep.* 59:162–165. doi:mm5906a3 [pii].
18. 2010. Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents – three states, 2009. *MMWR Morb.Mortal.Wkly.Rep.* 59:74–77. doi:mm5903a3 [pii].
19. 2010. Patient education series. Seasonal influenza (the flu). *Nursing.* 40:33. doi:10.1097/01.NURSE.0000387238.05776.38 [doi];00152193-201009000-00011 [pii].
20. 2010. Patient information. *Influenza. Am.Fam.Physician* 82:1097. doi:p722 [pii].

21. 2010. Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009. *MMWR Morb.Mortal.Wkly.Rep.* 58:1436–1440. doi:mm5851a2 [pii].
22. 2010. Update: influenza activity – United States, 2009–10 season. *MMWR Morb.Mortal.Wkly.Rep.* 59:901–908. doi:mm5929a2 [pii].
23. 2010. Update: influenza activity – United States, October 3–December 11, 2010. *MMWR Morb.Mortal.Wkly.Rep.* 59:1651–1655. doi:mm5950a4 [pii].
24. 2011. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture]. *Antibiot.Khimioter.* 56:3–9.
25. 2011. Antiviral drugs for influenza. *Med.Lett.Drugs Ther.* 53:1–3.
26. 2011. Infectious disease. Antiviral agents for the treatment and chemoprophylaxis of influenza. *Ann. Emerg.Med.* 58:299–303. doi:S0196-0644(11)01304-7 [pii];10.1016/j.annemergmed.2011.07.007 [doi].
27. 2011. Recommended composition of influenza virus vaccines for use in the 2011–2012 northern hemisphere influenza season. *Wkly.Epidemiol.Rec.* 86:86–90.
28. 2011. Update: influenza activity – United States, October 3, 2010–February 5, 2011. *MMWR Morb.Mortal.Wkly.Rep.* 60:175–181. doi:mm6006a4 [pii].
29. Aardema, H., J. E. Tulleken, R. J. van den Biggelaar, B. A. Wolters, C. M. de Jager, C. A. Boucher, and A. Riezebos-Brilman. 2010. [Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. *Ned.Tijdschr.Geneeskd.* 154:A1634.
30. Abdel-Rahman, S. M., J. G. Newland, and G. L. Kearns. 2011. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. *Paediatr.Drugs* 13:19–31. doi:3 [pii];10.2165/11536950-000000000-00000 [doi].
31. Abdo, A., C. Alfonso, G. Diaz, M. Wilford, M. Rocha, and N. Verdecia. 2011. Fatal 2009 pandemic influenza A (H1N1) in a bone marrow transplant recipient. *J.Infect.Dev.Ctres.* 5:132–137.
32. Abed, Y., P. Simon, and G. Boivin. 2010. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. *Antimicrob.Agents Chemother.* 54:2819–2822. doi:AAC.01681-09 [pii];10.1128/AAC.01681-09 [doi].
33. Accinelli, C., M. L. Sacca, J. Fick, M. Mencarelli, R. Lindberg, and B. Olsen. 2010. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. *Chemosphere* 79:891–897. doi:S0045-6535(10)00168-2 [pii];10.1016/j.chemosphere.2010.02.022 [doi].
34. Acosta, E. P. and D. W. Kimberlin. 2010. Determination of appropriate dosing of influenza drugs in pediatric patients. *Clin.Pharmacol.Ther.* 88:704–707. doi:clpt2010173 [pii];10.1038/clpt.2010.173 [doi].
35. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. *J.Infect.Dis.* 202:563–566. doi:10.1086/654930 [doi].
36. Adalja, A. 2009. Optimization of antiviral prescribing for influenza. *J.Hosp.Med.* 4:E28. doi:10.1002/jhm.538 [doi].
37. Adalja, A. A. 2010. Hematemesis in a 2009 H1N1 influenza patient. *Am.J.Emerg.Med.* 28:846–4. doi:S0735-6757(09)00636-6 [pii];10.1016/j.ajem.2009.12.012 [doi].
38. Adams, S. and C. Sandrock. 2010. Avian influenza: update. *Med.Princ.Pract.* 19:421–432. doi:000320299 [pii];10.1159/000320299 [doi].

39. Adisasmito, W., B. M. Hunter, R. Krumkamp, K. Latief, J. W. Rudge, P. Hanvoravongchai, and R. J. Coker. 2011. Pandemic Influenza and Health System Resource Gaps in Bali: An Analysis Through a Resource Transmission Dynamics Model. *Asia Pac.J.Public Health*. doi:1010539511421365 [pii];10.1177/1010539511421365 [doi].
40. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, F. Aghayev, M. Zaman, E. Bamgboye, N. Dogan, R. Coker, K. Starzyk, N. A. Dreyer, and S. Toovey. 2010. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. *J.Infect.Dis.* 202:1154–1160. doi:10.1086/656316 [doi].
41. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, M. Zaman, E. Bamgboye, N. Dogan, K. Starzyk, N. A. Dreyer, and S. Toovey. 2011. Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1). *J.Infect.Dis.* 204:810–811. doi:jir398 [pii];10.1093/infdis/jir398 [doi].
42. Aeffner, F., Z. P. Traylor, E. N. Yu, and I. C. Davis. 2011. Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. *Am.J.Physiol Lung Cell Mol. Physiol* 301:L99–L109. doi:ajplung.00398.2010 [pii];10.1152/ajplung.00398.2010 [doi].
43. Agrati, C., C. Gioia, E. Lalle, E. Cimini, C. Castilletti, O. Armignacco, F. N. Lauria, F. Ferraro, M. Antonini, G. Ippolito, M. R. Capobianchi, and F. Martini. 2010. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. *J.Infect.Dis.* 202:681–689. doi:10.1086/655469 [doi].
44. Agrawal, A. S., M. Sarkar, S. Ghosh, T. Roy, S. Chakrabarti, R. Lal, A. C. Mishra, M. S. Chadha, and M. Chawla-Sarkar. 2010. Genetic characterization of circulating seasonal Influenza A viruses (2005–2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India. *Infect. Genet.Evol.* 10:1188–1198. doi:S1567-1348(10)00207-8 [pii];10.1016/j.meegid.2010.07.019 [doi].
45. Agrawal, R., P. V. Rewatkar, G. R. Kokil, A. Verma, and A. Kalra. 2010. Oseltamivir: a first line defense against swine flu. *Med.Chem.* 6:247–251. doi:BSP/MC/Epub/052 [pii].
46. Ai, H., F. Zheng, C. Zhu, T. Sun, L. Zhang, X. Liu, X. Li, G. Zhu, and H. Liu. 2010. Discovery of novel influenza inhibitors targeting the interaction of dsRNA with the NS1 protein by structure-based virtual screening. *Int.J.Bioinform.Res.Appl.* 6:449–460. doi:32Q1497545044537 [pii].
47. Ainai, A., T. Ichinohe, S. Tamura, T. Kurata, T. Sata, M. Tashiro, and H. Hasegawa. 2010. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. *J.Med.Virol.* 82:476–484. doi:10.1002/jmv.21694 [doi].
48. Akyuz, S., A. Yilmaz, M. Bulbul, O. Erdogan, R. Renda, and G. Demircin. 2011. Do immunosuppressive patients really have a severe outcome with H1N1 virus infection? *J.Trop.Pediatr.* 57:129–131. doi:fmq054 [pii];10.1093/tropej/fmq054 [doi].
49. Al Aklabi, M. M., J. G. Weinkauff, A. Humar, and N. Ghorpade. 2010. Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1). *J.Heart Lung Transplant.* 29:898–899. doi:S1053-2498(10)00274-3 [pii];10.1016/j.healun.2010.04.017 [doi].
50. Al-Baghli, F. and W. Al-Ateeqi. 2011. Encephalitis-associated pandemic A (H1N1) 2009 in a Kuwaiti girl. *Med.Princ.Pract.* 20:191–195. doi:000321276 [pii];10.1159/000321276 [doi].
51. Albohy, A., S. Mohan, R. B. Zheng, B. M. Pinto, and C. W. Cairo. 2011. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes. *Bioorg. Med.Chem.* 19:2817–2822. doi:S0968-0896(11)00220-3 [pii];10.1016/j.bmc.2011.03.039 [doi].
52. Alfaresi, M., S. Albedwawi, and M. Hag-Ali. 2011. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in the United Arab Emirates. *Med.Princ.Pract.* 20 :97–99. doi:000319926 [pii];10.1159/000319926 [doi].

53. Alioglu, B., A. Tasar, C. Ozen, B. Selver, and Y. Dallar. 2010. An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report. *Pathophysiol.Haemost.Thromb.* 37:55–58. doi:000321379 [pii];10.1159/000321379 [doi].
54. Allen, I. C., C. B. Moore, M. Schneider, Y. Lei, B. K. Davis, M. A. Scull, D. Gris, K. E. Roney, A. G. Zimmermann, J. B. Bowzard, P. Ranjan, K. M. Monroe, R. J. Pickles, S. Sambhara, and J. P. Ting. 2011. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. *Immunity.* 34:854–865. doi:S1074-7613(11)00226-3 [pii];10.1016/j.immuni.2011.03.026 [doi].
55. Alonso, M., B. Rodriguez-Sanchez, M. Giannella, P. Catalan, J. Gayoso, Lopez Bernaldo de Quiros JC, E. Bouza, and d. Garcia, V. 2011. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. *J.Clin.Virol.* 50:114–118. doi:S1386-6532(10)00413-0 [pii];10.1016/j.jcv.2010.10.007 [doi].
56. Alonso-Tarres, C., C. Cortes-Lletget, S. Pintado, and A. Ricart. 2009. Severe influenza A (H1N1)v in patients without any known risk factor. *Crit Care* 13:425. doi:cc8150 [pii];10.1186/cc8150 [doi].
57. Amayiri, N. and F. Madanat. 2011. Retrospective analysis of pediatric cancer patients diagnosed with the pandemic H1N1 influenza infection. *Pediatr.Blood Cancer* 56:86–89. doi:10.1002/pbc.22805 [doi].
58. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011–2012. *Pediatrics.* 2011 Oct;128(4):813–25. [doi] 10.1542/peds.2011-2295. Epub 2011 Sep 2.
59. Ampofo, K., A. Herbener, A. J. Blaschke, C. Heyrend, M. Poritz, K. Korgenski, R. Rolfs, S. Jain, M. G. Carvalho, F. C. Pimenta, J. Daly, E. O. Mason, C. L. Byington, and A. T. Pavia. 2010. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. *Pediatr.Infect.Dis.J.* 29:905–909. doi:10.1097/INF.0b013e3181df2c70 [doi].
60. an der, H. M., U. Buchholz, G. Krause, G. Kirchner, H. Claus, and W. H. Haas. 2009. Breaking the waves: modelling the potential impact of public health measures to defer the epidemic peak of novel influenza A/H1N1. *PLoS.One.* 4:e8356. doi:10.1371/journal.pone.0008356 [doi].
61. An, S. C., L. L. Xu, F. D. Li, L. L. Bao, C. Qin, and Z. C. Gao. 2011. Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. *Med.Hypotheses* 77:1054–1057. doi:S0306-9877(11)00454-3 [pii];10.1016/j.mehy.2011.09.001 [doi].
62. Andersson, M. I., Z. G. Van, W. Preiser, E. Langenegger, and G. Theron. 2010. Pandemic flu (H1N1) 2009 and pregnancy. *S.Afr.Med.J.* 100:192, 194.
63. Andreas, L. B., M. T. Eddy, R. M. Pielak, J. Chou, and R. G. Griffin. 2010. Magic angle spinning NMR investigation of influenza A M2(18–60): support for an allosteric mechanism of inhibition. *J.Am. Chem.Soc.* 132:10958–10960. doi:10.1021/ja101537p [doi].
64. Angarone, M. 2011. Epidemiology and prevention of viral infections in patients with hematologic malignancies. *Infect.Disord.Drug Targets.* 11:27–33. doi:BSP/ ID DT /E-Pub/-0035-10-5 [pii].
65. Anraku, M., S. Husain, T. Mazulli, and A. F. Pierre. 2011. Peri-operative novel 2009 H1N1 influenza virus infection successfully treated with oseltamivir and zanamivir in a lung transplant recipient. *J.Heart Lung Transplant.* 30:354. doi:S1053-2498(10)00670-4 [pii];10.1016/j.healun.2010.10.001 [doi].

66. Anton, A., A. A. Lopez-Iglesias, T. Tortola, I. Ruiz-Camps, P. Abrisqueta, L. Llopart, M. A. Marcos, M. J. Martinez, G. Tudo, F. Bosch, A. Pahissa, M. T. de Anta, and T. Pumarola. 2010. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. *Diagn.Microbiol.Infect.Dis.* 68:214–219. doi:S0732-8893(10)00301-9 [pii];10.1016/j.diagmicrobio.2010.08.003 [doi].
67. Anton, A., M. A. Marcos, M. J. Martinez, S. Ramon, R. Isanta, M. P. de, M. T. de Anta, and T. Pumarola. 2010. Double (V27A/S31N) mutant 2009 pandemic influenza A (H1N1) virus isolated from adamantane non-treated immunocompetent child. *Diagn.Microbiol.Infect.Dis.* 67:114–115. doi:S0732-8893(09)00510-0 [pii];10.1016/j.diagmicrobio.2009.12.019 [doi].
68. Appuhamy, R. D., F. H. Beard, H. N. Phung, C. E. Selvey, F. A. Birrell, and T. H. Culleton. 2010. The changing phases of pandemic (H1N1) 2009 in Queensland: an overview of public health actions and epidemiology. *Med.J.Aust.* 192:94–97. doi:app10898\_fm [pii].
69. Arakawa, R., A. Bagashev, L. Song, K. Maurer, and K. E. Sullivan. 2010. Characterization of LRRFIP1. *Biochem.Cell Biol.* 88:899–906. doi:o10-014 [pii];10.1139/O10-014 [doi].
70. Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. *CMAJ.* 182:357–363. doi:cmaj.092127 [pii];10.1503/cmaj.092127 [doi].
71. Arias, C. F., M. Escalera-Zamudio, M. L. Soto-Del Rio, A. G. Cobian-Guemes, P. Isa, and S. Lopez. 2009. Molecular anatomy of 2009 influenza virus A (H1N1). *Arch.Med.Res.* 40:643–654. doi:S0188-4409(09)00196-9 [pii];10.1016/j.arcmed.2009.10.007 [doi].
72. Arinaminpathy, N. and A. R. McLean. 2009. Logistics of control for an influenza pandemic. *Epidemics.* 1:83–88. doi:S1755-4365(09)00024-3 [pii];10.1016/j.epidem.2009.04.001 [doi].
73. Arora, R., R. Chawla, R. Marwah, P. Arora, R. K. Sharma, V. Kaushik, R. Goel, A. Kaur, M. Silambarasan, R. P. Tripathi, and J. R. Bhardwaj. 2011. Potential of Complementary and Alternative Medicine in Preventive Management of Novel H1N1 Flu (Swine Flu) Pandemic: Thwarting Potential Disasters in the Bud. *Evid.Based.Complement Alternat.Med.* 2011:586506. doi:10.1155/2011/586506 [doi].
74. Arya, V., W. W. Carter, and S. M. Robertson. 2010. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. *Clin.Pharmacol. Ther.* 88:587–589. doi:clpt2010187 [pii];10.1038/clpt.2010.187 [doi].
75. Asai, N., Y. Ohkuni, A. Komatsu, R. Matsunuma, K. Nakashima, K. Ando, T. Iwasaki, D. Yasui, M. Misawa, Y. Otsuka, and N. Kaneko. 2011. A case of asthma-complicated influenza myocarditis. *J.Infect.Chemother.* 17:429–432. doi:10.1007/s10156-010-0128-7 [doi].
76. Ashraf, S., W. Kong, S. Wang, J. Yang, and R. Curtiss, III. 2011. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. *Vaccine* 29:3990–4002. doi:S0264-410X(11)00448-8 [pii];10.1016/j.vaccine.2011.03.066 [doi].
77. Astrahan, P. and I. T. Arkin. 2011. Resistance characteristics of influenza to amino-adamantyls. *Biochim.Biophys.Acta* 1808:547–553. doi:S0005-2736(10)00216-6 [pii];10.1016/j.bbamem.2010.06.018 [doi].
78. Astrahan, P., R. Flitman-Tene, E. R. Bennett, M. Krugliak, C. Gilon, and I. T. Arkin. 2011. Quantitative analysis of influenza M2 channel blockers. *Biochim.Biophys.Acta* 1808:394–398. doi:S0005-2736(10)00302-0 [pii];10.1016/j.bbamem.2010.08.021 [doi].
79. Astray, M. J. and M. A. Lopaz Perez. 2009. [Swine flu (H1N1) pandemic: challenges and repercussions for the health care system]. *Farm.Hosp.* 33:293–295. doi:13145787 [pii].

80. Atiee, G., K. Lasseter, S. Baughman, A. McCullough, P. Collis, A. Hollister, and J. Hernandez. 2011. Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans. *J.Clin.Pharmacol.* doi:0091270011414574 [pii];10.1177/0091270011414574 [doi].
81. Attema, A. E., A. K. Lugner, and T. L. Feenstra. 2010. Investment in antiviral drugs: a real options approach. *Health Econ.* 19:1240–1254. doi:10.1002/hec.1549 [doi].
82. Babon, J. A., J. Cruz, L. Orphin, P. Pazoles, M. D. Co, F. A. Ennis, and M. Terajima. 2009. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. *Hum.Immunol.* 70:711–721. doi:S0198-8859(09)00144-X [pii];10.1016/j.humimm.2009.06.004 [doi].
83. Bagashev, A., M. C. Fitzgerald, D. F. Larosa, P. P. Rose, S. Cherry, A. C. Johnson, and K. E. Sullivan. 2010. Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon response. *J.Interferon Cytokine Res.* 30:843–852. doi:10.1089/jir.2010.0017 [doi].
84. Bagdure, D., D. J. Curtis, E. Dobyns, M. P. Glode, and S. R. Dominguez. 2010. Hospitalized children with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for admission to the ICU. *PLoS.One.* 5:e15173. doi:10.1371/journal.pone.0015173 [doi].
85. Balannik, V., J. Wang, Y. Ohigashi, X. Jing, E. Magavern, R. A. Lamb, W. F. DeGrado, and L. H. Pinto. 2009. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. *Biochemistry* 48:11872–11882. doi:10.1021/bi9014488 [doi].
86. Balannik, V., P. Obrdlik, S. Inayat, C. Steensen, J. Wang, J. M. Rausch, W. F. DeGrado, B. Kelety, and L. H. Pinto. 2010. Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity. *Pflugers Arch.* 459:593–605. doi:10.1007/s00424-009-0760-1 [doi].
87. Balannik, V., V. Carnevale, G. Fiorin, B. G. Levine, R. A. Lamb, M. L. Klein, W. F. DeGrado, and L. H. Pinto. 2010. Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel. *Biochemistry* 49:696–708. doi:10.1021/bi901799k [doi].
88. Banerjee, D. and D. Kaul. 2010. Combined inhalational and oral supplementation of ascorbic acid may prevent influenza pandemic emergency: a hypothesis. *Nutrition* 26:128–132. doi:S0899-9007(09)00407-9 [pii];10.1016/j.nut.2009.09.015 [doi].
89. Bantia, S., D. Kellogg, C. D. Parker, and Y. S. Babu. 2010. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. *Antiviral Res.* 88:276–280. doi:S0166-3542(10)00743-6 [pii];10.1016/j.antiviral.2010.09.020 [doi].
90. Bantia, S., D. Kellogg, C. Parker, R. Upshaw, N. A. Ilyushina, and Y. S. Babu. 2011. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. *Antiviral Res.* 90:17–21. doi:S0166-3542(11)00029-5 [pii];10.1016/j.antiviral.2011.02.001 [doi].
91. Barak, S., A. Kushnir, E. Chulski, and D. Miron. 2010. Influenza A/H1N1 virus in very low-birth-weight premature infant: case report. *Am.J.Perinatol.* 27:513–515. doi:10.1055/s-0030-1247606 [doi].
92. Baranovich, T., R. Saito, Y. Suzuki, H. Zaraket, C. Dapat, I. Caperig-Dapat, T. Oguma, I. I. Shabana, T. Saito, and H. Suzuki. 2010. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008–2009 season. *J.Clin.Virol.* 47:23–28. doi:S1386-6532(09)00544-7 [pii];10.1016/j.jcv.2009.11.003 [doi].
93. Barbe, F., X. Saelens, D. Braeckmans, F. Lefevre, and K. V. Reeth. 2010. Role of IFN-alpha during the acute stage of a swine influenza virus infection. *Res.Vet.Sci.* 88 :172–178. doi:S0034-5288(09)00157-X [pii];10.1016/j.rvsc.2009.07.001 [doi].

94. Barber, M. R., J. R. Aldridge, Jr., R. G. Webster, and K. E. Magor. 2010. Association of RIG-I with innate immunity of ducks to influenza. *Proc.Natl.Acad.Sci.U.S.A* 107 :5913–5918. doi:1001755107 [pii];10.1073/pnas.1001755107 [doi].
95. Barefoot, B. E., K. Athearn, C. J. Sample, and E. A. Ramsburg. 2009. Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge. *Vaccine* 28:79–89. doi:S0264-410X(09)01472-8 [pii];10.1016/j.vaccine.2009.09.112 [doi].
96. Barik, S. 2010. siRNA for Influenza Therapy. *Viruses*. 2:1448–1457. doi:10.3390/v2071448 [doi];viruses-02-01448 [pii].
97. Barrero, P. R., M. Viegas, L. E. Valinotto, and A. S. Mistchenko. 2011. Genetic and phylogenetic analyses of influenza A H1N1pdm virus in Buenos Aires, Argentina. *J.Virol.* 85:1058–1066. doi:JVI.00936-10 [pii];10.1128/JVI.00936-10 [doi].
98. Barrett, C., K. Bisset, J. Leidig, A. Marathe, and M. Marathe. 2011. Economic and social impact of influenza mitigation strategies by demographic class. *Epidemics*. 3:19–31. doi:10.1016/j.epidem.2010.11.002 [doi].
99. Barrionuevo, R. L., A. C. Masuet, and J. M. Ramon Torrell. 2009. [Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study]. *Gac.Sanit.* 23:315–321. doi:S0213-9111(09)00093-4 [pii];10.1016/j.gaceta.2008.10.011 [doi].
100. Barry, J. M. 2009. Observations on past influenza pandemics. *Disaster.Med.Public Health Prep.* 3 Suppl 2:S95–S99. doi:10.1097/DMP.0b013e3181be82c5 [doi].
101. Barry, M. A. 2010. A 29-year-old woman with flu-like symptoms: review of influenza diagnosis and treatment. *JAMA* 304:671–678. doi:304/6/671 [pii];10.1001/jama.304.6.671 [doi].
102. Bassaganya-Riera, J., R. Song, P. C. Roberts, and R. Hontecillas. 2010. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. *Viral Immunol.* 23:343–352. doi:10.1089/vim.2010.0016 [doi].
103. Baum, A. and A. Garcia-Sastre. 2011. Differential recognition of viral RNA by RIG-I. *Virulence*. 2:166–169. doi:15481 [pii].
104. Baum, S. G. 2009. Oseltamivir resistance: what does it mean clinically? *Clin.Infect.Dis.* 49:1836–1837. doi:10.1086/648425 [doi].
105. Bautista, E., T. Chotpitayasunondh, Z. Gao, S. A. Harper, M. Shaw, T. M. Uyeki, S. R. Zaki, F. G. Hayden, D. S. Hui, J. D. Kettner, A. Kumar, M. Lim, N. Shindo, C. Penn, and K. G. Nicholson. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. *N.Engl.J.Med.* 362:1708–1719. doi:362/18/1708 [pii];10.1056/NEJMra1000449 [doi].
106. Baz, M., Y. Abed, P. Simon, M. E. Hamelin, and G. Boivin. 2010. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. *J.Infect.Dis.* 201:740–745. doi:10.1086/650464 [doi].
107. Bearman, G. M., S. Shankaran, and K. Elam. 2010. Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy. *Recent Pat Antiinfect.Drug Discov.* 5:152–156. doi:BSP/PRI/EPUB/00004 [pii].
108. Becker, N. G. and D. Wang. 2011. Can antiviral drugs contain pandemic influenza transmission? *PLoS.One.* 6:e17764. doi:10.1371/journal.pone.0017764 [doi].
109. Beigel, J. H. 2010. ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION. *Drugs Future.* 35:385–392. doi:10.1358/dof.2010.035.05.1487081 [doi].

110. Beigi, R. H., K. Han, R. Venkataramanan, G. D. Hankins, S. Clark, M. F. Hebert, T. Easterling, A. Zajicek, Z. Ren, D. R. Mattison, and S. N. Caritis. 2011. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. *Am.J.Obstet.Gynecol.* 204:S84–S88. doi:S0002-9378(11)00311-5 [pii];10.1016/j.ajog.2011.03.002 [doi].
111. Beliakova, N. V., S. V. Al'khovskii, E. S. Shevchenko, A. G. Prilipov, D. D. Abramov, L. V. Kolobukhina, L. N. Merkulova, S. V. Trushakova, and E. I. Burtseva. 2010. [Molecular genetic studies of the susceptibility of epidemic influenza A(H1N1) virus strains isolated in the 2006–2009 seasons in Russia to oseltamivir (Tamiflu)]. *Vopr.Virusol.* 55:10–13.
112. Belle, J., H. Cohen, N. Shindo, M. Lim, A. Velazquez-Berumen, J. B. Ndiokubwayo, and M. Cherian. 2010. Influenza preparedness in low-resource settings: a look at oxygen delivery in 12 African countries. *J.Infect.Dev.Ctries.* 4:419–424.
113. Bellissima, P. and G. Bellissima . 2011. [Pulmonary complications from pandemic AH1N1 influenza: clinical-radiological features]. *Infez.Med.* 19:20–27.
114. Belolipetskaia, V. G., S. V. Blagodatskikh, E. A. Zhabina, D. A. Kibalchich, D. F. Guranda, N. A. Belolipetskii, and L. I. Rudenko. 2011. [Comparative pharmacokinetics of antigrippin-maximum administered in capsules and powder for preparing solutions]. *Eksp.Klin.Farmakol.* 74:38–40.
115. Bender, M. and C. Bernheisel. 2010. Fever, cough, and hypoxia in a pregnant woman. *J.Fam.Pract.* 59:E9–11. doi:jfp\_5904j [pii].
116. Benfield, C. T., J. W. Lyall, and L. S. Tiley. 2010. The cytoplasmic location of chicken mx is not the determining factor for its lack of antiviral activity. *PLoS.One.* 5:e12151. doi:10.1371/journal.pone.0012151 [doi].
117. Bennack, E. and U. Holzgrabe. 2010. [Emergency admission of peramivir in the U.S.A]. *Pharm. Unserer Zeit* 39:9–10. doi:10.1002/pauz.200990126 [doi].
118. Bennett, S., R. N. Gunson, A. MacLean, R. Miller, and W. F. Carman. 2011. The validation of a real-time RT-PCR assay which detects influenza A and types simultaneously for influenza A H1N1 (2009) and oseltamivir-resistant (H275Y) influenza A H1N1 (2009). *J.Virol.Methods* 171:86–90. doi:S0166-0934(10)00360-5 [pii];10.1016/j.jviromet.2010.10.005 [doi].
119. Bergstrom, K. G. 2010. Tamiflu: what dermatologists need to know. *J.Drugs Dermatol.* 9:76–78.
120. Bernaola, E. 2009. [Why vaccinate to children against the flu]. *Rev.Esp.Quimioter.* 22 Suppl 1:15–17. doi:GripeEnriqueBernaola [pii].
121. Berthoud, T. K., M. Hamill, P. J. Lillie, L. Hwenda, K. A. Collins, K. J. Ewer, A. Millicic, H. C. Poyntz, T. Lambe, H. A. Fletcher, A. V. Hill, and S. C. Gilbert. 2011. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. *Clin.Infect.Dis.* 52:1–7. doi:ciq015 [pii];10.1093/cid/ciq015 [doi].
122. Bertisch, B., P. Vernazza, and K. Boggian. 2010. Patients with influenza A/H1N1v- associated pneumonia: the perspective of a tertiary care hospital in Switzerland. *Swiss.Med.Wkly.* 140:w13069. doi:smw-13069 [pii];10.4414/smw.2010.13069 [doi].
123. Bewick, T., P. Myles, S. Greenwood, J. S. Nguyen-Van-Tam, S. J. Brett, M. G. Semple, P. J. Openshaw, B. Bannister, R. C. Read, B. L. Taylor, J. McMenamin, J. E. Enstone, K. G. Nicholson, and W. S. Lim. 2011. Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults. *Thorax* 66:247–252. doi:thx.2010.151522 [pii];10.1136/thx.2010.151522 [doi].
124. Biatto, J. F., E. L. Costa, L. Pastore, E. G. Kallas, D. Deheinzeln, and G. Schettino. 2010. Prone position ventilation, recruitment maneuver and intravenous zanamivir in severe refractory hypoxemia caused by influenza A (H1N1). *Clinics.(Sao Paulo)* 65:1211–1213. doi:S1807-59322010001100026 [pii].



125. Bijl, D. 2011. Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects. *Int.J.Risk Saf Med.* 23:65–71. doi:P267TH7832P32713 [pii];10.3233/JRS-2011-0521 [doi].
126. Bing, F. H., J. Liu, Z. Li, G. B. Zhang, Y. F. Liao, J. Li, and C. Y. Dong. 2009. Anti-influenza-virus activity of total alkaloids from *Commelina communis* L. *Arch.Virol.* 154:1837–1840. doi:10.1007/s00705-009-0503-9 [doi].
127. Bloom, J. D., L. I. Gong, and D. Baltimore. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. *Science* 328:1272–1275. doi:328/5983/1272 [pii];10.1126/science.1187816 [doi].
128. Bodewes, R., J. H. Kreijtz, M. L. Hillaire, M. M. Geelhoed-Mieras, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2010. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. *J.Gen.Virol.* 91:1743–1753. doi:vir.0.020784-0 [pii];10.1099/vir.0.020784-0 [doi].
129. Bogoch, I. I., J. R. Andrews, F. M. Marty, and E. L. Hohmann. 2011. HIV-1 and 2009 H1N1 influenza A in adults. *J.Acquir.Immune.Defic.Syindr.* 56:e111–e113. doi:10.1097/QAI.0b013e31820a9afb [doi];00126334-201104010-00016 [pii].
130. Boibieux, A. 2010. [Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus]. *Ann.Fr.Anesth. Reanim.* 29:85–86. doi:S0750-7658(10)00006-7 [pii];10.1016/j.annfar.2010.01.005 [doi].
131. Boltz, D. A., B. Douangneun, P. Phommachanh, S. Sinthasak, R. Mondry, C. Obert, P. Seiler, R. Keating, Y. Suzuki, H. Hiramatsu, E. A. Govorkova, and R. G. Webster. 2010. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. *J.Gen.Virol.* 91:949–959. doi:vir.0.017459-0 [pii];10.1099/vir.0.017459-0 [doi].
132. Boltz, D. A., J. R. Aldridge, Jr., R. G. Webster, and E. A. Govorkova. 2010. Drugs in development for influenza. *Drugs* 70:1349–1362. doi:1 [pii];10.2165/11537960-000000000-00000 [doi].
133. Bonneux, L. 2009. [No evidence of fewer influenza complications with oseltamivir]. *Ned.Tijdschr. Geneeskd.* 153:A1127.
134. Bonneux, L. and D. W. Van. 2010. Preventing iatrogenic pandemics of panic. Do it in a NICE way. *BMJ* 340:c3065.
135. Bottcher-Friebertshauer, E., D. A. Stein, H. D. Klenk, and W. Garten. 2011. Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. *J.Virol.* 85:1554–1562. doi:JVI.01294-10 [pii];10.1128/JVI.01294-10 [doi].
136. Boudreault, A. A., H. Xie, W. Leisenring, J. Englund, L. Corey, and M. Boeckh. 2011. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. *Biol.Blood Marrow Transplant.* 17:979–986. doi:S1083-8791(10)00394-0 [pii];10.1016/j.bbmt.2010.09.014 [doi].
137. Boukhalova, M. S., T. B. Sotomayor, R. C. Point, L. M. Pletneva, G. A. Prince, and J. C. Blanco. 2010. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat *Sigmodon hispidus* model. *J.Interferon Cytokine Res.* 30:229–242. doi:10.1089/jir.2009.0025 [doi].
138. Bouslama, L., K. Hayashi, J. B. Lee, A. Ghorbel, and T. Hayashi. 2011. Potent virucidal effect of pheophorbide a and pyropheophorbide a on enveloped viruses. *J.Nat.Med.* 65:229–233. doi:10.1007/s11418-010-0468-8 [doi].

139. Boutolleau, D., N. Houhou, C. Deback, H. Agut, and F. Brun-Vezinet. 2010. Detection of pandemic (H1N1) 2009 virus in patients treated with oseltamivir. *Emerg.Infect.Dis.* 16:351–352. doi:10.3201/eid1602.091328 [doi].
140. Bozzo, P., N. Djokanovic, and G. Koren. 2009. H1N1 influenza in pregnancy: risks, vaccines, and antivirals. *J.Obstet.Gynaecol.Can.* 31:1172–1175.
141. Bramley, A. M., J. Bresee, and L. Finelli. 2009. Pediatric influenza. *Pediatr.Nurs.* 35:335–345.
142. Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M. Feeley, B. J. Ryan, J. L. Weyer, L. van der Weyden, E. Fikrig, D. J. Adams, R. J. Xavier, M. Farzan, and S. J. Elledge. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* 139:1243–1254. doi:S0092-8674(09)01564-5 [pii];10.1016/j.cell.2009.12.017 [doi].
143. Bresci, S., B. Borchi, S. Ambu, G. Taccetti, C. Braggion, and F. Leoncini. 2010. Case report: cystic fibrosis, lung transplantation, and the novel H1N1 flu. *Transplant.Proc.* 42:2270–2273. doi:S0041-1345(10)00686-X [pii];10.1016/j.transproceed.2010.05.028 [doi].
144. Brook, I. 2011. Microbiology of sinusitis. *Proc.Am.Thorac.Soc.* 8:90–100. doi:8/1/90 [pii];10.1513/pats.201006-038RN [doi].
145. Brookes, D. W., S. Miah, A. Lackenby, L. Hartgroves, and W. S. Barclay. 2011. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. *J.Antimicrob.Chemother.* 66:466–470. doi:dkq486 [pii];10.1093/jac/dkq486 [doi].
146. Brown, A. N., J. B. Bulitta, J. J. McSharry, Q. Weng, J. R. Adams, R. Kulawy, and G. L. Drusano. 2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. *Antimicrob.Agents Chemother.* 55:1747–1753. doi:AAC.01629-10 [pii];10.1128/AAC.01629-10 [doi].
147. Brown, A. N., J. J. McSharry, Q. Weng, E. M. Driebe, D. M. Engelthaler, K. Sheff, P. S. Keim, J. Nguyen, and G. L. Drusano. 2010. In vitro system for modeling influenza A virus resistance under drug pressure. *Antimicrob.Agents Chemother.* 54:3442–3450. doi:AAC.01385-09 [pii];10.1128/AAC.01385-09 [doi].
148. Brown, A. N., J. J. McSharry, Q. Weng, J. R. Adams, R. Kulawy, and G. L. Drusano. 2011. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. *Antimicrob.Agents Chemother.* 55:1740–1746. doi:AAC.01628-10 [pii];10.1128/AAC.01628-10 [doi].
149. Brown, C. M. 2010. Severe influenza A virus (H1N1) infection in pregnancy. *Obstet.Gynecol.* 115:412–414. doi:10.1097/AOG.0b013e3181cbc7c5 [doi];00006250-201002001-00006 [pii].
150. Brunner, J., J. Bogner, and U. Seybold. 2011. [Flu-like illness – how to rule in and manage influenza]. *MMW.Fortschr.Med.* 153:29–31, 33.
151. Bryans, J. T., W. W. Zent, R. R. Grunert, and D. C. Boughton. 1966. I-adamantanamine hydrochloride prophylaxis for experimentally induced A/equine 2 influenza virus infection. *Nature* 212:1542–1544.
152. Buchholz, U., S. Brockmann, S. Duwe, B. Schweiger, H. M. an der, B. Reinhardt, and S. Buda. 2010. Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses, Germany, 2007–8. *Euro.Surveill* 15.
153. Burch, J., M. Paulden, S. Conti, C. Stock, M. Corbett, N. J. Welton, A. E. Ades, A. Sutton, N. Cooper, A. J. Elliot, K. Nicholson, S. Duffy, C. McKenna, L. Stewart, M. Westwood, and S. Palmer . 2009. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. *Health Technol.Assess.* 13:1–iv. doi:10.3310/hta13580 [doi].

154. Burillon, M., E. Cheuret, and Y. Chaix. 2010. [Hemorrhagic lesion of the corpus callosum in influenza-associated encephalitis]. *Arch.Pediatr.* 17:491–494. doi:S0929-693X(10)00080-1 [pii];10.1016/j.arcped.2010.02.010 [doi].
155. Burke, J. D. and E. N. Fish. 2009. Antiviral strategies: the present and beyond. *Curr.Mol.Pharmacol.* 2:32–39.
156. Burns, K. E., C. Chant, O. Smith, B. Cuthbertson, R. Fowler, D. J. Cook, P. Kruger, S. Webb, J. Alhashemi, G. Dominguez-Cherit, C. Zala, G. D. Rubenfeld, and J. C. Marshall. 2011. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists – Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial. *Trials* 12:70. doi:1745-6215-12-70 [pii];10.1186/1745-6215-12-70 [doi].
157. Burns, S. M. 2009. H1N1 influenza is here. *J.Hosp.Infect.* 73:200–202. doi:S0195-6701(09)00320-X [pii];10.1016/j.jhin.2009.07.012 [doi].
158. Burrel, S., L. Roncin, M. E. Lafon, and H. Fleury. 2009. Oseltamivir susceptibility in south-western France during the 2007–8 and 2008–9 influenza epidemics and the ongoing influenza pandemic 2009. *Euro.Surveill* 14.
159. Busani, S., M. Girardis, E. Biagioni, A. Pasetto, and V. Sambri. 2010. Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection. *Am.J.Respir.Crit Care Med.* 182:1334. doi:182/10/1334 [pii].
160. Bussmann, B. M., S. Reiche, B. Bieniek, I. Krznanic, F. Ackermann, and C. Jassoy. 2010. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. *Virology* 397:7–13. doi:S0042-6822(09)00698-9 [pii];10.1016/j.virol.2009.11.003 [doi].
161. Cady, S. D., K. Schmidt-Rohr, J. Wang, C. S. Soto, W. F. DeGrado, and M. Hong. 2010. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. *Nature* 463:689–692. doi:nature08722 [pii];10.1038/nature08722 [doi].
162. Calatayud, L., S. Kurkela, P. E. Neave, A. Brock, S. Perkins, M. Zuckerman, M. Sudhanva, A. Bermingham, J. Ellis, R. Pebody, M. Catchpole, R. Heathcock, and H. Maguire. 2010. Pandemic (H1N1) 2009 virus outbreak in a school in London, April–May 2009: an observational study. *Epidemiol.Infect.* 138:183–191. doi:S0950268809991191 [pii];10.1017/S0950268809991191 [doi].
163. Calitri, C., C. Gabiano, S. Garazzino, M. Pinon, M. Zoppo, M. Cuozzo, C. Scolfaro, and P. A. Tovo. 2010. Clinical features of hospitalised children with 2009 H1N1 influenza virus infection. *Eur.J.Pediatr.* 169:1511–1515. doi:10.1007/s00431-010-1255-y [doi].
164. Calvaruso, V., M. Mazza, and P. L. Almasio. 2011. Pegylated-interferon-alpha(2a) in clinical practice: how to manage patients suffering from side effects. *Expert.Opin.Drug Saf* 10:429–435. doi:10.1517/14740338.2011.559161 [doi].
165. Calzada-Nova, G., W. Schnitzlein, R. Husmann, and F. A. Zuckermann. 2010. Characterization of the cytokine and maturation responses of pure populations of porcine plasmacytoid dendritic cells to porcine viruses and toll-like receptor agonists. *Vet.Immunol.Immunopathol.* 135:20–33. doi:S0165-2427(09)00352-3 [pii];10.1016/j.vetimm.2009.10.026 [doi].
166. Campanini, G., A. Piralla, F. Rovida, S. Puzelli, M. Facchini, F. Locatelli, L. Minoli, E. Percivalle, I. Donatelli, and F. Baldanti. 2010. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. *J.Clin.Virol.* 48:220–222. doi:S1386-6532(10)00149-6 [pii];10.1016/j.jcv.2010.03.027 [doi].
167. Campbell, A. P., S. T. Jacob, J. Kuypers, A. Wald, J. A. Englund, L. Corey, and M. Boeckh. 2010. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant

- recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. *Ann.Intern.Med.* 152:619–620. doi:152/9/619 [pii];10.1059/0003-4819-152-9-201005040-00022 [doi].
168. Campbell, J. P., K. M. Edwards, C. Ring, M. T. Drayson, J. A. Bosch, A. Inskip, J. E. Long, D. Pulsford, and V. E. Burns. 2010. The effects of vaccine timing on the efficacy of an acute eccentric exercise intervention on the immune response to an influenza vaccine in young adults. *Brain Behav.Immun.* 24:236–242. doi:S0889-1591(09)00465-6 [pii];10.1016/j.bbi.2009.10.001 [doi].
  169. Canaday, D. H., N. A. Amponsah, L. Jones, D. J. Tisch, T. R. Hornick, and L. Ramachandra. 2010. Influenza-induced production of interferon-alpha is defective in geriatric individuals. *J.Clin.Immunol.* 30:373–383. doi:10.1007/s10875-010-9374-9 [doi].
  170. Cane, A., E. Casanueva, T. Iolster, N. Sticco, L. Richards, P. Sosa, A. Pontoriero, M. Avaro, A. Zcech, E. Carabajal, A. Campos, E. Baumeister, M. A. Diez, M. Rojas, and M. R. Rivarola. 2010. First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina. *Pediatr.Infect.Dis.J.* 29:384. doi:10.1097/INF.0b013e3181cd7244 [doi];00006454-201004000-00029 [pii].
  171. Canini, L. and F. Carrat. 2011. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. *J.Virol.* 85:2764–2770. doi:JVI.01318-10 [pii];10.1128/JVI.01318-10 [doi].
  172. Cao, B., R. Li, Y. M. Liu, Z. X. Cao, X. Q. Geng, L. T. Lau, J. Lu, L. Wu, S. F. Cui, R. T. Bai, C. H. Yu, and C. Wang. 2008. [The impact of antibiotic treatment in patients with influenza-like illness]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi.* 31:483–487.
  173. Cao, B., X. W. Li, Y. Mao, J. Wang, H. Z. Lu, Y. S. Chen, Z. A. Liang, L. Liang, S. J. Zhang, B. Zhang, L. Gu, L. H. Lu, D. Y. Wang, and C. Wang. 2009. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. *N.Engl.J.Med.* 361:2507–2517. doi:NEJMoa0906612 [pii];10.1056/NEJMoa0906612 [doi].
  174. Caracciolo, A. B., P. Grenni, and M. L. Sacca. 2010. Effect of the antiviral drug oseltamivir (Tamiflu) on the bacterial community structure of a surface water ecosystem analyzed using fluorescence in situ hybridization. *Bull.EnvIRON.Contam Toxicol.* 85:443–446. doi:10.1007/s00128-010-0114-x [doi].
  175. Carcione, D., C. M. Giele, L. S. Goggin, K. S. Kwan, D. W. Smith, G. K. Dowse, D. B. Mak, and P. Effler. 2011. Secondary attack rate of pandemic influenza A(H1N1) 2009 in Western Australian households, 29 May–7 August 2009. *Euro.Surveill* 16.
  176. Carlescu, I., H. M. Osborn, J. Desbrieres, D. Scutaru, and M. Popa. 2010. Synthesis of poly(aspartimide)-based bio-glycoconjugates. *Carbohydr.Res.* 345:33–40. doi:S0008-6215(09)00406-6 [pii];10.1016/j.carres.2009.08.034 [doi].
  177. Carr, S., N. A. Ilyushina, J. Franks, E. E. Adderson, M. Caniza, E. A. Govorkova, and R. G. Webster. 2011. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. *Pediatr.Infect.Dis.J.* 30:284–288. doi:10.1097/INF.0b013e3181ff863b [doi].
  178. Carrasco, L. R., V. J. Lee, M. I. Chen, D. B. Matchar, J. P. Thompson, and A. R. Cook. 2011. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. *J.R.Soc.Interface* 8:1307–1313. doi:rsif.2010.0715 [pii];10.1098/rsif.2010.0715 [doi].
  179. Carrillo-Esper, R. 2009. Statins in influenza: time for a controlled clinical study. *Cir.Cir.* 77:351–352.
  180. Carrillo-Santistevé, P., S. Renard-Dubois, G. Cheron, M. Csaszar-Goutchkoff, M. Lecuit, O. Lortholary, and P. Bello. 2010. 2009 pandemic influenza A(H1N1) outbreak in a complex of schools in Paris, France, June 2009. *Euro.Surveill* 15.
  181. Carroll, T. D., S. R. Matzinger, M. Barro, L. Fritts, M. B. McChesney, C. J. Miller, and R. E. Johnston. 2011. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone (R) in rhesus macaques. *Vaccine* 29:931–940. doi:S0264-410X(10)01633-6 [pii];10.1016/j.vaccine.2010.11.024 [doi].

182. Casalegno, J. S., M. Bouscambert-Duchamp, V. Caro, I. Schuffenecker, M. Sabatier, A. Traversier, M. Valette, B. Lina, O. Ferraris, and V. Escuret. 2010. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. *Antiviral Res.* 87:242–248.
183. Casper, C., J. Englund, and M. Boeckh. 2010. How I treat influenza in patients with hematologic malignancies. *Blood* 115:1331–1342. doi:blood-2009-11-255455 [pii];10.1182/blood-2009-11-255455 [doi].
184. Casscells, S. W., E. Granger, A. M. Kress, A. Linton, M. Madjid, and L. Cottrell. 2009. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. *Circ.Cardiovasc.Qual.Outcomes.* 2:108–115. doi:CIRCOUTCOMES.108.820357 [pii];10.1161/CIRCOUTCOMES.108.820357 [doi].
185. Casscells, S. W., E. Granger, A. M. Kress, and A. Linton. 2009. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. *Int.J.Adolesc.Med.Health* 21:79–89.
186. Castillo, R., L. E. Holland, and D. A. Boltz. 2010. Peramivir and its use in H1N1 influenza. *Drugs Today (Barc.)* 46:399–408. doi:1459659 [pii];10.1358/dot.2010.46.6.1459659 [doi].
187. Cayley, W. E., Jr. 2010. Neuraminidase inhibitors for influenza treatment and prevention in healthy adults. *Am.Fam.Physician* 82:242–244. doi:d8566 [pii].
188. Cellerai, C., M. Perreau, V. Rozot, F. B. Enders, G. Pantaleo, and A. Harari. 2010. Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression. *J.Virol.* 84:3868–3878. doi:JVI.02565-09 [pii];10.1128/JVI.02565-09 [doi].
189. Cermelli, C., A. Cuoghi, M. Scuri, C. Bettua, R. G. Neglia, A. Ardizzoni, E. Blasi, T. Iannitti, and B. Palmieri. 2011. In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid. *Virol.J.* 8:141. doi:1743-422X-8-141 [pii];10.1186/1743-422X-8-141 [doi].
190. Chakravarthy, K. V., A. C. Bonoiu, W. G. Davis, P. Ranjan, H. Ding, R. Hu, J. B. Bowzard, E. J. Bergey, J. M. Katz, P. R. Knight, S. Sambhara, and P. N. Prasad. 2010. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. *Proc.Natl.Acad.Sci.U.S.A* 107:10172–10177. doi:0914561107 [pii];10.1073/pnas.0914561107 [doi].
191. Chan, D., J. Tarbin, M. Sharman, M. Carson, M. Smith, and S. Smith. 2011. Screening method for the analysis of antiviral drugs in poultry tissues using zwitterionic hydrophilic interaction liquid chromatography/tandem mass spectrometry. *Anal.Chim.Acta* 700:194–200. doi:S0003-2670(10)01430-3 [pii];10.1016/j.aca.2010.11.015 [doi].
192. Chan, P. A., N. T. Connell, A. M. Gabonay, B. Westley, J. M. Larkin, S. P. LaRosa, K. Chapin, and L. Mermel. 2010. Oseltamivir-resistant 2009–2010 pandemic influenza A (H1N1) in an immunocompromised patient. *Clin.Microbiol.Infect.* 16:1576–1578. doi:CLM3212 [pii];10.1111/j.1469-0691.2010.03212.x [doi].
193. Chan, Y. J., C. L. Lee, S. J. Hwang, C. P. Fung, F. D. Wang, D. H. Yen, C. H. Tsai, Y. M. Chen, and S. D. Lee. 2010. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. *J.Chin Med.Assoc.* 73:62–66. doi:S1726-4901(10)70003-4 [pii];10.1016/S1726-4901(10)70003-4 [doi].
194. Chang, H., C. Huang, J. Wu, F. Fang, W. Zhang, F. Wang, and Z. Chen. 2010. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. *Virol.J.* 7:197. doi:1743-422X-7-197 [pii];10.1186/1743-422X-7-197 [doi].

195. Chang, T. T., M. F. Sun, H. Y. Chen, F. J. Tsai, M. Fisher, J. G. Lin, and C. Y. Chen. 2011. Screening from the world's largest TCM database against H1N1 virus. *J.Biomol.Struct.Dyn.* 28:773–786. doi:c4309/Screening-from-the-Worlds-Largest-TCM-Database-Against-H1N1-Virus-p1 8013.html [pii].
196. Chang, W. C., K. L. Hartshorn, M. R. White, P. Moyo, I. C. Michelow, H. Koziel, B. T. Kinane, E. V. Schmidt, T. Fujita, and K. Takahashi. 2011. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. *Biochem.Pharmacol.* 81:388–395. doi:S0006-2952(10)00791-4 [pii];10.1016/j.bcp.2010.10.012 [doi].
197. Chantratita, W., C. Sukasem, S. Sirinavin, N. Sankuntaw, C. Srichantaratsamee, E. Pasomsub, and K. Malathum. 2011. Simultaneous detection and subtyping of H274Y-positive influenza A (H1N1) using pyrosequencing. *J.Infect.Dev.Ctries.* 5:348–352.
198. Charlier, C., O. Launay, H. Coignard-Biehler, M. Lecuit, and O. Lortholary. 2010. [Pregnancy: a high risk factor in influenza infection]. *Med.Sci.(Paris)* 26:100–104. doi:00/00/0E/E4/ [pii];10.1051/medsci/2010261100 [doi].
199. Charlier, C., V. Enouf, F. Lanternier, M. Grandadam, K. Amazzough, S. Blanche, M. Lecuit, O. Lortholary, and S. van der Werf. 2009. Kinetics of nasopharyngeal shedding of novel H1N1 (swine-like) influenza A virus in an immunocompetent adult under oseltamivir therapy. *Clin.Microbiol.Infect.* 15:1189–1191. doi:CLM3007 [pii];10.1111/j.1469-0691.2009.03007.x [doi].
200. Chaudhary, V., R. K. Singh, V. K. Agrawal, A. Agarwal, R. Kumar, and M. Sharma. 2010. Awareness, perception and myths towards swine flu in school children of Bareilly, Uttar Pradesh. *Indian J.Public Health* 54:161–164. doi:IndianJPublicHealth\_2010\_54\_3\_161\_75741 [pii];10.4103/0019-557X.75741 [doi].
201. Chawla, R., R. K. Sharma, and J. R. Bhardwaj. 2009. Influenza a (H1N1) outbreak and challenges for pharmacotherapy. *Indian J.Physiol Pharmacol.* 53:113–126.
202. Chen, H., C. L. Cheung, H. Tai, P. Zhao, J. F. Chan, V. C. Cheng, K. H. Chan, and K. Y. Yuen. 2009. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. *Emerg.Infect.Dis.* 15:1970–1972. doi:10.3201/eid1512.091057 [doi].
203. Chen, H., Y. L. Liu, S. H. He, Y. L. Zeng, and G. F. Wang. 2009. [Report of the first case of influenza A (H1N1) in mainland China]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi.* 32:482–484.
204. Chen, J. X., H. J. Xue, W. C. Ye, B. H. Fang, Y. H. Liu, S. H. Yuan, P. Yu, and Y. Q. Wang. 2009. Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. *Biol.Pharm. Bull.* 32:1385–1391. doi:JST.JSTAGE/bpb/32.1385 [pii].
205. Chen, L. F., N. J. Dailey, A. K. Rao, A. T. Fleischauer, I. Greenwald, V. M. Deyde, Z. S. Moore, D. J. Anderson, J. Duffy, L. V. Gubareva, D. J. Sexton, A. M. Fry, A. Srinivasan, and C. R. Wolfe. 2011. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients – North Carolina, 2009. *J.Infect.Dis.* 203:838–846. doi:jiq124 [pii];10.1093/infdis/jiq124 [doi].
206. Chen, M. Z., H. G. Xie, L. W. Yang, Z. H. Liao, and J. Yu. 2010. In vitro anti-influenza virus activities of sulfated polysaccharide fractions from *Gracilaria lemaneiformis*. *Viol.Sin.* 25:341–351. doi:10.1007/s12250-010-3137-x [doi].
207. Chen, N., B. A. Pinsky, B. P. Lee, M. Lin, and I. Schrijver. 2011. Ultrasensitive detection of drug-resistant pandemic 2009 (H1N1) influenza A virus by rare-variant-sensitive high-resolution melting-curve analysis. *J.Clin.Microbiol.* 49:2602–2609. doi:JCM.00277-11 [pii];10.1128/JCM.00277-11 [doi].

208. Chen, S. C., K. S. Liu, H. R. Chang, Y. T. Lee, C. C. Chen, and M. C. Lee. 2010. Rhabdomyolysis following pandemic influenza A (H1N1) infection. *Neth.J.Med.* 68:317–319.
209. Chen, S., J. A. Short, D. F. Young, M. J. Killip, M. Schneider, S. Goodbourn, and R. E. Randall. 2010. Heterocellular induction of interferon by negative-sense RNA viruses. *Virology* 407:247–255. doi:S0042-6822(10)00525-8 [pii];10.1016/j.virol.2010.08.008 [doi].
210. Chen, W. H., A. S. Cross, R. Edelman, M. B. Sztein, W. C. Blackwelder, and M. F. Pasetti. 2011. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. *Vaccine* 29:2865–2873. doi:S0264-410X(11)00230-1 [pii];10.1016/j.vaccine.2011.02.017 [doi].
211. Chen, Y. C., C. P. Lo, and T. P. Chang. 2010. Novel influenza A (H1N1)-associated encephalopathy/encephalitis with severe neurological sequelae and unique image features – a case report. *J.Neurol. Sci.* 298:110–113. doi:S0022-510X(10)00446-6 [pii];10.1016/j.jns.2010.09.010 [doi].
212. Chen, Y., W. Luo, W. L. Wu, Z. Fang, L. Xia, X. Gui, Y. Chen, H. Chen, J. W. Shih, and N. Xia. 2010. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. *Antiviral Res.* 87:81–84. doi:S0166-3542(10)00598-X [pii];10.1016/j.antiviral.2010.04.012 [doi].
213. Chen, Z., Y. H. Zheng, Y. Lin, P. J. Collins, and A. J. Hay. 2010. [Impact of avian influenza virus H5N1 neuraminidase mutations on the activity of neuraminidase and the sensibility to neuraminidase inhibitors]. *Zhonghua Yi.Xue.Za Zhi.* 90:1924–1928.
214. Cheng, F. W., C. H. Li, M. K. Shing, D. K. Cheuk, J. P. Yau, A. S. Ling, J. Y. Yang, and C. K. Li. 2010. Pandemic influenza A (2009-H1N1) infection in paediatric oncology patients in Hong Kong. *Br.J.Haematol.* 151:202–206. doi:BJH8351 [pii];10.1111/j.1365-2141.2010.08351.x [doi].
215. Cheng, P. K., A. P. To, T. W. Leung, P. C. Leung, C. W. Lee, and W. W. Lim. 2010. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). *Emerg.Infect.Dis.* 16:155–156. doi:10.3201/eid1601.091304 [doi].
216. Cheng, X., Q. Xu, E. Song, C. F. Yang, G. Kemble, and H. Jin. 2010. The hemagglutinin protein of influenza A/Vietnam/1203/2004 (H5N1) contributes to hyperinduction of proinflammatory cytokines in human epithelial cells. *Virology* 406:28–36. doi:S0042-6822(10)00438-1 [pii];10.1016/j.virol.2010.06.048 [doi].
217. Chidlow, G. R., G. B. Harnett, S. H. Williams, S. S. Tempone, D. J. Speers, A. C. Hurt, Y. M. Deng, and D. W. Smith. 2010. The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay. *J.Virol.Methods* 169:47–51. doi:S0166-0934(10)00226-0 [pii];10.1016/j.jviromet.2010.06.014 [doi].
218. Childs, J. E. and E. R. Gordon. 2009. Surveillance and control of zoonotic agents prior to disease detection in humans. *Mt.Sinai J.Med.* 76:421–428. doi:10.1002/msj.20133 [doi].
219. Chin, J., G. Koh, and D. Y. Lee. 2010. How necessary is a fast testkit for mitigation of pandemic flu? *J.R.Soc.Interface* 7:1033–1047. doi:rsif.2009.0471 [pii];10.1098/rsif.2009.0471 [doi].
220. Chishti, T. and P. Oakeshott. 2010. Do general practice patients who are prescribed Tamiflu actually take it? *Br.J.Gen.Pract.* 60:535. doi:10.3399/bjgp10X514891 [doi].
221. Choi, H. J., J. H. Song, and D. H. Kwon. 2011. Quercetin 3-rhamnoside Exerts Antiinfluenza A Virus Activity in Mice. *Phytother.Res.* doi:10.1002/ptr.3529 [doi].
222. Choi, S. M., A. A. Boudreault, H. Xie, J. A. Englund, L. Corey, and M. Boeckh. 2011. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. *Blood* 117:5050–5056. doi:blood-2010-11-319186 [pii];10.1182/blood-2010-11-319186 [doi].

223. Choi, W. I., J. J. Yim, J. Park, S. C. Kim, M. J. Na, W. Y. Lee, S. B. Hong, H. S. Choi, S. H. Jang, W. J. Kim, K. Jeon, J. H. Kim, J. C. Choi, C. H. Lee, C. H. Kim, and J. Y. Kim. 2011. Clinical characteristics and outcomes of H1N1-associated pneumonia among adults in South Korea. *Int.J.Tuberc.Lung Dis.* 15:270–5, i.
224. Choi, W. S., W. J. Kim, and H. J. Cheong. 2010. [The evaluation of policies on 2009 influenza pandemic in Korea]. *J.Prev.Med.Public Health* 43:105–108. doi:201003105 [pii];10.3961/jpmph.2010.43.2.105 [doi].
225. Cholewinska, G., J. Higersberger, R. Podlasin, A. Wiercinska-Drapalo, D. Lipowski, M. Olszynska-Krowicka, W. Przyjalkowski, and A. Horban. 2010. [Clinical manifestations, diagnosis and treatment of swine flu (A/H1N1) infection among patients hospitalized in the Hospital of Infectious Diseases in Warsaw in 2009]. *Przegl.Epidemiol.* 64:15–19.
226. Christensen, D., C. Foged, I. Rosenkrands, C. V. Lundberg, P. Andersen, E. M. Agger, and H. M. Nielsen. 2010. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. *Int.J.Pharm.* 390:19–24. doi:S0378-5173(09)00769-8 [pii];10.1016/j.ijpharm.2009.10.043 [doi].
227. Chuang, G. Y., D. Kozakov, R. Brenke, D. Beglov, F. Guarnieri, and S. Vajda. 2009. Binding hot spots and amantadine orientation in the influenza A virus M2 proton channel. *Biophys.J.* 97:2846–2853. doi:S0006-3495(09)01448-9 [pii];10.1016/j.bpj.2009.09.004 [doi].
228. Ciancio, B. C., T. J. Meerhoff, P. Kramarz, I. Bonmarin, K. Borgen, C. A. Boucher, U. Buchholz, S. Buda, F. Dijkstra, S. Dudman, S. Duwe, S. H. Hauge, O. Hungnes, A. Meijer, J. Mossong, W. J. Paget, N. Phin, M. van der Sande, B. Schweiger, and A. Nicoll. 2009. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007–8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. *Euro.Surveill* 14.
229. Cinti, S. K., A. R. Barnosky, S. E. Gay, S. D. Goold, M. M. Lozon, K. Kim, P. E. Rodgers, N. M. Baum, B. A. Cadwallender, C. D. Collins, C. M. Wright, and R. A. Winfield. 2009. Bacterial pneumonias during an influenza pandemic: how will we allocate antibiotics? *Biosecur.Bioterror.* 7:311–316. doi:10.1089/bsp.2009.0019 [doi].
230. Clark, I. and L. Alleva. 2009. Invited commentary on David Fedson's article. *Influenza.Other Respi. Viruses.* 3:199–201. doi:IRV98 [pii];10.1111/j.1750-2659.2009.00098.x [doi].
231. Clay, P. G., R. B. Adiga, T. A. Taylor, R. Alsup, P. M. Gerk, and M. McRae. 2011. Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza. *Obstet.Gynecol.* 118:463–467. doi:10.1097/AOG.0b013e31821b1b3e [doi];00006250-201108001-00020 [pii].
232. Coffin, S. E. 2010. In response to: Optimization of antiviral prescribing for influenza. *J.Hosp.Med.* 5:E31. doi:10.1002/jhm.551 [doi].
233. Coleman, C. H. 2009. Allocating vaccines and antiviral medications during an influenza pandemic. *Seton.Hall.Law Rev.* 39:1111–1123.
234. Conenello, G. M., J. R. Tisoncik, E. Rosenzweig, Z. T. Varga, P. Palese, and M. G. Katze. 2011. A single N66S mutation in the PB1-F2 protein of influenza A virus increases virulence by inhibiting the early interferon response in vivo. *J.Virol.* 85:652–662. doi:JV1.01987-10 [pii];10.1128/JV1.01987-10 [doi].
235. Confalonieri, M., P. D'Agaro, and C. Campello. 2010. Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection. *Intensive Care Med.* 36:1780–1781. doi:10.1007/s00134-010-1964-8 [doi].
236. Confalonieri, M., R. Cifaldi, L. Dreass, M. Viviani, M. Biolo, and M. Gabrielli. 2010. Methylprednisolone infusion for life-threatening H1N1-virus infection. *Ther.Adv.Respir.Dis.* 4:233–237. doi:1753465810376951 [pii];10.1177/1753465810376951 [doi].



237. Cook, C. 2010. Swine flu pandemic response not to be sneezed at. *Nurs.Manag.(Harrow.)* 17 :8–9.
238. Correia, V., H. R. de Andrade, L. A. Santos, A. Lackenby, and M. Zambon. 2010. Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. *Antiviral Res.* 86:128–136. doi:S0166-3542(10)00006-9 [pii];10.1016/j.antiviral.2010.01.002 [doi].
239. Cost, C., E. Brock, B. Adams-Huet, J. D. Siegel, and M. I. Ardura. 2011. 2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. *Pediatr.Blood Cancer* 56:127–133. doi:10.1002/psc.22771 [doi].
240. Couch, R. B. and B. R. Davis. 2010. Has oseltamivir been shown to be effective for treatment of H5N1 influenza? *J.Infect.Dis.* 202:1149–1151. doi:10.1086/656317 [doi].
241. Couturier, B. A., J. M. Bender, M. A. Schwarz, A. T. Pavia, K. E. Hanson, and R. C. She. 2010. Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients. *Influenza.Other Respi.Viruses.* 4:199–204. doi:IRV144 [pii];10.1111/j.1750-2659.2010.00144.x [doi].
242. Couzin-Frankel, J. 2010. Drug safety. New network to track drugs and vaccines in pregnancy. *Science* 327:1066–1067. doi:327/5969/1066 [pii];10.1126/science.327.5969.1066 [doi].
243. Creanga, A. A., T. F. Johnson, S. B. Graitcer, L. K. Hartman, T. Al-Samarrai, A. G. Schwarz, S. Y. Chu, J. E. Sackoff, D. J. Jamieson, A. D. Fine, C. K. Shapiro-Mendoza, L. E. Jones, T. M. Uyeki, S. Balter, C. L. Bish, L. Finelli, and M. A. Honein. 2010. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. *Obstet.Gynecol.* 115:717–726. doi:10.1097/AOG.0b013e3181d57947 [doi];00006250-201004000-00008 [pii].
244. Crouch, E., N. Nikolaidis, F. X. McCormack, B. McDonald, K. Allen, M. J. Rynkiewicz, T. M. Cafarella, M. White, K. Lewnard, N. Leymarie, J. Zaia, B. A. Seaton, and K. L. Hartshorn. 2011. Mutagenesis of Surfactant Protein D Informed by Evolution and X-ray Crystallography Enhances Defenses against Influenza A Virus in Vivo. *J.Biol.Chem.* 286:40681–40692. doi:M111.300673 [pii];10.1074/jbc.M111.300673 [doi].
245. Crum-Cianflone, N. F., L. E. Eberly, C. Duplessis, J. Maguire, A. Ganesan, D. Faix, G. Defang, Y. Bai, E. Iverson, T. Lalani, T. Whitman, P. J. Blair, C. Brandt, G. Macalino, and T. Burgess. 2011. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. *Clin.Infect. Dis.* 52:138–146. doi:ciq019 [pii];10.1093/cid/ciq019 [doi].
246. Cui, H., J. Jiang, W. Gu, C. Sun, D. Wu, T. Yang, and G. Yang. 2010. Photocatalytic inactivation efficiency of anatase Nano-TiO(2) Sol on the H(9) N(2) avian influenza virus. *Photochem.Photobiol.* 86:1135–1139. doi:PHP763 [pii];10.1111/j.1751-1097.2010.00763.x [doi].
247. Cunha, B. A., F. M. Perez, and N. Durie. 2010. Swine influenza (H1N1) and acute appendicitis. *Heart Lung* 39:544–546. doi:S0147-9563(10)00132-9 [pii];10.1016/j.hrtlng.2010.04.004 [doi].
248. Cunha, B. A., U. Syed, V. Thekkel, and M. Davis. 2010. Unusual nosocomial exposure to H1N1 influenza virus via open-chest cardiac massage. *Infect.Control Hosp.Epidemiol.* 31:775–776. doi:10.1086/653817 [doi].
249. Cunha, B., U. Syed, and S. Strollo. 2009. During the “herald wave” of the pandemic bacterial pneumonia relatively rare with fatal swine influenza (H1N1) pneumonia: if chest films have no focal segmental/lobar infiltrates, antibiotic therapy is unnecessary. *J.Chemother.* 21:584–589.
250. Da, D. L., A. Calistri, C. Chillemi, R. Cusinato, E. Franchin, C. Salata, D. Sgarabotto, G. Toscano, A. Gambino, and G. Palu. 2010. Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir. *Emerg.Infect.Dis.* 16:1813–1815. doi:10.3201/eid1611.100789 [doi].
251. Dale, S. E. 2010. The role of rapid antigen testing for influenza in the era of molecular diagnostics. *Mol.Diagn.Ther.* 14:205–214. doi:1 [pii];10.2165/11538430-000000000-00000 [doi].

252. Daneschwar, F., S. S. Tschudin, A. F. Widmer, and M. Battegay. 2010. [42-year-old obese man with H1N1 influenza A infection necessitating mechanical ventilation]. *Internist (Berl)* 51:1308–10, 1312. doi:10.1007/s00108-010-2642-1 [doi].
253. Danilenko, E. D., S. G. Gamalei, A. V. Bateneva, G. M. Sysoeva, G. M. Levagina, and V. I. Masycheva. 2011. [Biological properties of a prolonged action interferon inductor]. *Zh.Mikrobiol.Epidemiol. Immunobiol.* 57–61.
254. Danziger-Isakov, L., L. Cherkassky, H. Siegel, M. McManamon, K. Kramer, M. Budev, D. Sawinski, J. J. Augustine, D. E. Hricik, R. Fairchild, P. S. Heeger, and E. D. Poggio. 2010. Effects of influenza immunization on humoral and cellular alloreactivity in humans. *Transplantation* 89:838–844. doi:10.1097/TP.0b013e3181ca56f8 [doi].
255. Dao, T. T., P. H. Nguyen, H. S. Lee, E. Kim, J. Park, S. I. Lim, and W. K. Oh. 2011. Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from *Glycyrrhiza inflata*. *Bioorg.Med.Chem.Lett.* 21:294–298. doi:S0960-894X(10)01628-8 [pii];10.1016/j.bmcl.2010.11.016 [doi].
256. Dapat, C., R. Saito, Y. Kyaw, M. Naito, G. Hasegawa, Y. Suzuki, I. C. Dapat, H. Zaraket, T. M. Cho, D. Li, T. Oguma, T. Baranovich, and H. Suzuki. 2009. Epidemiology of human influenza A and B viruses in Myanmar from 2005 to 2007. *Intervirology* 52 :310–320. doi:000237738 [pii];10.1159/000237738 [doi].
257. Dapat, C., Y. Suzuki, R. Saito, Y. Kyaw, Y. Y. Myint, N. Lin, H. N. Oo, K. Y. Oo, N. Win, M. Naito, G. Hasegawa, I. C. Dapat, H. Zaraket, T. Baranovich, M. Nishikawa, T. Saito, and H. Suzuki. 2010. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. *Emerg.Infect.Dis.* 16:493–496. doi:10.3201/eid1603.091321 [doi].
258. Darwish, I., S. Mubareka, and W. C. Liles. 2011. Immunomodulatory therapy for severe influenza. *Expert.Rev.Anti.Infect.Ther.* 9:807–822. doi:10.1586/eri.11.56 [doi].
259. Das, R. R. 2011. Antivirals in treatment of H1N1 infection: are they really effective? *Eur.J.Pediatr.* 170:407. doi:10.1007/s00431-010-1384-3 [doi].
260. Das, R. R. 2011. Bacterial co-infection, antiviral therapy, and prevention of spread of H1N1 infection. *Pediatr.Pulmonol.* 46:621–622. doi:10.1002/ppul.21412 [doi].
261. Dashti-Khavidaki, S., H. Khalili, F. Gholamalipour, A. Soudbakhsh, A. H. Talasaz, M. Hajabdolbaghi, M. Rasoolinejad, A. T. Mokhtari, M. Fathi, M. T. Talebian, and S. Nasiripour. 2010. Approach to Pandemic 2009 influenza: first report from a main referral hospital for Pandemic H1N1 influenza care in Iran. *J.Infect.Dev.Ctries.* 4 :629–635.
262. Daude, M., J. M. Mansuy, J. Guitard, G. Basse, L. Esposito, J. Izopet, L. Rostaing, and N. Kamar. 2011. Influenza A (H1N1) virus-induced hepatocellular injury in a kidney transplant patient. *Transpl. Infect.Dis.* 13:70–72. doi:TID551 [pii];10.1111/j.1399-3062.2010.00551.x [doi].
263. Davies, B. E. 2010. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. *J.Antimicrob.Chemother.* 65 Suppl 2:ii5–ii10. doi:dkq015 [pii];10.1093/jac/dkq015 [doi].
264. Davis, C. S., C. R. Deburghgraeve, S. Yong, J. P. Parada, A. G. Palladino-Davis, E. Lowery, J. Gagermeier, and P. M. Fischella. 2010. Challenges in the diagnosis of 2009 H1N1 in a lung transplant patient and the long-term implications for prevention and treatment: a case report. *Transplant.Proc.* 42:4295–4299. doi:S0041-1345(10)01354-0 [pii];10.1016/j.transproceed.2010.09.028 [doi].
265. De, C. E. 2010. Strategies for the treatment of dengue virus infections: a narrative account. *Future. Med.Chem.* 2:601–608. doi:10.4155/fmc.10.15 [doi].
266. De, C. E. 2011. The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. *Med.Res.Rev.* 31:118–160. doi:10.1002/med.20179 [doi].

267. De, M. S., L. Sagliocca, F. D'Angelo, C. Morciano, P. Laricchiuta, E. Lacorte, and A. Mele. 2010. [Issues about the implementation of the guideline <<The management of influenza-like syndrome>>]. *Epidemiol.Prev.* 34:27–33.
268. Dean, A. S., C. R. Moffatt, A. Rosewell, D. E. Dwyer, R. I. Lindley, R. Booy, and C. R. Macintyre. 2010. Incompletely matched influenza vaccine still provides protection in frail elderly. *Vaccine* 28:864–867. doi:S0264-410X(09)00430-7 [pii];10.1016/j.vaccine.2009.03.024 [doi].
269. Deindl, P. and V. Varnholt. 2010. Correspondence (letter to the editor): Neurological complications. *Dtsch.Arztebl.Int.* 107:229. doi:10.3238/arztebl.2010.0229a [doi].
270. del, R. C. and J. Guarner. 2010. The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months. *Trans.Am.Clin.Climatol.Assoc.* 121:128–137.
271. del, R. C. and M. Hernandez-Avila. 2009. Lessons from previous influenza pandemics and from the Mexican response to the current influenza pandemic. *Arch.Med.Res.* 40 :677–680. doi:S0188-4409(09)00231-8 [pii];10.1016/j.arcmed.2009.12.005 [doi].
272. Delaney, J. W. and R. A. Fowler . 2010. 2009 influenza A (H1N1): a clinical review. *Hosp.Pract.* (Minneap.) 38:74–81.
273. Delogu, I., B. Pastorino, C. Baronti, A. Nougairède, E. Bonnet, and L. de, X. 2011. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. *Antiviral Res.* 90:99–107. doi:S0166-3542(11)00234-8 [pii];10.1016/j.antiviral.2011.03.182 [doi].
274. Dembinski, J. 2010. [Oseltamivir in pregnancy, lactation and neonatal period – comparison of international recommendations]. *Z.Geburtshilfe Neonatol.* 214:52–54. doi:10.1055/s-0030-1249676 [doi].
275. Demina, O. K., A. A. Sergeev, A. P. Agafonov, A. N. Shikov, A. O. Sementsova, A. A. Sergeev, A. N. Sergeev, and I. G. Drozdov. 2009. [Investigation of therapeutic and protective effect of Reaferon-ES Lipint on mice infected with avian influenza virus (subtype H5N1)]. *Antibiot.Khimioter.* 54:27–29.
276. Deng, J., Y. Zheng, C. Li, Z. Ma, H. Wang, and B. K. Rubin. 2010. Plastic bronchitis in three children associated with 2009 influenza A(H1N1) virus infection. *Chest* 138 :1486–1488. doi:138/6/1486 [pii];10.1378/chest.10-0548 [doi].
277. Deng, Y. M., N. Caldwell, A. Hurt, T. Shaw, A. Kelso, G. Chidlow, S. Williams, D. Smith, and I. Barr. 2011. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. *Antiviral Res.* 90:87–91. doi:S0166-3542(11)00052-0 [pii];10.1016/j.antiviral.2011.02.014 [doi].
278. Deriabin, P. G., G. A. Galegov, A. G. Botikov, E. I. Burtseva, D. V. Mishin, and M. I. Shchelkanov. 2011. [Effect of Zanamivir substance on infection induced by highly pathogenic avian influenza A/H5N1 in cell cultures]. *Vopr.Virusol.* 56:21–24.
279. Deyde, V. M., T. G. Sheu, A. A. Trujillo, M. Okomo-Adhiambo, R. Garten, A. I. Klimov, and L. V. Gubareva. 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. *Antimicrob.Agents Chemother.* 54:1102–1110. doi:AAC.01417-09 [pii];10.1128/AAC.01417-09 [doi].
280. Deyde, V., R. Garten, T. Sheu, C. Smith, A. Myrick, J. Barnes, X. Xu, M. Shaw, A. Klimov, and L. Gubareva. 2009. Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006–2008. *Influenza.Other Respi.Viruses.* 3:297–314. doi:IRV103 [pii];10.1111/j.1750-2659.2009.00103.x [doi].
281. Dharan, N. J., L. V. Gubareva, A. I. Klimov, A. E. Fiore, J. S. Bresee, and A. M. Fry. 2010. Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A (H1N1) infection during the 2007–2008 influenza season in the United States. *Clin.Infect.Dis.* 50:621–622. doi:10.1086/650178 [doi].

282. Dharan, N. J., M. Patton, A. M. Siston, J. Morita, E. Ramirez, T. R. Wallis, V. Deyde, L. V. Gubareva, A. I. Klimov, J. S. Bresee, and A. M. Fry. 2009. Outbreak of antiviral drug-resistant influenza A in long-term care facility, Illinois, USA, 2008. *Emerg.Infect.Dis.* 15:1973–1976. doi:10.3201/eid1512.081644 [doi].
283. Dharan, N. J., S. E. Beekmann, A. Fiore, L. Finelli, T. M. Uyeki, P. M. Polgreen, and A. M. Fry. 2010. Influenza antiviral prescribing practices during the 2007–08 and 2008–09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses. *Antiviral Res.* 88:182–186. doi:S0166-3542(10)00697-2 [pii];10.1016/j.antiviral.2010.08.010 [doi].
284. Di, G. S., D. Zileri, V. M. Sali, S. Farina, C. Di, V. S. Manzara, L. A. De, G. Pignataro, M. Prospero, F. A. Di, S. N. Gentiloni, G. Delogu, R. Cauda, M. Fabbiani, and G. Fadda. 2011. Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. *Eur.J.Clin.Microbiol.Infect.Dis.* 30:541–549. doi:10.1007/s10096-010-1116-7 [doi].
285. Diaz, A., R. Zaragoza, R. Granada, and M. Salavert. 2011. [Acute viral infections in immunocompetent patients]. *Med.Intensiva.* 35:179–185. doi:S0210-5691(11)00010-6 [pii];10.1016/j.medin.2011.01.001 [doi].
286. Dill, C. E. and M. A. Favata. 2009. Novel influenza A (H1N1) outbreak on board a US navy vessel. *Disaster.Med.Public Health Prep.* 3 Suppl 2:S117–S120. doi:10.1097/DMP.0b013e3181bf249b [doi].
287. Dimitrov, N. B., S. Goll, N. Hupert, B. Pourbohloul, and L. A. Meyers. 2011. Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza. *PLoS.One.* 6:e16094. doi:10.1371/journal.pone.0016094 [doi].
288. Dinler, G., G. Sensoy, M. Sungur, N. Asilioglu, H. A. Tasdemir, and A. G. Kalayci. 2010. Severe myopathy caused by the new pandemic influenza A (H1N1) in a child. *Trop.Doct.* 40:242–243. doi:td.2010.100024 [pii];10.1258/td.2010.100024 [doi].
289. Diogene, F. E., C. D. Rodriguez, and F. M. Bosch. 2010. [Use of antivirals in influenza pandemics]. *Aten.Primaria* 42:132–133. doi:S0212-6567(09)00567-8 [pii];10.1016/j.aprim.2009.10.009 [doi].
290. Dobrovolny, H. M., R. Gieschke, B. E. Davies, N. L. Jumbe, and C. A. Beauchemin. 2011. Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. *J.Theor.Biol.* 269:234–244. doi:S0022-5193(10)00545-X [pii];10.1016/j.jtbi.2010.10.017 [doi].
291. Dohna-Schwake, C., B. Schweiger, U. Felderhoff-Muser, M. Fiedler, G. M. Kaiser, A. Paul, P. Gerner, E. Lainka, and P. F. Hoyer. 2010. Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications. *Transplantation* 90:223–224. doi:10.1097/TP.0b013e3181e0a0df [doi];00007890-201007270-00018 [pii].
292. Dolin, R. 2011. Resistance to neuraminidase inhibitors. *Clin.Infect.Dis.* 52:438–439. doi:ciq184 [pii];10.1093/cid/ciq184 [doi].
293. Dolley-Hitze, T., M. C. Verdier, O. Tribut, T. Y. Le, and S. Marque. 2010. Oseltamivir dose adjustment in an H1N1 patient requiring haemodialysis. *Intensive Care Med.* 36:1618–1619. doi:10.1007/s00134-010-1943-0 [doi].
294. Dominguez, A., J. Alonso, J. Astray, M. Baricot, R. Canton, J. Castilla, A. Castro, M. Delgado, P. Godoy, F. Gonzalez-Candelas, V. Martin, J. M. Mayoral, J. M. Quintana, E. Perea, T. Pumarola, N. Soldevila, and S. Tamames. 2011. [Risk factors of influenza (H1N1) 2009 hospitalization and effectiveness of pharmaceutical and nonpharmaceutical interventions in its prevention: a case-control study]. *Rev.Esp.Salud Publica* 85:3–15. doi:S1135-57272011000100002 [pii];10.1590/S1135-57272011000100002 [doi].
295. Dondurei, E. A., L. V. Osidak, E. G. Golovacheva, A. K. Golovanova, I. V. Amosova, and L. N. Gladchenko. 2009. Acute viral infections with combined involvement of the respiratory and gastrointestinal tracts in children. Therapy with interferon. *Bull.Exp.Biol.Med.* 148:283–286.

296. Dong, C. X., K. Hayashi, J. B. Lee, and T. Hayashi. 2010. Characterization of structures and antiviral effects of polysaccharides from *Portulaca oleracea* L. *Chem.Pharm.Bull.(Tokyo)* 58:507–510. doi:JST.JSTAGE/cpb/58.507 [pii].
297. Donner, B., S. Bader-Weder, R. Schwarz, M. M. Peng, J. R. Smith, and V. Niranjana. 2011. Safety profile of oseltamivir during the 2009 influenza pandemic. *Pharmacoepidemiol.Drug Saf* 20:532–543. doi:10.1002/pds.2136 [doi].
298. Donner, B., V. Niranjana, and G. Hoffmann. 2010. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. *Drug Saf* 33:631–642. doi:3 [pii];10.2165/11536370-000000000-00000 [doi].
299. Dosekun, O., C. Kober, D. Richardson, A. Parkhouse, and M. Fisher. 2010. It's not all swine flu...are we missing opportunities to diagnose primary HIV infection in patients with flu symptoms? *Int.J.STD AIDS* 21:145–146. doi:21/2/145 [pii];10.1258/ijsa.2009.009514 [doi].
300. Doshi, S., L. Kamimoto, L. Finelli, A. Perez, A. Reingold, K. Gershman, K. Yousey-Hindes, K. Arnold, P. Ryan, R. Lynfield, C. Morin, J. Baumbach, E. B. Hancock, N. M. Bennett, S. Zansky, A. Thomas, W. Schaffner, and A. M. Fry. 2011. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005–2009. *J.Infect.Dis.* 204:1848–1856. doi:jir648 [pii];10.1093/infdis/jir648 [doi].
301. Doucet, J. D., M. A. Forget, C. Grange, R. N. Rouxel, N. Arbour, M. von, V, and R. Lapointe. 2011. Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes. *J.Gen.Virol.* 92:1162–1171. doi:vir.0.029777-0 [pii];10.1099/vir.0.029777-0 [doi].
302. Downes, J. E. and S. Marshall-Clarke. 2010. Innate immune stimuli modulate bone marrow-derived dendritic cell production in vitro by toll-like receptor-dependent and -independent mechanisms. *Immunology* 131:513–524. doi:IMM3324 [pii];10.1111/j.1365-2567.2010.03324.x [doi].
303. Droebner, K., S. Pleschka, S. Ludwig, and O. Planz. 2011. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. *Antiviral Res.* 92:195–203. doi:S0166-3542(11)00391-3 [pii];10.1016/j.antiviral.2011.08.002 [doi].
304. Du, L., G. Zhao, X. Zhang, Z. Liu, H. Yu, B. J. Zheng, Y. Zhou, and S. Jiang. 2010. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. *Biochem.Biophys.Res.Commun.* 397:580–585.
305. Du, L., G. Zhao, X. Zhang, Z. Liu, H. Yu, B. J. Zheng, Y. Zhou, and S. Jiang. 2010. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. *Biochem.Biophys.Res.Commun.* doi:S0006-291X(10)01094-6 [pii];10.1016/j.bbrc.2010.05.161 [doi].
306. Du, N., J. Zhou, X. Lin, Y. Zhang, X. Yang, Y. Wang, and Y. Shu. 2010. Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. *J.Virol.* 84:7822–7831. doi:JVI.00069-10 [pii];10.1128/JVI.00069-10 [doi].
307. Du, Q. S., R. B. Huang, S. Q. Wang, and K. C. Chou. 2010. Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. *PLoS.One.* 5:e9388. doi:10.1371/journal.pone.0009388 [doi].
308. Duan, S., D. A. Boltz, P. Seiler, J. Li, K. Bragstad, L. P. Nielsen, R. J. Webby, R. G. Webster, and E. A. Govorkova. 2010. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. *PLoS.Pathog.* 6:e1001022. doi:10.1371/journal.ppat.1001022 [doi].
309. Duan, S., D. A. Boltz, P. Seiler, J. Li, K. Bragstad, L. P. Nielsen, R. J. Webby, R. G. Webster, and E. A. Govorkova. 2011. Competitive transmissibility and fitness of oseltamivir-sensitive and resistant pandemic influenza H1N1 viruses in ferrets. *Influenza.Other Respi.Viruses.* 5 Suppl 1:79–82.

310. Duan, S., L. Gu, Y. Wang, R. Zheng, J. Lu, J. Yin, L. Guli, and M. Ball. 2009. Regulation of influenza virus-caused oxidative stress by Kegan Liyan oral prescription, as monitored by ascorbyl radical ESR signals. *Am.J.Chin Med.* 37:1167–1177. doi:S0192415X09007570 [pii].
311. Dudek, S. E., C. Luig, E. K. Pauli, U. Schubert, and S. Ludwig. 2010. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. *J.Virol.* 84:9439–9451. doi:JVI.00533-10 [pii];10.1128/JVI.00533-10 [doi].
312. Dulek, D. E., J. V. Williams, C. B. Creech, A. K. Schulert, H. A. Frangoul, J. Domm, M. R. Denison, and J. D. Chappell. 2010. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. *Clin. Infect.Dis.* 50:1493–1496. doi:10.1086/652655 [doi].
313. Dulyachai, W., J. Makkoch, P. Rianthavorn, M. Changpinyo, S. Prayangprecha, S. Payungporn, R. Tantilertcharoen, P. Kitikoon, and Y. Poovorawan. 2010. Perinatal pandemic (H1N1) 2009 infection, Thailand. *Emerg.Infect.Dis.* 16:343–344. doi:10.3201/eid1602.091733 [doi].
314. Duque, M. D., C. Ma, E. Torres, J. Wang, L. Naesens, J. Juarez-Jimenez, P. Camps, F. J. Luque, W. F. DeGrado, R. A. Lamb, L. H. Pinto, and S. Vazquez. 2011. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. *J.Med.Chem.* 54:2646–2657. doi:10.1021/jm101334y [doi].
315. Durando, P., G. Icardi, and F. Ansaldi. 2010. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. *Expert.Opin. Biol.Ther.* 10:639–651. doi:10.1517/14712591003724662 [doi].
316. Durrant, J. D. and J. A. McCammon. 2010. Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. *Comput.Biol.Chem.* 34:97–105. doi:S1476-9271(10)00021-6 [pii];10.1016/j.compbiolchem.2010.03.005 [doi].
317. Dutkowski, R. 2010. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. *J.Antimicrob.Chemother.* 65 Suppl 2:ii11–ii24. doi:dkq012 [pii];10.1093/jac/dkq012 [doi].
318. Dutkowski, R., J. R. Smith, and B. E. Davies. 2010. Safety and pharmacokinetics of oseltamivir at standard and high dosages. *Int.J.Antimicrob.Agents* 35:461–467. doi:S0924-8579(10)00038-5 [pii];10.1016/j.ijantimicag.2009.12.023 [doi].
319. Duval, X., S. van der Werf, T. Blanchon, A. Mosnier, M. Bouscambert-Duchamp, A. Tibi, V. Enouf, C. Charlois-Ou, C. Vincent, L. Andreoletti, F. Tubach, B. Lina, F. Mentre, and C. Lepout. 2010. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. *PLoS.Med.* 7:e1000362. doi:10.1371/journal.pmed.1000362 [doi].
320. Duwe, S. C., M. Wedde, P. Birkner, and B. Schweiger. 2011. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany. *Antiviral Res.* 89:115–118. doi:S0166-3542(10)00772-2 [pii];10.1016/j.antiviral.2010.11.001 [doi].
321. Duwe, S., A. Heider, C. Braun, B. Schweiger, and U. Buchholz. 2009. Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08. *J.Clin.Virol.* 46:295–297. doi:S1386-6532(09)00375-8 [pii];10.1016/j.jcv.2009.07.022 [doi].
322. Egel, B. A. 2010. The truth about Tamiflu? Zanamivir should be inhaled, not nebulised. *BMJ* 340:c131.
323. Earhart, K. C., N. M. Elsayed, M. D. Saad, L. V. Gubareva, A. Nayel, V. M. Deyde, A. Abdelsattar, A. S. Abdelghani, B. R. Boynton, M. M. Mansour, H. M. Essmat, A. Klimov, D. Shuck-Lee, M. R. Monteville, and J. A. Tjaden. 2009. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. *J.Infect.Public Health* 2:74–80. doi:S1876-0341(09)00031-8 [pii];10.1016/j.jiph.2009.04.004 [doi].

324. Easton, A. J., P. D. Scott, N. L. Edworthy, B. Meng, A. C. Marriott, and N. J. Dimmock. 2011. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. *Vaccine* 29:2777–2784. doi:S0264-410X(11)00174-5 [pii];10.1016/j.vaccine.2011.01.102 [doi].
325. Ebrahim, S. H., Z. A. Memish, T. M. Uyeki, T. A. Khoja, N. Marano, and S. J. McNabb. 2009. Public health. Pandemic H1N1 and the 2009 Hajj. *Science* 326:938–940. doi:1183210 [pii];10.1126/science.1183210 [doi].
326. Eggertson, L. 2010. Tamiflu still prudent for pandemic influenza, PHAC maintains. *CMAJ*. 182:E133–E134. doi:cmaj.109-3145 [pii];10.1503/cmaj.109-3145 [doi].
327. Ehrhardt, C., R. Seyer, E. R. Hrincius, T. Eierhoff, T. Wolff, and S. Ludwig. 2010. Interplay between influenza A virus and the innate immune signaling. *Microbes.Infect.* 12:81–87. doi:S1286-4579(09)00212-3 [pii];10.1016/j.micinf.2009.09.007 [doi].
328. Eiros Bouza, J. M., R. A. Perez, and S. J. Castrodeza. 2011. [Antivirals and pandemic flu]. *Aten. Primaria* 43:213. doi:S0212-6567(10)00200-3 [pii];10.1016/j.aprim.2010.02.013 [doi].
329. Elbahlawan, L., A. H. Gaur, W. Furman, S. Jeha, T. Woods, A. Norris, and R. R. Morrison. 2011. Severe H1N1-associated acute respiratory failure in immunocompromised children. *Pediatr.Blood Cancer* 57:625–628. doi:10.1002/pbc.22973 [doi].
330. Elbe, S. 2010. Haggling over viruses: the downside risks of securitizing infectious disease. *Health Policy Plan.* 25:476–485. doi:czq050 [pii];10.1093/heapol/czq050 [doi].
331. Elboim, M., R. Gazit, C. Gur, H. Ghadially, G. Betser-Cohen, and O. Mandelboim. 2010. Tumor immunoediting by NKp46. *J.Immunol.* 184:5637–5644. doi:jimmunol.0901644 [pii];10.4049/jimmunol.0901644 [doi].
332. Ellis, J. B. 2010. Antiviral pandemic risk assessment for urban receiving waters. *Water Sci.Technol.* 61:879–884. doi:10.2166/wst.2010.002 [doi].
333. Enstone, J. E., P. R. Myles, P. J. Openshaw, E. M. Gadd, W. S. Lim, M. G. Semple, R. C. Read, B. L. Taylor, J. McMenamin, C. Armstrong, B. Bannister, K. G. Nicholson, and J. S. Nguyen-Van-Tam. 2011. Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009–2010. *Emerg.Infect.Dis.* 17:592–598. doi:10.3201/eid1704.101679 [doi].
334. Erlikh, I. V., S. Abraham, and V. K. Kondamudi. 2010. Management of influenza. *Am.Fam.Physician* 82:1087–1095. doi:d8715 [pii].
335. Erman, E. S., L. V. Osidak, V. F. Sukhovetskaya, and V. P. Drinevskii. 2009. Efficiency of interferon inducer anaferon (pediatric formulation) in prophylaxis of acute respiratory infections in sickly children. *Bull.Exp.Biol.Med.* 148:270–274.
336. Escher, B. I., N. Bramaz, J. Lienert, J. Neuwoehner, and J. O. Straub. 2010. Mixture toxicity of the antiviral drug Tamiflu((R)) (oseltamivir ethylester) and its active metabolite oseltamivir acid. *Aquat. Toxicol.* 96:194–202. doi:S0166-445X(09)00364-6 [pii];10.1016/j.aquatox.2009.10.020 [doi].
337. Espinosa-Aguilar, L., J. S. Green, G. N. Forrest, E. D. Ball, R. T. Maziarz, L. Strasfeld, and R. A. Taplitz. 2011. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. *Biol.Blood Marrow Transplant.* 17:566–573. doi:S1083-8791(10)00319-8 [pii];10.1016/j.bbmt.2010.07.018 [doi].
338. Esposito, S., C. G. Molteni, C. Colombo, C. Daleno, V. Dacco, A. Lackenby, and N. Principi. 2010. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and *Pseudomonas aeruginosa* infection. *J.Clin.Virol.* 48:62–65. doi:S1386-6532(10)00091-0 [pii];10.1016/j.jcv.2010.02.019 [doi].

339. Esposito, S., C. G. Molteni, C. Daleno, A. Valzano, E. Fossali, D. L. Da, V. Cecinati, E. Bruzzese, R. Giacchino, C. Giaquinto, C. Galeone, A. Lackenby, and N. Principi. 2010. Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. *Virology* 7:202. doi:1743-422X-7-202 [pii];10.1186/1743-422X-7-202 [doi].
340. Evdokimov, A. A., N. A. Malyshev, D. N. Protsenko, A. S. Belevskii, A. I. Iaroshetskii, O. B. Murav'ev, P. V. Boitsov, and B. R. Gel'fand. 2010. [Experience in treating severe viral respiratory infection caused by influenza A (H1N1)]. *Anesteziol.Reanimatol.* 22–25.
341. Ezoe, H., Y. Akeda, Z. Piao, T. Aoshi, S. Koyama, T. Tanimoto, K. J. Ishii, and K. Oishi. 2011. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. *Vaccine* 29:1754–1761. doi:S0264-410X(10)01904-3 [pii];10.1016/j.vaccine.2010.12.117 [doi].
342. Fadnis, V. P. 2010. H1N1 guidelines. *Indian Pediatr.* 47:101–102.
343. Falagas, M. E., E. K. Vouloumanou, E. Baskouta, P. I. Rafailidis, K. Polyzos, and J. Rello. 2010. Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. *Int.J.Antimicrob. Agents* 35:421–430. doi:S0924-8579(10)00039-7 [pii];10.1016/j.ijantimicag.2010.01.006 [doi].
344. Falagas, M. E., P. K. Koletsi, E. K. Vouloumanou, P. I. Rafailidis, A. M. Kapaskelis, and J. Rello. 2010. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. *J.Antimicrob.Chemother.* 65:1330–1346. doi:dkq158 [pii];10.1093/jac/dkq158 [doi].
345. Fang, Y., T. Rowe, A. J. Leon, D. Banner, A. Danesh, L. Xu, L. Ran, S. E. Bosinger, Y. Guan, H. Chen, C. C. Cameron, M. J. Cameron, and D. J. Kelvin. 2010. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. *J.Virol.* 84:8369–8388. doi:JVI.02305-09 [pii];10.1128/JVI.02305-09 [doi].
346. Faruqui, F. and D. Mukundan. 2010. 2009 pandemic influenza: a review. *Curr.Opin.Pediatr.* 22:530–535. doi:10.1097/MOP.0b013e32833bb81a [doi].
347. Federico, M. 2011. HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step. *Virology* 417:37–49. doi:S0042-6822(11)00215-7 [pii];10.1016/j.virol.2011.05.002 [doi].
348. Fedichev, P., R. Timakhov, T. Pyrkov, E. Getmantsev, and A. Vinnik. 2011. Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo. *PLoS.Curr.* 3:RRN1253. doi:10.1371/currents.RRN1253 [doi];k/-/-/1nsj02vqpk8/1 [pii].
349. Feiterna-Sperling, C., A. Edelmann, R. Nickel, K. Magdorf, F. Bergmann, P. Rautenberg, B. Schweiger, V. Wahn, D. H. Kruger, and J. Hofmann. 2010. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children. *Clin.Infect.Dis.* 51 :e90–e94. doi:10.1086/657121 [doi].
350. Feng, F., N. Miura, N. Isoda, Y. Sakoda, M. Okamatsu, H. Kida, and S. Nishimura. 2010. Novel trivalent anti-influenza reagent. *Bioorg.Med.Chem.Lett.* 20:3772–3776. doi:S0960-894X(10)00530-5 [pii];10.1016/j.bmcl.2010.04.060 [doi].
351. Feng, Y. Q., T. S. Guo, L. M. Liu, Y. L. Li, B. Li, Z. G. Liu, Z. Q. Sun, M. Zhao, Y. L. Mao, and B. A. Li. 2010. [Clinical and laboratory characteristics of a new influenza A (H1N1) epidemic]. *Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue.Za Zhi.* 24:134–135.
352. Feng, Y., Y. Kong, P. F. Barnes, F. F. Huang, P. Klucar, X. Wang, B. Samten, M. Sengupta, B. Machona, R. Donis, A. R. Tvinnereim, and H. Shams. 2011. Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and *Mycobacterium tuberculosis*. *Infect.Immun.* 79:229–237. doi:IAI.00709-10 [pii];10.1128/IAI.00709-10 [doi].



353. Ferraris, O., V. Escuret, M. Bouscambert-Duchamp, B. Lina, and F. Morfin. 2010. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections]. *Pathol.Biol.(Paris)* 58:e69–e78. doi:S0369-8114(10)00032-5 [pii];10.1016/j.patbio.2010.01.011 [doi].
354. Finkel, B., C. Goodman, Y. Melamed, R. Kurs, and A. Bleich. 2010. Effect of antiviral amantadine treatment on elderly chronic schizophrenia patients. *Isr.Med.Assoc.J.* 12:536–538.
355. Fiore, A. E., A. Fry, D. Shay, L. Gubareva, J. S. Bresee, and T. M. Uyeki. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm.Rep.* 60:1–24. doi:rr6001a1 [pii].
356. Fiore, A. E., T. M. Uyeki, K. Broder, L. Finelli, G. L. Euler, J. A. Singleton, J. K. Iskander, P. M. Wortley, D. K. Shay, J. S. Bresee, and N. J. Cox. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm.Rep.* 59:1–62. doi:rr5908a1 [pii].
357. Fitzgerald, K. A. 2011. The interferon inducible gene: Viperin. *J.Interferon Cytokine Res.* 31:131–135. doi:10.1089/jir.2010.0127 [doi].
358. Flagg, A., L. Danziger-Isakov, C. Foster, C. Nasman, N. Smedira, J. Carl, C. Kwon, S. Davis, and G. Boyle. 2010. Novel 2009 H1N1 influenza virus infection requiring extracorporeal membrane oxygenation in a pediatric heart transplant recipient. *J.Heart Lung Transplant.* 29:582–584. doi:S1053-2498(09)01504-6 [pii];10.1016/j.healun.2009.11.600 [doi].
359. Flores, P., J. Guimaraes, and J. M. Videira Amaral. 2011. Th1 and th2 cytokine expression in nasopharyngeal secretions during acute bronchiolitis in children younger than two years old. *Allergol. Immunopathol.(Madr.)* 39:3–9. doi:S0301-0546(10)00153-9 [pii];10.1016/j.aller.2010.03.008 [doi].
360. Forrest, B. D., A. D. Steele, L. Hiemstra, R. Rappaport, C. S. Ambrose, and W. C. Gruber. 2011. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. *Vaccine* 29:3633–3639. doi:S0264-410X(11)00381-1 [pii];10.1016/j.vaccine.2011.03.029 [doi].
361. Forrester, M. B. 2010. Pattern of oseltamivir ingestions reported to Texas poison centers. *Hum.Exp. Toxicol.* 29:137–140. doi:0960327109357219 [pii];10.1177/0960327109357219 [doi].
362. Foster, G. R. 2010. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. *Drugs* 70:147–165. doi:3 [pii];10.2165/11531990-000000000-00000 [doi].
363. Fourment, M., S. Mardy, M. Channa, and P. Buchy. 2010. Evidence for persistence of and antiviral resistance and reassortment events in seasonal influenza virus strains circulating in Cambodia. *J.Clin. Microbiol.* 48:295–297. doi:JCM.01687-09 [pii];10.1128/JCM.01687-09 [doi].
364. Fox, A., P. Horby, N. H. Ha, N. M. Hoa le, N. T. Lam, C. Simmons, J. Farrar, K. N. Van, and H. Wertheim. 2010. Influenza A H5N1 and HIV co-infection: case report. *BMC.Infect.Dis.* 10:167. doi:1471-2334-10-167 [pii];10.1186/1471-2334-10-167 [doi].
365. Fox, B. D., Y. Raviv, D. Rozengarten, V. Rusanov, I. Bakal, and M. R. Kramer. 2010. Pandemic influenza (H1N1): impact on lung transplant recipients and candidates. *J.Heart Lung Transplant.* 29:1034–1038. doi:S1053-2498(10)00288-3 [pii];10.1016/j.healun.2010.05.007 [doi].
366. Fraaij, P. L., d. van, V, M. F. Beersma, A. Riezebos-Brilman, H. G. Niesters, A. A. van der Eijk, M. D. de Jong, M. D. Reis, A. M. Horrevorts, B. U. Ridwan, M. J. Wolfhagen, R. J. Houmes, J. T. van Dissel, R. A. Fouchier, A. C. Kroes, M. P. Koopmans, A. D. Osterhaus, and C. A. Boucher. 2011. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. *J.Infect.Dis.* 204:777–782. doi:jir397 [pii];10.1093/infdis/jir397 [doi].

367. France, M. W., S. Tai, P. J. Masel, V. L. Moore, T. L. McMahon, A. J. Ritchie, and S. C. Bell. 2010. The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis. *BMC.Pulm.Med.* 10:8. doi:1471-2466-10-8 [pii];10.1186/1471-2466-10-8 [doi].
368. Fridman, D., O. Kuzbari, and H. Minkoff. 2009. Novel influenza H1N1 in pregnancy: a report of two cases. *Infect.Dis.Obstet.Gynecol.* 2009:514353. doi:10.1155/2009/514353 [doi].
369. Fry, A. M., A. Perez, and L. Finelli. 2011. Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance. *JAMA* 306:160–162. doi:306/2/160 [pii];10.1001/jama.2011.950 [doi].
370. Fuhrman, C., I. Bonmarin, D. Bitar, T. Cardoso, N. Dupont, M. Herida, H. Isnard, B. Guidet, O. Mimos, J. C. Richard, C. Brun-Buisson, L. Brochard, A. Mailles, A. C. Paty, C. Saura, and D. Levy-Bruhl. 2011. Adult intensive-care patients with 2009 pandemic influenza A(H1N1) infection. *Epidemiol. Infect.* 139:1202–1209. doi:S0950268810002414 [pii];10.1017/S0950268810002414 [doi].
371. Fumagalli, L. L. and A. Lazzarin. 2009. Influenza A (H1N1) virus infection in Intensive Care Unit: the point of view of the infectious diseases consultant. *Minerva Anestesiol.* 75:599–601. doi:R02095789 [pii].
372. Fung, J. 2009. Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. *Expert.Rev.Anti.Infect.Ther.* 7:945–949. doi:10.1586/eri.09.79 [doi].
373. Furuse, Y., A. Suzuki, M. Kishi, N. Nukiwa, M. Shimizu, R. Sawayama, N. Fuji, and H. Oshitani. 2010. Occurrence of mixed populations of influenza A viruses that can be maintained through transmission in a single host and potential for reassortment. *J.Clin.Microbiol.* 48:369–374. doi:JCM.01795-09 [pii];10.1128/JCM.01795-09 [doi].
374. Fytas, C., A. Kolocouris, G. Fytas, G. Zoidis, C. Valmas, and C. F. Basler. 2010. Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II – Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus. *Bioorg.Chem.* 38:247–251. doi:S0045-2068(10)00072-6 [pii];10.1016/j.bioorg.2010.09.001 [doi].
375. Galegov, G. A., V. L. Andronova, and V. E. Nebol'sin. 2009. [Antiviral effect of Ingavirin against seasonal influenza virus A/H1N1 in MDCK cell culture]. *Antibiot.Khimioter.* 54:19–22.
376. Gamblin, S. J. and J. J. Skehel. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. *J.Biol.Chem.* 285:28403–28409. doi:R110.129809 [pii];10.1074/jbc.R110.129809 [doi].
377. Gandhoke, I., D. S. Rawat, A. Rai, S. Khare, and R. L. Ichhpujani. 2011. Pandemic Influenza A (H1N1) 2009 in India: duration of virus shedding in patients under antiviral treatment. *Indian J.Med.Microbiol.* 29:37–41. doi:IndianJMedMicrobiol\_2011\_29\_1\_37\_76522 [pii];10.4103/0255-0857.76522 [doi].
378. Gangehei, L., M. Ali, W. Zhang, Z. Chen, K. Wakame, and M. Haidari. 2010. Oligonol a low molecular weight polyphenol of lychee fruit extract inhibits proliferation of influenza virus by blocking reactive oxygen species-dependent ERK phosphorylation. *Phytomedicine.* 17:1047–1056. doi:S0944-7113(10)00108-X [pii];10.1016/j.phymed.2010.03.016 [doi].
379. Gao, L., S. Yu, Q. Chen, Z. Duan, J. Zhou, C. Mao, D. Yu, W. Zhu, J. Nie, and Y. Hou. 2010. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. *Vaccine* 28:4445–4451. doi:S0264-410X(10)00462-7 [pii];10.1016/j.vaccine.2010.03.062 [doi].
380. Gao, S., M. A. von der, S. Paeschke, J. Behlke, O. Haller, G. Kochs, and O. Daumke. 2010. Structural basis of oligomerization in the stalk region of dynamin-like MxA. *Nature* 465:502–506. doi:nature08972 [pii];10.1038/nature08972 [doi].
381. Garcia-Sastre, A. 2011. Induction and evasion of type I interferon responses by influenza viruses. *Virus Res.* 162:12–18. doi:S0168-1702(11)00411-4 [pii];10.1016/j.virusres.2011.10.017 [doi].

382. Garcia-Suarez, J., Y. Martin, M. Callejas, M. Rodriguez-Dominguez, J. C. Galan, and C. Burgaleta. 2010. Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non-Hodgkin lymphoma. *Br.J.Haematol.* 148:808–810. doi:BJH7997 [pii];10.1111/j.1365-2141.2009.07997.x [doi].
383. Garigliany, M. M. and D. J. Desmecht. 2011. N-acetylcysteine lacks universal inhibitory activity against influenza A viruses. *J.Negat.Results Biomed.* 10:5. doi:1477-5751-10-5 [pii];10.1186/1477-5751-10-5 [doi].
384. Garland, P., L. H. de, T. Sekine, K. Hoschler, S. Sriskandan, P. Patel, S. Brett, K. Stringaris, E. Loucaides, K. Howe, D. Marin, E. Kanfer, N. Cooper, D. Macdonald, A. Rahemtulla, M. Atkins, A. Danga, D. Milojkovic, I. Gabriel, A. Khoder, A. Alsuliman, J. Apperley, and K. Rezvani. 2011. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. *Biol.Blood Marrow Transplant.* 17:632–639. doi:S1083-8791(10)00340-X [pii];10.1016/j.bbmt.2010.08.002 [doi].
385. Garozzo, A., R. Timpanaro, A. Stivala, G. Bisignano, and A. Castro. 2011. Activity of *Melaleuca alternifolia* (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action. *Antiviral Res.* 89:83–88. doi:S0166-3542(10)00812-0 [pii];10.1016/j.antiviral.2010.11.010 [doi].
386. Garozzo, A., R. Timpanaro, B. Bisignano, P. M. Furneri, G. Bisignano, and A. Castro. 2009. In vitro antiviral activity of *Melaleuca alternifolia* essential oil. *Lett.Appl.Microbiol.* 49:806–808. doi:LAM2740 [pii];10.1111/j.1472-765X.2009.02740.x [doi].
387. Garrett, A. L., Y. S. Park, and I. Redlener. 2009. Mitigating absenteeism in hospital workers during a pandemic. *Disaster.Med.Public Health Prep.* 3 Suppl 2:S141–S147. doi:10.1097/DMP.0b013e3181c12959 [doi].
388. Gaur, A. H., B. Bagga, S. Barman, R. Hayden, A. Lamptey, J. M. Hoffman, D. Bhojwani, P. M. Flynn, E. Tuomanen, and R. Webby. 2010. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. *N.Engl.J.Med.* 362:88–89. doi:NEJMc0910893 [pii];10.1056/NEJMc0910893 [doi].
389. Gazak, R., K. Purchartova, P. Marhol, L. Zivna, P. Sedmera, K. Valentova, N. Kato, H. Matsumura, K. Kaihatsu, and V. Kren. 2010. Antioxidant and antiviral activities of silybin fatty acid conjugates. *Eur.J.Med.Chem.* 45:1059–1067. doi:S0223-5234(09)00626-6 [pii];10.1016/j.ejmech.2009.11.056 [doi].
390. Ge, H., Y. F. Wang, J. Xu, Q. Gu, H. B. Liu, P. G. Xiao, J. Zhou, Y. Liu, Z. Yang, and H. Su. 2010. Anti-influenza agents from Traditional Chinese Medicine. *Nat.Prod.Rep.* 27:1758–1780. doi:10.1039/c0np00005a [doi].
391. Ge, X., J. A. Gebe, P. L. Bollyky, E. A. James, J. Yang, L. J. Stern, and W. W. Kwok. 2010. Peptide-MHC cellular microarray with innovative data analysis system for simultaneously detecting multiple CD4 T-cell responses. *PLoS.One.* 5:e11355. doi:10.1371/journal.pone.0011355 [doi].
392. George, A., J. Benton, J. Pratt, M. O. Kim, K. A. Kalinyak, T. A. Kalfa, and C. H. Joiner. 2011. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. *Pediatr. Blood Cancer* 57:648–653. doi:10.1002/pbc.23030 [doi].
393. George, B., P. Ferguson, I. Kerridge, N. Gilroy, D. Gottlieb, and M. Hertzberg. 2011. The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients. *Biol.Blood Marrow Transplant.* 17:147–153. doi:S1083-8791(10)00295-8 [pii];10.1016/j.bbmt.2010.07.004 [doi].
394. Gerloff, N. A., J. R. Kremer, J. Mossong, M. Opp, and C. P. Muller. 2009. Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007–08. *Emerg.Infect.Dis.* 15:1523–1524. doi:10.3201/eid1509.090452 [doi].

395. German-Diaz, M., R. Pavo-Garcia, J. Diaz-Diaz, E. Giangaspro-Corradi, and S. Negreira-Cepeda. 2010. Adolescent with neuropsychiatric symptoms associated with novel influenza A (H1N1) virus infection. *Pediatr.Infect.Dis.J.* 29:570–571. doi:10.1097/INF.0b013e3181d411a9 [doi].
396. Gerritz, S. W., C. Cianci, S. Kim, B. C. Pearce, C. Deminie, L. Discotto, B. McAuliffe, B. F. Minassian, S. Shi, S. Zhu, W. Zhai, A. Pendri, G. Li, M. A. Poss, S. Edavettal, P. A. McDonnell, H. A. Lewis, K. Maskos, M. Mortl, R. Kiefersauer, S. Steinbacher, E. T. Baldwin, W. Metzler, J. Bryson, M. D. Healy, T. Philip, M. Zoeckler, R. Schartman, M. Sinz, V. H. Leyva-Grado, H. H. Hoffmann, D. R. Langley, N. A. Meanwell, and M. Krystal. 2011. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. *Proc.Natl.Acad.Sci.U.S.A* 108:15366–15371. doi:1107906108 [pii];10.1073/pnas.1107906108 [doi].
397. GeurtsvanKessel, C. H., I. M. Bergen, F. Muskens, L. Boon, H. C. Hoogsteden, A. D. Osterhaus, G. F. Rimmelzwaan, and B. N. Lambrecht. 2009. Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection. *PLoS.One.* 4:e7187. doi:10.1371/journal.pone.0007187 [doi].
398. Ghedin, E., J. Laplante, J. DePasse, D. E. Wentworth, R. P. Santos, M. L. Lepow, J. Porter, K. Stellrecht, X. Lin, D. Operario, S. Griesemer, A. Fitch, R. A. Halpin, T. B. Stockwell, D. J. Spiro, E. C. Holmes, and G. K. St. 2011. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. *J.Infect.Dis.* 203:168–174. doi:jjq040 [pii];10.1093/infdis/jiq040 [doi].
399. Ghosh, G. C., N. Nakada, N. Yamashita, and H. Tanaka. 2010. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. *Chemosphere* 81:13–17. doi:S0045-6535(10)00804-0 [pii];10.1016/j.chemosphere.2010.07.023 [doi].
400. Ghosh, G. C., N. Nakada, N. Yamashita, and H. Tanaka. 2010. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. *Environ.Health Perspect.* 118:103–107. doi:10.1289/ehp.0900930 [doi].
401. Ghosh, S. and J. Heffernan. 2010. Influenza pandemic waves under various mitigation strategies with 2009 H1N1 as a case study. *PLoS.One.* 5:e14307. doi:10.1371/journal.pone.0014307 [doi].
402. Giannattasio, A., V. A. Lo, M. T. Russo, M. R. Pirozzi, A. Barbarino, E. Ruberto, A. Campa, and A. Guarino. 2010. Pandemic flu: a comparative evaluation of clinical, laboratory, and radiographic findings in HIV-positive and negative children. *AIDS* 24:2292–2294. doi:10.1097/QAD.0b013e32833d2096 [doi].
403. Giannecchini, S., H. M. Wise, P. Digard, V. Clausi, P. E. Del, L. Vesco, S. Puzelli, I. Donatelli, and A. Azzi. 2011. Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. *Antiviral Res.* 92:64–72. doi:S0166-3542(11)00355-X [pii];10.1016/j.antiviral.2011.06.013 [doi].
404. Giesecke, J. 2010. Experiences of giving oseltamivir to school children during the 2009 influenza A(H1N1) pandemic. *Euro.Surveill* 15:ii/19570.
405. Gill, M. A., G. Bajwa, T. A. George, C. C. Dong, I. I. Dougherty, N. Jiang, V. N. Gan, and R. S. Gruchalla. 2010. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. *J.Immunol.* 184:5999–6006. doi:jimmunol.0901194 [pii];10.4049/jimmunol.0901194 [doi].
406. Ginocchio, C. C. 2011. Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens. *Clin.Infect.Dis.* 52 Suppl 4:S312–S325. doi:cir046 [pii];10.1093/cid/cir046 [doi].
407. Girard, M. P., J. S. Tam, O. M. Assossou, and M. P. Kiény. 2010. The 2009 A (H1N1) influenza virus pandemic: A review. *Vaccine* 28:4895–4902. doi:S0264-410X(10)00719-X [pii];10.1016/j.vaccine.2010.05.031 [doi].

408. Giraud, C., S. Manceau, M. Oualha, H. Chappuy, A. Mogenet, P. Duchene, S. Ducrocq, P. Hubert, and J. M. Treluyer . 2011. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. *Antimicrob.Agents Chemother.* 55:433–435. doi:AAC.00813-10 [pii];10.1128/AAC.00813-10 [doi].
409. Girmenia, C., C. Mercanti, V. Federico, M. Rea, V. A. De, V. Valle, A. Micozzi, R. Latagliata, M. Breccia, S. G. Morano, G. A. Brunetti, M. Sali, G. Delogu, R. Foa, G. Alimena, and G. Gentile. 2011. Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center. *Acta Haematol.* 126:1–7. doi:000323713 [pii];10.1159/000323713 [doi].
410. Glezen, W. P. 2010. Containing the novel influenza A (H1N1) virus. *Clin.Infect.Dis.* 50:869–870. doi:10.1086/650751 [doi].
411. Glikman, D., Z. Zonis, M. Hindiyeh, D. Ram, M. Mandelboim, E. Mendelson, and D. Engelhard. 2010. Development of oseltamivir resistance during oseltamivir therapy in a child with severe 2009 H1N1 influenza. *Pediatr.Infect.Dis.J.* 29:385–386. doi:10.1097/INF.0b013e3181cd9524 [doi];00006454-201004000-00030 [pii].
412. Goldfarb, I., B. Panda, B. Wylie, and L. Riley. 2011. Uptake of influenza vaccine in pregnant women during the 2009 H1N1 influenza pandemic. *Am.J.Obstet.Gynecol.* 204:S112–S115. doi:S0002-9378(11)00022-6 [pii];10.1016/j.ajog.2011.01.007 [doi].
413. Goldstein, E., A. Apolloni, B. Lewis, J. C. Miller, M. Macauley, S. Eubank, M. Lipsitch, and J. Wallinga. 2010. Distribution of vaccine/antivirals and the 'least spread line' in a stratified population. *J.R.Soc. Interface* 7:755–764. doi:rsif.2009.0393 [pii];10.1098/rsif.2009.0393 [doi].
414. Goldstein, E., B. J. Cowling, J. J. O'Hagan, L. Danon, V. J. Fang, A. Hagy, J. C. Miller, D. Reshef, J. Robins, P. Biedrzycki, and M. Lipsitch. 2010. Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. *BMC.Infect.Dis.* 10:211. doi:1471-2334-10-211 [pii];10.1186/1471-2334-10-211 [doi].
415. Goldstein, E., J. C. Miller, J. J. O'Hagan, and M. Lipsitch. 2010. Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic. *Influenza.Other Respi.Viruses.* 4:101–112. doi:IRV128 [pii];10.1111/j.1750-2659.2009.00128.x [doi].
416. Gomez-Lucia, E. and F. Rodriguez. 2010. Research paths to successful prevention and treatment of swine-derived H1N1 influenza virus infection. *Drug News Perspect.* 23:65–70. doi:1416985 [pii];10.1358/dnp.2010.23.1.1416985 [doi].
417. Goncalves, C., S. Perez, V. Osorio, M. Petrovic, M. F. Alpendurada, and D. Barcelo. 2011. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. *Environ.Sci. Technol.* 45:4307–4314. doi:10.1021/es1032629 [doi].
418. Gong, J. Z., Y. Liu, and W. F. Xu. 2009. Pharmacophore model of influenza neuraminidase inhibitors – a systematic review. *Pharmazie* 64:627–632.
419. Gong, T., Y. Jiang, Y. Wang, D. Yang, W. Li, Q. Zhang, W. Feng, B. Wang, Z. Jiang, and M. Li. 2010. Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry. *Arch. Virol.* 155:491–498. doi:10.1007/s00705-010-0608-1 [doi].
420. Gonzalez, R., F. Massoomi, and W. Neff. 2009. Emergency-use authorization of peramivir. *Am.J.Health Syst.Pharm.* 66:2162–2163. doi:66/24/2162 [pii];10.2146/ajhp090584 [doi].
421. Gonzalez-Canudas, J., J. M. Iglesias-Chiesa, Y. Romero-Antonio, C. Chavez-Cortes, J. G. Gay-Molina, and R. Rivas-Ruiz. 2011. [Cost-effectiveness in the detection of influenza H1N1: clinical data versus rapid tests]. *Rev.Panam.Salud Publica* 29:1–8. doi:S1020-49892011000100001 [pii].

422. Gonzalez-Parra, P. A., S. Lee, L. Velazquez, and C. Castillo-Chavez. 2011. A note on the use of optimal control on a discrete time model of influenza dynamics. *Math.Biosci.Eng* 8:183–197.
423. Gordon, C. L., K. Langan, P. G. Charles, R. Bellomo, G. K. Hart, J. Torresi, P. D. Johnson, and M. L. Grayson. 2011. Pooled human immunoglobulin therapy in critically ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. *Clin.Infect.Dis.* 52:422–426. doi:ciq082 [pii];10.1093/cid/ciq082 [doi].
424. Gordon, S. M. 2009. Update on 2009 pandemic influenza A (H1N1) virus. *Cleve.Clin.J.Med.* 76:577–582. doi:76/10/577 [pii];10.3949/ccjm.76a.05009 [doi].
425. Gotoh, K., Y. Tanaka, A. Nishikimi, R. Nakamura, H. Yamada, N. Maeda, T. Ishikawa, K. Hoshino, T. Uruno, Q. Cao, S. Higashi, Y. Kawaguchi, M. Enjoji, R. Takayanagi, T. Kaisho, Y. Yoshikai, and Y. Fukui. 2010. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. *J.Exp.Med.* 207:721–730. doi:jem.20091776 [pii];10.1084/jem.20091776 [doi].
426. Gou, Y. Z., B. Liu, W. Jiang, H. T. Yu, and X. F. Bai. 2010. The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study. *J.Int.Med.Res.* 38:2117–2125.
427. Govorkova, E. A., B. M. Marathe, A. Prevost, J. E. Rehg, and R. G. Webster. 2011. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. *Antiviral Res.* 91:81–88. doi:S0166-3542(11)00317-2 [pii];10.1016/j.antiviral.2011.05.008 [doi].
428. Govorkova, E. A., N. A. Ilyushina, B. M. Marathe, J. L. McClaren, and R. G. Webster. 2010. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. *J.Virol.* 84:8042–8050. doi:JVI.00689-10 [pii];10.1128/JVI.00689-10 [doi].
429. Govorkova, E. A., N. A. Ilyushina, B. M. Marathe, J. L. McClaren, and R. G. Webster. 2011. Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. *Influenza.Other Respi.Viruses.* 5 Suppl 1:90–93.
430. Gowdy, K. M., Q. T. Krantz, C. King, E. Boykin, I. Jaspers, W. P. Linak, and M. I. Gilmour. 2010. Role of oxidative stress on diesel-enhanced influenza infection in mice. *Part Fibre.Toxicol.* 7:34. doi:1743-8977-7-34 [pii];10.1186/1743-8977-7-34 [doi].
431. Graef, K. M., F. T. Vreede, Y. F. Lau, A. W. McCall, S. M. Carr, K. Subbarao, and E. Fodor. 2010. The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon. *J.Virol.* 84:8433–8445. doi:JVI.00879-10 [pii];10.1128/JVI.00879-10 [doi].
432. Graitcer, S. B., L. Gubareva, L. Kamimoto, S. Doshi, M. Vandermeer, J. Louie, C. Waters, Z. Moore, K. Sleeman, M. Okomo-Adhiambo, S. A. Marshall, G. K. St, C. Y. Pan, J. M. LaPlante, A. Klimov, and A. M. Fry. 2011. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. *Emerg.Infect.Dis.* 17:255–257. doi:10.3201/eid1702.101724 [doi].
433. Graiver, D. A., S. E. Saunders, C. L. Topliff, C. L. Kelling, and S. L. Bartelt-Hunt. 2010. Ethidium monoazide does not inhibit RT-PCR amplification of nonviable avian influenza RNA. *J.Virol.Methods* 164:51–54. doi:S0166-0934(09)00508-4 [pii];10.1016/j.jviromet.2009.11.024 [doi].
434. Grandea, A. G., III, O. A. Olsen, T. C. Cox, M. Renshaw, P. W. Hammond, P. Y. Chan-Hui, J. L. Mitcham, W. Cieplak, S. M. Stewart, M. L. Grantham, A. Pekosz, M. Kiso, K. Shinya, M. Hatta, Y. Kawaoka, and M. Moyle. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. *Proc.Natl.Acad.Sci.U.S.A* 107:12658–12663. doi:0911806107 [pii];10.1073/pnas.0911806107 [doi].

435. Gravenstein, S., A. Pop-Vicas, and A. Ambrozaitis. 2010. The 2009 A/H1N1 pandemic influenza and the nursing home. *Med.Health R.I.* 93:382–384.
436. Greatorex, J. S., R. F. Page, M. D. Curran, P. Digard, J. E. Enstone, T. Wreghitt, P. P. Powell, D. W. Sexton, R. Vivancos, and J. S. Nguyen-Van-Tam. 2010. Effectiveness of common household cleaning agents in reducing the viability of human influenza A/H1N1. *PLoS.One.* 5:e8987. doi:10.1371/journal.pone.0008987 [doi].
437. Greene, S. K., M. Kulldorff, J. Huang, R. J. Brand, K. P. Kleinman, J. Hsu, and R. Platt. 2011. Timely detection of localized excess influenza activity in Northern California across patient care, prescription, and laboratory data. *Stat.Med.* 30:549–559. doi:10.1002/sim.3883 [doi].
438. Greenwood, V. 2011. Curing the common cold. *Sci.Am.* 304:30–31.
439. Greer, L. G., J. S. Sheffield, V. L. Rogers, S. W. Roberts, D. D. McIntire, and G. D. Wendel, Jr. 2010. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. *Obstet.Gynecol.* 115:711–716. doi:10.1097/AOG.0b013e3181d44752 [doi];00006250-201004000-00007 [pii].
440. Greer, L. G., R. D. Leff, V. L. Rogers, S. W. Roberts, G. H. McCracken, Jr., G. D. Wendel, Jr., and J. S. Sheffield. 2011. Pharmacokinetics of oseltamivir according to trimester of pregnancy. *Am.J.Obstet. Gynecol.* 204:S89–S93. doi:S0002-9378(11)00314-0 [pii];10.1016/j.ajog.2011.03.005 [doi].
441. Greer, L. G., R. D. Leff, V. L. Rogers, S. W. Roberts, G. H. McCracken, Jr., G. D. Wendel, Jr., and J. S. Sheffield. 2011. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. *Am.J.Obstet. Gynecol.* 204:524. doi:S0002-9378(11)00149-9 [pii];10.1016/j.ajog.2011.01.056 [doi].
442. Grienke, U., M. Schmidtke, G. S. von, J. Kirchmair, K. R. Liedl, and J. M. Rollinger. 2011. Influenza neuraminidase: A druggable target for natural products. *Nat.Prod.Rep.* doi:10.1039/c1np00053e [doi].
443. Grienke, U., M. Schmidtke, J. Kirchmair, K. Pfarr, P. Wutzler, R. Durrwald, G. Wolber, K. R. Liedl, H. Stuppner, and J. M. Rollinger. 2010. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from *Alpinia katsumadai*. *J.Med.Chem.* 53:778–786. doi:10.1021/jm901440f [doi].
444. Griffiths, S. M., A. H. Wong, J. H. Kim, T. K. Yung, and J. T. Lau. 2010. Influence of country of study on student responsiveness to the H1N1 pandemic. *Public Health* 124:460–466. doi:S0033-3506(10)00116-2 [pii];10.1016/j.puhe.2010.03.027 [doi].
445. Gu, R. X., L. A. Liu, D. Q. Wei, J. G. Du, L. Liu, and H. Liu. 2011. Free energy calculations on the two drug binding sites in the M2 proton channel. *J.Am.Chem.Soc.* 133 :10817–10825. doi:10.1021/ja1114198 [doi].
446. Gubareva, L. V. and A. M. Fry. 2010. Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses. *J.Infect.Dis.* 201:656–658. doi:10.1086/650465 [doi].
447. Gubareva, L. V., A. A. Trujillo, M. Okomo-Adhiambo, V. P. Mishin, V. M. Deyde, K. Sleeman, H. T. Nguyen, T. G. Sheu, R. J. Garten, M. W. Shaw, A. M. Fry, and A. I. Klimov. 2010. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. *Antivir.Ther.* 15:1151–1159. doi:10.3851/IMP1678 [doi].
448. Guidot, D. M. 2010. A sigh of relief about treating influenza in individuals with alcohol-use disorders? *Alcohol Clin.Exp.Res.* 34:1432. doi:ACER1227 [pii];10.1111/j.1530-0277.2010.01227.x [doi].
449. Guo, H. and D. J. Topham. 2010. Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. *J.Virol.* 84:7750–7759. doi:JVI.00187-10 [pii];10.1128/JVI.00187-10 [doi].
450. Gupta, D. and V. K. Mootha. 2010. Neuraminidase inhibitors for influenza in healthy adults: what we don't know. *Natl.Med.J.India* 23:29–31.

451. Gupta, S. K., S. K. Gupta, S. Smita, M. Srivastava, X. Lai, U. Schmitz, Q. Rahman, O. Wolkenhauer, and J. Vera. 2011. Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains. *Infect.Genet.Evol.* 11:1072–1082. doi:S1567-1348(11)00099-2 [pii];10.1016/j.meegid.2011.03.018 [doi].
452. Gupta, Y. K. and B. M. Padhy. 2010. Issues in pharmacotherapy of 2009 H1N1 influenza infection. *J.Postgrad.Med.* 56:321–327. doi:jpgm\_2010\_56\_4\_321\_70945 [pii];10.4103/0022-3859.70945 [doi].
453. Haas, W. 2010. [Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?]. *MMW.Fortschr.Med.* 152:7.
454. Haasbach, E., E. K. Pauli, R. Spranger, D. Mitzner, U. Schubert, R. Kircheis, and O. Planz. 2011. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. *Antiviral Res.* 91:304–313. doi:S0166-3542(11)00373-1 [pii];10.1016/j.antiviral.2011.07.006 [doi].
455. Haasbach, E., K. Droebner, A. B. Vogel, and O. Planz. 2011. Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo. *J.Interferon Cytokine Res.* 31:515–525. doi:10.1089/jir.2010.0071 [doi].
456. Hagiwara, K., Y. Kondoh, A. Ueda, K. Yamada, H. Goto, T. Watanabe, T. Nakata, H. Osada, and Y. Aida. 2010. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. *Biochem.Biophys.Res.Commun.* 394:721–727. doi:S0006-291X(10)00496-1 [pii];10.1016/j.bbrc.2010.03.058 [doi].
457. Haidari, M., M. Ali, C. S. Ward, III, and M. Madjid. 2009. Pomegranate (*Punica granatum*) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir. *Phytomedicine.* 16:1127–1136. doi:S0944-7113(09)00165-2 [pii];10.1016/j.phymed.2009.06.002 [doi].
458. Haidari, M., W. Zhang, L. Ganjehei, M. Ali, and Z. Chen. 2011. Inhibition of MLC phosphorylation restricts replication of influenza virus – a mechanism of action for anti-influenza agents. *PLoS.One.* 6:e21444. doi:10.1371/journal.pone.0021444 [doi];PONE-D-11-04846 [pii].
459. Hajjibolbaghi, M., S. Jam, S. SeyedAlinaghi, S. Jafari, B. M. Badie, and D. Sabzvari. 2010. Adverse reactions of trivalent influenza vaccine in HIV-infected individuals. *Acta Med.Iran* 48:95–100.
460. Halasa, N. B. 2010. Update on the 2009 pandemic influenza A H1N1 in children. *Curr.Opin.Pediatr.* 22:83–87. doi:10.1097/MOP.0b013e3283350317 [doi];00008480-201002000-00015 [pii].
461. Haldar, J., C. L. Alvarez de, T. M. Tumpey, L. V. Gubareva, J. Chen, and A. M. Klibanov. 2010. Bifunctional polymeric inhibitors of human influenza A viruses. *Pharm.Res.* 27:259–263. doi:10.1007/s11095-009-0013-1 [doi].
462. Halder, N., J. K. Kelso, and G. J. Milne. 2010. Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic. *BMC.Public Health* 10:168. doi:1471-2458-10-168 [pii];10.1186/1471-2458-10-168 [doi].
463. Halder, N., J. K. Kelso, and G. J. Milne. 2010. Developing guidelines for school closure interventions to be used during a future influenza pandemic. *BMC.Infect.Dis.* 10 :221. doi:1471-2334-10-221 [pii];10.1186/1471-2334-10-221 [doi].
464. Hale, B. G., J. Steel, R. A. Medina, B. Manicassamy, J. Ye, D. Hickman, R. Hai, M. Schmolke, A. C. Lowen, D. R. Perez, and A. Garcia-Sastre. 2010. Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. *J.Virol.* 84:6909–6922. doi:JVI.00081-10 [pii];10.1128/JVI.00081-10 [doi].
465. Hale, B. G., R. A. Albrecht, and A. Garcia-Sastre. 2010. Innate immune evasion strategies of influenza viruses. *Future.Microbiol.* 5:23–41. doi:10.2217/fmb.09.108 [doi].



466. Haller, O., S. Gao, M. A. von der, O. Daumke, and G. Kochs. 2010. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. *J.Biol.Chem.* 285:28419–28424. doi:R110.145839 [pii];10.1074/jbc.R110.145839 [doi].
467. Hamelin, M. E., M. Baz, Y. Abed, C. Couture, P. Joubert, E. Beaulieu, N. Bellerose, M. Plante, C. Mallett, G. Schumer, G. P. Kobinger, and G. Boivin. 2010. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. *PLoS.Pathog.* 6:e1001015. doi:10.1371/journal.ppat.1001015 [doi].
468. Han, B., H. Yang, Q. L. Wang, W. Chen, C. W. Qian, and S. Xiong. 2011. [Purification of Cyanovirin-N with antiviral activity and preparation as well as modification of its polyclonal antibody]. *Xi.Bao.Yu Fen.Zi.Mian.Yi.Xue.Za Zhi.* 27:531–534.
469. Handel, A., I. M. Longini, Jr., and R. Antia. 2009. Intervention strategies for an influenza pandemic taking into account secondary bacterial infections. *Epidemics.* 1:185–195. doi:10.1016/j.epidem.2009.09.001 [doi].
470. Hanfling, D. and J. L. Hick. 2009. Hospitals and the novel H1N1 outbreak: the mouse that roared? *Disaster.Med.Public Health Prep.* 3 Suppl 2:S100–S106. doi:10.1097/DMP.0b013e3181bf2483 [doi].
471. Haroon, S. M., G. P. Barbosa, and P. J. Saunders. 2011. The determinants of health-seeking behaviour during the A/H1N1 influenza pandemic: an ecological study. *J.Public Health (Oxf)* 33:503–510. doi:fdr029 [pii];10.1093/pubmed/fdr029 [doi].
472. Harrington, J. E., Jr. and E. B. Hsu. 2010. Stockpiling anti-viral drugs for a pandemic: the role of Manufacturer Reserve Programs. *J.Health Econ.* 29:438–444. doi:S0167-6296(10)00019-6 [pii];10.1016/j.jhealeco.2010.02.004 [doi].
473. Harris, P. N., R. Dixit, F. Francis, P. G. Buettner, C. Leahy, B. Burgher, A. Egan, M. Proud, R. Jayalath, A. Grewal, and R. E. Norton. 2010. Pandemic influenza H1N1 2009 in north Queensland – risk factors for admission in a region with a large indigenous population. *Commun.Dis.Intell.* 34:102–109.
474. Harter, G., O. Zimmermann, L. Maier, A. Schubert, T. Mertens, P. Kern, and J. Wöhrle. 2010. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. *Clin.Infect.Dis.* 50:1249–1251. doi:10.1086/651604 [doi].
475. Hartley, D. M., N. P. Nelson, and E. N. Perencevich. 2009. Antiviral drugs for treatment of patients infected with pandemic (H1N1) 2009 virus. *Emerg.Infect.Dis.* 15:1851–1852. doi:10.3201/eid1511.090720 [doi].
476. Harvala, H., R. Gunson, P. Simmonds, A. Hardie, S. Bennett, F. Scott, H. Roddie, J. McKnight, T. Walsh, D. Rowney, A. Clark, J. Bremner, C. Aitken, and K. Templeton. 2010. The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November–December, 2009. *Euro.Surveill* 15.
477. Hasegawa, M., T. Okada, H. Sakata, E. Nakayama, T. Fuchigami, Y. Inamo, H. Mugishima, T. Tajima, S. Iwata, M. Morozumi, K. Ubukata, H. Watanabe, and T. Takahashi. 2011. Pandemic (H1N1) 2009-associated pneumonia in children, Japan. *Emerg.Infect.Dis.* 17:279–282. doi:10.3201/eid1702.091904 [doi].
478. Hasegawa, S., R. Hirano, K. Hashimoto, Y. Haneda, K. Shirabe, and T. Ichiyama. 2011. Characteristics of atopic children with pandemic H1N1 influenza viral infection: pandemic H1N1 influenza reveals 'occult' asthma of childhood. *Pediatr.Allergy Immunol.* 22:e119–e123. doi:10.1111/j.1399-3038.2010.01090.x [doi].
479. Hashem, A. M., A. S. Flaman, A. Farnsworth, E. G. Brown, D. G. Van, R. He, and X. Li. 2009. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. *PLoS.One.* 4:e8350. doi:10.1371/journal.pone.0008350 [doi].

480. Hassantoufighi, A., H. Zhang, M. Sandbulte, J. Gao, J. Manischewitz, L. King, H. Golding, T. M. Straight, and M. C. Eichelberger. 2010. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. *Vaccine* 28:790–797. doi:S0264-410X(09)01596-5 [pii];10.1016/j.vaccine.2009.10.066 [doi].
481. Hata, M., S. Tanaka, Y. Yasui, N. Fujiwara, S. Kobayashi, and H. Minagawa. 2010. Rapid genotypic assay for detection of oseltamivir-resistant influenza A (H1N1) viruses. *J.Clin.Microbiol.* 48:1983–1984. doi:JCM.01862-09 [pii];10.1128/JCM.01862-09 [doi].
482. Hatakeyama, S. 2010. [Drug-resistant influenza viruses: an overview]. *Nihon Rinsho* 68:1671–1678.
483. Hatori, A., J. Yui, K. Yanamoto, T. Yamasaki, K. Kawamura, M. Takei, T. Arai, T. Fukumura, and M. R. Zhang. 2011. Determination of radioactivity in infant, juvenile and adult rat brains after injection of anti-influenza drug [(1)(1)C]oseltamivir using PET and autoradiography. *Neurosci.Lett.* 495:187–191. doi:S0304-3940(11)00359-4 [pii];10.1016/j.neulet.2011.03.055 [doi].
484. Hatta, Y., K. Hershberger, K. Shinya, S. C. Proll, R. R. Dubielzig, M. Hatta, M. G. Katze, Y. Kawaoka, and M. Suresh. 2010. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. *PLoS.Pathog.* 6:e1001139. doi:10.1371/journal.ppat.1001139 [doi].
485. Haura, L., B. Warachit, J. Makkoch, and Y. Poovorawan. 2009. Hemoptysis in children with pandemic influenza H1N1 2009 infection. *Southeast Asian J.Trop.Med.Public Health* 40:1259–1263.
486. Hawkes, M., S. Schuh, M. Ipp, A. Bitnun, S. E. Richardson, P. C. Parkin, D. Stephens, and D. Tran. 2011. Natural history of pandemic H1N1 2009 influenza infection in healthy pediatric outpatients. *Acad.Pediatr.* 11:66–74. doi:S1876-2859(10)00355-4 [pii];10.1016/j.acap.2010.12.010 [doi].
487. Hayakawa, T., A. Morimoto, Y. Nozaki, Y. Kashii, T. Aihara, K. Maeda, and M. Y. Momoi. 2011. Mesenteric venous thrombosis in a child with type 2 protein S deficiency. *J.Pediatr.Hematol.Oncol.* 33:141–143. doi:10.1097/MPH.0b013e3181fce4d4 [doi].
488. Hayashi, J., M. Murata, N. Furusyo, T. Hoshina, and N. Shimono. 2010. [Measures taken by a university hospital for the prevention and control of the 2009 H1N1 influenza]. *Nihon Rinsho* 68:1707–1712.
489. Hayashi, K., K. Narutaki, Y. Nagaoka, T. Hayashi, and S. Uesato. 2010. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. *Biol.Pharm.Bull.* 33:1199–1205. doi:JST.JSTAGE/bpb/33.1199 [pii].
490. Hayden, F. G. and M. D. de Jong. 2011. Emerging influenza antiviral resistance threats. *J.Infect.Dis.* 203:6–10. doi:jiq012 [pii];10.1093/infdis/jiq012 [doi].
491. Hayward, A. 2009. Influenza A (H1N1) pandemic: true or false alarm. *J.Epidemiol.Community Health* 63:775–776. doi:63/10/775 [pii];10.1136/jech.2009.096628 [doi].
492. Hayward, A. 2010. Does treatment with oseltamivir prevent transmission of influenza to household contacts? *Clin.Infect.Dis.* 50:715–716. doi:10.1086/650459 [doi].
493. He, F., Q. Liu, Y. Liu, J. Zhou, Z. Gao, H. Xiao, and Z. Yang. 2011. [Antiviral activity of Ouyi antipyretic detoxicate soft capsule against influenza a virus H1N1 in vitro]. *Zhongguo Zhong.Yao Za Zhi.* 36:1993–1996.
494. He, J. J., S. Yan, M. Zhang, W. L. Wang, and S. S. Zheng. 2010. Novel H1N1 influenza A virus infection in a patient with acute rejection after liver transplantation. *Hepatobiliary.Pancreat.Dis.Int.* 9:658–660. doi:1429 [pii].
495. He, W. Y., R. M. Gao, X. Q. Li, J. D. Jiang, and Y. H. Li. 2010. [In vitro anti-influenza virus activity of 10 traditional Chinese medicines]. *Yao Xue.Xue.Bao.* 45:395–398.

496. He, Z., G. Wu, L. Ouyang, Y. Lu, and P. Pi. 2010. [Healing of pregnant patient with severe H1N1 and literature review]. *Zhong.Nan.Da.Xue.Xue.Bao.Yi.Xue.Ban.* 35:534–536. doi:10.3969/j.issn.1672-7347.2010.05.021 [doi].
497. Hedlund, M., L. M. Aschenbrenner, K. Jensen, J. L. Larson, and F. Fang. 2010. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. *J.Infect.Dis.* 201:1007–1015. doi:10.1086/651170 [doi].
498. Heinonen, S., H. Silvennoinen, P. Lehtinen, R. Vainionpaa, and T. Heikkinen. 2011. Feasibility of diagnosing influenza within 24 hours of symptom onset in children 1–3 years of age. *Eur.J.Clin.Microbiol.Infect.Dis.* 30:387–392. doi:10.1007/s10096-010-1098-5 [doi].
499. Heinonen, S., H. Silvennoinen, P. Lehtinen, R. Vainionpaa, T. Vahlberg, T. Ziegler, N. Ikonen, T. Puhakka, and T. Heikkinen. 2010. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. *Clin.Infect.Dis.* 51:887–894. doi:10.1086/656408 [doi].
500. Helfenberger, S., A. Tschopp, L. Robyn, C. Hatz, and P. Schlagenhauf. 2010. Knowledge, attitudes, and practices of business travelers regarding influenza and the use of antiviral medication. *J.Travel.Med.* 17:367–373. doi:10.1111/j.1708-8305.2010.00467.x [doi].
501. Hensley, S. E., S. R. Das, J. S. Gibbs, A. L. Bailey, L. M. Schmidt, J. R. Bennink, and J. W. Yewdell. 2011. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. *PLoS.One.* 6:e15190. doi:10.1371/journal.pone.0015190 [doi].
502. Hernan, M. A. and M. Lipsitch. 2011. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. *Clin.Infect.Dis.* 53:277–279. doi:cir400 [pii];10.1093/cid/cir400 [doi].
503. Hernandez, J. E., J. Grainger, L. Simonsen, P. Collis, L. Edelman, and W. P. Sheridan. 2011. Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment. *Influenza.Other Respi.Viruses.* doi:10.1111/j.1750-2659.2011.00303.x [doi].
504. Hernandez, J. E., R. Adiga, R. Armstrong, J. Bazan, H. Bonilla, J. Bradley, R. Dretler, M. G. Ison, J. E. Mangino, S. Maroushek, A. K. Shetty, A. Wald, C. Ziebold, J. Elder, A. S. Hollister, and W. Sheridan. 2011. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. *Clin.Infect.Dis.* 52:695–706. doi:cir001 [pii];10.1093/cid/cir001 [doi].
505. Hernandez, J. M., V. Lopez-Rodas, and E. Costas. 2010. Antiviral agents: to treat or not to treat? An old dilemma revisited in light of new data from the 2009 influenza A(H1N1) pandemic. *J.Clin.Virol.* 49:145–146. doi:S1386-6532(10)00268-4 [pii];10.1016/j.jcv.2010.07.001 [doi].
506. Herrmann, M. 2009. [Acute infections of the upper airways]. *MMW.Fortschr.Med.* 151:26–29.
507. Hersh, A. L. and R. S. Stafford. 2011. Antiviral prescribing by office-based physicians during the 2009 H1N1 pandemic. *Ann.Intern.Med.* 154:74–76. doi:154/1/74 [pii];10.1059/0003-4819-154-1-201101040-00019 [doi].
508. Hersh, A. L., J. C. Herigon, K. Ampofo, A. T. Pavia, and J. G. Newland. 2011. Rapid increase in use of antiviral therapy for hospitalized children with influenza during the 2009 H1N1 epidemic. *Pediatr.Infect.Dis.J.* 30:895–897. doi:10.1097/INF.0b013e3182214e28 [doi].
509. Hewagama, S., S. P. Walker, R. L. Stuart, C. Gordon, P. D. Johnson, N. D. Friedman, M. O'Reilly, A. C. Cheng, and M. L. Giles. 2010. 2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. *Clin.Infect.Dis.* 50:686–690. doi:10.1086/650460 [doi].
510. Hiba, V., M. Chowers, I. Levi-Vinograd, B. Rubinovitch, L. Leibovici, and M. Paul. 2011. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. *J.Antimicrob.Chemother.* 66:1150–1155. doi:dkr089 [pii];10.1093/jac/dkr089 [doi].

511. Hien, T. T., M. F. Boni, J. E. Bryant, T. T. Ngan, M. Wolbers, T. D. Nguyen, N. T. Truong, N. T. Dung, d. Q. Ha, V. M. Hien, T. T. Thanh, N. T. Nhu le, T. T. Uyen le, P. T. Nhien, N. T. Chinh, N. V. Chau, J. Farrar, and H. R. van Doorn. 2010. Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis. *PLoS.Med.* 7:e1000277. doi:10.1371/journal.pmed.1000277 [doi].
512. Higuera Iglesias, A. L., K. Kudo, T. Manabe, A. E. Corcho Berdugo, B. A. Corrales, R. L. Alfaro, G. R. Guevara, M. E. Manjarrez Zavala, J. Takasaki, S. Izumi, E. Bautista, and J. R. Perez Padilla. 2011. Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico. *PLoS.One.* 6:e21838. doi:10.1371/journal.pone.0021838 [doi];PONE-D-11-01654 [pii].
513. Hillaire, M. L., E. M. van, S. E. van Trierum, R. D. van, X. Saelens, R. A. Romijn, W. Hemrika, R. A. Fouchier, T. Kuiken, A. D. Osterhaus, H. P. Haagsman, and G. F. Rimmelzwaan. 2011. Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro. *PLoS. One.* 6:e25005. doi:10.1371/journal.pone.0025005 [doi];PONE-D-11-08565 [pii].
514. Hill-Cawthorne, G. A., S. Schelenz, M. Lawes, and S. Dervisevic. 2010. Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. *Emerg.Infect.Dis.* 16:1185–1186. doi:10.3201/eid1607.091579 [doi].
515. Hindiyeh, M., D. Ram, M. Mandelboim, T. Meningher, S. Hirsh, J. Robinov, V. Levy, S. Orzitzer, R. Azar, Z. Grossman, and E. Mendelson. 2010. Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR. *J.Clin. Microbiol.* 48:1884–1887. doi:JCM.02540-09 [pii];10.1128/JCM.02540-09 [doi].
516. Hirotsu, N., A. Takahashi, Y. Hatori, and K. Miyakawa. 2010. [How have we understood and responded clinically to pandemic H1N1 2009?]. *Nihon Rinsho* 68:1713–1717.
517. Hitaoka, S., M. Harada, T. Yoshida, and H. Chuman. 2010. Correlation analyses on binding affinity of sialic acid analogues with influenza virus neuraminidase-1 using ab initio MO calculations on their complex structures. *J.Chem.Inf.Model.* 50:1796–1805. doi:10.1021/ci100225b [doi].
518. Ho, L. N., J. P. Chung, and K. L. Choy. 2010. Oseltamivir-induced mania in a patient with H1N1. *Am.J.Psychiatry* 167:350. doi:167/3/350 [pii];10.1176/appi.ajp.2009.09101421 [doi].
519. Hoffmann, G., C. Funk, S. Fowler, M. B. Otteneder, A. Breidenbach, C. R. Rayner, T. Chu, and E. P. Prinssen. 2009. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. *Antimicrob.Agents Chemother.* 53:4753–4761. doi:AAC.01541-08 [pii];10.1128/AAC.01541-08 [doi].
520. Hoffmann, H. H., A. Kunz, V. A. Simon, P. Palese, and M. L. Shaw. 2011. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. *Proc.Natl.Acad.Sci.U.S.A* 108:5777–5782. doi:1101143108 [pii];10.1073/pnas.1101143108 [doi].
521. Holder, B. P., L. E. Liao, P. Simon, G. Boivin, and C. A. Beauchemin. 2011. Design considerations in building in silico equivalents of common experimental influenza virus assays. *Autoimmunity* 44:282–293. doi:10.3109/08916934.2011.523267 [doi].
522. Holder, B. P., P. Simon, L. E. Liao, Y. Abed, X. Bouhy, C. A. Beauchemin, and G. Boivin. 2011. Assessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model. *PLoS.One.* 6:e14767. doi:10.1371/journal.pone.0014767 [doi].
523. Hollingsworth, T. D., D. Klinkenberg, H. Heesterbeek, and R. M. Anderson. 2011. Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives. *PLoS.Comput.Biol.* 7:e1001076. doi:10.1371/journal.pcbi.1001076 [doi].
524. Hollister, A. S. and W. P. Sheridan. 2011. The emergency use authorization of peramivir IV: a view from the manufacturer. *Clin.Pharmacol.Ther.* 89:172–174. doi:clpt2010278 [pii];10.1038/clpt.2010.278 [doi].

525. Holmes, E. C. 2010. Virology. Helping the resistance. *Science* 328:1243–1244. doi:328/5983/1243 [pii];10.1126/science.1190994 [doi].
526. Holzgrabe, U. 2011. [How safe was oseltamivir care in the flu pandemic?]. *Pharm.Unserer Zeit* 40:151–154.
527. Holzgrabe, U., M. Schlitzer, and T. Steinmetzer. 2011. [Pharmazie in unserer Zeit 2/2011]. *Pharm. Unserer Zeit* 40:95. doi:10.1002/pauz.201190011 [doi].
528. Homsí, S., N. Milojkovic, and Y. Homsí. 2010. Clinical pathological characteristics and management of acute respiratory distress syndrome resulting from influenza A (H1N1) virus. *South.Med.J.* 103:786–790. doi:10.1097/SMJ.0b013e3181e6ca0c [doi].
529. Hong-Geller, E. and S. N. Micheva-Viteva. 2010. Functional gene discovery using RNA interference-based genomic screens to combat pathogen infection. *Curr.Drug Discov.Technol.* 7:86–94. doi:ABSTRACT # 18 [pii].
530. Hooff, G. P., R. J. Meesters, J. J. van Kampen, N. A. van Huizen, B. Koch, A. F. Al Hadithy, G. T. van, A. D. Osterhaus, R. A. Gruters, and T. M. Luider. 2011. Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate – a validated assay for the clinic. *Anal.Bioanal.Chem.* 400:3473–3479. doi:10.1007/s00216-011-5050-z [doi].
531. Hossain, M. J., S. Perez, Z. Guo, L. M. Chen, and R. O. Donis. 2010. Establishment and characterization of a Madin-Darby canine kidney reporter cell line for influenza A virus assays. *J.Clin. Microbiol.* 48:2515–2523. doi:JCM.02286-09 [pii];10.1128/JCM.02286-09 [doi].
532. Howard, W. A., M. Peiris, and F. G. Hayden. 2011. Report of the ‘mechanisms of lung injury and immunomodulator interventions in influenza’ workshop, 21 March 2010, Ventura, California, USA. *Influenza.Other Respi.Viruses.* 5:453–475. doi:10.1111/j.1750-2659.2011.00278.x [doi].
533. Hsieh, Y. H., K. F. Chen, C. A. Gaydos, R. E. Rothman, and G. D. Kelen. 2010. Antiviral prescriptions to U.S. ambulatory care visits with a diagnosis of influenza before and after high level of adamantane resistance 2005–06 season. *PLoS.One.* 5:e8945. doi:10.1371/journal.pone.0008945 [doi].
534. Hsu, A. C., I. Barr, P. M. Hansbro, and P. A. Wark. 2011. Human influenza is more effective than avian influenza at antiviral suppression in airway cells. *Am.J.Respir.Cell Mol.Biol.* 44:906–913. doi:2010-01570C [pii];10.1165/rcmb.2010-01570C [doi].
535. Hsu J., Santesso N., Mustafa R., Brozek J., Chen Y. L., Hopkins J. P., Cheung A., Hovhannisyán G., Ivanova L., Flottorp S. A., Saeterdal I, Wong A. D., Tian J., Uyeki T. M., Akl E. A., Alonso-Coello P., Smáill F., Schünemann H. J. Antivirals for Treatment of Influenza: A Systematic Review and Meta-analysis of Observational Studies. *Ann Intern Med.* 2012 Apr 3;156(7):512–24 [doi].
536. Hu, F., W. Luo, S. D. Cady, and M. Hong. 2011. Conformational plasticity of the influenza A M2 transmembrane helix in lipid bilayers under varying pH, drug binding, and membrane thickness. *Biochim.Biophys.Acta* 1808:415–423. doi:S0005-2736(10)00329-9 [pii];10.1016/j.bbamem.2010.09.014 [doi].
537. Hu, W., S. Zeng, C. Li, Y. Jie, Z. Li, and L. Chen. 2010. Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. *J.Med.Chem.* 53:3831–3834. doi:10.1021/jm901664a [doi].
538. Huang, Y. C., W. C. Li, K. C. Tsao, C. G. Huang, C. H. Chiu, and T. Y. Lin. 2009. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. *Pediatr.Infect.Dis.J.* 28:647–648. doi:10.1097/INF.0b013e3181986bf9 [doi].
539. Hufford, M. M., T. S. Kim, J. Sun, and T. J. Braciale. 2011. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. *J.Exp.Med.* 208:167–180. doi:jem.20101850 [pii];10.1084/jem.20101850 [doi].

540. Hui, D. S., N. Lee, and P. K. Chan. 2010. Clinical management of pandemic 2009 influenza A(H1N1) infection. *Chest* 137:916–925. doi:chest.09-2344 [pii];10.1378/chest.09-2344 [doi].
541. Hultberg, A., N. J. Temperton, V. Rosseels, M. Koenders, M. Gonzalez-Pajuelo, B. Schepens, L. I. Ibanez, P. Vanlandschoot, J. Schillemans, M. Saunders, R. A. Weiss, X. Saelens, J. A. Melerio, C. T. Verrips, G. S. Van, and H. J. de Haard. 2011. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. *PLoS.One.* 6:e17665. doi:10.1371/journal.pone.0017665 [doi].
542. Hupert, N., W. Xiong, K. King, M. Castorena, C. Hawkins, C. Wu, and J. A. Muckstadt. 2009. Uncertainty and operational considerations in mass prophylaxis workforce planning. *Disaster.Med. Public Health Prep.* 3 Suppl 2:S121–S131. doi:10.1097/DMP.0b013e3181be9c39 [doi].
543. Hurt, A. C., J. K. Holien, M. W. Parker, and I. G. Barr. 2009. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. *Drugs* 69:2523–2531. doi:1 [pii];10.2165/11531450-000000000-00000 [doi].
544. Hurt, A. C., Nor'e SS, J. M. McCaw, H. R. Fryer, J. Mosse, A. R. McLean, and I. G. Barr. 2010. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. *J.Virol.* 84:9427–9438. doi:JVI.00373-10 [pii];10.1128/JVI.00373-10 [doi].
545. Hurt, A. C., S. Lowther, D. Middleton, and I. G. Barr. 2010. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. *Antiviral Res.* 87:361–366. doi:S0166-3542(10)00642-X [pii];10.1016/j.antiviral.2010.06.009 [doi].
546. Hurt, A. C., Y. M. Deng, J. Ernest, N. Caldwell, L. Leang, P. Iannello, N. Komadina, R. Shaw, D. Smith, D. E. Dwyer, A. R. Tramontana, R. T. Lin, K. Freeman, A. Kelso, and I. G. Barr. 2011. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. *Euro.Surveill* 16.
547. Iatsyshina, S. B., A. N. Minenko, T. E. Kushakova, M. N. Praded, A. V. Kudriavtseva, G. A. Shipulin, V. V. Maleev, and V. I. Pokrovskii. 2010. [Pandemic influenza A/H1N1 (sw2009) in Russia: epidemiology, diagnosis, clinical picture, and treatment]. *Ter.Arkh.* 82:10–14.
548. Ibanez, L. I., F. M. De, A. Hultberg, T. Verrips, N. Temperton, R. A. Weiss, W. Vandeveld, B. Schepens, P. Vanlandschoot, and X. Saelens. 2011. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. *J.Infect.Dis.* 203:1063–1072. doi:jjq168 [pii];10.1093/infdis/jiq168 [doi].
549. Ichiyama, T. 2010. Acute encephalopathy/encephalitis in childhood: a relatively common and potentially devastating clinical syndrome. *Brain Dev.* 32:433–434. doi:S0387-7604(10)00027-6 [pii];10.1016/j.braindev.2010.01.006 [doi].
550. Ilyushina, N. A., J. P. Seiler, J. E. Rehg, R. G. Webster, and E. A. Govorkova. 2010. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. *PLoS.Pathog.* 6:e1000933. doi:10.1371/journal.ppat.1000933 [doi].
551. Imai, H., K. Shinya, R. Takano, M. Kiso, Y. Muramoto, S. Sakabe, S. Murakami, M. Ito, S. Yamada, M. T. Le, C. A. Nidom, Y. Sakai-Tagawa, K. Takahashi, Y. Omori, T. Noda, M. Shimajima, S. Kakugawa, H. Goto, K. Iwatsuki-Horimoto, T. Horimoto, and Y. Kawaoka. 2010. The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. *PLoS.Pathog.* 6:e1001106. doi:10.1371/journal.ppat.1001106 [doi].
552. InFACT Global H1N1 Collaboration. InFACT: a global critical care research response to H1N1. *Lancet* Volume 375, Issue 9708, 2–8 January 2010, Pages 11–13 [doi].
553. Inoue, M., T. Barkham, Y. S. Leo, K. P. Chan, A. Chow, C. W. Wong, L. R. Tze Chuen, S. Maurer-Stroh, R. Lin, and C. Lin. 2010. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. *Emerg.Infect.Dis.* 16:1633–1636. doi:10.3201/eid1610.100688 [doi].

554. Intharathep, P., T. Rungrotmongkol, P. Decha, N. Nunthaboot, N. Kaiyawet, T. Kerdcharoen, P. Sompornpisut, and S. Hannongbua. 2011. Evaluating how rimantadines control the proton gating of the influenza A M2-proton port via allosteric binding outside of the M2-channel: MD simulations. *J.Enzyme Inhib.Med.Chem.* 26:162–168. doi:10.3109/14756366.2010.482530 [doi].
555. Inusa, B., M. Zuckerman, N. Gadong, M. Afif, S. Arnott, P. Heath, G. Marais, P. Robertson, H. Payne, O. Wilkey, and D. C. Rees. 2010. Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. *Blood* 115:2329–2330. doi:115/11/2329 [pii];10.1182/blood-2009-12-260836 [doi].
556. Isaacs, D. 2010. Lessons from the swine flu: pandemic, panic and/or pandemonium? *J.Paediatr.Child Health* 46:623–626.
557. Ishikawa, H., K. Tanaka, E. Kutsukake, T. Fukui, H. Sasaki, A. Hata, S. Noda, and T. Matsumoto. 2010. IFN-gamma production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells. *Virology* 407:325–332. doi:S0042-6822(10)00560-X [pii];10.1016/j.virol.2010.08.030 [doi].
558. Ishikawa, H., T. Suzuki, H. Orita, T. Uchimar, and Y. Hayashi. 2010. High-yielding synthesis of the anti-influenza neuraminidase inhibitor (-)-oseltamivir by two “one-pot” sequences. *Chemistry*. 16:12616–12626. doi:10.1002/chem.201001108 [doi].
559. Ishizuka, H., S. Yoshiba, H. Okabe, and K. Yoshihara. 2010. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. *J.Clin.Pharmacol.* 50:1319–1329. doi:0091270009356297 [pii];10.1177/0091270009356297 [doi].
560. Iskander, M., A. Kesson, D. Dwyer, L. Rost, M. Pym, H. Wang, M. McCaskill, and R. Booy. 2009. The burden of influenza in children under 5 years admitted to the Children’s Hospital at Westmead in the winter of 2006. *J.Paediatr.Child Health* 45:698–703. doi:JPC1597 [pii];10.1111/j.1440-1754.2009.01597.x [doi].
561. Ison, M. G. 2010. Epidemiology, Prevention, and Management of Influenza in Patients with Hematologic Malignancy. *Infect.Disord.Drug Targets*. doi:BSP/ ID DT /E-Pub/-0038-10-5 [pii].
562. Ison, M. G. 2010. Influenza, including the novel H1N1, in organ transplant patients. *Curr.Opin.Infect. Dis.* 23:365–373. doi:10.1097/QCO.0b013e32833bc1c3 [doi].
563. Ison, M. G. 2011. Epidemiology, prevention, and management of influenza in patients with hematologic malignancy. *Infect.Disord.Drug Targets*. 11:34–39. doi:BSP/ ID DT /E-Pub/-0038-10-5 [pii].
564. Ison, M. G. and H. H. Hirsch. 2010. Influenza: a recurrent challenge to transplantation. *Transpl.Infect. Dis.* 12:95–97. doi:TID501 [pii];10.1111/j.1399-3062.2010.00501.x [doi].
565. Ison, M. G. and N. Lee. 2010. Influenza 2010–2011: lessons from the 2009 pandemic. *Cleve. Clin.J.Med.* 77:812–820. doi:77/11/812 [pii];10.3949/ccjm.77a.10135 [doi].
566. Ison, M. G., M. D. de Jong, K. J. Gilligan, E. S. Higgs, A. T. Pavia, J. Pierson, and F. G. Hayden. 2010. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. *J.Infect.Dis.* 201:1654–1662. doi:10.1086/652498 [doi].
567. Iten, A., L. Kaiser, and D. Lew . 2010. [Influenza A (H1N1) and antibiotic resistance in constant progress]. *Rev.Med.Suisse* 6:114–119.
568. Iwai, A., T. Shiozaki, T. Kawai, S. Akira, Y. Kawaoka, A. Takada, H. Kida, and T. Miyazaki. 2010. Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1. *J.Biol.Chem.* 285:32064–32074. doi:M110.112458 [pii];10.1074/jbc.M110.112458 [doi].

569. Iwai, Y., H. Takahashi, D. Hatakeyama, K. Motoshima, M. Ishikawa, K. Sugita, Y. Hashimoto, Y. Harada, S. Itamura, T. Odagiri, M. Tashiro, Y. Sei, K. Yamaguchi, and T. Kuzuhara. 2010. Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. *Bioorg.Med.Chem.* 18:5379–5390. doi:S0968-0896(10)00454-2 [pii];10.1016/j.bmc.2010.05.035 [doi].
570. Izumo, T., T. Maekawa, M. Ida, A. Noguchi, Y. Kitagawa, H. Shibata, H. Yasui, and Y. Kiso. 2010. Effect of intranasal administration of *Lactobacillus pentosus* S-PT84 on influenza virus infection in mice. *Int.Immunopharmacol.* 10:1101–1106. doi:S1567-5769(10)00199-2 [pii];10.1016/j.intimp.2010.06.012 [doi].
571. Jablonski, J. J., D. Basu, D. A. Engel, and H. M. Geysen. 2011. Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1. *Bioorg.Med.Chem.* doi:S0968-0896(11)00834-0 [pii];10.1016/j.bmc.2011.10.026 [doi].
572. Jackson, R. J., K. L. Cooper, P. Tappenden, A. Rees, E. L. Simpson, R. C. Read, and K. G. Nicholson. 2011. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. *J.Infect.* 62:14–25. doi:S0163-4453(10)00301-4 [pii];10.1016/j.jinf.2010.10.003 [doi].
573. Jagannath, V. A., G. V. Asokan, Z. Fedorowicz, J. S. Singaram, and T. W. Lee. 2010. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. *Cochrane.Database.Syst.Rev.* CD008139. doi:10.1002/14651858.CD008139.pub2 [doi].
574. Jain, S. and A. M. Fry. 2011. Peramivir: another tool for influenza treatment? *Clin.Infect.Dis.* 52:707–709. doi:cir010 [pii];10.1093/cid/cir010 [doi].
575. Jamali, A., F. Sabahi, T. Bamdad, H. Hashemi, F. Mahboudi, and M. T. Kheiri. 2010. A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. *Clin.Vaccine Immunol.* 17:683–687. doi:CVI.00445-09 [pii];10.1128/CVI.00445-09 [doi].
576. Jameson, J. M., J. Cruz, A. Costanzo, M. Terajima, and F. A. Ennis. 2010. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. *Cell Immunol.* 264:71–77. doi:S0008-8749(10)00121-8 [pii];10.1016/j.cellimm.2010.04.013 [doi].
577. Jamieson, B., R. Jain, B. Carleton, and R. D. Goldman. 2009. Use of oseltamivir in children. *Can.Fam.Physician* 55:1199–1201. doi:55/12/1199 [pii].
578. Jamil, B. and S. F. Mahmood. 2010. H1N1 2009 in Karachi: a situational analysis. *J.Pak.Med.Assoc.* 60:250–252.
579. Janies, D. A., I. O. Voronkin, J. Studer, J. Hardman, B. B. Alexandrov, T. W. Treseder, and C. Valson. 2010. Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages. *Int.J.Health Geogr.* 9:13. doi:1476-072X-9-13 [pii];10.1186/1476-072X-9-13 [doi].
580. Jarhult, J. D., S. Muradrasoli, J. Wahlgren, H. Soderstrom, G. Orozovic, G. Gunnarsson, C. Brojer, N. Latorre-Margalef, J. Fick, R. Grabic, J. Lennerstrand, J. Waldenstrom, A. Lundkvist, and B. Olsen. 2011. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. *PLoS.One.* 6:e24742. doi:10.1371/journal.pone.0024742 [doi];PONE-D-11-12170 [pii].
581. Jefferson, T., M. C. Del, L. Dooley, E. Ferroni, L. A. Al-Ansary, G. A. Bawazeer, M. L. van Driel, S. Nair, R. Foxlee, and A. Rivetti. 2010. Physical interventions to interrupt or reduce the spread of respiratory viruses: a Cochrane review. *Health Technol.Assess.* 14:347–476.
582. Jefferson, T., M. Jones, P. Doshi, M. C. Del, L. Dooley, and R. Foxlee. 2010. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane.Database.Syst.Rev.* CD001265. doi:10.1002/14651858.CD001265.pub3 [doi].



583. Jefferson, T., M. Jones, P. Doshi, M. C. Del, L. Dooley, and R. Foxlee. 2010. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review. *Health Technol.Assess.* 14:355–458.
584. Jefferson, T., P. Doshi, M. Thompson, and C. Heneghan. 2011. Ensuring safe and effective drugs: who can do what it takes? *BMJ* 342:c7258.
585. Jelenkovic, A. 2010. [Counterfeit drugs and other products and substances: review of drugs for influenza prevention and treatment including pandemic influenza a (H1N1) 2009]. *Vojnosanit.Pregl.* 67:501–506.
586. Jensen, R., I. K. Severinsen, K. Terp, Y. Boyko, L. P. Nielsen, and M. Storgaard. 2010. [Influenza A H1N1v treated with extracorporeal membrane oxygenation]. *Ugeskr.Laeger* 172:2311–2312. doi:VP09090450 [pii].
587. Jeong, H. J., Y. B. Ryu, S. J. Park, J. H. Kim, H. J. Kwon, J. H. Kim, K. H. Park, M. C. Rho, and W. S. Lee. 2009. Neuraminidase inhibitory activities of flavonols isolated from *Rhodiola rosea* roots and their in vitro anti-influenza viral activities. *Bioorg.Med.Chem.* 17:6816–6823. doi:S0968-0896(09)00800-1 [pii];10.1016/j.bmc.2009.08.036 [doi].
588. Jewell, N. A., T. Cline, S. E. Mertz, S. V. Smirnov, E. Flano, C. Schindler, J. L. Grieves, R. K. Durbin, S. V. Kotenko, and J. E. Durbin. 2010. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. *J.Virol.* 84:11515–11522. doi:JVI.01703-09 [pii];10.1128/JVI.01703-09 [doi].
589. Ji, X. Y., Z. J. Zhong, S. T. Xue, S. Meng, W. Y. He, R. M. Gao, Y. H. Li, and Z. R. Li. 2010. Synthesis and antiviral activities of synthetic glutarimide derivatives. *Chem.Pharm.Bull.(Tokyo)* 58:1436–1441. doi:JST.JSTAGE/cpb/58.1436 [pii].
590. Jia, D., R. Rahbar, R. W. Chan, S. M. Lee, M. C. Chan, B. X. Wang, D. P. Baker, B. Sun, J. S. Peiris, J. M. Nicholls, and E. N. Fish. 2010. Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. *PLoS.One.* 5:e13927. doi:10.1371/journal.pone.0013927 [doi].
591. Jiang, H., S. Zhang, Q. Wang, J. Wang, L. Geng, and T. Toyoda. 2010. Influenza virus genome C4 promoter/origin attenuates its transcription and replication activity by the low polymerase recognition activity. *Virology* 408:190–196. doi:S0042-6822(10)00610-0 [pii];10.1016/j.virol.2010.09.022 [doi].
592. Jiang, J., A. J. Bennett, E. Fisher, Y. Williams-Bey, H. Shen, and D. M. Murasko. 2009. Limited expansion of virus-specific CD8 T cells in the aged environment. *Mech.Ageing Dev.* 130:713–721. doi:S0047-6374(09)00114-6 [pii];10.1016/j.mad.2009.08.007 [doi].
593. Jiang, S., R. Li, L. Du, and S. Liu. 2010. Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. *Protein Cell* 1:342–354. doi:10.1007/s13238-010-0054-6 [doi].
594. Jiang, T. J., J. Y. Zhang, W. G. Li, Y. X. Xie, X. W. Zhang, Y. Wang, L. Jin, F. S. Wang, and M. Zhao. 2010. Preferential loss of Th17 cells is associated with CD4 T cell activation in patients with 2009 pandemic H1N1 swine-origin influenza A infection. *Clin.Immunol.* 137:303–310. doi:S1521-6616(10)00676-5 [pii];10.1016/j.clim.2010.07.010 [doi].
595. Jiang, T., H. Zhao, X. F. Li, Y. Q. Deng, J. Liu, L. J. Xu, J. F. Han, R. Y. Cao, E. D. Qin, and C. F. Qin. 2011. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. *Antiviral Res.* 89:124–126. doi:S0166-3542(10)00816-8 [pii];10.1016/j.antiviral.2010.11.013 [doi].
596. Jiang, Y. N. and H. Y. Mo. 2009. [Effects of Tankejing dry powder inhaler on the inflammatory damage in the lungs of mice infected by FM1]. *Zhong.Yao Cai.* 32:1093–1097.

597. Jidar, K., S. Ingen-Housz-Oro, M. Beylot-Barry, C. Paul, D. Chaoui, M. Sigal-Grinberg, P. Morel, L. Dubertret, and H. Bachelez. 2009. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. *Br.J.Dermatol.* 161:660–663. doi:BJD9230 [pii];10.1111/j.1365-2133.2009.09230.x [doi].
598. Jimenez, M. F., B. P. El, M. P. Salcedo, A. V. Von Ameln, F. P. Mastalir, and L. D. Braun. 2010. Outcomes for pregnant women infected with the influenza A (H1N1) virus during the 2009 pandemic in Porto Alegre, Brazil. *Int.J.Gynaecol.Obstet.* 111:217–219. doi:S0020-7292(10)00380-2 [pii];10.1016/j.ijgo.2010.06.024 [doi].
599. Jimenez-Baranda, S., B. Greenbaum, O. Manches, J. Handler, R. Rabadan, A. Levine, and N. Bhardwaj. 2011. Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells. *J.Virol.* 85:3893–3904. doi:JVI.01908-10 [pii];10.1128/JVI.01908-10 [doi].
600. Johnson, P. V., B. M. Blair, S. Zeller, C. N. Kotton, and E. L. Hohmann. 2011. Attenuated *Listeria monocytogenes* vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. *Microbiol.Immunol.* 55:304–317. doi:10.1111/j.1348-0421.2011.00322.x [doi].
601. Jones, J. C., E. W. Settles, C. R. Brandt, and S. Schultz-Cherry. 2011. Identification of the minimal active sequence of an anti-influenza virus peptide. *Antimicrob.Agents Chemother.* 55:1810–1813. doi:AAC.01428-10 [pii];10.1128/AAC.01428-10 [doi].
602. Jonges, M., W. M. Liu, d. van, V. R. Jacobi, I. Pronk, C. Boog, M. Koopmans, A. Meijer, and E. Soethout. 2010. Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. *J.Clin.Microbiol.* 48:928–940. doi:JCM.02045-09 [pii];10.1128/JCM.02045-09 [doi].
603. Josko, D. 2010. Molecular virology in the clinical laboratory. *Clin.Lab Sci.* 23:231–236.
604. Josset, L., J. Textoris, B. Loriod, O. Ferraris, V. Moules, B. Lina, C. N'guyen, J. J. Diaz, and M. Rosa-Calatrava. 2010. Gene expression signature-based screening identifies new broadly effective influenza a antivirals. *PLoS.One.* 5. doi:10.1371/journal.pone.0013169 [doi].
605. Jost, S., J. Reardon, E. Peterson, D. Poole, R. Bosch, G. Alter, and M. Altfeld. 2011. Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza. *Immunology* 132:516–526. doi:10.1111/j.1365-2567.2010.03394.x [doi].
606. Ju, H. Q., Y. F. Xiang, B. J. Xin, Y. Pei, J. X. Lu, Q. L. Wang, M. Xia, C. W. Qian, Z. Ren, S. Y. Wang, Y. F. Wang, and G. W. Xing. 2011. Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. *Bioorg.Med.Chem.Lett.* 21:1675–1677. doi:S0960-894X(11)00121-1 [pii];10.1016/j.bmcl.2011.01.098 [doi].
607. Julander, J. G., J. Hagloch, S. Latimer, N. Motter, A. Dagley, D. L. Barnard, D. F. Smee, and J. D. Morrey. 2011. Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus. *Antiviral Res.* 92:228–236. doi:S0166-3542(11)00412-8 [pii];10.1016/j.antiviral.2011.08.011 [doi].
608. Kabanov, A. S., T. A. Kosogova, L. N. Shishkina, T. V. Tepliakova, M. O. Skarnovich, N. A. Mazurkova, L. I. Puchkova, E. M. Malkova, E. A. Stavskii, and I. G. Drozdov. 2011. [Study of antiviral activity of extracts obtained from basidial fungi against influenza viruses of different subtypes in experiments in vitro and in vivo]. *Zh.Mikrobiol.Epidemiol.Immunobiol.* 40–43.
609. Kaefer, V., J. G. Smedo, V. F. Silva Kahl, R. G. Von Borowsky, J. Ganesini, T. B. Ledur Kist, P. Pereira, and J. N. Picada. 2010. DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. *J.Appl.Toxicol.* 30:745–753. doi:10.1002/jat.1550 [doi].
610. Kaiho, I. 2010. [Local administrative measures for outbreak of H1N1 influenza – Chiba prefecture]. *Nihon Rinsho* 68:1702–1706.

611. Kalus, U., A. Grigorov, O. Kadecki, J. P. Jansen, H. Kieseewetter, and H. Radtke. 2009. Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract. A prospective, randomised, placebo-controlled clinical study. *Antiviral Res.* 84:267–271. doi:S0166-3542(09)00488-4 [pii];10.1016/j.antiviral.2009.10.001 [doi].
612. Kamate, S. K., A. Agrawal, H. Chaudhary, K. Singh, P. Mishra, and K. Asawa. 2010. Public knowledge, attitude and behavioural changes in an Indian population during the Influenza A (H1N1) outbreak. *J.Infect.Dev.Ctries.* 4:7–14.
613. Kamigaki, T., R. Tamaki, and H. Oshitani. 2010. [Lessons learned from pandemic (H1N1) 2009: Japan and global prospective]. *Nihon Rinsho* 68:1605–1610.
614. Kandeel, A., S. Manoncourt, K. E. Abd el, A. N. Mohamed Ahmed, S. El-Refai, H. Essmat, J. Tjaden, C. C. de Mattos, K. C. Earhart, A. A. Marfin, and N. El-Sayed. 2010. Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006–2009. *Emerg.Infect.Dis.* 16:1101–1107. doi:10.3201/eid1607.091695 [doi].
615. Kane, E. M. 2009. Achieving clinical equality in an influenza pandemic: patent realities. *Seton.Hall. Law Rev.* 39:1137–1172.
616. Kanmaz, G., O. Erdeve, S. S. Oguz, N. Uras, and U. Dilmen. 2011. Influenza a (H1N1) virus pneumonia in newborns: experience of a referral level III neonatal intensive care unit in Turkey. *Pediatr.Pulmonol.* 46:201–202. doi:10.1002/ppul.21343 [doi].
617. Kanmaz, H. G., S. S. Oguz, O. Erdeve, N. Uras, S. Unlu, N. Danisman, L. Mollamahmutoglu, and U. Dilmen. 2011. Dealing with pandemic influenza A during postpartum and early neonatal period in a busy family-centered neonatal intensive care unit. *J.Matern.Fetal Neonatal Med.* 24:804–807. doi:10.3109/14767058.2010.531308 [doi].
618. Kao, R. Y., D. Yang, L. S. Lau, W. H. Tsui, L. Hu, J. Dai, M. P. Chan, C. M. Chan, P. Wang, B. J. Zheng, J. Sun, J. D. Huang, J. Madar, G. Chen, H. Chen, Y. Guan, and K. Y. Yuen. 2010. Identification of influenza A nucleoprotein as an antiviral target. *Nat.Biotechnol.* 28:600–605. doi:nbt.1638 [pii];10.1038/nbt.1638 [doi].
619. Kao, T. M., C. H. Wang, Y. C. Chen, W. J. Ko, and S. C. Chang. 2009. The first case of severe novel H1N1 influenza successfully rescued by extracorporeal membrane oxygenation in Taiwan. *J.Formos. Med.Assoc.* 108:894–898. doi:S0929-6646(09)60422-8 [pii];10.1016/S0929-6646(09)60422-8 [doi].
620. Karkar, A., M. Abdelrahman, M. R. Jasim, and W. AlOyouni. 2010. H1N1 in dialysis units: prevention and management. *Saudi.J.Kidney Dis.Transpl.* 21:715–719. doi:SaudiJKidneyDisTranspl\_2010\_21\_4\_715\_64657 [pii].
621. Karpala, A. J., C. Stewart, J. McKay, J. W. Lowenthal, and A. G. Bean. 2011. Characterization of chicken Mda5 activity: regulation of IFN-beta in the absence of RIG-I functionality. *J.Immunol.* 186:5397–5405. doi:jimmunol.1003712 [pii];10.4049/jimmunol.1003712 [doi].
622. Karpenko, I., S. Deev, O. Kiselev, V. Charushin, V. Rusinov, E. Ulomsky, E. Deeva, D. Yanvarev, A. Ivanov, O. Smirnova, S. Kochetkov, O. Chupakhin, and M. Kukhanova. 2010. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. *Antimicrob.Agents Chemother.* 54:2017–2022. doi:AAC.01186-09 [pii];10.1128/AAC.01186-09 [doi].
623. Karplus, R., S. Sanset, R. Zaidenstein, D. Schneider, and M. Berkovitch. 2010. Suspected oseltamivir-induced bradycardia. *Int.J.Infect.Dis.* 14 Suppl 3:e374–e375. doi:S1201-9712(10)02390-8 [pii];10.1016/j.ijid.2010.03.009 [doi].
624. Kato, Y. 2010. [Pneumonia and acute respiratory distress syndrome due to pandemic influenza H1N1 2009]. *Nihon Rinsho* 68:1666–1670.

625. Kawai, N., H. Ikematsu, N. Hirotsu, T. Maeda, T. Kawashima, O. Tanaka, S. Yamauchi, K. Kawamura, S. Matsuura, M. Nishimura, N. Iwaki, and S. Kashiwagi. 2009. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. *Clin.Infect.Dis.* 49:1828–1835. doi:10.1086/648424 [doi].
626. Kawai, N., H. Ikematsu, O. Tanaka, S. Matsuura, T. Maeda, S. Yamauchi, N. Hirotsu, M. Nishimura, N. Iwaki, and S. Kashiwagi. 2011. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007–2008 and 2008–2009 seasons. *J.Infect.Chemother.* 17:375–381. doi:10.1007/s10156-010-0179-9 [doi].
627. Kay, M., D. M. Zerr, J. A. Englund, B. L. Cadwell, J. Kuypers, P. Swenson, T. S. Kwan-Gett, S. L. Bell, and J. S. Duchin. 2011. Shedding of pandemic (H1N1) 2009 virus among health care personnel, Seattle, Washington, USA. *Emerg.Infect.Dis.* 17:639–644. doi:10.3201/eid1704.100866 [doi].
628. Kazakova, O. B., E. V. Tret'iakova, I. E. Smirnova, L. V. Spirikhin, G. A. Tolstikov, E. V. Chudov, G. V. Bazekin, and A. F. Ismagilova. 2010. [Synthesis and anti-inflammatory activity of quinopimaric acid derivatives]. *Bioorg.Khim.* 36:277–282. doi:36n2F277L282 [pii].
629. Kazakova, O. B., G. V. Giniyatullina, E. Y. Yamansarov, and G. A. Tolstikov. 2010. Betulin and ursolic acid synthetic derivatives as inhibitors of Papilloma virus. *Bioorg.Med.Chem.Lett.* 20:4088–4090. doi:S0960-894X(10)00724-9 [pii];10.1016/j.bmcl.2010.05.083 [doi].
630. Kazakova, O. B., N. I. Medvedeva, I. P. Baikova, G. A. Tolstikov, T. V. Lopatina, M. S. Lunusov, and L. Zaprutko. 2010. [Synthesis of triterpenoid acylates – an effective reproduction inhibitors of influenza A (H1N1) and papilloma viruses]. *Bioorg.Khim.* 36:841–848. doi:36n6F841L848 [pii].
631. Keating, G. M. 2009. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. *Drugs* 69:2633–2660. doi:8 [pii];10.2165/11203660-000000000-00000 [doi].
632. Keiner, B., B. Maenz, R. Wagner, G. Cattoli, I. Capua, and H. D. Klenk. 2010. Intracellular distribution of NS1 correlates with the infectivity and interferon antagonism of an avian influenza virus (H7N1). *J.Virol.* 84:11858–11865. doi:JVI.01011-10 [pii];10.1128/JVI.01011-10 [doi].
633. Kelso, J. K., N. Halder, and G. J. Milne. 2010. The impact of case diagnosis coverage and diagnosis delays on the effectiveness of antiviral strategies in mitigating pandemic influenza A/H1N1 2009. *PLoS.One.* 5:e13797. doi:10.1371/journal.pone.0013797 [doi].
634. Keogh-Brown, M. R., R. D. Smith, J. W. Edmunds, and P. Beutels. 2010. The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands. *Eur.J.Health Econ.* 11:543–554. doi:10.1007/s10198-009-0210-1 [doi].
635. Keresztes, P. A. 2009. Novel influenza A (H1N1): what nurses need to know. *Medsurg.Nurs.* 18:302–304.
636. Kerry, P. S., J. Ayllon, M. A. Taylor, C. Hass, A. Lewis, A. Garcia-Sastre, R. E. Randall, B. G. Hale, and R. J. Russell. 2011. A transient homotypic interaction model for the influenza A virus NS1 protein effector domain. *PLoS.One.* 6:e17946. doi:10.1371/journal.pone.0017946 [doi].
637. Khandaker, G. M., G. M. Khandaker, C. Dibben, Y. Zurynski, E. J. Elliott, and R. Booy. 2010. Mania in a patient with H1N1: is oseltamivir the culprit or a red herring? *Am.J.Psychiatry* 167:1129–1130. doi:167/9/1129-a [pii];10.1176/appi.ajp.2010.10030429 [doi].
638. Khandaker, G., B. Doyle, D. E. Dwyer, and R. Booy. 2010. Managing outbreaks of viral respiratory infection in aged care facilities – challenges and difficulties during the first pandemic wave. *Med.J.Aust.* 192:722. doi:letters\_210610\_fm-1 [pii].

639. Kharfan-Dabaja, M. A., A. Velez, K. Richards, J. N. Greene, T. Field, and R. Sandin. 2010. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. *Int.J.Hematol.* 91:124–127. doi:10.1007/s12185-009-0464-5 [doi].
640. Khazeni, N., D. W. Hutton, A. M. Garber, and D. K. Owens. 2009. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. *Ann.Intern.Med.* 151:840–853. doi:0000605-200912150-00156 [pii];10.1059/0003-4819-151-12-200912150-00156 [doi].
641. Khurana, E., R. H. Devane, P. M. Dal, and M. L. Klein. 2011. Computational study of drug binding to the membrane-bound tetrameric M2 peptide bundle from influenza A virus. *Biochim.Biophys.Acta* 1808:530–537. doi:S0005-2736(10)00124-0 [pii];10.1016/j.bbamem.2010.03.025 [doi].
642. Kiatboonsri, S., C. Kiatboonsri, and P. Theerawit. 2010. Fatal respiratory events caused by zanamivir nebulization. *Clin.Infect.Dis.* 50:620. doi:10.1086/650176 [doi].
643. Kiefer, B. 2010. [The World Health Organization, the BMJ and the truth]. *Rev.Med.Suisse* 6:1272.
644. Killingley, B., J. Enstone, R. Booy, A. Hayward, J. Oxford, N. Ferguson, and J. N. Van-Tam. 2011. Potential role of human challenge studies for investigation of influenza transmission. *Lancet Infect.Dis.* 11:879–886. doi:S1473-3099(11)70142-6 [pii];10.1016/S1473-3099(11)70142-6 [doi].
645. Killingley, B., J. Greatorex, S. Cauchemez, J. E. Enstone, M. Curran, R. C. Read, W. S. Lim, A. Hayward, K. G. Nicholson, and J. S. Nguyen-Van-Tam. 2010. Virus shedding and environmental deposition of novel A (H1N1) pandemic influenza virus: interim findings. *Health Technol.Assess.* 14:237–354. doi:10.3310/hta14460-04 [doi].
646. Kim, H. S., J. H. Kim, S. Y. Shin, Y. A. Kang, H. G. Lee, J. S. Kim, J. K. Lee, and B. Cho. 2011. Fatal cases of 2009 pandemic influenza A (H1N1) in Korea. *J.Korean Med.Sci.* 26:22–27. doi:10.3346/jkms.2011.26.1.22 [doi].
647. Kim, J. H., H. S. Yoo, J. S. Lee, E. G. Lee, H. K. Park, Y. H. Sung, S. Kim, H. S. Kim, S. Y. Shin, and J. K. Lee. 2010. The spread of pandemic H1N1 2009 by age and region and the comparison among monitoring tools. *J.Korean Med.Sci.* 25:1109–1112. doi:10.3346/jkms.2010.25.7.1109 [doi].
648. Kim, K., K. H. Kim, H. Y. Kim, H. K. Cho, N. Sakamoto, and J. Cheong. 2010. Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway. *FEBS Lett.* 584:707–712. doi:S0014-5793(09)01065-5 [pii];10.1016/j.febslet.2009.12.019 [doi].
649. Kim, S. H. and S. K. Samal. 2010. Inhibition of host innate immune responses and pathogenicity of recombinant Newcastle disease viruses expressing NS1 genes of influenza A viruses. *J.Gen.Virol.* 91:1996–2001. doi:vir.0.021766-0 [pii];10.1099/vir.0.021766-0 [doi].
650. Kim, Y., S. Narayanan, and K. O. Chang. 2010. Inhibition of influenza virus replication by plant-derived isoquercetin. *Antiviral Res.* 88:227–235. doi:S0166-3542(10)00703-5 [pii];10.1016/j.antiviral.2010.08.016 [doi].
651. Kimberlin, D. W., J. Escude, J. Gantner, J. Ott, M. Dronet, T. A. Stewart, P. Jester, D. T. Redden, W. Chapman, and R. Hammond. 2010. Targeted antiviral prophylaxis with oseltamivir in a summer camp setting. *Arch.Pediatr.Adolesc.Med.* 164:323–327. doi:2009.299 [pii];10.1001/archpediatr.2009.299 [doi].
652. Kimberlin, D. W., M. Shalabi, M. J. Abzug, D. Lang, R. F. Jacobs, G. Storch, J. S. Bradley, K. C. Wade, O. Ramilo, J. R. Romero, M. Shelton, C. Leach, J. Guzman-Cottrill, J. Robinson, N. Abughali, J. Englund, J. Griffin, P. Jester, G. A. Cloud, and R. J. Whitley. 2010. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. *Pediatr.Infect.Dis.J.* 29:195–198. doi:10.1097/INF.0b013e3181bbf26b [doi].

653. Kimmel, M., D. Keller, S. Farmer, and D. E. Warrino. 2010. A controlled clinical trial to evaluate the effect of GanedenBC(30) on immunological markers. *Methods Find.Exp.Clin.Pharmacol.* 32:129–132. doi:1423881 [pii];10.1358/mf.2010.32.2.1423881 [doi].
654. Kinlaw, K., D. H. Barrett, and R. J. Levine. 2009. Ethical guidelines in pandemic influenza: recommendations of the Ethics Subcommittee of the Advisory Committee of the Director, Centers for Disease Control and Prevention. *Disaster.Med.Public Health Prep.* 3 Suppl 2:S185–S192. doi:10.1097/DMP.0b013e3181ac194f [doi].
655. Kirby, T. 2010. Jim Bishop: the Chief Medical Officer of Australia. *Lancet* 375:1517. doi:S0140-6736(10)60645-9 [pii];10.1016/S0140-6736(10)60645-9 [doi].
656. Kirchmair, J., J. M. Rollinger, K. R. Liedl, N. Seidel, A. Krumbholz, and M. Schmidtke. 2011. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. *Future.Med.Chem.* 3:437–450. doi:10.4155/fmc.10.292 [doi].
657. Kirchmair, J., S. Distinto, K. R. Liedl, P. Markt, J. M. Rollinger, D. Schuster, G. M. Spitzer, and G. Wolber. 2011. Development of anti-viral agents using molecular modeling and virtual screening techniques. *Infect.Disord.Drug Targets.* 11:64–93. doi:BSP/ ID DT /E-Pub/-0002-11-1 [pii].
658. Kirkby, R. and P. Herscu. 2010. Homeopathic trial design in influenza treatment. *Homeopathy.* 99:69–75. doi:S1475-4916(09)00087-3 [pii];10.1016/j.homp.2009.09.001 [doi].
659. Kiselev, O. I., A. B. Komissarov, M. A. Stukova, Z. Buzitskaia, M. M. Pisareva, E. A. Elpaeva, D. M. Danilenko, N. I. Konovalova, T. M. Gudkova, V. A. Grigor'eva, T. S. Smirnova, A. V. Slita, E. A. Romanovskaia-Roman'ko, L. M. Tsybalova, A. A. Sominina, M. I. Erokin, and M. P. Grudin. 2011. [The 2009 pandemic influenza in Russia. I. Diagnosis and molecular biological characteristics of the virus]. *Vopr.Virusol.* 56:17–21.
660. Kiso, M., K. Shinya, M. Shimojima, R. Takano, K. Takahashi, H. Katsura, S. Kakugawa, M. T. Le, M. Yamashita, Y. Furuta, M. Ozawa, and Y. Kawaoka. 2010. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. *PLoS.Pathog.* 6 :e1001079. doi:10.1371/journal.ppat.1001079 [doi].
661. Kiso, M., K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, Q. M. Le, M. Ozawa, Y. Furuta, and Y. Kawaoka. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. *Proc.Natl.Acad. Sci.U.S.A* 107:882–887. doi:0909603107 [pii];10.1073/pnas.0909603107 [doi].
662. Kiso, M., M. Ozawa, M. T. Le, H. Imai, K. Takahashi, S. Kakugawa, T. Noda, T. Horimoto, and Y. Kawaoka. 2011. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. *J.Virol.* 85:4667–4672. doi:JVI.00047-11 [pii];10.1128/JVI.00047-11 [doi].
663. Kiso, M., S. Kubo, M. Ozawa, Q. M. Le, C. A. Nidom, M. Yamashita, and Y. Kawaoka. 2010. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. *PLoS.Pathog.* 6:e1000786. doi:10.1371/journal.ppat.1000786 [doi].
664. Kitano, M., Y. Itoh, M. Kodama, H. Ishigaki, M. Nakayama, T. Nagata, H. Ishida, H. Tsuchiya, R. Torii, K. Baba, R. Yoshida, A. Sato, and K. Ogasawara. 2010. Establishment of a cynomolgus macaque model of influenza B virus infection. *Virology* 407:178–184. doi:S0042-6822(10)00523-4 [pii];10.1016/j.virol.2010.08.006 [doi].
665. Klebe, G. and M. Schlitzer. 2011. [M2 inhibitors and neuraminidase inhibitors]. *Pharm.Unserer Zeit* 40:144–150.
666. Kochs, G., S. Bauer, C. Vogt, T. Frenz, J. Tschopp, U. Kalinke, and Z. Waibler. 2010. Thogoto virus infection induces sustained type I interferon responses that depend on RIG-I-like helicase signaling of conventional dendritic cells. *J.Virol.* 84:12344–12350. doi:JVI.00931-10 [pii];10.1128/JVI.00931-10 [doi].

667. Kohlmeier, J. E., T. Cookenham, A. D. Roberts, S. C. Miller, and D. L. Woodland. 2010. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. *Immunity*. 33:96–105. doi:S1074-7613(10)00242-6 [pii];10.1016/j.immuni.2010.06.016 [doi].
668. Kohno, S., H. Kida, M. Mizuguchi, and J. Shimada. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. *Antimicrob.Agents Chemother*. 54:4568–4574. doi:AAC.00474-10 [pii];10.1128/AAC.00474-10 [doi].
669. Kohno, S., H. Kida, M. Mizuguchi, N. Hirotsu, T. Ishida, J. Kadota, and J. Shimada. 2011. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. *Antimicrob.Agents Chemother*. 55:2803–2812. doi:AAC.01718-10 [pii];10.1128/AAC.01718-10 [doi].
670. Kolobukhina, L. V., M. I. Shchelkanov, L. N. Merkulova, M. V. Bazarova, E. I. Burtseva, E. I. Samokhvalov, S. V. Al'khovskii, A. G. Prilipov, I. T. Fediakina, E. S. Proshina, V. A. Aristova, T. N. Morozova, O. A. Sutochnikova, R. A. Ponomarenko, N. A. Malyshev, A. M. Maslov, and A. G. Chuchalin. 2011. [Etiotropic therapy of influenza: lessons from the last pandemic]. *Vestn.Ross.Akad. Med.Nauk*35–40.
671. Komiya, N., Y. Gu, H. Kamiya, Y. Yahata, Y. Yasui, K. Taniguchi, and N. Okabe. 2010. Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009. *J.Infect*. 61:284–288. doi:S0163-4453(10)00202-1 [pii];10.1016/j.jinf.2010.06.019 [doi].
672. Kopel, E., M. Mandelboim, Z. Amitai, I. Grotto, M. Hindiyeh, E. Kaliner, E. Mendelson, and I. Volovik. 2010. Possible recurrent pandemic (H1N1) 2009 infection, Israel. *Emerg.Infect.Dis*. 16:1321–1322. doi:10.3201/eid1608.100436 [doi].
673. Koranyi, K., D. Yontz, Z. Rohrer, A. Leber, and O. Ramilo. 2010. Pericardial effusion complicating novel influenza A (H1N1) infection in an infant. *Pediatr.Infect.Dis.J*. 29:782–783. doi:10.1097/INF.0b013e3181de4952 [doi];00006454-201008000-00028 [pii].
674. Kornev, A. B., A. S. Peregudov, V. M. Martynenko, J. Balzarini, B. Hoorelbeke, and P. A. Troshin. 2011. Synthesis and antiviral activity of highly water-soluble polycarboxylic derivatives of [70] fullerene. *Chem.Commun.(Camb)* 47:8298–8300. doi:10.1039/c1cc12209f [doi].
675. Kotsimbos, T., G. Waterer, C. Jenkins, P. M. Kelly, A. Cheng, R. J. Hancox, M. Holmes, R. Wood-Baker, S. Bowler, L. Irving, and P. Thompson. 2010. Influenza A/H1N1\_09: Australia and New Zealand's winter of discontent. *Am.J.Respir.Crit Care Med*. 181:300–306. doi:181/4/300 [pii];10.1164/rccm.200912-1878CP [doi].
676. Koyama, K., M. Takahashi, M. Oitate, N. Nakai, H. Takakusa, S. Miura, and O. Okazaki. 2009. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. *Antimicrob.Agents Chemother*. 53:4845–4851. doi:AAC.00731-09 [pii];10.1128/AAC.00731-09 [doi].
677. Koyama, K., M. Takahashi, N. Nakai, H. Takakusa, T. Murai, M. Hoshi, N. Yamamura, N. Kobayashi, and O. Okazaki. 2010. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats. *Xenobiotica* 40:207–216. doi:10.3109/00498250903447691 [doi].
678. Koyuncu, M. and R. Erol. 2010. Optimal resource allocation model to mitigate the impact of pandemic influenza: a case study for Turkey. *J.Med.Syst*. 34:61–70.
679. Kozakov, D., G. Y. Chuang, D. Beglov, and S. Vajda. 2010. Where does amantadine bind to the influenza virus M2 proton channel? *Trends Biochem.Sci*. 35:471–475. doi:S0968-0004(10)00050-2 [pii];10.1016/j.tibs.2010.03.006 [doi].
680. Kozhenkov, S., M. Sedova, Y. Dubinina, A. Gupta, A. Ray, J. Ponomarenko, and M. Baitaluk. 2011. BiologicalNetworks – tools enabling the integration of multi-scale data for the host-pathogen studies. *BMC.Syst.Biol*. 5:7. doi:1752-0509-5-7 [pii];10.1186/1752-0509-5-7 [doi].

681. Krawitz, C., M. A. Mraheil, M. Stein, C. Imirzalioglu, E. Domann, S. Pleschka, and T. Hain. 2011. Inhibitory activity of a standardized elderberry liquid extract against clinically-relevant human respiratory bacterial pathogens and influenza A and B viruses. *BMC.Complement Altern.Med.* 11:16. doi:1472-6882-11-16 [pii];10.1186/1472-6882-11-16 [doi].
682. Krishnan, S. K., S. Ganguly, R. Veerasamy, and B. Jan. 2011. Synthesis, antiviral and cytotoxic investigation of 2-phenyl-3-substituted quinazolin-4(3H)-ones. *Eur.Rev.Med.Pharmacol.Sci.* 15:673–681.
683. Krug, R. M. and J. M. Aramini. 2009. Emerging antiviral targets for influenza A virus. *Trends Pharmacol.Sci.* 30:269–277. doi:S0165-6147(09)00055-8 [pii];10.1016/j.tips.2009.03.002 [doi].
684. Kruker, A. T. and M. Krause. 2010. ["Oseltamivir-induced delirium"]. *Ther.Umsch.* 67:613–615. doi:10.1024/0040-5930/a000106 [doi].
685. Krumm, S. A., J. M. Ndungu, J. J. Yoon, M. Dochow, A. Sun, M. Natchus, J. P. Snyder, and R. K. Plemper. 2011. Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. *PLoS.One.* 6:e20069. doi:10.1371/journal.pone.0020069 [doi];PONE-D-11-01284 [pii].
686. Kryazhimskiy, S., J. Dushoff, G. A. Bazykin, and J. B. Plotkin. 2011. Prevalence of epistasis in the evolution of influenza A surface proteins. *PLoS.Genet.* 7:e1001301. doi:10.1371/journal.pgen.1001301 [doi].
687. Krystal, M. R. and N. A. Meanwell. 2009. Influenza – the case for combination therapy. *Curr.Opin. Investig.Drugs* 10:746–749.
688. Kubo, S., M. Kakuta, and M. Yamashita. 2010. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses]. *Jpn.J.Antibiot.* 63:337–346.
689. Kubo, S., T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita. 2010. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. *Antimicrob.Agents Chemother.* 54 :1256–1264. doi:AAC.01311-09 [pii];10.1128/AAC.01311-09 [doi].
690. Kudva, A., E. V. Scheller, K. M. Robinson, C. R. Crowe, S. M. Choi, S. R. Slight, S. A. Khader, P. J. Dubin, R. I. Enelow, J. K. Kolls, and J. F. Alcorn. 2011. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. *J.Immunol.* 186:1666–1674. doi:jimmunol.1002194 [pii];10.4049/jimmunol.1002194 [doi].
691. Kuehn, B. M. 2011. Antiviral drugs underused in US patients for 2009 influenza A(H1N1) pandemic. *JAMA* 305:1080, 1082–1080, 1083. doi:305/11/1080 [pii];10.1001/jama.2011.284 [doi].
692. Kuiken, T., J. van den Brand, R. D. van, M. Pantin-Jackwood, and D. E. Swayne. 2010. Comparative pathology of select agent influenza a virus infections. *Vet.Pathol.* 47:893–914. doi:0300985810378651 [pii];10.1177/0300985810378651 [doi].
693. Kulkarni, R. and A. Kinikar. 2010. Transient hyperglycemia in a H1N1 positive child on oseltamivir. *Indian Pediatr.* 47:812–813.
694. Kulkarni, R., A. Kinikar, and C. Valvi. 2011. Clinical profile of H1N1 positive HIV- infected children. *Indian Pediatr.* 48:131–132. doi:S097475591000256-2 [pii].
695. Kumaki, Y., C. W. Day, D. F. Smee, J. D. Morrey, and D. L. Barnard. 2011. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. *Antiviral Res.* 92:329–340. doi:S0166-3542(11)00424-4 [pii];10.1016/j.antiviral.2011.09.001 [doi].
696. Kumar, A. 2011. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. *J.Antimicrob.Chemother.* 66:959–963. doi:dkr090 [pii];10.1093/jac/dkr090 [doi].



697. Kumar, D., M. G. Michaels, M. I. Morris, M. Green, R. K. Avery, C. Liu, L. Danziger-Isakov, V. Stosor, M. Estabrook, S. Gantt, K. A. Marr, S. Martin, F. P. Silveira, R. R. Razonable, U. D. Allen, M. E. Levi, G. M. Lyon, L. E. Bell, S. Huprikar, G. Patel, K. S. Gregg, K. Pursell, D. Helmersen, K. G. Julian, K. Shiley, B. Bono, V. R. Dharnidharka, G. Alavi, J. S. Kalpoe, S. Shoham, G. E. Reid, and A. Humar. 2010. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. *Lancet Infect.Dis.* 10:521–526. doi:S1473-3099(10)70133-X [pii];10.1016/S1473-3099(10)70133-X [doi].
698. Kumar, D., M. I. Morris, C. N. Kotton, S. A. Fischer, M. G. Michaels, U. Allen, E. A. Blumberg, M. Green, A. Humar, and M. G. Ison. 2010. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. *Am.J.Transplant.* 10:18–25. doi:AJT2960 [pii];10.1111/j.1600-6143.2009.02960.x [doi].
699. Kumar, K. S., S. Ganguly, R. Veerasamy, and C. E. De. 2010. Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. *Eur.J.Med.Chem.* 45:5474–5479. doi:S0223-5234(10)00554-4 [pii];10.1016/j.ejmech.2010.07.058 [doi].
700. Kumar, N., N. R. Sharma, H. Ly, T. G. Parslow, and Y. Liang. 2011. Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses. *Antimicrob.Agents Chemother.* 55:5553–5559. doi:AAC.00725-11 [pii];10.1128/AAC.00725-11 [doi].
701. Kumar, N., Y. Liang, T. G. Parslow, and Y. Liang. 2011. Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication. *J.Virol.* 85:2818–2827. doi:JVI.01969-10 [pii];10.1128/JVI.01969-10 [doi].
702. Kumar, P., V. Sood, R. Vyas, N. Gupta, A. C. Banerjea, and M. Khanna. 2010. Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs. *Antiviral Res.* 87:204–212. doi:S0166-3542(10)00601-7 [pii];10.1016/j.antiviral.2010.05.001 [doi].
703. Kumar, S., P. L. Havens, M. J. Chusid, R. E. Willoughby, Jr., P. Simpson, and K. J. Henrickson. 2010. Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. *Pediatr.Infect.Dis.J.* 29:591–594.
704. Kung, Y. M. 2010. A close-up view of flu. *Nurse Pract.* 35:47–52. doi:10.1097/01.NPR.0000369943.56890.d2 [doi];00006205-201004000-00015 [pii].
705. Kuo, R. L., C. Zhao, M. Malur, and R. M. Krug. 2010. Influenza A virus strains that circulate in humans differ in the ability of their NS1 proteins to block the activation of IRF3 and interferon-beta transcription. *Virology* 408:146–158. doi:S0042-6822(10)00600-8 [pii];10.1016/j.virol.2010.09.012 [doi].
706. Kute, V. B., S. M. Godara, K. R. Goplani, M. R. Gumber, P. R. Shah, A. V. Vanikar, V. R. Shah, and H. L. Trivedi . 2011. High mortality in critically ill patients infected with 2009 pandemic influenza A (H1N1) with pneumonia and acute kidney injury. *Saudi.J.Kidney Dis.Transpl.* 22:83–89. doi:SaudiJKI dneyDisTranspl\_2011\_22\_1\_83\_74362 [pii].
707. Kute, V., K. R. Goplani, S. M. Godara, P. R. Shah, A. V. Vanikar, and H. L. Trivedii. 2011. Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient – safe and effective without any immunosuppressive drug interaction. *J.Assoc.Physicians India* 59:49–51.
708. Kutzler, M. A., K. A. Kraynyak, S. J. Nagle, R. M. Parkinson, D. Zharikova, M. Chattergoon, H. Maguire, K. Muthumani, K. Ugen, and D. B. Weiner. 2010. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. *Gene Ther.* 17:72–82. doi:gt2009112 [pii];10.1038/gt.2009.112 [doi].
709. Kwan-Gett, T. S., A. Baer, and J. S. Duchin. 2009. Spring 2009 H1N1 influenza outbreak in King County, Washington. *Disaster.Med.Public Health Prep.* 3 Suppl 2:S109–S116. doi:10.1097/DMP.0b013e3181c6b818 [doi].

710. Kwiatek, M., J. Kocik, and M. Bartoszcz. 2009. [The substances active against influenza virus. Possibilities and prospects of application]. *Przeegl.Epidemiol.* 63:487–494.
711. Kwon, H. J., H. H. Kim, S. Y. Yoon, Y. B. Ryu, J. S. Chang, K. O. Cho, M. C. Rho, S. J. Park, and W. S. Lee. 2010. In vitro inhibitory activity of *Alpinia katsumadai* extracts against influenza virus infection and hemagglutination. *Viol.J.* 7:307. doi:1743-422X-7-307 [pii];10.1186/1743-422X-7-307 [doi].
712. Kwon, N. H., J. E. Kim, B. K. Cho, and H. J. Park. 2011. A novel influenza a (H1N1) virus as a possible cause of pityriasis rosea? *J.Eur.Acad.Dermatol.Venereol.* 25:368–369. doi:JDV3725 [pii];10.1111/j.1468-3083.2010.03725.x [doi].
713. Kwon, Y. K., S. J. Joh, M. C. Kim, M. S. Kang, Y. J. Lee, J. H. Kwon, and J. H. Kim. 2010. The susceptibility of magpies to a highly pathogenic avian influenza virus subtype H5N1. *Poult.Sci.* 89:1156–1161. doi:89/6/1156 [pii];10.3382/ps.2009-00549 [doi].
714. Labro, M. T. and J. Etienne. 2010. [The strategy against influenza]. *Rev.Prat.* 60:81–92.
715. Lackenby, A., G. J. Moran, R. Pebody, S. Miah, L. Calatayud, S. Bolotin, I. Vipond, P. Muir, M. Guiver, J. McMenamin, A. Reynolds, C. Moore, R. Gunson, C. Thompson, M. Galiano, A. Bermingham, J. Ellis, and M. Zambon. 2011. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. *Euro.Surveill* 16.
716. Lagace-Wiens, P. R., E. Rubinstein, and A. Gumel. 2010. Influenza epidemiology – past, present, and future. *Crit Care Med.* 38:e1–e9. doi:10.1097/CCM.0b013e3181cbaf34 [doi].
717. Lai, K. Y., W. Y. Ng, P. K. Osburga Chan, K. F. Wong, and F. Cheng. 2010. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. *Ann.Intern.Med.* 152:687–688. doi:152/10/687 [pii];10.1059/0003-4819-152-10-201005180-00017 [doi].
718. Lan, Y., Y. Zhang, L. Dong, D. Wang, W. Huang, L. Xin, L. Yang, X. Zhao, Z. Li, W. Wang, X. Li, C. Xu, L. Yang, J. Guo, M. Wang, Y. Peng, Y. Gao, Y. Guo, L. Wen, T. Jiang, and Y. Shu. 2010. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. *Antivir.Ther.* 15:853–859. doi:10.3851/IMP1656 [doi].
719. Langlois, R. A., D. K. Meyerholz, R. A. Coleman, R. T. Cook, T. J. Waldschmidt, and K. L. Legge. 2010. Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming mice. *Alcohol Clin.Exp.Res.* 34:1425–1431. doi:ACER1226 [pii];10.1111/j.1530-0277.2010.01226.x [doi].
720. Lannang, A. M., G. N. Louh, B. M. Biloa, J. Komguem, C. D. Mbazona, B. L. Sondengam, L. Naesens, C. Pannecouque, C. E. De, and e. H. Sayed El Ashry. 2010. Cytotoxicity of natural compounds isolated from the seeds of *Garcinia afzelii*. *Planta Med.* 76 :708–712. doi:10.1055/s-0029-1240627 [doi].
721. Lapinsky, S. E. 2010. Epidemic viral pneumonia. *Curr.Opin.Infect.Dis.* 23:139–144. doi:10.1097/QCO.0b013e328336eaae [doi].
722. Lapinsky, S. E. 2010. H1N1 novel influenza A in pregnant and immunocompromised patients. *Crit Care Med.* 38:e52–e57. doi:10.1097/CCM.0b013e3181c85d5f [doi].
723. Lattes, R., N. Jacob, J. de la Fuente, G. Fragale, and P. Massari. 2010. Pandemic influenza A/H1N1 and organ donation. *Transpl.Infect.Dis.* 12:169–172. doi:TID494 [pii];10.1111/j.1399-3062.2010.00494.x [doi].
724. Lau, Y. F., L. H. Tang, E. E. Ooi, and K. Subbarao. 2010. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. *Virology* 406:80–87. doi:S0042-6822(10)00448-4 [pii];10.1016/j.virol.2010.07.008 [doi].
725. Launes, C., J. J. Garcia-Garcia, I. Jordan, A. Martinez-Planas, L. Selva, and C. Munoz-Almagro. 2011. 2009 Influenza A H1N1 infections: delays in starting treatment with oseltamivir were associated with a more severe disease. *Pediatr.Infect.Dis.J.* 30:622–625. doi:10.1097/INF.0b013e3182093397 [doi].

726. Launes, C., S. Rives, A. Catala, R. Berruero, T. Toll, M. Camos, C. Munoz-Almagro, J. J. Garcia-Garcia, and J. Estella. 2010. Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. *Br.J.Haematol.* 149:874–878. doi:BJH8178 [pii];10.1111/j.1365-2141.2010.08178.x [doi].
727. Lautenbach, E., S. Saint, D. K. Henderson, and A. D. Harris. 2010. Initial response of health care institutions to emergence of H1N1 influenza: experiences, obstacles, and perceived future needs. *Clin.Infect.Dis.* 50:523–527. doi:10.1086/650169 [doi].
728. Law, A. H., D. C. Lee, K. Y. Yuen, M. Peiris, and A. S. Lau. 2010. Cellular response to influenza virus infection: a potential role for autophagy in CXCL10 and interferon-alpha induction. *Cell Mol.Immunol.* 7:263–270. doi:cmi201025 [pii];10.1038/cmi.2010.25 [doi].
729. Lawrenz, M., J. Wereszczynski, R. Amaro, R. Walker, A. Roitberg, and J. A. McCammon. 2010. Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy. *Proteins* 78:2523–2532. doi:10.1002/prot.22761 [doi].
730. Le, G. R., E. Bouguyon, C. Chevalier, J. Vidic, C. B. Da, O. Leymarie, C. Bourdieu, L. Decamps, S. Dhone-Pollet, and B. Delmas. 2010. Influenza A virus protein PB1-F2 exacerbates IFN-beta expression of human respiratory epithelial cells. *J.Immunol.* 185:4812–4823. doi:jimmunol.0903952 [pii];10.4049/jimmunol.0903952 [doi].
731. Le, L., E. H. Lee, D. J. Hardy, T. N. Truong, and K. Schulten. 2010. Molecular dynamics simulations suggest that electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases. *PLoS. Comput.Biol.* 6. doi:10.1371/journal.pcbi.1000939 [doi].
732. Le, N. C., P. Hillyer, S. Munir, C. C. Winter, T. McCarty, A. Bukreyev, P. L. Collins, R. L. Rabin, and U. J. Buchholz. 2010. Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells. *PLoS.One.* 5:e15017. doi:10.1371/journal.pone.0015017 [doi].
733. Le, Q. M., H. F. Wertheim, N. D. Tran, H. R. van Doorn, T. H. Nguyen, and P. Horby. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. *N.Engl.J.Med.* 362:86–87. doi:NEJMc0910448 [pii];10.1056/NEJMc0910732 [doi].
734. Ledesma, J., D. Vicente, F. Pozo, G. Cilla, S. P. Castro, J. S. Fernandez, M. P. Ruiz, J. M. Navarro, J. C. Galan, M. Fernandez, J. Reina, A. Larrauri, M. T. Cuevas, I. Casas, and P. P. Brena. 2011. Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain. *J.Clin.Virol.* 51:205–208. doi:S1386-6532(11)00148-X [pii];10.1016/j.jcv.2011.04.008 [doi].
735. Lee, B. Y., J. H. Tai, R. R. Bailey, S. M. McGlone, A. E. Wiringa, S. M. Zimmer, K. J. Smith, and R. K. Zimmerman. 2011. Economic model for emergency use authorization of intravenous peramivir. *Am.J.Manag.Care* 17:e1–e9.
736. Lee, B. Y., J. H. Tai, R. R. Bailey, S. M. McGlone, A. E. Wiringa, S. M. Zimmer, K. J. Smith, and R. K. Zimmerman. 2011. Economic model for emergency use authorization of intravenous peramivir. *Am.J.Manag.Care* 17:e1–e9. doi:12799 [pii].
737. Lee, B. Y., R. R. Bailey, A. E. Wiringa, T. M. Assi, and R. H. Beigi. 2009. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. *Obstet. Gynecol.* 114:971–980. doi:10.1097/AOG.0b013e3181bdfed [doi];00006250-200911000-00004 [pii].
738. Lee, B. Y., S. M. McGlone, R. R. Bailey, A. E. Wiringa, S. M. Zimmer, K. J. Smith, and R. K. Zimmerman. 2010. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. *PLoS.One.* 5:e11284. doi:10.1371/journal.pone.0011284 [doi].

739. Lee, D. H., C. W. Kim, J. H. Kim, J. S. Lee, M. K. Lee, J. C. Choi, B. W. Choi, S. H. Choi, and J. W. Chung. 2010. Risk factors for laboratory-confirmed household transmission of pandemic H1N1 2009 infection. *Am.J.Infect.Control* 38:e43–e45. doi:S0196-6553(10)00664-4 [pii];10.1016/j.ajic.2010.05.017 [doi].
740. Lee, D. H., S. S. Shin, B. Y. Jun, and J. K. Lee. 2010. [National level response to pandemic (H1N1) 2009]. *J.Prev.Med.Public Health* 43:99–104. doi:201003099 [pii];10.3961/jpmph.2010.43.2.99 [doi].
741. Lee, K. Y., J. W. Rhim, and J. H. Kang. 2011. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases. *Med.Hypotheses* 76:64–69. doi:S0306-9877(10)00336-1 [pii];10.1016/j.mehy.2010.08.032 [doi].
742. Lee, M. H., C. Arrecubieta, F. J. Martin, A. Prince, A. C. Borczuk, and F. D. Lowy. 2010. A postinfluenza model of *Staphylococcus aureus* pneumonia. *J.Infect.Dis.* 201:508–515. doi:10.1086/650204 [doi].
743. Lee, N., K. W. Choi, P. K. Chan, D. S. Hui, G. C. Lui, B. C. Wong, R. Y. Wong, W. Y. Sin, W. M. Hui, K. L. Ngai, C. S. Cockram, R. W. Lai, and J. J. Sung. 2010. Outcomes of adults hospitalised with severe influenza. *Thorax* 65:510–515. doi:65/6/510 [pii];10.1136/thx.2009.130799 [doi].
744. Lee, N., P. K. Chan, C. K. Wong, K. T. Wong, K. W. Choi, G. M. Joynt, P. Lam, M. C. Chan, B. C. Wong, G. C. Lui, W. W. Sin, R. Y. Wong, W. Y. Lam, A. C. Yeung, T. F. Leung, H. Y. So, A. W. Yu, J. J. Sung, and D. S. Hui. 2011. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. *Antivir.Ther.* 16:237–247. doi:10.3851/IMP1722 [doi].
745. Lee, S. M., J. L. Gardy, C. Y. Cheung, T. K. Cheung, K. P. Hui, N. Y. Ip, Y. Guan, R. E. Hancock, and J. S. Peiris. 2009. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. *PLoS.One.* 4:e8072. doi:10.1371/journal.pone.0008072 [doi].
746. Lee, S., G. Chowell, and C. Castillo-Chavez. 2010. Optimal control for pandemic influenza: the role of limited antiviral treatment and isolation. *J.Theor.Biol.* 265:136–150. doi:S0022-5193(10)00186-4 [pii];10.1016/j.jtbi.2010.04.003 [doi].
747. Lee, V. J., D. C. Lye, and A. Wilder-Smith. 2009. Combination strategies for pandemic influenza response – a systematic review of mathematical modeling studies. *BMC.Med.* 7:76. doi:1741-7015-7-76 [pii];10.1186/1741-7015-7-76 [doi].
748. Lee, V. J., J. Yap, A. R. Cook, M. I. Chen, J. K. Tay, B. H. Tan, J. P. Loh, S. W. Chew, W. H. Koh, R. Lin, L. Cui, C. W. Lee, W. K. Sung, C. W. Wong, M. L. Hibberd, W. L. Kang, B. Seet, and P. A. Tambyah. 2010. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. *N.Engl.J.Med.* 362:2166–2174. doi:362/23/2166 [pii];10.1056/NEJMoa0908482 [doi].
749. Lee, V. J., J. Yap, J. K. Tay, I. Barr, Q. Gao, H. J. Ho, B. H. Tan, P. M. Kelly, P. A. Tambyah, A. Kelso, and M. I. Chen. 2010. Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009. *BMC.Infect.Dis.* 10:164. doi:1471-2334-10-164 [pii];10.1186/1471-2334-10-164 [doi].
750. Lee, V. J., J. Yap, S. Maurer-Stroh, R. T. Lee, F. Eisenhaber, J. K. Tay, P. J. Ting, J. P. Loh, C. W. Wong, B. H. Tan, E. S. Koay, P. M. Kelly, and M. L. Hibberd. 2011. Investigation of causes of oseltamivir chemoprophylaxis failures during influenza A (H1N1-2009) outbreaks. *J.Clin.Virol.* 50:104–108. doi:S1386-6532(10)00410-5 [pii];10.1016/j.jcv.2010.10.004 [doi].
751. Lee, V. J., M. Y. Tok, V. T. Chow, K. H. Phua, E. E. Ooi, P. A. Tambyah, and M. I. Chen. 2009. Economic analysis of pandemic influenza vaccination strategies in Singapore. *PLoS.One.* 4:e7108. doi:10.1371/journal.pone.0007108 [doi].

752. Leibbrandt, A., C. Meier, M. König-Schuster, R. Weinmullner, D. Kalthoff, B. Pflugfelder, P. Graf, B. Frank-Gehrke, M. Beer, T. Fazekas, H. Unger, E. Prieschl-Grassauer, and A. Grassauer. 2010. Iota-carrageenan is a potent inhibitor of influenza A virus infection. *PLoS One*. 5:e14320. doi:10.1371/journal.pone.0014320 [doi].
753. Lemaitre, F., C. E. Luyt, F. Rouillet-Renoleau, A. Nieszkowska, N. Zahr, C. Fernandez, R. Farinotti, and A. Combes. 2010. Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. *Intensive Care Med*. 36:1273–1274. doi:10.1007/s00134-010-1882-9 [doi].
754. Leneva, I. A., I. T. Fediakina, M. I. Eroshkin, N. V. Gudova, A. A. Romanovskaia, D. M. Danilenko, S. M. Vinogradova, A. I. Lepeshkin, and A. M. Shestopalov. 2010. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models]. *Vopr. Virusol.* 55:19–27.
755. Leonov, H., P. Astrahan, M. Krugliak, and I. T. Arkin. 2011. How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? *J. Am. Chem. Soc.* 133 :9903–9911. doi:10.1021/ja202288m [doi].
756. Lera, E., N. T. Worner, M. Sancosmed, A. Fabregas, A. Casquero, S. Melendo, M. Miserachs, T. Tortola, A. Borrego, M. Campins, F. Moraga, C. Figueras, and R. Cebrian. 2011. Clinical and epidemiological characteristics of patients with influenza A (H1N1) 2009 attended to at the emergency room of a children's hospital. *Eur. J. Pediatr.* 170:371–378. doi:10.1007/s00431-011-1399-4 [doi].
757. Leung, G. M. and A. Nicoll. 2010. Reflections on pandemic (H1N1) 2009 and the international response. *PLoS Med.* 7. doi:10.1371/journal.pmed.1000346 [doi].
758. Leung, T. W., A. L. Tai, P. K. Cheng, M. S. Kong, and W. Lim. 2009. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. *J. Clin. Virol.* 46:298–299. doi:S1386-6532(09)00381-3 [pii];10.1016/j.jcv.2009.08.004 [doi].
759. Leung, Y. H., M. P. Li, and S. K. Chuang. 2011. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. *Epidemiol. Infect.* 139:41–44. doi:S0950268810001445 [pii];10.1017/S0950268810001445 [doi].
760. Levin, D., R. O. Cadigan, P. D. Biddinger, S. Condon, and H. K. Koh. 2009. Altered standards of care during an influenza pandemic: identifying ethical, legal, and practical principles to guide decision making. *Disaster Med. Public Health Prep.* 3 Suppl 2:S132–S140. doi:10.1097/DMP.0b013e3181ac3dd2 [doi].
761. Li, C. C., L. Wang, H. L. Eng, H. L. You, L. S. Chang, K. S. Tang, Y. J. Lin, H. C. Kuo, I. K. Lee, J. W. Liu, E. Y. Huang, and K. D. Yang. 2010. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. *Emerg. Infect. Dis.* 16:1265–1272. doi:10.3201/eid1608.091918 [doi].
762. Li, G. X., Y. J. Zhou, H. Yu, Z. J. Tian, L. P. Yan, Q. Zhang, S. P. Hu, and G. Z. Tong. 2010. Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice. *Res. Vet. Sci.* 88:345–351. doi:S0034-5288(09)00221-5 [pii];10.1016/j.rvsc.2009.09.005 [doi].
763. Li, H. and S. X. Wang. 2010. Clinical features of 2009 pandemic influenza A (H1N1) virus infection in chronic hemodialysis patients. *Blood Purif.* 30:172–177. doi:000320143 [pii];10.1159/000320143 [doi].
764. Li, H. B., D. Yan, J. B. Wang, J. Y. Wang, Z. C. Bei, L. Wei, and X. H. Xiao. 2009. [Biological evaluation of *Radix Isatidis* based on neuraminidase activity assay]. *Yao Xue. Xue. Bao.* 44:162–166.

765. Li, I. W., I. F. Hung, K. K. To, K. H. Chan, S. S. Wong, J. F. Chan, V. C. Cheng, O. T. Tsang, S. T. Lai, Y. L. Lau, and K. Y. Yuen. 2010. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. *Chest* 137:759–768. doi:chest.09-3072 [pii];10.1378/chest.09-3072 [doi].
766. Li, J., R. Fan, Y. Li, and X. Li. 2009. China's efforts at avian influenza treatment and prevention. *Biosci.Trends* 3:1–2.
767. Li, J., Y. Xu, Y. Q. Chen, Y. Ge, L. H. Zhang, X. L. Xu, T. S. Wu, Y. S. Chen, J. Wang, J. N. Liu, L. P. Wei, C. Qiu, X. N. Zhong, M. X. Huang, J. B. Xin, R. P. Luo, M. S. Zhao, Z. Q. Li, C. P. Hu, W. Zhao, H. Wang, W. Zhang, L. S. Guo, Q. Y. Wang, L. N. Zhou, Z. A. Liang, J. Q. Ma, Y. J. Liu, Y. M. Jiang, W. S. Xie, J. F. Sheng, and Z. C. Gao. 2009. [Relationship between clinical features and prognosis of highly pathogenic avian influenza A/H5N1 infection in humans in mainland China]. *Zhonghua Jie. He.He.Hu Xi.Za Zhi.* 32:335–341.
768. Li, Q., Z. Zhao, D. Zhou, Y. Chen, W. Hong, L. Cao, J. Yang, Y. Zhang, W. Shi, Z. Cao, Y. Wu, H. Yan, and W. Li. 2011. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. *Peptides* 32:1518–1525. doi:S0196-9781(11)00207-5 [pii];10.1016/j.peptides.2011.05.015 [doi].
769. Li, W., G. Wang, H. Zhang, G. Xin, D. Zhang, J. Zeng, X. Chen, Y. Xu, Y. Cui, and K. Li. 2010. Effects of NS1 variants of H5N1 influenza virus on interferon induction, TNFalpha response and p53 activity. *Cell Mol.Immunol.* 7:235–242. doi:cmi20106 [pii];10.1038/cmi.2010.6 [doi].
770. Li, Y., A. Larrimer, T. Curtiss, J. Kim, A. Jones, H. Baird-Tomlinson, A. Pekosz, and P. D. Olivo. 2009. Influenza virus assays based on virus-inducible reporter cell lines. *Influenza.Other Respi.Viruses.* 3:241–251.
771. Li, Y., E. B. Hsu, and J. M. Links. 2010. Healthcare system cost evaluation of antiviral stockpiling for pandemic influenza preparedness. *Biosecur.Bioterror.* 8:119–128. doi:10.1089/bsp.2009.0050 [doi].
772. Li, Y., E. Y. Chan, J. Li, C. Ni, X. Peng, E. Rosenzweig, T. M. Tumpey, and M. G. Katze. 2010. MicroRNA expression and virulence in pandemic influenza virus-infected mice. *J.Virol.* 84:3023–3032. doi:JVI.02203-09 [pii];10.1128/JVI.02203-09 [doi].
773. Li, Y., Y. Hu, Y. Jin, G. Zhang, J. Wong, L. Q. Sun, and M. Wang. 2011. Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. *J.Gene Med.* 13:60–72. doi:10.1002/jgm.1536 [doi].
774. Liang, Q. L., J. Luo, K. Zhou, J. X. Dong, and H. X. He. 2011. Immune-related gene expression in response to H5N1 avian influenza virus infection in chicken and duck embryonic fibroblasts. *Mol. Immunol.* 48:924–930. doi:S0161-5890(11)00002-2 [pii];10.1016/j.molimm.2010.12.011 [doi].
775. Liang, X. and Z. Y. Li. 2010. Ion channels as antiviral targets. *Viol.Sin.* 25:267–280. doi:10.1007/s12250-010-3136-y [doi].
776. Liao, W., F. Y. Goh, R. J. Betts, D. M. Kemeny, J. Tam, B. H. Bay, and W. S. Wong. 2011. A novel anti-apoptotic role for apolipoprotein L2 in IFN-gamma-induced cytotoxicity in human bronchial epithelial cells. *J.Cell Physiol* 226:397–406. doi:10.1002/jcp.22345 [doi].
777. Liao, Y. C., Y. C. Hsieh, W. C. Chang, J. L. Huang, C. T. Ting, and T. J. Wu. 2011. Fulminant myocarditis in an adult with 2009 pandemic influenza A (H1N1 influenza) infection. *J.Chin Med. Assoc.* 74:130–133. doi:S1726-4901(11)00030-X [pii];10.1016/j.jcma.2011.01.028 [doi].
778. Lim, M. L., C. Y. Chong, W. S. Tee, W. Y. Lim, and J. J. Chee. 2010. Influenza A/H1N1 (2009) infection in pregnancy – an Asian perspective. *BJOG.* 117:551–556. doi:BJO2522 [pii];10.1111/j.1471-0528.2010.02522.x [doi].

779. Lim, M. L., W. Y. Lim, N. W. Tee, S. H. Lim, and J. J. Chee. 2010. Obstetric outcomes of influenza A H1N1 (2009) infection in pregnancy – experience of a Singapore tertiary hospital. *Ann.Acad.Med. Singapore* 39:295–4.
780. Lin, C. H., T. T. Chang, M. F. Sun, H. Y. Chen, F. J. Tsai, K. L. Chang, M. Fisher, and C. Y. Chen. 2011. Potent inhibitor design against H1N1 swine influenza: structure-based and molecular dynamics analysis for M2 inhibitors from traditional Chinese medicine database. *J.Biomol.Struct. Dyn.* 28:471–482. doi:c4308/Potent-Inhibitor-Design-Against-H1N1-Swine-Influenza-Structure-based -and-Molecular-Dynamics-Analysis-for-M2-Inhibitors-from-Traditional-Chines e-Medicine-Database-p17925.html [pii].
781. Lin, K. L., S. Sweeney, B. D. Kang, E. Ramsburg, and M. D. Gunn. 2011. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. *J.Immunol.* 186:508–515. doi:jimmunol.1001002 [pii];10.4049/jimmunol.1001002 [doi].
782. Lin, X., J. Zhou, Y. Zhang, J. Wu, F. Zhang, Z. Li, Y. Zhang, S. Bi, Y. Shu, and Y. Wang. 2009. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. *Biochem.Biophys.Res.Commun.* 390:1305–1308. doi:S0006-291X(09)02133-0 [pii];10.1016/j.bbrc.2009.10.142 [doi].
783. Lin, Y. P., V. Gregory, P. Collins, J. Kloess, S. Wharton, N. Cattle, A. Lackenby, R. Daniels, and A. Hay. 2010. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? *J.Virol.* 84:6769–6781. doi:JVI.00458-10 [pii];10.1128/JVI.00458-10 [doi].
784. Lindegardh, N., W. Hanpithakpong, B. Kamanikom, J. Farrar, T. T. Hien, P. Singhasivanon, N. J. White, and N. P. Day. 2011. Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS. *Bioanalysis.* 3:157–165. doi:10.4155/bio.10.189 [doi].
785. Lindemann, L., H. Jacobsen, D. Schuhbauer, F. Knoflach, S. Gatti, J. G. Wettstein, H. Loetscher, T. Chu, M. Ebeling, J. C. Paulson, E. Prinssen, and M. Brockhaus. 2010. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. *Eur.J.Pharmacol.* 628:6–10. doi:S0014-2999(09)01035-8 [pii];10.1016/j.ejphar.2009.11.020 [doi].
786. Linden, K., O. Moser, A. Simon, A. M. Eis-Hubinger, G. Fleischhack, M. Born, H. Tschampa, T. Rosenbaum, B. Koster, and M. Lentze. 2011. [Transient splenic lesion in influenza A H1N1 2009 infection]. *Radiologe* 51:220–222. doi:10.1007/s00117-011-2131-0 [doi].
787. Ling, L. M., A. L. Chow, D. C. Lye, A. S. Tan, P. Krishnan, L. Cui, N. N. Win, M. Chan, P. L. Lim, C. C. Lee, and Y. S. Leo. 2010. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. *Clin.Infect.Dis.* 50:963–969. doi:10.1086/651083 [doi].
788. Liong, T., K. L. Lee, Y. S. Poon, S. Y. Lam, C. P. Chan, C. S. Yue, C. M. Chu, K. Y. Yuen, and K. I. Law. 2009. The first novel influenza A (H1N1) fatality despite antiviral treatment and extracorporeal membrane oxygenation in Hong Kong. *Hong.Kong.Med.J.* 15:381–384.
789. Liu, A. L., F. Yang, M. Zhu, D. Zhou, M. Lin, S. M. Lee, Y. T. Wang, and G. H. Du. 2010. In vitro anti-influenza viral activities of stilbenoids from the lianas of *Gnetum pendulum*. *Planta Med.* 76:1874–1876. doi:10.1055/s-0030-1250030 [doi].
790. Liu, C., B. S. Schwartz, S. Vallabhaneni, M. Nixon, P. V. Chin-Hong, S. A. Miller, C. Chiu, L. Damon, and W. L. Drew. 2010. Pandemic (H1N1) 2009 infection in patients with hematologic malignancy. *Emerg.Infect.Dis.* 16:1910–1917. doi:10.3201/eid1612.100772 [doi].
791. Liu, F. H., M. Y. Li, J. Luo, W. Y. Li, B. N. Wang, Y. Yang, Y. Kuang, B. Zuo, X. Y. Ma, and Z. H. Jiang. 2010. [Study on the activity against influenza A virus with traditional Chinese medicine Kanggan granules]. *Zhonghua Yi.Xue.Za Zhi.* 90:1863–1865.
792. Liu, G., S. Xiong, Y. F. Xiang, C. W. Guo, F. Ge, C. R. Yang, Y. J. Zhang, Y. F. Wang, and K. Kitazato. 2011. Antiviral activity and possible mechanisms of action of pentagalloylglucose (PGG) against influenza A virus. *Arch.Virol.* 156:1359–1369. doi:10.1007/s00705-011-0989-9 [doi].

793. Liu, H. L., Y. Lv, D. X. Zheng, Y. L. Zhao, C. Y. Sun, W. Zhang, J. M. Li, and Z. L. Wang. 2010. [Detection of molecular markers of amantadine resistance in avian influenza viruses by pyrosequencing]. *Bing.Du Xue.Bao.* 26:392–395.
794. Liu, H., X. Yao, C. Wang, and J. Han. 2010. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. *Mol.Pharm.* 7:894–904. doi:10.1021/mp100041b [doi].
795. Liu, H., Y. Lv, W. Huang, M. Yan, W. Zhang, M. Li, Q. Wang, J. Li, D. Zheng, Y. Zhao, C. Sun, and Z. Wang. 2010. [Detection of molecular markers of amantadine resistance in swine influenza viruses by pyrosequencing]. *Wei Sheng Wu Xue.Bao.* 50:395–399.
796. Liu, S., R. Li, R. Zhang, C. C. Chan, B. Xi, Z. Zhu, J. Yang, V. K. Poon, J. Zhou, M. Chen, J. Munch, F. Kirchhoff, S. Pleschka, T. Haarmann, U. Dietrich, C. Pan, L. Du, S. Jiang, and B. Zheng. 2011. CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry. *Eur.J.Pharmacol.* 660:460–467. doi:S0014-2999(11)00403-1 [pii];10.1016/j.ejphar.2011.04.013 [doi].
797. Liu, W., T. Jiang, X. F. Li, F. Tang, M. T. Wei, M. Yu, H. Zhao, X. D. Yu, L. J. Liu, C. F. Qin, and W. C. Cao. 2010. Community transmission of pandemic influenza A (H1N1) in China. *Infect.Control Hosp. Epidemiol.* 31:961–963. doi:10.1086/655020 [doi].
798. Liu, Y., F. Jing, Y. Xu, Y. Xie, F. Shi, H. Fang, M. Li, and W. Xu. 2011. Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. *Bioorg.Med.Chem.* 19:2342–2348. doi:S0968-0896(11)00127-1 [pii];10.1016/j.bmc.2011.02.019 [doi].
799. Liu, Z., Z. Guo, G. Wang, D. Zhang, H. He, G. Li, Y. Liu, D. Higgins, A. Walsh, L. Shanahan-Prendergast, and J. Lu. 2009. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. *Eur.J.Pharm.Sci.* 38:215–223. doi:S0928-0987(09)00189-4 [pii];10.1016/j.ejps.2009.07.004 [doi].
800. Liu, Z., Z. Q. Yang, and H. Xiao. 2010. Antiviral activity of the effective monomers from *Folium Isatidis* against influenza virus in vivo. *Viol.Sin.* 25:445–451. doi:10.1007/s12250-010-3142-0 [doi].
801. Loginova, S. I., S. V. Borisevich, G. V. Borisevich, V. P. Bondarev, and A. V. Variukhin. 2010. [Estimation of in vitro Monclavit-1 virucide activity against influenza virus A (H5N1)]. *Antibiot. Khimioter.* 55:17–20.
802. Loginova, S. I., S. V. Borisevich, I. A. Semenova, G. V. Borisevich, V. A. Maksimov, V. P. Bondarev, and V. E. Nebol'sin. 2009. [In vitro investigation of Ingavirin efficacy against influenza B virus]. *Antibiot. Khimioter.* 54:13–15.
803. Loginova, S. I., S. V. Borisevich, I. V. Semenova, V. A. Maksimov, V. P. Bondarev, and V. E. Nebol'sin. 2009. [In vitro activity of Ingavirin against influenza virus A (H3N2)]. *Antibiot.Khimioter.* 54:23–26.
804. Loginova, S. I., S. V. Borisevich, O. M. Shkلياeva, V. A. Maksimov, V. P. Bondarev, and V. E. Nebol'sin. 2010. [Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1)]. *Antibiot.Khimioter.* 55:10–12.
805. Loginova, S. I., S. V. Borisevich, V. A. Maksimov, V. P. Bondarev, S. K. Kotovskaia, V. L. Rusinov, V. N. Charushin, and O. N. Chupakhin. 2010. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. *Antibiot.Khimioter.* 55:25–28.
806. Loginova, S. I., S. V. Borisevich, V. A. Maksimov, V. P. Bondarev, S. K. Kotovskaia, V. L. Rusinov, V. N. Charushin, and O. N. Chupakhin. 2011. [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. *Antibiot.Khimioter.* 56:10–12.
807. Loginova, S. Y., S. V. Borisevich, V. N. Shchukina, M. V. Lykov, G. V. Borisevich, V. P. Bondarev, V. E. Nebolsin, O. A. Sutochnikova, and A. G. Chychalin. 2010. [Study of Ingavirin antiviral activity against Mexican pandemic influenza virus A/H1N1/2009 in vitro and in vivo]. *Antibiot.Khimioter.* 55:17–21.



808. Lohiya, G. S., L. Tan-Figueroa, and V. Krishna. 2010. Serious pH1N1 influenza illness and pneumonia despite inactivated vaccine: success of prompt diagnosis and treatment. *J.Natl.Med.Assoc.* 102:950–952.
809. Longtin, J., S. Patel, A. Eshaghi, E. Lombos, R. Higgins, D. Alexander, R. Olsha, J. Doyle, D. Tran, A. Sarabia, C. Lee, N. Bastien, Y. Li, D. Low, G. Boivin, and J. Gubbay. 2011. Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada. *J.Clin.Virol.* 50:257–261. doi:S1386-6532(10)00494-4 [pii];10.1016/j.jcv.2010.12.007 [doi].
810. Looker, C., K. Carville, K. Grant, and H. Kelly. 2010. Influenza A (H1N1) in Victoria, Australia: a community case series and analysis of household transmission. *PLoS.One.* 5:e13702. doi:10.1371/journal.pone.0013702 [doi].
811. Lopes, V. R., M. Schmidtke, F. M. Helena, R. Martins, and V. Vasconcelos. 2011. Cytotoxicity in L929 fibroblasts and inhibition of herpes simplex virus type 1 Kupka by estuarine cyanobacteria extracts. *Toxicol.In Vitro* 25:944–950. doi:S0887-2333(11)00060-9 [pii];10.1016/j.tiv.2011.03.003 [doi].
812. Lopez, C. H., R. F. Roca, and J. V. Daunis. 2009. [Pneumonia and the acute respiratory distress syndrome due to influenza A (H1N1) virus]. *Med.Intensiva.* 33:455–458. doi:S0210-5691(09)00087-4 [pii];10.1016/j.medin.2009.09.004 [doi].
813. Lopez-Sune, E., M. Tuset, M. Laguno, A. Moreno, and J. M. Miro. 2010. [Characteristics of hepatitis and influenza antivirals: update 2009]. *Enferm.Infecc.Microbiol.Clin.* 28:253–17. doi:S0213-005X(10)00066-2 [pii];10.1016/j.eimc.2010.02.001 [doi].
814. Louie, J. K., D. A. Wadford, A. Norman, and D. J. Jamieson. 2011. 2009 pandemic influenza A (H1N1) and vaccine failure in pregnancy. *Obstet.Gynecol.* 117:470–472. doi:10.1097/AOG.0b013e3181fd2e38 [doi];00006250-201102001-00017 [pii].
815. Louie, J. K., D. J. Jamieson, and S. A. Rasmussen. 2011. 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California. *Am.J.Obstet.Gynecol.* 204:144–146. doi:S0002-9378(10)01112-9 [pii];10.1016/j.ajog.2010.08.057 [doi].
816. Louie, J. K., S. Gavali, M. Acosta, M. C. Samuel, K. Winter, C. Jean, C. A. Glaser, B. T. Matyas, and R. Schechter. 2010. Children hospitalized with 2009 novel influenza A(H1N1) in California. *Arch. Pediatr.Adolesc.Med.* 164:1023–1031. doi:164/11/1023 [pii];10.1001/archpediatrics.2010.203 [doi].
817. Lovegrove, M. C., N. Shehab, C. M. Hales, K. Poneleit, E. Crane, and D. S. Budnitz. 2011. Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemic. *Public Health Rep.* 126:312–317.
818. Loving, C. L., S. L. Brockmeier, A. L. Vincent, M. V. Palmer, R. E. Sacco, and T. L. Nicholson. 2010. Influenza virus coinfection with *Bordetella bronchiseptica* enhances bacterial colonization and host responses exacerbating pulmonary lesions. *Microb.Pathog.* 49:237–245. doi:S0882-4010(10)00106-3 [pii];10.1016/j.micpath.2010.06.004 [doi].
819. Low, C. Y., T. Kee, K. P. Chan, L. L. Oon, C. K. Tan, N. W. Tee, and B. H. Tan. 2010. Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore. *Transplantation* 90:1016–1021. doi:10.1097/TP.0b013e3181f546cf [doi].
820. Luetkemeyer, A. F., D. V. Havlir, and J. S. Currier. 2010. Complications of HIV disease and antiretroviral treatment. *Top.HIV.Med.* 18:57–65.
821. Lugner, A. K. and M. J. Postma. 2009. Mitigation of pandemic influenza: review of cost-effectiveness studies. *Expert.Rev.Pharmacoecon.Outcomes.Res.* 9:547–558. doi:10.1586/erp.09.56 [doi].
822. Lugner, A. K., S. D. Mylius, and J. Wallinga. 2010. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. *Health Econ.* 19:518–531. doi:10.1002/hec.1485 [doi].

823. Lui, G., O. Manches, J. Angel, J. P. Molens, L. Chaperot, and J. Plumas. 2009. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. *PLoS.One*. 4:e7111. doi:10.1371/journal.pone.0007111 [doi].
824. Luke, J. M., G. G. Simon, J. Soderholm, J. S. Errett, J. T. August, M. Gale, Jr., C. P. Hodgson, and J. A. Williams. 2011. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. *J.Virol.* 85:1370–1383. doi:JVI.01250-10 [pii];10.1128/JVI.01250-10 [doi].
825. Lunemann, J. D., M. Tintore, B. Messmer, T. Strowig, A. Rovira, H. Perkal, E. Caballero, C. Munz, X. Montalban, and M. Comabella. 2010. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. *Ann.Neurol.* 67:159–169. doi:10.1002/ana.21886 [doi].
826. Luo, R. P., Y. M. Zhu, Z. Y. Xu, J. P. Gao, and S. J. Yu. 2006. [Report of the first human case of H5N1 avian influenza pneumonia in Hunan, China]. *Zhonghua Er.Ke.Za Zhi.* 44:342–345.
827. Luo, W. and M. Hong. 2010. Conformational changes of an ion channel detected through water-protein interactions using solid-state NMR spectroscopy. *J.Am.Chem.Soc.* 132:2378–2384. doi:10.1021/ja9096219 [doi].
828. L'vov, D. K., E. I. Burtseva, and V. V. Lavrishcheva. 2011. [Information of the Center for Ecology and Epidemiology of Influenza, D. I. Ivanovsky Research Institute of Virology, Russian Academy of Medical Sciences, on the results of the 2009–2010 influenza and acute respiratory viral infection epidemic season (at week 40 of 2009 to week 22 of 2010) in the world and Russia]. *Vopr.Virusol.* 56:44–49.
829. L'vov, D. K., E. I. Burtseva, G. A. Galegov, N. V. Beliakova, E. S. Shevchenko, L. V. Kolobukhina, L. N. Merkulova, A. G. Prilipov, I. A. Leneva, N. I. Baranov, V. N. Gorelikov, and D. D. Abramov. 2010. [Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments]. *Vopr.Virusol.* 55:10–14.
830. L'vov, D. K., E. I. Burtseva, M. I. Shchelkanov, A. G. Prilipov, L. V. Kolobukhina, N. A. Malyshev, M. V. Bazarova, L. N. Merkulova, P. G. Deriabina, A. G. Kuz'michev, I. T. Fediakina, T. V. Grebennikova, E. V. Usachev, G. K. Sadykova, E. S. Shevchenko, S. V. Trushakova, V. V. Lavrishcheva, S. Al'khovskii, E. I. Samokhvalov, N. V. Beliakova, V. T. Ivanova, T. A. Oskerko, O. E. Latyshev, A. M. Beliaev, A. L. Beliaev, and E. L. Feodoritova. 2010. [Spread of new pandemic influenza A(H1N1)v virus in Russia]. *Vopr.Virusol.* 55:4–9.
831. Lynch, M. M., E. W. Mitchell, J. L. Williams, K. Brumbaugh, M. Jones-Bell, D. E. Pinkney, C. M. Layton, P. W. Mersereau, J. S. Kendrick, P. E. Medina, and L. R. Smith. 2011. Pregnant and Recently Pregnant Women's Perceptions about Influenza A Pandemic (H1N1) 2009: Implications for Public Health and Provider Communication. *Matern.Child Health J.* doi:10.1007/s10995-011-0865-y [doi].
832. Ma, B., C. S. Dela Cruz, D. Hartl, M. J. Kang, S. Takyar, R. J. Homer, C. G. Lee, and J. A. Elias. 2011. RIG-like helicase innate immunity inhibits vascular endothelial growth factor tissue responses via a type I IFN-dependent mechanism. *Am.J.Respir.Crit Care Med.* 183:1322–1335. doi:201008-12760C [pii];10.1164/rccm.201008-12760C [doi].
833. Ma, R., Y. Xu, M. Bi, and P. Guo . 2010. [Effects of Yinqiao detoxification oral liquid on NK cell viability and serum concentration of IFN-gamma in SCID mouse infected by influenza virus FM1]. *Zhongguo Zhong.Yao Za Zhi.* 35:1456–1459.
834. Ma, W., D. Brenner, Z. Wang, B. Dauber, C. Ehrhardt, K. Hogner, S. Herold, S. Ludwig, T. Wolff, K. Yu, J. A. Richt, O. Planz, and S. Pleschka. 2010. The NS segment of an H5N1 highly pathogenic avian influenza virus (HPAIV) is sufficient to alter replication efficiency, cell tropism, and host range of an H7N1 HPAIV. *J.Virol.* 84:2122–2133. doi:JVI.01668-09 [pii];10.1128/JVI.01668-09 [doi].
835. Mackert, M., B. Love, and A. E. Holton. 2011. Journalism as health education: media coverage of a nonbranded pharma web site. *Telemed.J.E.Health* 17:88–94. doi:10.1089/tmj.2010.0127 [doi].

836. Maddry, J. A., X. Chen, C. B. Jonsson, S. Ananthan, J. Hobrath, D. F. Smee, J. W. Noah, D. Noah, X. Xu, F. Jia, C. Maddox, M. I. Sosa, E. L. White, and W. E. Severson. 2011. Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen. *J.Biomol.Screen.* 16:73–81. doi:1087057110384613 [pii];10.1177/1087057110384613 [doi].
837. Madhi, S. A., M. Maskew, A. Koen, L. Kuwanda, T. G. Besselaar, D. Naidoo, C. Cohen, M. Valette, C. L. Cutland, and I. Sanne. 2011. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. *Clin.Infect.Dis.* 52:128–137. doi:ciq004 [pii];10.1093/cid/ciq004 [doi].
838. Madsen, L., A. Nielsen, and J. Lundgren. 2010. [Naturally occurring oseltamivir resistance in influenza A]. *Ugeskr.Laeger* 172:2165–2167. doi:VP03090098 [pii].
839. Maeda, N., R. Nakamura, Y. Hirose, S. Murosaki, Y. Yamamoto, T. Kase, and Y. Yoshikai. 2009. Oral administration of heat-killed *Lactobacillus plantarum* L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. *Int.Immunopharmacol.* 9:1122–1125. doi:S1567-5769(09)00164-7 [pii];10.1016/j.intimp.2009.04.015 [doi].
840. Mahony, J. B., S. Chong, K. Luinstra, A. Petrich, and M. Smieja. 2010. Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses. *J.Clin.Virol.* 49:277–282. doi:S1386-6532(10)00328-8 [pii];10.1016/j.jcv.2010.08.006 [doi].
841. Mai, B. K. and M. S. Li. 2011. Neuraminidase inhibitor R-125489 – a promising drug for treating influenza virus: steered molecular dynamics approach. *Biochem.Biophys.Res.Commun.* 410:688–691. doi:S0006-291X(11)01015-1 [pii];10.1016/j.bbrc.2011.06.057 [doi].
842. Mai, B. K., M. H. Viet, and M. S. Li. 2010. Top leads for swine influenza A/H1N1 virus revealed by steered molecular dynamics approach. *J.Chem.Inf.Model.* 50:2236–2247. doi:10.1021/ci100346s [doi].
843. Makarenkova, I. D., P. G. Deriabin, D. K. L'vov, T. N. Zviagintseva, and N. N. Besednova. 2010. [Antiviral activity of sulfated polysaccharide from the brown algae *Laminaria japonica* against avian influenza A (H5N1) virus infection in the cultured cells]. *Vopr.Virusol.* 55:41–45.
844. Makedonas, G., N. Hutnick, D. Haney, A. C. Amick, J. Gardner, G. Cosma, A. R. Hersperger, D. Dolfi, E. J. Wherry, G. Ferrari, and M. R. Betts. 2010. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. *PLoS.Pathog.* 6:e1000798. doi:10.1371/journal.ppat.1000798 [doi].
845. Malaisree, M., T. Rungrotmongkol, N. Nunthaboot, O. Aruksakunwong, P. Intharathap, P. Decha, P. Sompornpisut, and S. Hannongbua. 2009. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. *Amino.Acids* 37:725–732. doi:10.1007/s00726-008-0201-z [doi].
846. Malamud, D., W. R. Abrams, C. A. Barber, D. Weissman, M. Rehtanz, and E. Golub. 2011. Antiviral activities in human saliva. *Adv.Dent.Res.* 23:34–37. doi:23/1/34 [pii];10.1177/0022034511399282 [doi].
847. Malato, L., V. Llavador, E. Marmier, J. Youssef, W. C. Balick, H. Roze, E. Bessede, and H. J. Fleury. 2011. Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. *Euro.Surveill* 16.
848. Malinoski, C. P. and P. I. Marcus. 2010. Lipopolysaccharide: a potent inhibitor of viral-mediated type-I interferon induction. *J.Interferon Cytokine Res.* 30:279–282. doi:10.1089/jir.2009.0086 [doi].
849. Mallick, A. I., P. Parvizi, L. R. Read, E. Nagy, S. Behboudi, and S. Sharif. 2011. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. *Vaccine* 29:1657–1665. doi:S0264-410X(10)01819-0 [pii];10.1016/j.vaccine.2010.12.046 [doi].

850. Maltezou, H. C. 2010. Novel (pandemic) influenza A H1N1 in healthcare facilities: implications for prevention and control. *Scand.J.Infect.Dis.* 42:412–420. doi:10.3109/00365541003699649 [doi].
851. Maltezou, H. C. and S. Tsiodras . 2009. Antiviral agents for influenza: molecular targets, concerns of resistance, and new treatment options. *Curr.Drug Targets.* 10:1041–1048.
852. Mammias, I. N., C. Koutsaftiki, K. Papantzimas, Z. Symeonoglou, M. Koussouri, M. Theodoridou, and N. Myriokefalitakis. 2011. Thrombocytic thrombocytopenic purpura in a child with A/H1N1 influenza infection. *J.Clin.Virol.* 51:146–147. doi:S1386-6532(11)00103-X [pii];10.1016/j.jcv.2011.03.001 [doi].
853. Mancuso, C. E., M. P. Gabay, L. M. Steinke, and S. J. Vanosdol. 2010. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. *Ann.Pharmacother.* 44:1240–1249. doi:aph.1P031 [pii];10.1345/aph.1P031 [doi].
854. Mandelboim, M., M. Hindiyeh, T. Meninger, and E. Mendelson. 2010. Possible transmission of pandemic (H1N1) 2009 virus with oseltamivir resistance. *Emerg.Infect.Dis.* 16:873–874. doi:10.3201/eid1605.091835 [doi].
855. Manicassamy, B., S. Manicassamy, A. Belicha-Villanueva, G. Pisanelli, B. Pulendran, and A. Garcia-Sastre. 2010. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. *Proc.Natl.Acad.Sci.U.S.A* 107:11531–11536. doi:0914994107 [pii];10.1073/pnas.0914994107 [doi].
856. Manz, B., V. Gotz, K. Wunderlich, J. Eisel, J. Kirchmair, J. Stech, O. Stech, G. Chase, R. Frank, and M. Schwemmler. 2011. Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus. *J.Biol.Chem.* 286:8414–8424. doi:M110.205534 [pii];10.1074/jbc.M110.205534 [doi].
857. Marathe, A., B. Lewis, C. Barrett, J. Chen, M. Marathe, S. Eubank, and Y. Ma. 2011. Comparing effectiveness of top-down and bottom-up strategies in containing influenza. *PLoS.One.* 6:e25149. doi:10.1371/journal.pone.0025149 [doi];PONE-D-11-06258 [pii].
858. Maravi-Poma, E., I. Martin-Loeches, E. Regidor, C. Laplaza, K. Cambra, S. Aldunate, J. E. Guerrero, A. Loza-Vazquez, E. Arnau, J. Almirall, L. Lorente, A. Arenzana, M. Magret, V. R. Reig, E. Marquez, N. Gonzalez, J. F. Bermejo-Martin, and J. Rello. 2011. Severe 2009 A/H1N1v influenza in pregnant women in Spain. *Crit Care Med.* 39:945–951. doi:10.1097/CCM.0b013e318208ee12 [doi].
859. Marcelli, D., C. Marelli, and N. Richards. 2009. Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. *Nephrol.Dial.Transplant.* 24:3566–3572. doi:gfp557 [pii];10.1093/ndt/gfp557 [doi].
860. Marchiori, E., G. Zanetti, and B. Hochegger. 2011. Diffuse alveolar hemorrhage in infectious diseases. *Chest* 139:228. doi:139/1/228 [pii];10.1378/chest.10-1627 [doi].
861. Marcus, P. I., J. M. Ngunjiri, M. J. Sekellick, L. Wang, and C. W. Lee. 2010. In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines. *J.Virol.* 84:10974–10981. doi:JVI.00502-10 [pii];10.1128/JVI.00502-10 [doi].
862. Mareiniss, D. P., J. M. Hirshon, and F. Levy. 2010. Planning for a pandemic: a view from the accident and emergency department. *Br.J.Hosp.Med.(Lond)* 71:64–65.
863. Marfo, K., J. Chapochnik-Friedmann, E. Akalin, and A. Lu. 2009. Postexposure prophylaxis of H1N1 with oseltamivir in a newly transplanted kidney recipient receiving intense immunosuppressive therapy. *Transplant.Proc.* 41:4411–4413. doi:S0041-1345(09)01302-5 [pii];10.1016/j.transproceed.2009.09.052 [doi].
864. Marin, M. L., B. B. Oliveira, S. L. Cipriano, C. A. Suslik, and J. Faintuch. 2010. Oseltamivir compounding in the hospital pharmacy during the (H1N1) influenza pandemic. *Clinics.(Sao Paulo)* 65:1081–1086. doi:S1807-59322010001100004 [pii].

865. Maritz, J., L. Maree, and W. Preiser. 2010. Pandemic influenza A (H1N1) 2009: the experience of the first six months. *Clin.Chem.Lab Med.* 48:11–21. doi:10.1515/CCLM.2010.023 [doi].
866. Marriott, A. C. and N. J. Dimmock. 2010. Defective interfering viruses and their potential as antiviral agents. *Rev.Med.Virol.* 20:51–62. doi:10.1002/rmv.641 [doi].
867. Martin, M. P., S. Seth, D. G. Koutsonanos, J. Jacob, R. W. Compans, and I. Skountzou. 2010. Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. *PLoS.One.* 5:e10897. doi:10.1371/journal.pone.0010897 [doi].
868. Martin-Loeches, I., A. Rodriguez, J. Bonastre, R. Zaragoza, R. Sierra, A. Marques, J. Julia-Narvaez, E. Diaz, and J. Rello. 2011. Severe pandemic (H1N1)v influenza A infection: report on the first deaths in Spain. *Respirology.* 16:78–85. doi:10.1111/j.1440-1843.2010.01874.x [doi].
869. Maryon-Davis, A. R. 2010. The truth about Tamiflu? Data access is matter of trust. *BMJ* 340:c134.
870. Masic, A., X. Lu, J. Li, G. K. Mutwiri, L. A. Babiuk, E. G. Brown, and Y. Zhou. 2010. Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs. *Vaccine* 28:7098–7108. doi:S0264-410X(10)01112-6 [pii];10.1016/j.vaccine.2010.08.003 [doi].
871. Mason, D. P., S. C. Murthy, J. J. Yun, M. Machuzak, R. Shrestha, R. K. Avery, K. R. McCurry, M. M. Budev, and G. B. Pettersson. 2011. Lung transplantation in a recipient with novel 2009 H1N1 influenza: lessons learned. *Thorac.Cardiovasc.Surg.* 59:126–127. doi:10.1055/s-0030-1250240 [doi].
872. Mason, V. L. 2010. International society for antiviral research – 23rd international conference. *IDrugs.* 13:363–365.
873. Mata, M., E. Morcillo, C. Gimeno, and J. Cortijo. 2011. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). *Biochem.Pharmacol.* 82:548–555. doi:S0006-2952(11)00327-3 [pii];10.1016/j.bcp.2011.05.014 [doi].
874. Matarrese, P., L. Nencioni, P. Checconi, L. Ciarlo, L. Gambardella, B. Ascione, R. Sgarbanti, E. Garaci, W. Malorni, and A. T. Palamara. 2011. Pepstatin A alters host cell autophagic machinery and leads to a decrease in influenza A virus production. *J.Cell Physiol* 226:3368–3377. doi:10.1002/jcp.22696 [doi].
875. Matin, M. and R. Goldschmidt. 2009. Influenza management guide 2009–2010. *Am.Fam.Physician* 80:1220.
876. Matin, M. and R. H. Goldschmidt. 2010. Influenza management guide 2010–2011. *Am.Fam.Physician* 82:1054. doi:d8748 [pii].
877. Matkowska-Kocjan, A. and A. Chybicka. 2009. [Vaccination in paediatric oncohaematology]. *Med. Wieku.Rozwoj.* 13:302–310.
878. Matskevich, A. A., J. S. Jung, M. Schumann, M. Cascallo, and K. Moelling. 2009. Vero cells as a model to study the effects of adenoviral gene delivery vectors on the RNAi system in context of viral infection. *J.Innate.Immun.* 1:389–394. doi:000191408 [pii];10.1159/000191408 [doi].
879. Matsubara, T., A. Onishi, T. Saito, A. Shimada, H. Inoue, T. Taki, K. Nagata, Y. Okahata, and T. Sato. 2010. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. *J.Med.Chem.* 53:4441–4449. doi:10.1021/jm1002183 [doi].
880. Matsumoto, K. 2010. [History of pandemic influenza in Japan]. *Nihon Rinsho* 68:1595–1601.

881. Matsuya, Y., N. Suzuki, S. Y. Kobayashi, T. Miyahara, H. Ochiai, and H. Nemoto. 2010. Synthesis and anti-influenza virus activity of dihydrofuran-fused perhydrophenanthrenes with a benzyloxy-type side-chain. *Bioorg.Med.Chem.* 18:1477–1481. doi:S0968-0896(10)00033-7 [pii];10.1016/j.bmc.2010.01.014 [doi].
882. Matsuzaki, Y., K. Mizuta, Y. Aoki, A. Suto, C. Abiko, K. Sanjoh, K. Sugawara, E. Takashita, T. Itagaki, Y. Katsushima, M. Ujike, M. Obuchi, T. Odagiri, and M. Tashiro. 2010. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. *Viol.J.* 7:53. doi:1743-422X-7-53 [pii];10.1186/1743-422X-7-53 [doi].
883. Mayburd, A. L. 2010. Influenza antiviral therapeutics. *Recent Pat Antiinfect.Drug Discov.* 5:64–75. doi:Abstract 14 for E. Pub [pii].
884. McCullers, J. A. 2011. Preventing and treating secondary bacterial infections with antiviral agents. *Antivir.Ther.* 16:123–135. doi:10.3851/IMP1730 [doi].
885. McGill, J., R. N. Van, and K. L. Legge. 2010. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. *J.Exp.Med.* 207:521–534. doi:jem.20091711 [pii];10.1084/jem.20091711 [doi].
886. McLean, E., R. G. Pebody, C. Campbell, M. Chamberland, C. Hawkins, J. S. Nguyen-Van-Tam, I. Oliver, G. E. Smith, C. Ihekweazu, S. Bracebridge, H. Maguire, R. Harris, G. Kafatos, P. J. White, E. Wynne-Evans, J. Green, R. Myers, A. Underwood, T. Dallman, T. Wreghitt, M. Zambon, J. Ellis, N. Phin, B. Smyth, J. McMenamin, and J. M. Watson. 2010. Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol.Infect.* 138:1531–1541. doi:S0950268810001366 [pii];10.1017/S0950268810001366 [doi].
887. McSharry, J. J. and G. L. Drusano. 2011. Antiviral pharmacodynamics in hollow fibre bioreactors. *Antivir.Chem.Chemother.* 21:183–192. doi:10.3851/IMP1770 [doi].
888. Mehta, T., E. McGrath, S. Bheemreddy, H. Salimnia, N. Abdel-Haq, J. Y. Ang, L. Lum, P. Chandrasekar, and G. J. Alangaden. 2010. Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR. *J.Clin.Microbiol.* 48:4326–4328. doi:JCM.01190-10 [pii];10.1128/JCM.01190-10 [doi].
889. Melchjorsen, J., H. Kristiansen, R. Christiansen, J. Rintahaka, S. Matikainen, S. R. Paludan, and R. Hartmann. 2009. Differential regulation of the OASL and OAS1 genes in response to viral infections. *J.Interferon Cytokine Res.* 29:199–207. doi:10.1089/jir.2008.0050 [doi];10.1089/jir.2008.0050 [pii].
890. Melendi, G. A., D. Bridget, A. C. Monsalvo, F. F. Laham, P. Acosta, M. F. Delgado, F. P. Polack, and P. M. Irusta. 2011. Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses. *Virus Genes* 42:46–54. doi:10.1007/s11262-010-0545-9 [doi].
891. Melendi, G. A., S. Coviello, N. Bhat, J. Zea-Hernandez, F. M. Ferolla, and F. P. Polack. 2010. Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus. *Acta Paediatr.* 99:1517–1521. doi:APA1862 [pii];10.1111/j.1651-2227.2010.01862.x [doi].
892. Melgar, M., R. E. De-Leon, M. Geronimo, M. Ramirez, E. J. Asturias, F. Antillon-Klussmann, D. Guimera, and M. A. Caniza. 2011. How we optimized prevention and control of pandemic 2009 influenza A (H1N1) in a resource-limited nation's pediatric oncology unit. *Am.J.Infect.Control* 39:534–535. doi:S0196-6553(10)00989-2 [pii];10.1016/j.ajic.2010.10.012 [doi].
893. Mellouli, F., M. Ouederni, N. Dhoub, M. A. Hajkacem, A. Slim, and M. Bejaoui. 2010. Successful treatment of influenza A virus by oseltamivir in bone marrow transplant recipients. *Pediatr.Transplant.* 14:178–181. doi:PTR1114 [pii];10.1111/j.1399-3046.2008.01114.x [doi].

894. Memoli, M. J., A. S. Davis, K. Proudfoot, D. S. Chertow, R. J. Hrabal, T. Bristol, and J. K. Taubenberger. 2011. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. *J.Infect.Dis.* 203:348–357. doi:jjq067 [pii];10.1093/infdis/jjq067 [doi].
895. Memoli, M. J., R. J. Hrabal, A. Hassantoufighi, B. W. Jagger, Z. M. Sheng, M. C. Eichelberger, and J. K. Taubenberger. 2010. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. *J.Infect.Dis.* 201:1397–1403. doi:10.1086/651610 [doi].
896. Memoli, M. J., R. J. Hrabal, A. Hassantoufighi, M. C. Eichelberger, and J. K. Taubenberger. 2010. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. *Clin.Infect.Dis.* 50:1252–1255. doi:10.1086/651605 [doi].
897. Mendenhall, M., A. Russell, T. Juelich, E. L. Messina, D. F. Smee, A. N. Freiberg, M. R. Holbrook, Y. Furuta, J. C. de la Torre, J. H. Nunberg, and B. B. Gowen. 2011. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. *Antimicrob.Agents Chemother.* 55:782–787. doi:AAC.01219-10 [pii];10.1128/AAC.01219-10 [doi].
898. Meng, S., L. Yang, C. Xu, Z. Qin, H. Xu, Y. Wang, L. Sun, and W. Liu. 2011. Recombinant chicken interferon-alpha inhibits H9N2 avian influenza virus replication in vivo by oral administration. *J.Interferon Cytokine Res.* 31:533–538. doi:10.1089/jir.2010.0123 [doi].
899. Merry, T. and S. Astrautsova. 2010. Alternative approaches to antiviral treatments: focusing on glycosylation as a target for antiviral therapy. *Biotechnol.Appl.Biochem.* 56:103–109. doi:BA20100010 [pii];10.1042/BA20100010 [doi].
900. Metzgar, D., C. A. Myers, K. L. Russell, D. Faix, P. J. Blair, J. Brown, S. Vo, D. E. Swayne, C. Thomas, D. A. Stenger, B. Lin, A. P. Malanoski, Z. Wang, K. M. Blaney, N. C. Long, J. M. Schnur, M. D. Saad, L. A. Borsuk, A. M. Lichanska, M. C. Lorence, B. Weslowski, K. O. Schafer, and C. Tibbetts. 2010. Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants. *PLoS.One.* 5:e8995. doi:10.1371/journal.pone.0008995 [doi].
901. Meunier, I. and M. von, V. 2011. NS1-mediated delay of type I interferon induction contributes to influenza A virulence in ferrets. *J.Gen.Virol.* 92:1635–1644. doi:vir.0.032193-0 [pii];10.1099/vir.0.032193-0 [doi].
902. Meunier, I., S. Pillet, J. N. Simonsen, and M. von, V. 2010. Influenza pathogenesis: lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. *Crit Care Med.* 38:e21–e29. doi:10.1097/CCM.0b013e3181c8b4d5 [doi].
903. Meyerhoff, A. and P. Lietman. 2010. Losing the opportunity to study influenza drugs. *JAMA* 303:878–879. doi:303/9/878 [pii];10.1001/jama.2010.234 [doi].
904. Michaelis, M., H. W. Doerr, and J. Cinatl, Jr. 2009. An influenza A H1N1 virus revival – pandemic H1N1/09 virus. *Infection* 37:381–389. doi:10.1007/s15010-009-9181-5 [doi].
905. Miller, A. C., F. Safi, S. Hussain, R. A. Subramanian, E. M. Elamin, and R. Sinert. 2010. Novel influenza A(H1N1) virus among gravid admissions. *Arch.Intern.Med.* 170:868–873. doi:170/10/868 [pii];10.1001/archinternmed.2010.126 [doi].
906. Mirochnick, M. and D. Clarke. 2011. Oseltamivir pharmacokinetics in pregnancy: a commentary. *Am.J.Obstet.Gynecol.* 204:S94–S95. doi:S0002-9378(11)00233-X [pii];10.1016/j.ajog.2011.02.043 [doi].
907. Mitamura, K. 2010. [Pandemic (H1N1) 2009 in children]. *Nihon Rinsho* 68:1643–1649.
908. Mitrasinovic, P. M. 2010. Advances in the structure-based design of the influenza A neuraminidase inhibitors. *Curr.Drug Targets.* 11:315–326. doi:CDT-Azevedo HT-5 [pii].

909. Mitrasinovic, P. M. 2011. Comment on ‘Comment on “Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)”’. *Biophys.Chem.* 154:102. doi:S0301-4622(11)00009-3 [pii];10.1016/j.bpc.2011.01.008 [doi].
910. Mochalova, L., R. Bright, X. Xu, E. Korchagina, A. Chinarev, N. Bovin, and A. Klimov. 2010. Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors. *Glycoconj.J.* 27:321–327. doi:10.1007/s10719-010-9280-7 [doi].
911. Moghadas, S. M., C. S. Bowman, G. Rost, D. N. Fisman, and J. Wu. 2009. Post-exposure prophylaxis during pandemic outbreaks. *BMC.Med.* 7:73. doi:1741-7015-7-73 [pii];10.1186/1741-7015-7-73 [doi].
912. Moghadas, S. M., N. J. Pizzi, J. Wu, S. E. Tamblyn, and D. N. Fisman. 2011. Canada in the face of the 2009 H1N1 pandemic. *Influenza.Other Respi.Viruses.* 5:83–88. doi:10.1111/j.1750-2659.2010.00184.x [doi].
913. Mohan, S., S. McAtamney, T. Haselhorst, I. M. von, and B. M. Pinto. 2010. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. *J.Med.Chem.* 53:7377–7391. doi:10.1021/jm100822f [doi].
914. Mohapatra, P. R. 2010. Responding to gaps in India’s health system. *Indian J.Med.Res.* 131:461–462.
915. Mohapatra, P. R. and S. Kashyap. 2010. H1N1 influenza pneumonia. *Indian J.Chest Dis.Allied Sci.* 52:105–106.
916. Moll, H. P., T. Maier, A. Zommer, T. Lavoie, and C. Brostjan. 2011. The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. *Cytokine* 53:52–59. doi:S1043-4666(10)00688-5 [pii];10.1016/j.cyto.2010.09.006 [doi].
917. Monsalvo, A. C., J. P. Batalle, M. F. Lopez, J. C. Krause, J. Klemenc, J. Z. Hernandez, B. Maskin, J. Bugna, C. Rubinstein, L. Aguilar, L. Dalurzo, R. Libster, V. Savy, E. Baumeister, L. Aguilar, G. Cabral, J. Font, L. Solari, K. P. Weller, J. Johnson, M. Echavarria, K. M. Edwards, J. D. Chappell, J. E. Crowe, Jr., J. V. Williams, G. A. Melendi, and F. P. Polack. 2011. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. *Nat.Med.* 17:195–199. doi:nm.2262 [pii];10.1038/nm.2262 [doi].
918. Montagu, A., V. Roy, J. Balzarini, R. Snoeck, G. Andrei, and L. A. Agrofoglio. 2011. Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. *Eur.J.Med.Chem.* 46:778–786. doi:S0223-5234(10)00873-1 [pii];10.1016/j.ejmech.2010.12.017 [doi].
919. Montane, E., J. Lecumberri, and M. L. Pedro-Botet. 2011. [Influenza A, pregnancy and neuraminidase inhibitors]. *Med.Clin.(Barc.)* 136:688–693. doi:S0025-7753(10)00266-6 [pii];10.1016/j.medcli.2010.02.006 [doi].
920. Moore, C., M. Galiano, A. Lackenby, T. Abdelrahman, R. Barnes, M. R. Evans, C. Fegan, S. Froude, M. Hastings, S. Knapper, E. Litt, N. Price, R. Salmon, M. Temple, and E. Davies. 2011. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. *J.Infect.Dis.* 203 :18–24. doi:jiq007 [pii];10.1093/infdis/jiq007 [doi].
921. Morgan, O. W., S. Parks, T. Shim, P. A. Blevins, P. M. Lucas, R. Sanchez, N. Walea, F. Loustalot, M. R. Duffy, M. J. Shim, S. Guerra, F. Guerra, G. Mills, J. Verani, B. Alsip, S. Lindstrom, B. Shu, S. Emery, A. L. Cohen, M. Menon, A. M. Fry, F. Dawood, V. P. Fonseca, and S. J. Olsen. 2010. Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April–May 2009. *Emerg.Infect.Dis.* 16:631–637. doi:10.3201/eid1604.091658 [doi].
922. Morimoto, K., K. Kishimura, T. Nagami, N. Kodama, Y. Ogama, M. Yokoyama, S. Toda, T. Chiyoda, R. Shimada, A. Inano, T. Kano, I. Tamai, and T. Ogiwara. 2011. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. *J.Pharm.Sci.* 100:3854–3861. doi:10.1002/jps.22627 [doi].



923. Morioka, I., S. Arakawa, and M. Matsuo. 2010. [Clinical features of, treatments and preventions for newborns with pandemic influenza A (H1N1) 2009]. *Nihon Rinsho* 68:1656–1658.
924. Morton, M. J., E. B. Hsu, S. H. Shah, Y. H. Hsieh, and T. D. Kirsch. 2011. Pandemic influenza and major disease outbreak preparedness in US emergency departments: a selected survey of emergency health professionals. *Am.J.Disaster.Med.* 6:187–195.
925. Moseley, C. E., R. G. Webster, and J. R. Aldridge. 2010. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. *Influenza.Other Respi.Viruses.* 4:307–311. doi:IRV155 [pii];10.1111/j.1750-2659.2010.00155.x [doi].
926. Moss, R. B., R. T. Davey, R. T. Steigbigel, and F. Fang. 2010. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. *J.Antimicrob.Chemother.* 65:1086–1093. doi:dkq100 [pii];10.1093/jac/dkq100 [doi].
927. Moss, R., J. M. McCaw, and J. McVernon. 2011. Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic. *PLoS.One.* 6:e14505. doi:10.1371/journal.pone.0014505 [doi].
928. Mosshammer, D. and M. Eissler. 2010. Correspondence (letter to the editor): Comparison group would have been useful. *Dtsch.Arztebl.Int.* 107:229–230. doi:10.3238/arztebl.2010.0229b [doi].
929. Motard, J., R. Rouxel, A. Paun, M. von, V. M. Bisailon, and J. P. Perreault. 2011. A novel ribozyme-based prophylaxis inhibits influenza a virus replication and protects from severe disease. *PLoS.One.* 6:e27327. doi:10.1371/journal.pone.0027327 [doi];PONE-D-11-12908 [pii].
930. Moules, V., O. Ferraris, O. Terrier, E. Giudice, M. Yver, J. P. Rolland, M. Bouscambert-Duchamp, C. Bergeron, M. Ottmann, E. Fournier, A. Traversier, C. Boule, A. Rivoire, Y. Lin, A. Hay, M. Valette, R. Marquet, M. Rosa-Calatrava, N. Naffakh, G. Schoehn, D. Thomas, and B. Lina. 2010. In vitro characterization of naturally occurring influenza. *Virology* 404:215–224. doi:S0042-6822(10)00297-7 [pii];10.1016/j.virol.2010.04.030 [doi].
931. Moura, F. E. 2010. Influenza in the tropics. *Curr.Opin.Infect.Dis.* 23:415–420. doi:10.1097/QCO.0b013e32833cc955 [doi].
932. Moyad, M. A., L. E. Robinson, E. T. Zawada, J. Kittelsrud, D. G. Chen, S. G. Reeves, and S. Weaver. 2010. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. *J.Altern.Complement Med.* 16:213–218. doi:10.1089/acm.2009.0310 [doi].
933. Mu, Y. P., Z. Y. Zhang, X. R. Chen, X. H. Xi, Y. F. Lu, Y. W. Tang, and H. Z. Lu. 2010. Clinical features, treatments and prognosis of the initial cases of pandemic influenza H1N1 2009 virus infection in Shanghai China. *QJM.* 103:311–317. doi:hcq012 [pii];10.1093/qjmed/hcq012 [doi].
934. Mueller, M. R., P. J. Smith, J. P. Baumbach, J. P. Palumbo, J. I. Meek, K. Gershman, M. Vandermeer, A. R. Thomas, C. E. Long, R. Belflower, N. L. Spina, K. G. Martin, R. Lynfield, K. P. Openo, P. D. Kirley, L. E. Pasutti, B. G. Barnes, W. Schaffner, and L. Kamimoto. 2010. Influenza testing and antiviral prescribing practices among emergency department clinicians in 9 states during the 2006 to 2007 influenza season. *Ann.Emerg.Med.* 55:32–39. doi:S0196-0644(09)01557-1 [pii];10.1016/j.annemergmed.2009.09.019 [doi].
935. Mukhopadhyay, S., A. T. Philip, and R. Stoppacher. 2010. Pathologic findings in novel influenza A (H1N1) virus (“Swine Flu”) infection: contrasting clinical manifestations and lung pathology in two fatal cases. *Am.J.Clin.Pathol.* 133:380–387. doi:133/3/380 [pii];10.1309/AJCPXY17SULQKSWK [doi].
936. Munir, M. 2010. TRIM proteins: another class of viral victims. *Sci.Signal.* 3:jc2. doi:scisignal.3118jc2 [pii];10.1126/scisignal.3118jc2 [doi].
937. Na, S., Y. P. Chong, M. N. Kim, W. Y. Kim, W. Kim, S. B. Hong, C. M. Lim, Y. Koh, J. W. Kwon, S. J. Hong, S. O. Lee, S. H. Choi, Y. S. Kim, J. H. Woo, and S. H. Kim. 2011. Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. *J.Med.Virol.* 83:5–9. doi:10.1002/jmv.21935 [doi].

938. Nadjar, Y., E. Coutelas, P. Prouteau, F. Panzer, D. Paquet, C. Saint-Val, and A. Creange. 2011. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis. *Clin.Neurol.Neurosurg.* 113:316–322. doi:S0303-8467(10)00401-4 [pii];10.1016/j.clineuro.2010.12.013 [doi].
939. Nagarajan, S., C. Tosh, H. V. Murugkar, G. Venkatesh, M. Katare, R. Jain, P. Behera, R. Khandia, S. Tripathi, D. D. Kulkarni, and S. C. Dubey. 2010. Isolation and molecular characterization of a H5N1 virus isolated from a Jungle crow (*Corvus macrohynchos*) in India. *Virus Genes* 41:30–36. doi:10.1007/s11262-010-0477-4 [doi].
940. Nagase, H., K. Moriwaki, M. Kamae, S. Yanagisawa, and I. Kamae. 2009. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. *Value.Health* 12 Suppl 3:S62–S65. doi:VHE629 [pii];10.1111/j.1524-4733.2009.00629.x [doi].
941. Nakai, A., H. Minakami, N. Unno, S. Saito, M. Morikawa, Y. Yoshimura, and T. Terao. 2011. Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009 – low mortality rate may be due to early antiviral use. *J.Infect.* 62:232–233. doi:S0163-4453(11)00003-X [pii];10.1016/j.jinf.2011.01.002 [doi].
942. Nakamura, K., B. S. Schwartz, N. Lindegardh, C. Keh, and B. J. Guglielmo. 2010. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. *Clin. Infect.Dis.* 50:e47–e49. doi:10.1086/651166 [doi].
943. Nakamura, S., K. M. Davis, and J. N. Weiser. 2011. Synergistic stimulation of type I interferons during influenza virus coinfection promotes *Streptococcus pneumoniae* colonization in mice. *J.Clin.Invest* 121:3657–3665. doi:57762 [pii];10.1172/JCI57762 [doi].
944. Nakanishi, H., T. Muta, T. Fujisaki, R. Yoshitomi, T. Kubo, and E. Yokota. 2010. Pandemic (H1N1) 2009-associated ARDS rescued by neuraminidase inhibitors with emergency use of extracorporeal membrane oxygenation. *Intern.Med.* 49:1901–1905. doi:JST.JSTAGE/internalmedicine/49.3745 [pii].
945. Nakauchi, M., M. Ujike, M. Obuchi, E. Takashita, I. Takayama, M. Ejima, K. Oba, N. Konomi, T. Odagiri, M. Tashiro, and T. Kageyama. 2011. Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay. *J.Med.Virol.* 83:1121–1127. doi:10.1002/jmv.22101 [doi].
946. Namendys-Silva, S. A. and M. Hernandez-Garay. 2010. Hydrocortisone therapy for patients with H1N1 influenza A infection. *Intensive Care Med.* 36:1097–1. doi:10.1007/s00134-010-1814-8 [doi].
947. Namendys-Silva, S. A., C. Perez-Jimenez, P. Cornejo-Juarez, D. Vilar-Compte, and P. Volkow. 2011. Prolonged lymphopenia in a patient with lymphoma and severe Pandemic influenza A H1N1 2009 virus infection. *Influenza.Other Respi.Viruses.* 5:167–169. doi:10.1111/j.1750-2659.2010.00193.x [doi].
948. Narain, J. P., R. Kumar, and R. Bhatia. 2009. Pandemic (H1N1) 2009: epidemiological, clinical and prevention aspects. *Natl.Med.J.India* 22:242–247.
949. Narayanan, A., C. Bailey, F. Kashanchi, and K. Kehn-Hall. 2011. Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses. *Expert.Opin.Investig.Drugs* 20:239–254. doi:10.1517/13543784.2011.547852 [doi].
950. Narula, T., M. Safley, and B. P. deBoisblanc. 2010. H1N1-associated acute respiratory distress syndrome. *Am.J.Med.Sci.* 340:499–504. doi:10.1097/MAJ.0b013e3181d94fa5 [doi];0000441-201012000-00016 [pii].
951. Naughtin, M., J. C. Dyason, S. Mardy, S. Sorn, I. M. von, and P. Buchy. 2011. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus. *Antimicrob.Agents Chemother.* 55:2004–2010. doi:AAC.01773-10 [pii];10.1128/AAC.01773-10 [doi].

952. Nayak, J. L. and J. J. Treanor. 2009. Antiviral treatment and prophylaxis of influenza virus in children. *Pediatr. Ann.* 38:667–674. doi:10.3928/00904481-20091117-07 [doi].
953. Newall, A. T., J. G. Wood, N. Oudin, and C. R. Macintyre. 2010. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. *Emerg. Infect. Dis.* 16:224–230. doi:10.3201/eid1602.090571 [doi].
954. Ng, S., B. J. Cowling, V. J. Fang, K. H. Chan, D. K. Ip, C. K. Cheng, T. M. Uyeki, P. M. Houck, J. S. Malik Peiris, and G. M. Leung. 2010. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. *Clin. Infect. Dis.* 50:707–714. doi:10.1086/650458 [doi].
955. Ngai, K. L., W. Y. Lam, N. Lee, T. F. Leung, D. S. Hui, and P. K. Chan. 2010. Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza A H1N1 (H275Y) oseltamivir-resistant and wild-type viruses. *J. Med. Virol.* 82:1295–1298. doi:10.1002/jmv.21783 [doi].
956. Nguyen, H. T., A. M. Fry, P. A. Loveless, A. I. Klimov, and L. V. Gubareva. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. *Clin. Infect. Dis.* 51:983–984. doi:10.1086/656439 [doi].
957. Nguyen, H. T., T. G. Sheu, V. P. Mishin, A. I. Klimov, and L. V. Gubareva. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. *Antimicrob. Agents Chemother.* 54:3671–3677. doi:AAC.00581-10 [pii];10.1128/AAC.00581-10 [doi].
958. Nguyen, J. T., J. D. Hoopes, M. H. Le, D. F. Smee, A. K. Patick, D. J. Faix, P. J. Blair, M. D. de Jong, M. N. Prichard, and G. T. Went. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. *PLoS One.* 5:e9332. doi:10.1371/journal.pone.0009332 [doi].
959. Nguyen-Van-Tam, J. S. 2010. Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience. *J. Antimicrob. Chemother.* 65 Suppl 2:ii3–ii4. doi:dkq033 [pii];10.1093/jac/dkq033 [doi].
960. Nguyen-Van-Tam, J. S. and K. G. Nicholson. 2011. Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic. *J. Clin. Virol.* 50:183. doi:S1386-6532(10)00425-7 [pii];10.1016/j.jcv.2010.10.019 [doi].
961. Nguyen-Van-Tam, J. S., P. J. Openshaw, A. Hashim, E. M. Gadd, W. S. Lim, M. G. Semple, R. C. Read, B. L. Taylor, S. J. Brett, J. McMenamin, J. E. Enstone, C. Armstrong, and K. G. Nicholson. 2010. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May–September 2009). *Thorax* 65:645–651. doi:65/7/645 [pii];10.1136/thx.2010.135210 [doi].
962. Nickel, C. H., F. P. Stephan, M. Dangel, K. Blume, R. Gehrlich, A. Dumoulin, S. Tschudin, D. I. Keller, H. H. Hirsch, A. F. Widmer, and R. Bingisser. 2009. First wave of the influenza A/H1N1v pandemic in Switzerland. *Swiss. Med. Wkly.* 139:731–737. doi:smw-12952 [pii];smw-12952 [doi].
963. Nicoll, A., A. Ammon, G. A. Amato, B. Ciancio, P. Zucs, I. Devaux, F. Plata, A. Mazick, K. Molbak, T. Asikainen, and P. Kramarz. 2010. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. *Public Health* 124:14–23. doi:S0033-3506(09)00367-9 [pii];10.1016/j.puhe.2009.12.001 [doi].
964. Nielsen, J. S., D. A. Wick, E. Tran, B. H. Nelson, and J. R. Webb. 2010. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. *J. Immunol. Methods* 360:149–156. doi:S0022-1759(10)00199-7 [pii];10.1016/j.jim.2010.07.003 [doi].

965. Niikura, M., N. Bance, S. Mohan, and P. B. Mario. 2011. Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro. *Antiviral Res.* 90:160–163. doi:S0166-3542(11)00232-4 [pii];10.1016/j.antiviral.2011.03.180 [doi].
966. Nishide, M., K. Tsujimoto, M. Uozaki, K. Ikeda, H. Yamasaki, A. H. Koyama, and T. Arakawa. 2011. Effects of electrolytes on virus inactivation by acidic solutions. *Int.J.Mol.Med.* 27:803–809. doi:10.3892/ijmm.2011.668 [doi].
967. Nishiura, H. and H. Oshitani. 2011. Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment. *J.Int.Med.Res.* 39:619–628.
968. Nishiyama, M., Y. Yoshida, M. Sato, M. Nishioka, T. Kato, T. Kanai, T. Ishiwata, H. Wakamatsu, S. Nakagawa, A. Kawana, and S. Nonoyama. 2010. Characteristics of paediatric patients with 2009 pandemic influenza A(H1N1) and severe, oxygen-requiring pneumonia in the Tokyo region, 1 September–31 October 2009. *Euro.Surveill* 15.
969. Njouom, R., S. A. Mba, D. N. Noah, V. Gregory, P. Collins, P. Cappy, A. Hay, and D. Rousset. 2010. Circulation of human influenza viruses and emergence of Oseltamivir-resistant A(H1N1) viruses in Cameroon, Central Africa. *BMC.Infect.Dis.* 10:56. doi:1471-2334-10-56 [pii];10.1186/1471-2334-10-56 [doi].
970. Noah, T. L., H. Zhou, J. Monaco, K. Horvath, M. Herbst, and I. Jaspers. 2011. Tobacco smoke exposure and altered nasal responses to live attenuated influenza virus. *Environ.Health Perspect.* 119:78–83. doi:10.1289/ehp.1002258 [doi].
971. Noguera-Julian, A., A. C. Provencs, P. Soler-Palacin, M. Espiau, A. Mur, M. Mendez, and C. Fortuny. 2011. Pandemic influenza a (2009 H1N1) in human immunodeficiency virus-infected catalan children. *Pediatr.Infect.Dis.J.* 30:173–175. doi:10.1097/INF.0b013e3181f5358b [doi].
972. North, F., P. Varkey, G. A. Bartel, D. L. Cox, P. L. Jensen, and R. J. Stroebel. 2010. Can an office practice telephonic response meet the needs of a pandemic? *Telemed.J.E.Health* 16:1012–1016. doi:10.1089/tmj.2010.0102 [doi].
973. Nowak, D. A., G. Griebel, and A. Bock. 2011. Acute myelopathy associated with H1N1 virus infection. *J.Neurol.* 258:34–36. doi:10.1007/s00415-010-5676-3 [doi].
974. Nukiwa, N., A. Suzuki, Y. Furuse, K. Shimabukuro, T. Odagiri, I. Khandaker, and H. Oshitani. 2010. Simplified screening method for detecting oseltamivir resistant pandemic influenza A (H1N1) 2009 virus by a RT-PCR/restriction fragment length polymorphism assay. *J.Virol.Methods* 170:165–168. doi:S0166-0934(10)00318-6 [pii];10.1016/j.jviromet.2010.09.005 [doi].
975. Nukiwa, N., T. Kamigaki, and H. Oshitani. 2010. Fatal cases of pandemic (H1N1) 2009 influenza despite their early antiviral treatment in Japan. *Clin.Infect.Dis.* 51:993–994. doi:10.1086/656443 [doi].
976. Oakley, A. J., S. Barrett, T. S. Peat, J. Newman, V. A. Streltsov, L. Waddington, T. Saito, M. Tashiro, and J. L. McKimm-Breschkin. 2010. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. *J.Med.Chem.* 53:6421–6431. doi:10.1021/jm100621s [doi].
977. Obratzsova, E. V., L. V. Osidak, E. G. Golovacheva, O. I. Afanas'eva, K. K. Mil'kint, E. G. Koroleva, V. P. Drinevskii, and I. A. Vasil'eva. 2009. Interferon status in children during acute respiratory infections. Therapy with interferon. *Bull.Exp.Biol.Med.* 148:275–278.
978. O'Brien, K. B., S. Schultz-Cherry, and L. J. Knoll. 2011. Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection. *J.Virol.* 85:8680–8688. doi:JVI.05142-11 [pii];10.1128/JVI.05142-11 [doi].
979. O'Connor, A. M., A. M. Crawley, and J. B. Angel. 2010. Interleukin-7 enhances memory CD8(+) T-cell recall responses in health but its activity is impaired in human immunodeficiency virus infection. *Immunology* 131:525–536. doi:IMM3325 [pii];10.1111/j.1365-2567.2010.03325.x [doi].

980. Odaira, F., H. Takahashi, T. Toyokawa, Y. Tsuchihashi, T. Kodama, Y. Yahata, T. Sunagawa, K. Taniguchi, and N. Okabe. 2009. Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A(H1N1)v outbreak in Kobe, Japan, May–June 2009. *Euro.Surveill* 14.
981. Ogata, M., K. I. Hidari, T. Murata, S. Shimada, W. Kozaki, E. Y. Park, T. Suzuki, and T. Usui. 2009. Chemoenzymatic synthesis of sialoglycopolypeptides as glycomimetics to block infection by avian and human influenza viruses. *Bioconjug.Chem.* 20:538–549. doi:10.1021/bc800460p [doi];10.1021/bc800460p [pii].
982. Oh, W. S., S. J. Lee, C. S. Lee, J. A. Hur, A. C. Hur, Y. S. Park, S. T. Heo, I. G. Bae, S. W. Park, E. S. Kim, H. B. Kim, K. H. Song, K. S. Lee, S. R. Lee, J. S. Yeom, S. J. Lee, B. N. Kim, Y. G. Kwak, J. H. Lee, Y. K. Kim, H. Y. Kim, N. J. Kim, and M. D. Oh. 2011. A prediction rule to identify severe cases among adult patients hospitalized with pandemic influenza A (H1N1) 2009. *J.Korean Med.Sci.* 26:499–506. doi:10.3346/jkms.2011.26.4.499 [doi].
983. Ohnishi, K. and F. Nakamura-Uchiyama. 2010. Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1). *J.Infect.Chemother.* 16:62–63. doi:10.1007/s10156-009-0006-3 [doi].
984. Okada, T., M. Morozumi, K. Matsubara, O. Komiyama, K. Ubukata, T. Takahashi, and S. Iwata. 2011. Characteristic findings of pediatric inpatients with pandemic (H1N1) 2009 virus infection among severe and nonsevere illnesses. *J.Infect.Chemother.* 17:238–245. doi:10.1007/s10156-010-0115-z [doi].
985. Okamoto, E. 2010. Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu ‘ado’ from Japan. *Expert. Rev.Pharmacoecon.Outcomes.Res.* 10:17–24. doi:10.1586/erp.09.70 [doi].
986. Okomo-Adhiambo, M., G. J. Demmler-Harrison, V. M. Deyde, T. G. Sheu, X. Xu, A. I. Klimov, and L. V. Gubareva. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. *Antimicrob.Agents Chemother.* 54:1834–1841. doi:AAC.01608-09 [pii];10.1128/AAC.01608-09 [doi].
987. Okomo-Adhiambo, M., H. T. Nguyen, K. Sleeman, T. G. Sheu, V. M. Deyde, R. J. Garten, X. Xu, M. W. Shaw, A. I. Klimov, and L. V. Gubareva. 2010. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. *Antiviral Res.* 85:381–388. doi:S0166-3542(09)00534-8 [pii];10.1016/j.antiviral.2009.11.005 [doi].
988. O’Leary, M. F., J. D. Chappell, C. W. Stratton, R. M. Cronin, M. B. Taylor, and Y. W. Tang. 2010. Complex febrile seizures followed by complete recovery in an infant with high-titer 2009 pandemic influenza A (H1N1) virus infection. *J.Clin.Microbiol.* 48:3803–3805. doi:JCM.00825-10 [pii];10.1128/JCM.00825-10 [doi].
989. Olson, M. R., B. E. Russ, P. C. Doherty, and S. J. Turner. 2010. The role of epigenetics in the acquisition and maintenance of effector function in virus-specific CD8 T cells. *IUBMB.Life* 62:519–526. doi:10.1002/iub.351 [doi].
990. Oluoyomi-Obi, T., L. Avery, C. Schneider, A. Kumar, S. Lapinsky, S. Menticoglou, and R. Zarychanski. 2010. Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 Influenza A. *J.Obstet.Gynaecol.Can.* 32:443–452.
991. O’Malley, P. 2009. Bird flu, swine flu, and resistant influenza: the scary development of antiviral-resistant strains-part 2: novel A(H1N1): the flu we never expected. *Clin.Nurse Spec.* 23:293–295. doi:10.1097/NUR.0b013e3181bc3257 [doi];00002800-200911000-00004 [pii].
992. O’Malley, P. 2010. Intravenous peramivir emergency use authorization 2009: update for the clinical nurse specialist. *Clin.Nurse Spec.* 24:51–53. doi:10.1097/NUR.0b013e3181cf5599 [doi];00002800-201003000-00004 [pii].

993. Omi, S. 2010. [Novel influenza H1N1 pandemic: lesson learned]. *Nihon Rinsho* 68:1602–1604.
- O'Neill, A. M., E. J. Livant, and S. J. Ewald. 2010. Interferon alpha-induced inhibition of infectious bursal disease virus in chicken embryo fibroblast cultures differing in Mx genotype. *Avian Dis.* 54:802–806.
994. Onishchenko, G. G. 2010. [Epidemiologic situation on influenza caused by high pathogenic virus A (H1N1) in Russian Federation and in the world]. *Zh.Mikrobiol.Epidemiol.Immunobiol.* 3–9.
995. Ooi, L. S., W. S. Ho, K. L. Ngai, L. Tian, P. K. Chan, S. S. Sun, and V. E. Ooi. 2010. Narcissus tazetta lectin shows strong inhibitory effects against respiratory syncytial virus, influenza A (H1N1, H3N2, H5N1) and B viruses. *J.Biosci.* 35:95–103.
996. Ooi, P. L., F. Y. Lai, C. L. Low, R. Lin, C. Wong, M. Hibberd, and P. A. Tambyah. 2010. Clinical and molecular evidence for transmission of novel influenza A(H1N1/2009) on a commercial airplane. *Arch.Intern.Med.* 170:913–915. doi:170/10/913 [pii];10.1001/archinternmed.2010.127 [doi].
997. Operario, D. J., M. J. Moser, and G. K. St. 2010. Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. *J.Clin.Microbiol.* 48:3517–3524. doi:JCM.01031-10 [pii];10.1128/JCM.01031-10 [doi].
998. Orozovic, G., K. Orozovic, J. Lennerstrand, and B. Olsen. 2011. Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds. *PLoS.One.* 6:e16028. doi:10.1371/journal.pone.0016028 [doi].
999. Ortiz, R. 2009. [Antivirals in the flu prevention]. *Rev.Esp.Quimioter.* 22 Suppl 1:7–9. doi:GripeRaulOrtiz [pii].
1000. Oshima, S., E. Nemoto, M. Kuramochi, Y. Saitoh, and D. Kobayashi. 2009. Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice. *J.Pharm.Pharmacol.* 61:1397–1400. doi:10.1211/jpp/61.10.0018 [doi].
1001. Osterlund, P., J. Pirhonen, N. Ikonen, E. Ronkko, M. Strengell, S. M. Makela, M. Broman, O. J. Hamming, R. Hartmann, T. Ziegler, and I. Julkunen. 2010. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. *J.Virol.* 84:1414–1422. doi:JVI.01619-09 [pii];10.1128/JVI.01619-09 [doi].
1002. Osztoivits, J., C. Balazs, and J. Feher. 2009. [H1N1 influenza – pandemic, 2009]. *Orv.Hetil.* 150:2265–2273. doi:Y4028Q87W11121NV [pii];10.1556/OH.2009.28766 [doi].
1003. Ott, S. R., P. M. Lepper, B. Hauptmeier, R. Bals, M. W. Pletz, C. Schumann, C. Steininger, M. Kleines, and H. Geerdes-Fenge. 2010. [The impact of viruses in lower respiratory tract infections of the adult. Part III: therapy and prevention]. *Pneumologie* 64:115–123. doi:10.1055/s-0029-1215189 [doi].
1004. Ottmann, M., M. B. Duchamp, J. S. Casalegno, E. Frobert, V. Moules, O. Ferraris, M. Valette, V. Escuret, and B. Lina. 2010. Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance. *Antivir.Ther.* 15:721–726. doi:10.3851/IMP1576 [doi].
1005. Ou, Q., Y. Lu, Q. Huang, and X. Cheng. 2009. Clinical analysis of 150 cases with the novel influenza A (H1N1) virus infection in Shanghai, China. *Biosci.Trends* 3:127–130.
1006. Oughton, M., A. Dascal, D. Laporta, H. Charest, M. Afilalo, and M. Miller. 2011. Evidence of viremia in 2 cases of severe pandemic influenza A H1N1/09. *Diagn.Microbiol.Infect.Dis.* 70:213–217. doi:S0732-8893(10)00584-5 [pii];10.1016/j.diagmicrobio.2010.12.013 [doi].
1007. Oyazato, Y., A. Nishiyama, and M. Adachi. 2010. [Case of novel influenza A (H1N1) encephalopathy with transient low TSH level]. *No To Hattatsu* 42:377–379.
1008. Ozdemir, H., E. Ciftci, E. U. Ince, M. Ertem, E. Ince, and U. Dogru. 2011. Hemophagocytic lymphohistiocytosis associated with 2009 pandemic influenza A (H1N1) virus infection. *J.Pediatr.Hematol.Oncol.* 33:135–137. doi:10.1097/MPH.0b013e3181f46baf [doi].

1009. Ozkan, G., S. Ulusoy, K. Kaynar, F. Oztuna, M. Cansiz, and N. Kazaz. 2010. Swine H1N1 infection in a renal transplant recipient. *Exp.Clin.Transplant.* 8:318–320.
1010. Pabbaraju, K., S. Wong, D. K. Kits, and J. D. Fox. 2010. Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008). *Can.J.Infect.Dis.Med. Microbiol.* 21:e87–e91.
1011. Pachler, K. and R. Vlasak. 2011. Influenza C virus NS1 protein counteracts RIG-I-mediated IFN signalling. *Virologia.* 8:48. doi:1743-422X-8-48 [pii];10.1186/1743-422X-8-48 [doi].
1012. Pada, S. and P. A. Tambyah. 2011. Overview/reflections on the 2009 H1N1 pandemic. *Microbes. Infect.* 13:470–478. doi:S1286-4579(11)00039-6 [pii];10.1016/j.micinf.2011.01.009 [doi].
1013. Pai, M. P. and T. P. Lodise, Jr. 2011. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. *Antimicrob.Agents Chemother.* 55:5640–5645. doi:AAC.00422-11 [pii];10.1128/AAC.00422-11 [doi].
1014. Palacios, G., M. Hornig, D. Cisterna, N. Savji, A. V. Bussetti, V. Kapoor, J. Hui, R. Tokarz, T. Briese, E. Baumeister, and W. I. Lipkin. 2009. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. *PLoS.One.* 4:e8540. doi:10.1371/journal.pone.0008540 [doi].
1015. Palm, M., M. M. Garigliany, F. Cornet, and D. Desmecht. 2010. Interferon-induced Sus scrofa Mx1 blocks endocytic traffic of incoming influenza A virus particles. *Vet.Res.* 41:29. doi:10.1051/vetres/2010001 [doi];v09542 [pii].
1016. Pano-Pardo, J. R., A. Martin-Quiros, M. Romero-Gomez, J. Maldonado, A. Martin-Vega, A. Rico-Nieto, M. Mora-Rillo, F. Grill, J. Garcia-Rodriguez, J. R. Arribas, J. Carratala, and J. Rodriguez-Bano. 2011. Perspectives from Spanish infectious diseases professionals on 2009 A (H1N1) influenza: the third half. *Clin.Microbiol.Infect.* 17:845–850. doi:CLM3322 [pii];10.1111/j.1469-0691.2010.03322.x [doi].
1017. Papp, I., C. Sieben, A. L. Sisson, A. Herrmann, and R. Haag. 2010. Inhibition of influenza virus activity by newly designed multivalent glycoarchitectures. *J.Control Release* 148:e114–e115. doi:S0168-3659(10)00568-7 [pii];10.1016/j.jconrel.2010.07.086 [doi].
1018. Papp, I., C. Sieben, A. L. Sisson, J. Kostka, C. Bottcher, K. Ludwig, A. Herrmann, and R. Haag. 2011. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes. *Chembiochem.* 12:887–895. doi:10.1002/cbic.201000776 [doi].
1019. Papp, I., C. Sieben, K. Ludwig, M. Roskamp, C. Bottcher, S. Schlecht, A. Herrmann, and R. Haag. 2010. Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles. *Small* 6:2900–2906. doi:10.1002/sml.201001349 [doi].
1020. Parakh, A., A. Kumar, V. Kumar, A. K. Dutta, and S. Khare. 2010. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1): an experience from a tertiary care center in north India. *Indian J.Pediatr.* 77:981–985. doi:10.1007/s12098-010-0168-0 [doi].
1021. Parikh, F. S. 2011. Experience from influenza A (H1N1) pandemic 2009 – is prevention better than cure? *J.Assoc.Physicians India* 59:11–12.
1022. Park, A. Y., W. H. Kim, J. A. Kang, H. J. Lee, C. K. Lee, and H. R. Moon. 2011. Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation. *Bioorg.Med.Chem.* 19:3945–3955. doi:S0968-0896(11)00379-8 [pii];10.1016/j.bmc.2011.05.026 [doi].
1023. Park, J. W. and W. H. Jo. 2009. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir. *J.Chem.Inf.Model.* 49:2735–2741. doi:10.1021/ci900348n [doi].

1024. Park, J. W. and W. H. Jo. 2010. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. *Eur.J.Med.Chem.* 45:536–541. doi:S0223-5234(09)00542-X [pii];10.1016/j.ejmech.2009.10.040 [doi].
1025. Park, K. H., S. O. Lee, S. H. Choi, M. N. Kim, J. H. Lee, H. Yi, M. S. Kim, E. H. Hong, Y. S. Kim, J. H. Woo, and S. H. Kim. 2011. Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus. *Scand.J.Infect.Dis.* 43:151–155. doi:10.3109/00365548.2010.515608 [doi].
1026. Paton, N. I., L. Lee, Y. Xu, E. E. Ooi, Y. B. Cheung, S. Archuleta, G. Wong, and A. Wilder-Smith. 2011. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. *Lancet Infect.Dis.* 11:677–683. doi:S1473-3099(11)70065-2 [pii];10.1016/S1473-3099(11)70065-2 [doi].
1027. Payungporn, S., N. Panjaworayan, J. Makkoch, and Y. Poovorawan. 2010. Molecular characteristics of the human pandemic influenza A virus (H1N1). *Acta Virol.* 54:155–163.
1028. Peacey, M., R. J. Hall, S. Sonnberg, M. Ducatez, S. Paine, M. Nicol, J. C. Ralston, D. Bandaranayake, V. Hope, R. J. Webby, and S. Huang. 2010. Pandemic (H1N1) 2009 and seasonal influenza A (H1N1) co-infection, New Zealand, 2009. *Emerg.Infect.Dis.* 16:1618–1620.
1029. Pebody, R. G., R. Harris, G. Kafatos, M. Chamberland, C. Campbell, J. S. Nguyen-Van-Tam, E. McLean, N. Andrews, P. J. White, E. Wynne-Evans, J. Green, J. Ellis, T. Wreghitt, S. Bracebridge, C. Ihekweazu, I. Oliver, G. Smith, C. Hawkins, R. Salmon, B. Smyth, J. McMenamin, M. Zambon, N. Phin, and J. M. Watson. 2011. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. *Emerg.Infect.Dis.* 17:990–999. doi:10.3201/eid1706.101161 [doi].
1030. Pedersen, G., A. Halstensen, H. Sjursen, A. Naess, E. K. Kristoffersen, and R. J. Cox. 2011. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. *Scand.J.Immunol.* 74:210–218. doi:10.1111/j.1365-3083.2011.02561.x [doi].
1031. Peiris, J. S., C. Y. Cheung, C. Y. Leung, and J. M. Nicholls. 2009. Innate immune responses to influenza A H5N1: friend or foe? *Trends Immunol.* 30:574–584. doi:S1471-4906(09)00175-6 [pii];10.1016/j.it.2009.09.004 [doi].
1032. Peperzak, V., Y. Xiao, E. A. Veraar, and J. Borst. 2010. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. *J.Clin.Invest* 120:168–178. doi:40178 [pii];10.1172/JCI40178 [doi].
1033. Perlroth, D. J., R. J. Glass, V. J. Davey, D. Cannon, A. M. Garber, and D. K. Owens. 2010. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States. *Clin.Infect.Dis.* 50:165–174. doi:10.1086/649867 [doi].
1034. Perret, P. C. 2010. [Pandemic influenza one year after the first wave: what did we learn?]. *Rev. Chilena.Infectol.* 27:144–147. doi:S0716-10182010000200008 [pii];/S0716-10182010000200008 [doi].
1035. Peters, P. J., J. Skarbinski, J. K. Louie, S. Jain, M. Roland, S. G. Jani, L. Finelli, and J. T. Brooks. 2011. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1) – United States, spring and summer 2009. *Clin.Infect.Dis.* 52 Suppl 1:S183–S188. doi:ciq036 [pii];10.1093/cid/ciq036 [doi].
1036. Petersen, E., D. B. Keld, S. Ellermann-Eriksen, S. Gubbels, S. Ilkjaer, S. Jensen-Fangel, and C. Lindskov. 2011. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. *Scand.J.Infect.Dis.* 43:495–503. doi:10.3109/00365548.2011.556144 [doi].
1037. Peterson, E., T. Ryser, S. Funk, D. Inouye, M. Sharma, H. Qin, T. A. Cross, and D. D. Busath. 2011. Functional reconstitution of influenza A M2(22-62). *Biochim.Biophys.Acta* 1808:516–521. doi:S0005-2736(10)00364-0 [pii];10.1016/j.bbamem.2010.10.010 [doi].



1038. Petinaux, B., L. May, R. Katz, J. Luk, and I. A. Goldenberg. 2009. H1N1 and institutions of higher education. *Am.J.Disaster.Med.* 4:287–298.
1039. Peuschel, K. E. 2011. Some clinical evidence of the hypothesis of an indirect antiviral effect of propranolol through immunoactivation. *Med.Hypotheses* 76:689–691. doi:S0306-9877(11)00046-6 [pii];10.1016/j.mehy.2011.01.034 [doi].
1040. Picone, O., O. Ami, C. Vauloup-Fellous, V. Martinez, M. Guillet, C. Dupont-Bernabe, A. C. Donnadiou, C. Trichot, M. V. Senat, H. Fernandez, and R. Frydman. 2009. [Pandemic influenza A H1N1 2009 flu during pregnancy: Epidemiology, diagnosis and management]. *J.Gynecol.Obstet.Biol.Reprod.(Paris)* 38:615–628. doi:S0368-2315(09)00259-2 [pii];10.1016/j.jgyn.2009.09.016 [doi].
1041. Pielak, R. M. and J. J. Chou. 2010. Flu channel drug resistance: a tale of two sites. *Protein Cell* 1:246–258. doi:10.1007/s13238-010-0025-y [doi].
1042. Pietrantonio, A., E. Dofrelli, A. Tinari, M. G. Ammendolia, S. Puzelli, C. Fabiani, I. Donatelli, and F. Superti. 2010. Bovine lactoferrin inhibits influenza A virus induced programmed cell death in vitro. *Biometals* 23:465–475. doi:10.1007/s10534-010-9323-3 [doi].
1043. Pinter, G., I. Bereczki, G. Batta, R. Otvos, F. Sztaricskai, E. Roth, E. Ostorhazi, F. Rozgonyi, L. Naesens, M. Szarvas, Z. Boda, and P. Herczegh. 2010. Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. *Bioorg.Med.Chem.Lett.* 20:2713–2717. doi:S0960-894X(10)00411-7 [pii];10.1016/j.bmcl.2010.03.080 [doi].
1044. Pitak-Arnnop, P., S. Schubert, K. Dhanuthai, K. Sappayatosok, U. Bauer, P. Ngamwannagul, U. G. Liebert, and A. Hemprich. 2010. Swine-origin H1N1 influenza A virus and dental practice: a critical review. *Clin.Oral Investig.* 14:11–17. doi:10.1007/s00784-009-0373-2 [doi].
1045. Pizzorno, A., X. Bouhy, Y. Abed, and G. Boivin. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. *J.Infect.Dis.* 203:25–31. doi:jjq010 [pii];10.1093/infdis/jjq010 [doi].
1046. Pizzorno, A., Y. Abed, and G. Boivin. 2011. Influenza drug resistance. *Semin.Respir.Crit Care Med.* 32:409–422. doi:10.1055/s-0031-1283281 [doi].
1047. Pleschka, S., M. Stein, R. Schoop, and J. B. Hudson. 2009. Anti-viral properties and mode of action of standardized *Echinacea purpurea* extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). *Viol.J.* 6:197. doi:1743-422X-6-197 [pii];10.1186/1743-422X-6-197 [doi].
1048. Poletti, P., M. Ajelli, and S. Merler. 2011. The effect of risk perception on the 2009 H1N1 pandemic influenza dynamics. *PLoS.One.* 6:e16460. doi:10.1371/journal.pone.0016460 [doi].
1049. Porntrakulpipat, S., S. Supankong, A. Chatchawanchonteera, and P. Pakdee. 2010. RNA interference targeting nucleocapsid protein (C) inhibits classical swine fever virus replication in SK-6 cells. *Vet. Microbiol.* 142:41–44. doi:S0378-1135(09)00458-1 [pii];10.1016/j.vetmic.2009.09.041 [doi].
1050. Postma, M. J., G. Milne, E. A. Nelson, B. Pyenson, M. Basili, R. Coker, J. Oxford, and L. P. Garrison, Jr. 2010. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. *Expert.Rev.Anti.Infect.Ther.* 8:1431–1439. doi:10.1586/eri.10.136 [doi].
1051. Powell, N. D., J. W. Mays, M. T. Bailey, M. L. Hanke, and J. F. Sheridan. 2011. Immunogenic dendritic cells primed by social defeat enhance adaptive immunity to influenza A virus. *Brain Behav.Immun.* 25:46–52. doi:S0889-1591(10)00417-4 [pii];10.1016/j.bbi.2010.07.243 [doi].
1052. Power, C., T. W. Marfleet, L. Qualtiere, W. Xiao, and P. Bretscher. 2010. Development of Th1 imprints to rBCG expressing a foreign protein: implications for vaccination against HIV-1 and diverse influenza strains. *J.Biomed.Biotechnol.* 2010:591348. doi:10.1155/2010/591348 [doi].
1053. Preziosi, P. 2011. Influenza pharmacotherapy: present situation, strategies and hopes. *Expert.Opin. Pharmacother.* 12:1523–1549. doi:10.1517/14656566.2011.566557 [doi].

1054. Principi, N., S. Esposito, and P. Marchisio. 2011. Present and future of influenza prevention in pediatrics. *Expert.Opin.Biol.Ther.* 11:641–653. doi:10.1517/14712598.2011.562495 [doi].
1055. Prosper, O., O. Saucedo, D. Thompson, G. Torres-Garcia, X. Wang, and C. Castillo-Chavez. 2011. Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza. *Math.Biosci.Eng* 8:141–170.
1056. Prusty, B. K., A. Karlas, T. F. Meyer, and T. Rudel. 2011. Genome-wide RNAi screen for viral replication in mammalian cell culture. *Methods Mol.Biol.* 721:383–395. doi:10.1007/978-1-61779-037-9\_24 [doi].
1057. Pulverer, J. E., U. Rand, S. Lienenklaus, D. Kugel, N. Zietara, G. Kochs, R. Naumann, S. Weiss, P. Staeheli, H. Hauser, and M. Koster. 2010. Temporal and spatial resolution of type I and III interferon responses in vivo. *J.Virol.* 84:8626–8638. doi:JV1.00303-10 [pii];10.1128/JVI.00303-10 [doi].
1058. Puzelli, S., M. Facchini, M. A. Di, C. Fabiani, A. Lackenby, M. Zambon, and I. Donatelli. 2011. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. *Antiviral Res.* 90:205–212. doi:S0166-3542(11)00282-8 [pii];10.1016/j.antiviral.2011.04.003 [doi].
1059. Qiao, L., H. Phipps-Yonas, B. Hartmann, T. M. Moran, S. C. Sealfon, and F. Hayot. 2010. Immune response modeling of interferon beta-pretreated influenza virus-infected human dendritic cells. *Biophys.J.* 98:505–514. doi:S0006-3495(09)01723-8 [pii];10.1016/j.bpj.2009.10.049 [doi].
1060. Qin, G., K. Yu, T. Shi, C. Luo, G. Li, W. Zhu, and H. Jiang. 2010. How does influenza virus escape from amantadine? *J.Phys.Chem.B* 114:8487–8493. doi:10.1021/jp911588y [doi].
1061. Qiu, Z. and Z. Feng. 2010. Transmission dynamics of an influenza model with vaccination and antiviral treatment. *Bull.Math.Biol.* 72:1–33. doi:10.1007/s11538-009-9435-5 [doi].
1062. Querci, M., M. E. Stryjewski, F. Herrera, E. Temporiti, W. Alcalá, N. Chavez, L. Figueras, F. Barberis, M. Echavarría, C. Videla, A. Martínez, G. Carballal, and P. Bonvehi. 2011. Healthcare personnel infected with novel influenza A H1N1 virus in university hospitals in Buenos Aires, Argentina. *Scand.J.Infect.Dis.* 43:70–74. doi:10.3109/00365548.2010.515244 [doi].
1063. Quispe-Laime, A. M., J. D. Bracco, P. A. Barberio, C. G. Campagne, V. E. Rolfo, R. Umberger, and G. U. Meduri. 2010. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. *Intensive Care Med.* 36:33–41. doi:10.1007/s00134-009-1727-6 [doi].
1064. Racette, R. J. 2009. Will we be judged ready for the influenza pandemic? *Healthc.Manage.Forum* 22:6–23.
1065. Raj, R., M. Cerdan, A. Yepeshurtado, R. Kimbrough, and K. Nugent. 2009. Novel swine-origin (S-OIV) H1N1 influenza A pneumonia in a lung transplant patient: a case report and review of the literature on performance characteristics of rapid screening tests for the S-OIV. *Am.J.Med.Sci.* 338:506–508. doi:10.1097/MAJ.0b013e3181c78a64 [doi];00000441-200912000-00018 [pii].
1066. Rajatonirina, S., J. M. Heraud, L. Randrianasolo, N. Razanajatovo, T. Ramandimbisoa, M. Ratsitorahina, and V. Richard. 2011. Pandemic influenza A(H1N1) 2009 virus outbreak among boarding school pupils in Madagascar: compliance and adverse effects of prophylactic oseltamivir treatment. *J.Infect.Dev.Ctries.* 5:156–162.
1067. Rajik, M. and K. Yusoff. 2011. Peptide inhibitors against influenza virus. *Antivir.Chem.Chemother.* 21:151–154. doi:10.3851/IMP1728 [doi].
1068. Rameix-Welti, M. A., S. Munier, G. S. Le, F. Cuvelier, F. Agou, V. Enouf, N. Naffakh, and S. van der Werf. 2011. Neuraminidase of 2007–2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. *Antivir.Ther.* 16:597–603. doi:10.3851/IMP1804 [doi].

1069. Ramirez-Gonzalez, J. E., E. Gonzalez-Duran, P. Alcantara-Perez, C. Wong-Arambula, H. Olivera-Diaz, I. Cortez-Ortiz, G. Barrera-Badillo, H. Nguyen, L. Gubareva, I. Lopez-Martinez, J. A. Diaz-Quinonez, M. A. Lezana-Fernandez, H. L. Gatell-Ramirez, J. A. Cordova Villalobos, M. Hernandez-Avila, and C. Alpuche-Aranda. 2011. Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. *Emerg.Infect.Dis.* 17:283–286. doi:10.3201/eid1702.100897 [doi].
1070. Ramsey, C. and A. Kumar. 2011. H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. *Curr.Opin.Crit Care* 17:64–71. doi:10.1097/MCC.0b013e3283427259 [doi].
1071. Ranasinghe, C., F. Eysers, J. Stambas, D. B. Boyle, I. A. Ramshaw, and A. J. Ramsay. 2011. A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/ rFPV and poxvirus-poxvirus prime boost immunisations. *Vaccine* 29:3008–3020. doi:S0264-410X(11)00178-2 [pii];10.1016/j.vaccine.2011.01.106 [doi].
1072. Rance, K. S. 2009. Influenza's widening scope. Dangers prompt broader vaccination. *Adv.Nurse Pract.* 17:39–42, 57.
1073. Ranjan, P., L. Jayashankar, V. Deyde, H. Zeng, W. G. Davis, M. B. Pearce, J. B. Bowzard, M. A. Hoelscher, V. Jeisy-Scott, M. E. Wiens, S. Gangappa, L. Gubareva, A. Garcia-Sastre, J. M. Katz, T. M. Tumpey, T. Fujita, and S. Sambhara. 2010. 5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication. *Virol.J.* 7:102. doi:1743-422X-7-102 [pii];10.1186/1743-422X-7-102 [doi].
1074. Rao, J. R., A. K. Jha, R. K. Rawal, A. Sharon, C. W. Day, D. L. Barnard, D. F. Smee, and C. K. Chu. 2010. (-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). *Bioorg.Med.Chem. Lett.* 20:2601–2604. doi:S0960-894X(10)00274-X [pii];10.1016/j.bmcl.2010.02.074 [doi].
1075. Rashad, A. E., A. H. Shamroukh, R. E. Abdel-Megeid, A. Mostafa, M. A. Ali, and K. Banert. 2010. A facile synthesis and anti-avian influenza virus (H5N1) screening of some novel pyrazolopyrimidine nucleoside derivatives. *Nucleosides Nucleotides Nucleic Acids* 29:809–820. doi:930374927 [pii];10.1080/15257770.2010.529480 [doi].
1076. Rashad, A. E., A. H. Shamroukh, R. E. Abdel-Megeid, A. Mostafa, R. el-Shesheny, A. Kandeil, M. A. Ali, and K. Banert. 2010. Synthesis and screening of some novel fused thiophene and thienopyrimidine derivatives for anti-avian influenza virus (H5N1) activity. *Eur.J.Med.Chem.* 45:5251–5257. doi:S0223-5234(10)00623-9 [pii];10.1016/j.ejmech.2010.08.044 [doi].
1077. Raza, A., H. Shareef, H. Salim, R. Khushal, and H. Bokhari. 2011. Selection of predicted siRNA as potential antiviral therapeutic agent against influenza virus. *Bioinformatics.* 6:340–343.
1078. Raziorrouh, B., W. Schraut, T. Gerlach, D. Nowack, N. H. Gruner, A. Ulsenheimer, R. Zachoval, M. Wachtler, M. Spannagl, J. Haas, H. M. Diepolder, and M. C. Jung. 2010. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. *Hepatology* 52:1934–1947. doi:10.1002/hep.23936 [doi].
1079. Razonable, R. R. and A. J. Eid. 2009. Viral infections in transplant recipients. *Minerva Med.* 100:479–501. doi:R10092971 [pii].
1080. Reading, P. C., P. G. Whitney, D. L. Pickett, M. D. Tate, and A. G. Brooks. 2010. Influenza viruses differ in ability to infect macrophages and to induce a local inflammatory response following intraperitoneal injection of mice. *Immunol.Cell Biol.* 88:641–650. doi:icb201011 [pii];10.1038/icb.2010.11 [doi].
1081. Reddy, D. 2010. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. *J.Antimicrob.Chemother.* 65 Suppl 2:ii35–ii40. doi:dkq014 [pii];10.1093/jac/dkq014 [doi].
1082. Redelman-Sidi, G. 2010. Influenza in patients with hematologic disease: an ounce of prevention is worth a pound of cure. *Leuk.Lymphoma* 51:1954–1956. doi:10.3109/10428194.2010.510226 [doi].

1083. Reece, P. A. 2010. Treatment options for H5N1: lessons learned from the H1N1 pandemic. *Postgrad. Med.* 122:134–141. doi:10.3810/pgm.2010.09.2210 [doi].
1084. Reemers, S. S., M. J. Groot Koerkamp, F. C. Holstege, E. W. van, and L. Vervelde. 2009. Cellular host transcriptional responses to influenza A virus in chicken tracheal organ cultures differ from responses in in vivo infected trachea. *Vet.Immunol.Immunopathol.* 132:91–100. doi:S0165-2427(09)00161-5 [pii];10.1016/j.vetimm.2009.04.021 [doi].
1085. Rehwinkel, J., C. P. Tan, D. Goubau, O. Schulz, A. Pichlmair, K. Bier, N. Robb, F. Vreede, W. Barclay, E. Fodor, and Reis e Sousa. 2010. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. *Cell* 140:397–408. doi:S0092-8674(10)00021-8 [pii];10.1016/j.cell.2010.01.020 [doi].
1086. Rello, J., A. Rodriguez, P. Ibanez, L. Socias, J. Cebrian, A. Marques, J. Guerrero, S. Ruiz-Santana, E. Marquez, F. Del Nogal-Saez, F. Alvarez-Lerma, S. Martinez, M. Ferrer, M. Avellanas, R. Granada, E. Maravi-Poma, P. Albert, R. Sierra, L. Vidaur, P. Ortiz, d. P. Prieto, I. B. Galvan, and C. Leon-Gil. 2009. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. *Crit Care* 13:R148. doi:cc8044 [pii];10.1186/cc8044 [doi].
1087. Renaud, C., A. A. Boudreault, J. Kuypers, K. H. Lofy, L. Corey, M. J. Boeckh, and J. A. Englund. 2011. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. *Emerg.Infect. Dis.* 17:653–660. doi:10.3201/eid1704.101429 [doi].
1088. Renaud, C., J. Kuypers, and L. Corey. 2010. Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. *J.Clin.Virol.* 49:21–25. doi:S1386-6532(10)00263-5 [pii];10.1016/j.jcv.2010.06.019 [doi].
1089. Renaud, C., J. Kuypers, F. Aspesberro, M. Rosenfeld, and J. A. Englund. 2011. Emergence of oseltamivir-resistant pandemic H1N1 in an immunocompetent child with severe status asthmaticus. *J.Asthma* 48:572–575. doi:10.3109/02770903.2011.582660 [doi].
1090. Renaud, C., S. A. Pergam, C. Polyak, R. Jain, J. Kuypers, J. A. Englund, L. Corey, and M. J. Boeckh. 2010. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. *Transpl.Infect.Dis.* 12:513–517. doi:10.1111/j.1399-3062.2010.00582.x [doi].
1091. Rendon-Macias, M. E., F. A. Hernandez-Romano, J. Iglesias-Leboreiro, and I. Bernardez-Zapata. 2010. [Therapeutic conduct in children attended in emergency room during the epidemic of influenza A H1N1]. *Rev.Med.Inst.Mex.Seguro.Soc.* 48:607–614.
1092. Resa-Infante, P., N. Jorba, R. Coloma, and J. Ortin. 2011. The influenza virus RNA synthesis machine: advances in its structure and function. *RNA.Biol.* 8:207–215. doi:14513 [pii].
1093. Rezza, G. 2009. Swine-origin influenza virus A(H1N1)v: lessons learnt from the early phase of the epidemic. *Eur.J.Public Health* 19:572–573. doi:ckp156 [pii];10.1093/eurpub/ckp156 [doi].
1094. Richard, M., O. Ferraris, A. Erny, M. Barthelemy, A. Traversier, M. Sabatier, A. Hay, Y. P. Lin, R. J. Russell, and B. Lina. 2011. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. *Antimicrob.Agents Chemother.* 55:2942–2952. doi:AAC.01699-10 [pii];10.1128/AAC.01699-10 [doi].
1095. Ridao-Cano, N., A. I. Sanchez-Fructuoso, A. Rodriguez-Moreno, and A. Barrientos. 2010. H1N1 2009 influenza in kidney transplant patients. *Transplantation* 90:224–225. doi:10.1097/TP.0b013e3181e065f7 [doi];00007890-201007270-00019 [pii].
1096. Ringel, J. S., M. Moore, J. Zambrano, and N. Lurie. 2009. Will routine annual influenza prevention and control systems serve the United States well in a pandemic? *Disaster.Med.Public Health Prep.* 3 Suppl 2:S160–S165. doi:10.1097/DMP.0b013e3181ad1833 [doi].

1097. Riquelme, R., M. Riquelme, M. L. Rioseco, C. Inzunza, Y. Gomez, C. Contreras, J. Riquelme, P. Peyrani, T. Wiemken, and J. Ramirez. 2010. Characteristics of hospitalised patients with 2009 H1N1 influenza in Chile. *Eur.Respir.J.* 36:864–869. doi:09031936.00180409 [pii];10.1183/09031936.00180409 [doi].
1098. Rodriguez, A., E. Diaz, I. Martin-Loeches, A. Sandiumenge, L. Canadell, J. J. Diaz, J. C. Figueira, A. Marques, F. Alvarez-Lerma, J. Valles, B. Baladin, F. Garcia-Lopez, B. Suberviola, R. Zaragoza, S. Trefler, J. Bonastre, J. Blanquer, and J. Rello. 2011. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. *J.Antimicrob.Chemother.* 66:1140–1149. doi:dkq511 [pii];10.1093/jac/dkq511 [doi].
1099. Rodriguez, A., L. Socias, J. E. Guerrero, J. C. Figueira, N. Gonzalez, E. Maravi-Poma, L. Lorente, M. Martin, A. Albaya-Moreno, A. Algora-Weber, J. Valles, C. Leon-Gil, T. Lisboa, C. Balasini, M. Villabon, R. Perez-Padilla, D. Barahona, and J. Rello. 2010. [Pandemic influenza A in the ICU: experience in Spain and Latin America. GETGAG/SEMICYUC/(Spanish Working Group on Severe Pandemic Influenza A/SEMICYUC)]. *Med.Intensiva.* 34:87–94. doi:S0210-5691(09)00173-9 [pii];10.1016/j.medin.2009.12.005 [doi].
1100. Rogers, V. L., J. S. Sheffield, S. W. Roberts, D. D. McIntire, J. P. Luby, S. Trevino, and G. D. Wendel, Jr. 2010. Presentation of seasonal influenza A in pregnancy: 2003–2004 influenza season. *Obstet. Gynecol.* 115:924–929. doi:10.1097/AOG.0b013e3181da0c5e [doi];00006250-201005000-00009 [pii].
1101. Rohn, A., H. H. Kessler, T. Valentin, W. Linkesch, and P. Neumeister. 2011. Prophylactic oseltamivir treatment for prevention of donor-recipient influenza A H1N1 virus transmission does not compromise stem cell mobilization or engraftment. *Bone Marrow Transplant.* 46:312–313. doi:bmt201097 [pii];10.1038/bmt.2010.97 [doi].
1102. Romanovskaia, A. A., A. M. Durymanov, K. A. Sharshov, A. V. Zaikovskaia, I. M. Susloparov, A. M. Shestopalov, I. A. Leneva, and I. G. Drozdov. 2009. [Investigation of susceptibility of influenza viruses A (H1N1), the cause of infection in humans in April–May 2009, to antivirals in MDCK cell culture]. *Antibiot.Khimioter.* 54:41–47.
1103. Romantsov, M. G., F. I. Ershov, and A. L. Kovalenko. 2011. [Problems in treating influenza and acute respiratory infection in children]. *Eksp.Klin.Farmakol.* 74:41–45.
1104. Rosenberg, M., C. Tram, A. Kuper, and N. Daneman. 2010. Rash associated with pandemic (H1N1) influenza. *CMAJ.* 182:E146. doi:cmaj.091678 [pii];10.1503/cmaj.091678 [doi].
1105. Rosenborg, S. 2010. [Can oseltamivir (Tamiflu) be used in dialysis-requiring renal failure?]. *Lakartidningen* 107:116–117.
1106. Rosenfeld, L. A., P. Etkind, A. Grasso, A. J. Adams, and M. C. Rothholz. 2011. Extending the reach: local health department collaboration with community pharmacies in Palm Beach County, Florida for H1N1 influenza pandemic response. *J.Public Health Manag.Pract.* 17:439–448. doi:10.1097/PHH.0b013e31821138ae [doi];00124784-201109000-00008 [pii].
1107. Rothberg, M. B. and S. D. Haessler. 2010. Complications of seasonal and pandemic influenza. *Crit Care Med.* 38:e91–e97. doi:10.1097/CCM.0b013e3181c92eeb [doi].
1108. Rowe, T., D. Banner, A. Farooqui, D. C. Ng, A. A. Kelvin, S. Rubino, S. S. Huang, Y. Fang, and D. J. Kelvin. 2010. In vivo ribavirin activity against severe pandemic H1N1 Influenza A/Mexico/4108/2009. *J.Gen.Virol.* 91:2898–2906. doi:vir.0.024323-0 [pii];10.1099/vir.0.024323-0 [doi].
1109. Ruigrok, R. W., T. Crepin, D. J. Hart, and S. Cusack. 2010. Towards an atomic resolution understanding of the influenza virus replication machinery. *Curr.Opin.Struct.Biol.* 20:104–113. doi:S0959-440X(09)00195-X [pii];10.1016/j.sbi.2009.12.007 [doi].

1110. Ruiz-Carrascoso, G., I. Casas, F. Pozo, C. Perez-Gonzalez, J. Reina, and P. Perez-Brena. 2010. Development and implementation of influenza A virus subtyping and detection of genotypic resistance to neuraminidase inhibitors. *J.Med.Virol.* 82:843–853. doi:10.1002/jmv.21692 [doi].
1111. Ruiz-Carrascoso, G., I. Casas, F. Pozo, M. Gonzalez-Vincent, and P. Perez-Brena. 2010. Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant. *Antivir.Ther.* 15:1059–1063. doi:10.3851/IMP1657 [doi].
1112. Rungrotmongkol, T., M. Malaisree, N. Nunthaboot, P. Sompornpisut, and S. Hannongbua. 2010. Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach. *Amino.Acids* 39:393–398. doi:10.1007/s00726-009-0452-3 [doi].
1113. Rungrotmongkol, T., P. Yotmanee, N. Nunthaboot, and S. Hannongbua. 2011. Computational studies of influenza A virus at three important targets: hemagglutinin, neuraminidase and M2 protein. *Curr. Pharm.Des* 17:1720–1739. doi:BSP/CPD/E-Pub/000476 [pii].
1114. Rungrotmongkol, T., T. Udommaneethanakit, M. Malaisree, N. Nunthaboot, P. Intharathep, P. Sompornpisut, and S. Hannongbua. 2009. How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? *Biophys.Chem.* 145:29–36. doi:S0301-4622(09)00160-4 [pii];10.1016/j.bpc.2009.08.006 [doi].
1115. Rungrotmongkol, T., T. Udommaneethanakit, V. Frecer, and S. Miertus. 2010. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance. *Comb.Chem.High Throughput.Screen.* 13:268–277. doi:CCHTS # 46 [pii].
1116. Ruuskanen, O., E. Lahti, L. C. Jennings, and D. R. Murdoch. 2011. Viral pneumonia. *Lancet* 377:1264–1275. doi:S0140-6736(10)61459-6 [pii];10.1016/S0140-6736(10)61459-6 [doi].
1117. Ryu, Y. B., H. J. Jeong, S. Y. Yoon, J. Y. Park, Y. M. Kim, S. J. Park, M. C. Rho, S. J. Kim, and W. S. Lee. 2011. Influenza virus neuraminidase inhibitory activity of phlorotannins from the edible brown alga *Ecklonia cava*. *J.Agric.Food Chem.* 59:6467–6473. doi:10.1021/jf2007248 [doi].
1118. Sachedina, N. and L. J. Donaldson. 2010. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. *Lancet* 376:1846–1852. doi:S0140-6736(10)61195-6 [pii];10.1016/S0140-6736(10)61195-6 [doi].
1119. Saenz, R. A., M. Quinlivan, D. Elton, S. Macrae, A. S. Blunden, J. A. Mumford, J. M. Daly, P. Digard, A. Cullinane, B. T. Grenfell, J. W. McCauley, J. L. Wood, and J. R. Gog. 2010. Dynamics of influenza virus infection and pathology. *J.Virol.* 84:3974–3983. doi:JVI.02078-09 [pii];10.1128/JVI.02078-09 [doi].
1120. Saha, A., N. Jha, N. K. Dubey, V. K. Gupta, and M. Kalaivani. 2010. Swine-origin influenza A (H1N1) in Indian children. *Ann.Trop.Paediatr.* 30:51–55. doi:10.1179/146532810X12637745452031 [doi].
1121. Saha, R. K., T. Takahashi, Y. Kurebayashi, K. Fukushima, A. Minami, N. Kinbara, M. Ichitani, Y. M. Sagesaka, and T. Suzuki. 2010. Antiviral effect of strictinin on influenza virus replication. *Antiviral Res.* 88:10–18. doi:S0166-3542(10)00641-8 [pii];10.1016/j.antiviral.2010.06.008 [doi].
1122. Sahin, D. Y., M. Demir, B. Kurtaran, and A. Usal. 2010. A case of myocarditis mimicking acute coronary syndrome associated with H1N1 influenza A virus infection. *Turk.Kardiyol.Dern.Ars* 38:572–575.
1123. Sahini, L., A. Tempczyk-Russell, and R. Agarwal. 2010. Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response. *PLoS.One.* 5:e9268. doi:10.1371/journal.pone.0009268 [doi].
1124. Saito, R. 2010. [High prevalence of antiviral resistant influenza, and reduced clinical effectiveness of the antivirals against resistant influenza strains]. *Jpn.J.Antibiot.* 63:81–91.

1125. Saito, R., I. Sato, Y. Suzuki, T. Baranovich, R. Matsuda, N. Ishitani, C. Dapat, I. C. Dapat, H. Zaraket, T. Oguma, and H. Suzuki. 2010. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. *Pediatr.Infect.Dis.J.* 29:898–904. doi:10.1097/INF.0b013e3181de9d24 [doi].
1126. Saladino, R., M. Barontini, M. Crucianelli, L. Nencioni, R. Sgarbanti, and A. T. Palamara. 2010. Current advances in anti-influenza therapy. *Curr.Med.Chem.* 17:2101–2140. doi:BSP/CMC/E-Pub/127 [pii].
1127. Salahuddin, P. and A. U. Khan. 2010. Structural and functional analysis of NS1 and NS2 proteins of H1N1 subtype. *Genomics Proteomics.Bioinformatics.* 8:190–199. doi:S1672-0229(10)60021-6 [pii];10.1016/S1672-0229(10)60021-6 [doi].
1128. Sambhara, S. and G. A. Poland. 2010. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. *Annu.Rev.Med.* 61:187–198. doi:10.1146/annurev.med.050908.132031 [doi].
1129. Samejima, T., N. Takayanagi, T. Ishiguro, Y. Miyahara, T. Yanagisawa, and Y. Sugita. 2010. [Case of novel influenza A (H1N1) pneumonia with shrinkage of a pulmonary lesion]. *Nihon Kokyuki.Gakkai Zasshi* 48:930–937.
1130. Samra, T., M. Pawar, and A. Yadav. 2011. Comparative evaluation of acute respiratory distress syndrome in patients with and without H1N1 infection at a tertiary care referral center. *Indian J.An aesth.* 55:47–51. doi:10.4103/0019-5049.76602 [doi].
1131. Sanchez, R. O., P. A. Gonzalez, S. Gomez-Puerta, G. J. Noda, R. A. Vega, J. C. Aguila Benites, A. L. Suarez, N. C. Parra, and J. R. Toledo Alonso. 2011. Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens. *Comp Immunol. Microbiol.Infect.Dis.* 34:259–265. doi:S0147-9571(10)00088-3 [pii];10.1016/j.cimid.2010.12.001 [doi].
1132. Sanchez-Torrent, L., M. Trivino-Rodriguez, P. Suero-Toledano, G. Claret-Teruel, C. Munoz-Almagro, L. Martinez-Sanchez, I. Jordan-Garcia, and J. J. Garcia-Garcia. 2010. Novel influenza A (H1N1) encephalitis in a 3-month-old infant. *Infection* 38:227–229. doi:10.1007/s15010-010-0014-3 [doi].
1133. Sander, B., A. Nizam, L. P. Garrison, Jr., M. J. Postma, M. E. Halloran, and I. M. Longini, Jr. 2009. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. *Value.Health* 12:226–233. doi:S1098-3015(10)60699-7 [pii];10.1111/j.1524-4733.2008.00437.x [doi].
1134. Sandvik, D. and J. M. Keegan. 2010. H1N1 influenza in elderly nursing home residents. *J.Am.Med. Dir.Assoc.* 11:11–12. doi:S1525-8610(09)00401-0 [pii];10.1016/j.jamda.2009.10.011 [doi].
1135. Sanekata, T., T. Fukuda, T. Miura, H. Morino, C. Lee, K. Maeda, K. Araki, T. Otake, T. Kawahata, and T. Shibata. 2010. Evaluation of the antiviral activity of chlorine dioxide and sodium hypochlorite against feline calicivirus, human influenza virus, measles virus, canine distemper virus, human herpesvirus, human adenovirus, canine adenovirus and canine parvovirus. *Biocontrol.Sci.* 15:45–49. doi:JST.JSTAGE/bio/15.45 [pii].
1136. Sanz, H. F., N. M. Malanda, B. M. Veiga, and M. P. Sanjuan Lopez. 2010. [New challenges in community-acquired pneumonia]. *Arch.Bronconeumol.* 46 Suppl 6:22–26. doi:S0300-2896(10)70039-9 [pii];10.1016/S0300-2896(10)70039-9 [doi].
1137. Sarti, E., G. Manuell-Lee, J. L. Mosqueda, F. Gabilondo, A. de la Torre, V. Arreguin, G. Dominguez-Cheritt, A. E. Macias, and J. A. Cordova-Villalobos. 2010. [Influenza A H1N1 (2009): considerations at the time of declaring the end of the contingency in Mexico]. *Rev.Invest Clin.* 62:289–298.
1138. Sato, E., T. Nakamura, and H. Koide. 2011. Rhabdomyolysis induced by influenza A infection: case report and review of literature. *Ther.Apher.Dial.* 15:208–209. doi:10.1111/j.1744-9987.2010.00900.x [doi].

1139. Sato, T. and H. Moriuchi. 2011. [Antiviral drugs]. *Nihon Rinsho* 69:505–510.
1140. Sato, Y., K. Morimoto, M. Hirayama, and K. Hori. 2011. High mannose-specific lectin (KAA-2) from the red alga *Kappaphycus alvarezii* potently inhibits influenza virus infection in a strain-independent manner. *Biochem.Biophys.Res.Commun.* 405:291–296. doi:S0006-291X(11)00050-7 [pii];10.1016/j.bbrc.2011.01.031 [doi].
1141. Savarino, A. 2011. Use of chloroquine in viral diseases. *Lancet Infect.Dis.* 11:653–654. doi:S1473-3099(11)70092-5 [pii];10.1016/S1473-3099(11)70092-5 [doi].
1142. Savinova, O. V., N. I. Pavlova, and E. I. Boreko. 2009. [New betulin derivatives in combination with rimantadine for inhibition of influenza virus reproduction]. *Antibiot.Khimioter.* 54:16–20.
1143. Sawabuchi, T., S. Suzuki, K. Iwase, C. Ito, D. Mizuno, H. Togari, I. Watanabe, S. R. Talukder, J. Chida, and H. Kido. 2009. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. *Respirology.* 14:1173–1179. doi:RES1639 [pii];10.1111/j.1440-1843.2009.01639.x [doi].
1144. Sawamura, R., T. Shimizu, Y. Sun, K. Yasukawa, M. Miura, M. Toriyama, S. Motohashi, W. Watanabe, K. Konno, and M. Kurokawa. 2010. In vitro and in vivo anti-influenza virus activity of diarylheptanoids isolated from *Alpinia officinarum*. *Antivir.Chem.Chemother.* 21:33–41. doi:10.3851/IMP1676 [doi].
1145. Sawamura, R., Y. Sun, K. Yasukawa, T. Shimizu, W. Watanabe, and M. Kurokawa. 2010. Antiviral activities of diarylheptanoids against influenza virus in vitro. *J.Nat.Med.* 64:117–120. doi:10.1007/s11418-009-0372-2 [doi].
1146. Scagnolari, C., S. Trombetti, A. Solda, C. Selvaggi, K. Monteleone, L. Spano, A. Pierangeli, M. Clementi, O. Turriziani, and G. Antonelli. 2011. Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. *J.Interferon Cytokine Res.* 31:475–479. doi:10.1089/jir.2010.0125 [doi].
1147. Schaberg, T. and R. Burger. 2010. [The 2009/2010 pandemic]. *Pneumologie* 64:755–767. doi:10.1055/s-0030-1255949 [doi].
1148. Schaberg, T., T. Bauer, K. Dalhoff, S. Ewig, D. Kohler, J. Lorenz, G. Rohde, M. W. Pletz, S. Rosseau, B. Schaaf, N. Suttrop, T. Welte, W. Haas, and A. Reuss. 2010. [Management of a new influenza A/H1N1 virus pandemic within the hospital. Statement of the German Society of Pneumology]. *Pneumologie* 64:124–129. doi:10.1055/s-0029-1243862 [doi].
1149. Schatz, M., C. D. Chambers, K. L. Jones, C. Louik, and A. A. Mitchell. 2011. Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. *Am.J.Obstet.Gynecol.* 204:S64–S68. doi:S0002-9378(11)00086-X [pii];10.1016/j.ajog.2011.01.047 [doi].
1150. Scheible, K., G. Zhang, J. Baer, M. Azadniv, K. Lambert, G. Pryhuber, J. J. Treanor, and D. J. Topham. 2011. CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. *Vaccine* 29:2159–2168. doi:S0264-410X(10)01846-3 [pii];10.1016/j.vaccine.2010.12.073 [doi].
1151. Schirmer, P. and M. Holodniy. 2009. Oseltamivir for treatment and prophylaxis of influenza infection. *Expert.Opin.Drug Saf* 8:357–371. doi:10.1517/14740330902840519
1152. Schneider, R. B., J. G. Benitez, A. D'Angelo, and K. Tyo. 2010. Pandemic influenza: antiviral preparedness and health care workers. *Disaster.Med.Public Health Prep.* 4:55–61. doi:01273293-201003000-00012 [pii].
1153. Schneider, R. B., J. G. Benitez, A. D'Angelo, and K. Tyo. 2010. Pandemic Influenza: Antiviral Preparedness and Health Care Workers. *Disaster.Med.Public Health Prep.* doi:10.1097/DMP.0b013e3181cb4156 [doi].
1154. Schnitzler, S. U. and P. Schnitzler. 2009. An update on swine-origin influenza virus A/H1N1: a review. *Virus Genes* 39:279–292. doi:10.1007/s11262-009-0404-8 [doi].



1155. Schreuder, M. F., M. van der Flier, N. B. Knops, L. Koster-Kamphuis, and R. J. Bruggemann. 2010. Oseltamivir dosing in children undergoing hemodialysis. *Clin.Infect.Dis.* 50:1427–1428. doi:10.1086/652287 [doi].
1156. Schuchat, A., B. P. Bell, and S. C. Redd. 2011. The science behind preparing and responding to pandemic influenza: the lessons and limits of science. *Clin.Infect.Dis.* 52 Suppl 1:S8–12. doi:ciq007 [pii];10.1093/cid/ciq007 [doi].
1157. Schulz, O., A. Pichlmair, J. Rehwinkel, N. C. Rogers, D. Scheuner, H. Kato, O. Takeuchi, S. Akira, R. J. Kaufman, and Reis e Sousa. 2010. Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. *Cell Host.Microbe* 7:354–361. doi:S1931-3128(10)00135-6 [pii];10.1016/j.chom.2010.04.007 [doi].
1158. Scott, A., R. More, and R. C. Freebairn. 2010. Tongue swelling complicating management of a ventilated patient with acute respiratory distress syndrome secondary to novel influenza A (H1N1). *Anaesth.Intensive Care* 38:370–372.
1159. Scott, K. 2010. Pandemic influenza H1N1 2009 – the Canadian experience. *J.Popul.Ther.Clin. Pharmacol.* 17:e358–e362.
1160. Seale, A. C., F. S. Toussaint, A. Finn, and J. I. Fraser. 2011. Prescribing in a pandemic: best use of oseltamivir in paediatric intensive care. *Arch.Dis.Child* 96:902–903. doi:adc.2010.183806 [pii];10.1136/adc.2010.183806 [doi].
1161. Seale, H., K. F. Ward, N. Zwar, D. Van, J. Leask, and C. R. Macintyre. 2010. Examining the knowledge of and attitudes to pandemic influenza among general practice staff. *Med.J.Aust.* 192:378–380. doi:sea10925\_fm [pii].
1162. Seale, H., Q. Wang, P. Yang, D. E. Dwyer, Y. Zhang, X. Wang, X. Li, and C. R. Macintyre. 2010. Hospital Health Care Workers' Understanding of and Attitudes Toward Pandemic Influenza in Beijing. *Asia Pac.J.Public Health.* doi:1010539510365097 [pii];10.1177/1010539510365097 [doi].
1163. Sebastian, M. R., R. Lodha, and S. K. Kabra. 2009. Swine origin influenza (swine flu). *Indian J.Pediatr.* 76:833–841. doi:10.1007/s12098-009-0170-6 [doi].
1164. Seeds, R. E., S. Mukhopadhyay, I. M. Jones, S. Gordon, and J. L. Miller. 2011. The role of myeloid receptors on murine plasmacytoid dendritic cells in induction of type I interferon. *Int. Immunopharmacol.* 11:794–801. doi:S1567-5769(11)00048-8 [pii];10.1016/j.intimp.2011.01.013 [doi].
1165. Seibert, C. W., M. Kaminski, J. Philipp, D. Rubbenstroth, R. A. Albrecht, F. Schwalm, S. Stertz, R. A. Medina, G. Kochs, A. Garcia-Sastre, P. Staeheli, and P. Palese. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. *J.Virol.* 84 :11219–11226. doi:JVI.01424-10 [pii];10.1128/JVI.01424-10 [doi].
1166. Seidel, A., D. Smith, E. Yung, L. Aquino, T. Srivastava, V. Pullarkat, R. Spielberger, S. J. Forman, and D. J. Diamond. 2011. CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults. *Biol.Blood Marrow Transplant.* 17:524–533. doi:S1083-8791(10)00196-5 [pii];10.1016/j.bbmt.2010.04.015 [doi].
1167. Seitz, C., T. Frensing, D. Hoper, G. Kochs, and U. Reichl. 2010. High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state. *J.Gen.Virol.* 91:1754–1763. doi:vir.0.020370-0 [pii];10.1099/vir.0.020370-0 [doi].
1168. Selvam, P., M. Chandramohan, B. L. Hurst, and D. F. Smee. 2010. Activity of isatine-sulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture. *Antivir.Chem.Chemother.* 20:143–146. doi:10.3851/IMP1471 [doi].
1169. Semenova, N. P., E. N. Prokudina, D. K. Livov, and V. E. Nebol'sin. 2010. [Effect of the antiviral drug Ingaviruin on intracellular transformations and import into the nucleus of influenza A virus nucleocapsid protein]. *Vopr.Virusol.* 55:17–20.

1170. Seo, S. U., H. J. Kwon, H. J. Ko, Y. H. Byun, B. L. Seong, S. Uematsu, S. Akira, and M. N. Kweon. 2011. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. *PLoS.Pathog.* 7:e1001304. doi:10.1371/journal.ppat.1001304 [doi].
1171. Serkedjieva, J., E. Nikolova, and N. Kirilov. 2010. Synergistic inhibition of influenza A virus replication by a plant polyphenol-rich extract and epsilon-aminocaproic acid in vitro and in vivo. *Acta Virol.* 54:137–145.
1172. Sert, A., A. Yazar, D. Odabas, and H. Bilgin. 2010. An unusual cause of fever in a neonate: influenza A (H1N1) virus pneumonia. *Pediatr.Pulmonol.* 45:734–736. doi:10.1002/ppul.21245 [doi].
1173. Seth, S., M. V. Templin, G. Severson, and O. Baturevych. 2010. A potential therapeutic for pandemic influenza using RNA interference. *Methods Mol.Biol.* 623:397–422. doi:10.1007/978-1-60761-588-0\_26 [doi].
1174. Sethi, S. K. 2010. H1N1 infection: a pediatric nephrologist's perspective. *Clin.Exp.Nephrol.* 14:300–301. doi:10.1007/s10157-010-0281-4 [doi].
1175. Sevetoglu, E., B. Kural, A. E. Beskardes, and S. Hatipoglu. 2011. Exertional rhabdomyolysis after influenza A (H3N2) infection in a basketball player boy. *Ann.Trop.Paediatr.* 31:93–96. doi:10.1179/1465328110Y.0000000005 [doi].
1176. Shah, P. D. and J. F. McDyer. 2010. Viral infections in lung transplant recipients. *Semin.Respir.Crit Care Med.* 31:243–254. doi:10.1055/s-0030-1249120 [doi].
1177. Shahid, Z., A. Kleppinger, B. Gentleman, A. R. Falsey, and J. E. McElhaney. 2010. Clinical and immunologic predictors of influenza illness among vaccinated older adults. *Vaccine* 28:6145–6151. doi:S0264-410X(10)01031-5 [pii];10.1016/j.vaccine.2010.07.036 [doi].
1178. Shang, R. F., J. P. Liang, Z. Y. Na, H. J. Yang, Y. Lu, L. Y. Hua, W. Z. Guo, Y. Cui, and L. Wang. 2010. In vivo inhibition of NAS preparation on H9N2 subtype AIV. *Viol.Sin.* 25:145–150. doi:10.1007/s12250-010-3082-8 [doi].
1179. Shanmugam, R. S. and S. Shankar . 2009. Swine flu: need to adopt safety measures. *Nurs.J.India* 100:176–178.
1180. Shapira, S. D., I. Gat-Viks, B. O. Shum, A. Dricot, M. M. de Grace, L. Wu, P. B. Gupta, T. Hao, S. J. Silver, D. E. Root, D. E. Hill, A. Regev, and N. Hacohen. 2009. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. *Cell* 139:1255–1267. doi:S0092-8674(09)01565-7 [pii];10.1016/j.cell.2009.12.018 [doi].
1181. Shapshak, P., F. Chiappelli, C. Somboonwit, and J. Sinnott. 2011. The influenza pandemic of 2009: lessons and implications. *Mol.Diagn.Ther.* 15:63–81. doi:1 [pii];10.2165/11590660-000000000-00000 [doi].
1182. Sharomi, O., C. N. Podder, A. B. Gumel, S. M. Mahmud, and E. Rubinstein. 2011. Modelling the transmission dynamics and control of the novel 2009 swine influenza (H1N1) pandemic. *Bull.Math. Biol.* 73:515–548. doi:10.1007/s11538-010-9538-z [doi].
1183. Sharp, J. K., J. Hereth, and J. Fasanello. 2011. Bronchoscopic findings in a child with pandemic novel H1N1 influenza A and methicillin-resistant *Staphylococcus aureus*. *Pediatr.Pulmonol.* 46:92–95. doi:10.1002/ppul.21306 [doi].
1184. Shaw, D. M. 2010. Transatlantic issues: report from Scotland. *Camb.Q.Healthc.Ethics* 19:310–320. doi:S0963180110000083 [pii];10.1017/S0963180110000083 [doi].
1185. Shen, C. H., O. Talay, V. S. Mahajan, I. B. Leskov, H. N. Eisen, and J. Chen. 2010. Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues. *Proc.Natl.Acad.Sci.U.S.A* 107:22587–22592. doi:1016350108 [pii];10.1073/pnas.1016350108 [doi].

1186. Shen, Y. and H. Lu. 2010. Pandemic (H1N1) 2009, Shanghai, China. *Emerg.Infect.Dis.* 16:1011–1013. doi:10.3201/eid1606.090991 [doi].
1187. Sherman, S. E., J. Foster, and S. Vaid. 2009. Emergency Use Authority and 2009 H1N1 influenza. *Biosecur.Bioterror.* 7:245–250. doi:10.1089/bsp.2009.0040 [doi].
1188. Sheu, T. G., A. M. Fry, R. J. Garten, V. M. Deyde, T. Shwe, L. Bullion, P. J. Peebles, Y. Li, A. I. Klimov, and L. V. Gubareva. 2011. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008–2010. *J.Infect.Dis.* 203:13–17. doi:jjq005 [pii];10.1093/infdis/jiq005 [doi].
1189. Sheu, T. G., V. M. Deyde, R. J. Garten, A. I. Klimov, and L. V. Gubareva. 2010. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. *Antiviral Res.* 85:354–360. doi:S0166-3542(09)00509-9 [pii];10.1016/j.antiviral.2009.10.022 [doi].
1190. Shi, D., D. Yang, E. P. Prinssen, B. E. Davies, and B. Yan. 2011. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. *J.Infect.Dis.* 203:937–942. doi:jjq145 [pii];10.1093/infdis/jiq145 [doi].
1191. Shibnev, V. A., T. M. Garayev, M. P. Finogenova, E. S. Shevchenko, and E. I. Burtseva. 2011. [New adamantane derivatives and ways of overcoming the resistance of influenza A viruses to rimantadine and amantadine]. *Vopr.Virusol.* 56:36–39.
1192. Shih, S. R., J. T. Horng, L. L. Poon, T. C. Chen, J. Y. Yeh, H. P. Hsieh, S. N. Tseng, C. Chiang, W. L. Li, Y. S. Chao, and J. T. Hsu. 2010. BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. *J.Antimicrob.Chemother.* 65:63–71. doi:dkp393 [pii];10.1093/jac/dkp393 [doi].
1193. Shih, S. R., T. Y. Chu, G. R. Reddy, S. N. Tseng, H. L. Chen, W. F. Tang, M. S. Wu, J. Y. Yeh, Y. S. Chao, J. T. Hsu, H. P. Hsieh, and J. T. Horng. 2010. Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity. *J.Biomed.Sci.* 17:13. doi:1423-0127-17-13 [pii];10.1186/1423-0127-17-13 [doi].
1194. Shim, E., G. B. Chapman, and A. P. Galvani. 2010. Decision making with regard to antiviral intervention during an influenza pandemic. *Med.Decis.Making* 30:E64–E81. doi:0272989X10374112 [pii];10.1177/0272989X10374112 [doi].
1195. Shin, S. Y., C. Kang, J. Gwack, J. H. Kim, H. S. Kim, Y. A. Kang, H. G. Lee, J. S. Kim, J. K. Lee, and S. H. Kim. 2011. Drug-resistant pandemic (H1N1) 2009, South Korea. *Emerg.Infect.Dis.* 17:702–704. doi:10.3201/eid1704.101467 [doi].
1196. Shin, W. J., K. H. Lee, M. H. Park, and B. L. Seong. 2010. Broad-spectrum antiviral effect of *Agrimonia pilosa* extract on influenza viruses. *Microbiol.Immunol.* 54:11–19. doi:MIM173 [pii];10.1111/j.1348-0421.2009.00173.x [doi].
1197. Shirey, K. A., Q. M. Nhu, K. C. Yim, Z. J. Roberts, J. R. Tejjaro, D. L. Farber, J. C. Blanco, and S. N. Vogel. 2011. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. *J.Leukoc.Biol.* 89:351–357. doi:jlbb.0410216 [pii];10.1189/jlbb.0410216 [doi].
1198. Shishkina, L. I., M. O. Skarnovich, A. S. Kabanov, A. A. Sergeev, S. A. Tarasov, S. A. Sergeeva, Epshtein, E. M. Malkova, E. A. Stavskii, and I. G. Drozdov. 2011. [Study of efficacy of anaferon pediatric in mice infected by pandemic influenza virus A(H1N1/09)v]. *Zh.Mikrobiol.Epidemiol. Immunobiol.* 83–86.
1199. Shishkina, L. N., M. O. Skarnovich, A. S. Kabanov, A. A. Sergeev, S. E. Olkin, S. A. Tarasov, M. V. Belopolskaya, S. A. Sergeeva, O. I. Epstein, E. M. Malkova, E. A. Stavsky, and I. G. Drozdov. 2010. Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09). *Bull.Exp.Biol.Med.* 149:612–614.

1200. Shishkina, L. N., V. E. Nebol'sin, A. S. Kabanov, M. O. Skarnovich, N. A. Mazurkova, A. A. Sergeev, O. A. Serova, E. A. Stavskii, and I. G. Drozdov. 2011. [In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v]. *Zh.Mikrobiol.Epidemiol.Immunobiol.* 93:93–96.
1201. Shishkina, L. N., V. E. Nebol'sin, A. S. Kabanov, M. O. Skarnovich, U. B. Erdyneeva, N. A. Mazurkova, O. A. Serova, E. A. Stavskii, and I. G. Drozdov. 2010. [In vitro efficacy of Ingavirin against the pandemic influenza virus A(H1N1/09)v]. *Antibiot.Khimioter.* 55:12–16.
1202. Shishkina, L. N., V. E. Nebol'sin, M. O. Skarnovich, A. S. Kabanov, A. A. Sergeev, U. B. Erdyneeva, O. A. Serova, O. K. Demina, A. P. Agafonov, E. A. Stavskii, and I. G. Drozdov. 2010. [In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus]. *Antibiot.Khimioter.* 55:32–35.
1203. Shu, M., Z. Lin, Y. Zhang, Y. Wu, H. Mei, and Y. Jiang. 2011. Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus. *J.Mol.Model.* 17:587–592. doi:10.1007/s00894-010-0757-x [doi].
1204. Siedler, K. and H. Skopnik. 2010. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. *Pediatr.Infect.Dis.J.* 29:495–498. doi:10.1097/INF.0b013e3181cc4d01 [doi].
1205. Simon, P., B. P. Holder, X. Bouhy, Y. Abed, C. A. Beauchemin, and G. Boivin. 2011. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. *J.Clin.Microbiol.* 49:715–717. doi:JCM.01732-10 [pii];10.1128/JCM.01732-10 [doi].
1206. Singer, A. C., V. Colizza, H. Schmitt, J. Andrews, D. Balcan, W. E. Huang, V. D. Keller, A. Vespignani, and R. J. Williams. 2011. Assessing the ecotoxicologic hazards of a pandemic influenza medical response. *Environ.Health Perspect.* 119:1084–1090. doi:10.1289/ehp.1002757 [doi].
1207. Singh, K., S. Vasoo, J. Stevens, P. Schreckenberger, and G. Trenholme. 2010. Pitfalls in diagnosis of pandemic (novel) A/H1N1 2009 influenza. *J.Clin.Microbiol.* 48:1501–1503. doi:JCM.02483-09 [pii];10.1128/JCM.02483-09 [doi].
1208. Singh, S., H. Toro, D. C. Tang, W. E. Briles, L. M. Yates, R. T. Kopulos, and E. W. Collisson. 2010. Non-replicating adenovirus vectors expressing avian influenza virus hemagglutinin and nucleocapsid proteins induce chicken specific effector, memory and effector memory CD8(+) T lymphocytes. *Virology* 405:62–69. doi:S0042-6822(10)00299-0 [pii];10.1016/j.virol.2010.05.002 [doi].
1209. Singh, S., W. E. Briles, B. Lupiani, and E. W. Collisson. 2010. Avian influenza viral nucleocapsid and hemagglutinin proteins induce chicken CD8+ memory T lymphocytes. *Virology* 399:231–238. doi:S0042-6822(09)00814-9 [pii];10.1016/j.virol.2009.12.029 [doi].
1210. Sinha, M. 2009. Swine flu. *J.Infect.Public Health* 2:157–166. doi:S1876-0341(09)00061-6 [pii];10.1016/j.jiph.2009.08.006 [doi].
1211. Sipo, I., M. Knauf, H. Fechner, W. Poller, O. Planz, R. Kurth, and S. Norley. 2011. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). *Vaccine* 29:1690–1699. doi:S0264-410X(10)01810-4 [pii];10.1016/j.vaccine.2010.12.037 [doi].
1212. Sistigu, A., L. Bracci, M. Valentini, E. Proietti, R. Bona, D. R. Negri, A. R. Ciccaglione, E. Tritarelli, R. Nisini, M. Equestre, A. Costantino, C. Marcantonio, S. M. Santini, C. Lapenta, S. Donati, P. Tataseo, M. Miceli, A. Cara, and M. Federico. 2011. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. *Vaccine* 29:3465–3475. doi:S0264-410X(11)00294-5 [pii];10.1016/j.vaccine.2011.02.059 [doi].

1213. Siston, A. M., S. A. Rasmussen, M. A. Honein, A. M. Fry, K. Seib, W. M. Callaghan, J. Louie, T. J. Doyle, M. Crockett, R. Lynfield, Z. Moore, C. Wiedeman, M. Anand, L. Tabony, C. F. Nielsen, K. Waller, S. Page, J. M. Thompson, C. Avery, C. B. Springs, T. Jones, J. L. Williams, K. Newsome, L. Finelli, and D. J. Jamieson. 2010. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. *JAMA* 303:1517–1525. doi:303/15/1517 [pii];10.1001/jama.2010.479 [doi].
1214. Skalli, S., E. Ferreira, J. F. Bussieres, and B. Allenet. 2010. [Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?]. *Ann.Pharm.Fr.* 68:269–274. doi:S0003-4509(10)00067-2 [pii];10.1016/j.pharma.2010.04.005 [doi].
1215. Skarbinski, J., S. Jain, A. Bramley, E. J. Lee, J. Huang, D. Kirschke, A. Stone, T. Wedlake, S. M. Richards, S. Page, P. Ragan, L. Bullion, D. Neises, R. M. Williams, B. P. Petrucci, M. Vandermeer, K. H. Lofy, J. Gindler, and L. Finelli. 2011. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States – September–October 2009. *Clin.Infect.Dis.* 52 Suppl 1:S50–S59. doi:ciq021 [pii];10.1093/cid/ciq021 [doi].
1216. Skountzou, I., M. P. Martin, B. Wang, L. Ye, D. Koutsonanos, W. Weldon, J. Jacob, and R. W. Compans. 2010. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. *Vaccine* 28:4103–4112. doi:S0264-410X(09)01080-9 [pii];10.1016/j.vaccine.2009.07.058 [doi].
1217. Skret-Magierlo, J., A. Florek, A. Skret, Z. Piechota, K. Botiuk, M. Pajak, and P. Kokot. 2010. Severe A/H1N1 influenza in four pregnant women in Podkarpacie Province of Poland. *Ginekol.Pol.* 81:227–231.
1218. Slater, F. R., A. C. Singer, S. Turner, J. J. Barr, and P. L. Bond. 2011. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu(R)) and loss of nutrient removal performance. *FEMS Microbiol.Lett.* 315:17–22. doi:10.1111/j.1574-6968.2010.02163.x [doi].
1219. Sleeman, K., V. P. Mishin, V. M. Deyde, Y. Furuta, A. I. Klimov, and L. V. Gubareva. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. *Antimicrob.Agents Chemother.* 54:2517–2524. doi:AAC.01739-09 [pii];10.1128/AAC.01739-09 [doi].
1220. Smee, D. F., B. L. Hurst, and M. H. Wong. 2011. Effects of TheraMax on influenza virus infections in cell culture and in mice. *Antivir.Chem.Chemother.* 21:231–237. doi:10.3851/IMP1744 [doi].
1221. Smee, D. F., B. L. Hurst, M. H. Wong, E. B. Tarbet, Y. S. Babu, K. Klumpp, and J. D. Morrey. 2010. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. *Antiviral Res.* 88:38–44. doi:S0166-3542(10)00667-4 [pii];10.1016/j.antiviral.2010.07.003 [doi].
1222. Smee, D. F., B. L. Hurst, M. H. Wong, K. W. Bailey, E. B. Tarbet, J. D. Morrey, and Y. Furuta. 2010. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. *Antimicrob.Agents Chemother.* 54:126–133. doi:AAC.00933-09 [pii];10.1128/AAC.00933-09 [doi].
1223. Smith, A. M. and A. S. Perelson. 2011. Influenza A virus infection kinetics: quantitative data and models. *Wiley.Interdiscip.Rev.Syst.Biol.Med.* 3:429–445. doi:10.1002/wsbm.129 [doi].
1224. Smith, J. R. 2010. Oseltamivir in human avian influenza infection. *J.Antimicrob.Chemother.* 65 Suppl 2:ii25–ii33. doi:dkq013 [pii];10.1093/jac/dkq013 [doi].
1225. Smith, J. R., C. R. Rayner, B. Donner, M. Wollenhaupt, K. Klumpp, and R. Dutkowski. 2011. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. *Adv.Ther.* 28:927–959. doi:10.1007/s12325-011-0072-7 [doi].
1226. Smith, J. R., R. E. Ariano, and S. Toovey. 2010. The use of antiviral agents for the management of severe influenza. *Crit Care Med.* 38:e43–e51. doi:10.1097/CCM.0b013e3181c85229 [doi].

1227. Smith, S. M. and J. G. Gums. 2010. Antivirals for influenza: strategies for use in pediatrics. *Paediatr. Drugs* 12:285–299. doi:2 [pii];10.2165/11532530-000000000-00000 [doi].
1228. Smith-Norowitz, T. A., D. Wong, M. Kusonruksa, K. B. Norowitz, R. Joks, H. G. Durkin, and M. H. Bluth. 2011. Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. *Int.J.Med.Sci.* 8:239–244.
1229. Smits, S. L., L. A. de, J. M. van den Brand, L. M. Leijten, W. F. van IJcken, M. J. Eijkemans, A. G. van, T. Kuiken, A. C. Andeweg, A. D. Osterhaus, and B. L. Haagmans. 2010. Exacerbated innate host response to SARS-CoV in aged non-human primates. *PLoS.Pathog.* 6:e1000756. doi:10.1371/journal.ppat.1000756 [doi].
1230. Socan, M., K. Prosenc, and N. Tevz-Cizej. 2010. Influenza A(H1N1) outbreak in a long-term care facility for severely handicapped residents, Slovenia, March–April 2009. *Euro.Surveill* 15:19577.
1231. Soepandi, P. Z., E. Burhan, H. Mangunegoro, A. Nawas, T. Y. Aditama, L. Partakusuma, F. Isbaniah, M. Ikhsan, B. Swidarmoko, A. Sutiyoso, S. Malik, R. Benamore, J. K. Baird, and W. R. Taylor. 2010. Clinical course of avian influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005–2008. *Chest* 138:665–673. doi:chest.09-2644 [pii];10.1378/chest.09-2644 [doi].
1232. Solorzano-Santos, F., L. Perez-de la Cruz, S. P. Melendez-Blanco, M. T. Munoz, G. C. Huerta-Garcia, M. G. Miranda-Novales, and G. Vazquez-Rosales. 2010. [Rapid immune response against hepatitis B using an accelerated intradermal vaccination schedule]. *Rev.Med.Inst.Mex.Seguro.Soc.* 48:603–606.
1233. Song, G., S. Yang, W. Zhang, Y. Cao, P. Wang, N. Ding, Z. Zhang, Y. Guo, and Y. Li. 2009. Discovery of the first series of small molecule H5N1 entry inhibitors. *J.Med.Chem.* 52:7368–7371. doi:10.1021/jm900275m [doi].
1234. Song, J. H. and H. J. Choi. 2011. Silymarin efficacy against influenza A virus replication. *Phytomedicine.* 18:832–835. doi:S0944-7113(11)00049-3 [pii];10.1016/j.phymed.2011.01.026 [doi].
1235. Song, X., J. Chen, K. Sakwiwatkul, R. Li, and S. Hu. 2010. Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re. *Int.Immunopharmacol.* 10:351–356. doi:S1567-5769(09)00384-1 [pii];10.1016/j.intimp.2009.12.009 [doi].
1236. Soubies, S. M., C. Volmer, J. L. Guerin, and R. Volmer. 2010. Truncation of the NS1 protein converts a low pathogenic avian influenza virus into a strong interferon inducer in duck cells. *Avian Dis.* 54:527–531.
1237. Souza, T. M., J. I. Salluh, F. A. Bozza, M. Mesquita, M. Soares, F. C. Motta, M. T. Pitrowsky, O. M. de Lourdes, V. P. Mishin, L. V. Gubareva, A. Whitney, S. A. Rocco, V. M. Goncalves, V. P. Marques, E. Velasco, and M. M. Siqueira. 2010. H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis. *PLoS.One.* 5:e14158. doi:10.1371/journal.pone.0014158 [doi].
1238. Speers, D. J., S. H. Williams, M. Pinder, H. R. Moody, A. C. Hurt, and D. W. Smith. 2010. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. *Med.J.Aust.* 192:166–168. doi:spe11148\_fm [pii].
1239. Sposato, B., L. Croci, E. Canneti, T. M. Di, M. G. Migliorini, A. Ricci, S. Mariotta, and M. Toti. 2010. Influenza A H1N1 and severe asthma exacerbation. *Eur.Rev.Med.Pharmacol.Sci.* 14:487–490.
1240. Spradlin, T. L., B. H. Clardy, E. M. Payne, and J. Vinson. 2010. H1N1 influenza in pregnancy: cause for concern. *Obstet.Gynecol.* 115:185–186. doi:10.1097/AOG.0b013e3181c8ad6b [doi];00006250-201001000-00034 [pii].
1241. Sriram, P., M. Kumar, R. Renitha, N. Mondal, and V. B. Bhat. 2010. Clinical profile of swine flu in children at Puducherry. *Indian J.Pediatr.* 77:1093–1095. doi:10.1007/s12098-010-0198-7 [doi].

1242. Staikowsky, F., C. Vanhecke, C. D'Andrea, A. Souab, R. Rakotoson, and A. Michault. 2011. [Outbreak of influenza pandemic virus A(H1N1) 2009 infections in the Emergency Department, Saint-Pierre, Reunion Island, July–September 2009]. *Bull.Soc.Pathol.Exot.* 104:125–134. doi:10.1007/s13149-011-0144-6 [doi].
1243. Stark, C., E. Garman, J. McMenemy, D. McCormick, and K. Oates. 2010. Major incidents in rural areas: managing a pandemic A/H1N1/2009 cluster. *Rural.Remote.Health* 10:1413. doi:1413 [pii].
1244. Steain, M. C., D. E. Dwyer, A. C. Hurt, C. Kol, N. K. Saksena, A. L. Cunningham, and B. Wang. 2009. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. *Antiviral Res.* 84:242–248. doi:S0166-3542(09)00463-X [pii];10.1016/j.antiviral.2009.09.010 [doi].
1245. Steel, H. M. and A. F. Peppercorn. 2010. Fatal respiratory events caused by zanamivir nebulization. *Clin.Infect.Dis.* 51:121. doi:10.1086/653450 [doi].
1246. Steel, J., P. Staeheli, S. Mubareka, A. Garcia-Sastre, P. Palese, and A. C. Lowen. 2010. Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. *J.Virol.* 84:21–26. doi:JVI.01732-09 [pii];10.1128/JVI.01732-09 [doi].
1247. Steidle, S., L. Martinez-Sobrido, M. Mordstein, S. Lienenklaus, A. Garcia-Sastre, P. Staeheli, and G. Kochs. 2010. Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. *J.Virol.* 84:12761–12770. doi:JVI.00701-10 [pii];10.1128/JVI.00701-10 [doi].
1248. Steinmetzer, T. 2011. [Strategies for development of new influenza medication]. *Pharm.Unserer Zeit* 40:160–168.
1249. Stewart, C. R., A. J. Karpala, S. Lowther, J. W. Lowenthal, and A. G. Bean. 2011. Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. *PLoS.One.* 6:e21552. doi:10.1371/journal.pone.0021552 [doi];PONE-D-11-06590 [pii].
1250. Stoner, T. D., S. Krauss, R. M. DuBois, N. J. Negovetich, D. E. Stallknecht, D. A. Senne, M. R. Gramer, S. Swafford, T. DeLiberto, E. A. Govorkova, and R. G. Webster. 2010. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. *J.Virol.* 84:9800–9809. doi:JVI.00296-10 [pii];10.1128/JVI.00296-10 [doi].
1251. Strong, M., J. Burrows, E. Stedman, and P. Redgrave. 2010. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. *Euro.Surveill* 15:ii/19565.
1252. Strutt, T. M., K. K. McKinstry, J. P. Dibble, C. Winchell, Y. Kuang, J. D. Curtis, G. Huston, R. W. Dutton, and S. L. Swain. 2010. Memory CD4+ T cells induce innate responses independently of pathogen. *Nat.Med.* 16:558–64, 1p. doi:nm.2142 [pii];10.1038/nm.2142 [doi].
1253. Su, C. Y., T. J. Cheng, M. I. Lin, S. Y. Wang, W. I. Huang, S. Y. Lin-Chu, Y. H. Chen, C. Y. Wu, M. M. Lai, W. C. Cheng, Y. T. Wu, M. D. Tsai, Y. S. Cheng, and C. H. Wong. 2010. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. *Proc.Natl.Acad.Sci.U.S.A* 107:19151–19156. doi:1013592107 [pii];10.1073/pnas.1013592107 [doi].
1254. Subbarao, I., L. Rubinson, and J. J. James. 2009. H1N1: revealing the collective resolve of medicine and public health. *Disaster.Med.Public Health Prep.* 3 Suppl 2:S93–S94. doi:10.1097/DMP.0b013e3181c74bba [doi].
1255. Subbramanian, R. A., S. Basha, R. C. Brady, S. Hazenfeld, M. T. Shata, and D. I. Bernstein. 2010. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. *Hum.Immunol.* 71:957–963. doi:S0198-8859(10)00440-4 [pii];10.1016/j.humimm.2010.07.005 [doi].

1256. Sugaya, N. and Y. Ohashi. 2010. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. *Antimicrob.Agents Chemother.* 54:2575–2582. doi:AAC.01755-09 [pii];10.1128/AAC.01755-09 [doi].
1257. Suh, M., J. Lee, H. J. Chi, Y. K. Kim, D. Y. Kang, N. W. Hur, K. H. Ha, D. H. Lee, and C. S. Kim. 2010. [Mathematical modeling of the novel influenza A (H1N1) virus and evaluation of the epidemic response strategies in the Republic of Korea]. *J.Prev.Med.Public Health* 43:109–116. doi:201003109 [pii];10.3961/jpmph.2010.43.2.109 [doi].
1258. Suhaila, M., J. W. Tang, H. K. Lee, C. Lin, P. A. Tambyah, H. K. Yap, S. H. Quak, and E. S. Koay. 2011. Mixtures of oseltamivir-sensitive and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children. *Pediatr.Infect.Dis.J.* 30:625–627. doi:10.1097/INF.0b013e31820929ab [doi].
1259. Sui, Z., Q. Chen, F. Fang, M. Zheng, and Z. Chen. 2010. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. *Vaccine* 28:7690–7698. doi:S0264-410X(10)01329-0 [pii];10.1016/j.vaccine.2010.09.019 [doi].
1260. Sullivan, S. J., R. M. Jacobson, W. R. Dowdle, and G. A. Poland. 2010. 2009 H1N1 influenza. *Mayo Clin.Proc.* 85:64–76. doi:mcp.2009.0588 [pii];10.4065/mcp.2009.0588 [doi].
1261. Sultana, I., J. Gao, L. Markoff, and M. C. Eichelberger. 2011. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. *Vaccine* 29:2601–2606. doi:S0264-410X(11)00086-7 [pii];10.1016/j.vaccine.2011.01.047 [doi].
1262. Sun, J., S. Cai, H. Mei, J. Li, N. Yan, and Y. Wang. 2010. Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase. *J.Mol.Model.* 16:1809–1818. doi:10.1007/s00894-010-0685-9 [doi].
1263. Sun, J., S. Cai, H. Mei, J. Li, N. Yan, Q. Wang, Z. Lin, and D. Huo. 2010. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3- $\alpha$ ] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase. *Chem.Biol.Drug Des* 76:245–254. doi:JPP1006 [pii];10.1111/j.1747-0285.2010.01006.x [doi].
1264. Sun, L., G. V. Hemgard, S. A. Susanto, and M. Wirth. 2010. Caveolin-1 influences human influenza A virus (H1N1) multiplication in cell culture. *Virology* 7:108. doi:1743-422X-7-108 [pii];10.1186/1743-422X-7-108 [doi].
1265. Sun, Y., J. Liu, M. Yang, F. Gao, J. Zhou, Y. Kitamura, B. Gao, P. Tien, Y. Shu, A. Iwamoto, Z. Chen, and G. F. Gao. 2010. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A\*0201 derived from the H5N1 subtype of influenza A viruses. *J.Gen.Virol.* 91:919–930. doi:vir.0.016766-0 [pii];10.1099/vir.0.016766-0 [doi].
1266. Sundararajan, A., R. Ganapathy, L. Huan, J. R. Dunlap, R. J. Webby, G. J. Kotwal, and M. Y. Sangster. 2010. Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins. *Antiviral Res.* 88:1–9. doi:S0166-3542(10)00668-6 [pii];10.1016/j.antiviral.2010.06.014 [doi].
1267. Suppiah, J., M. A. Yusof, K. A. Othman, T. S. Saraswathy, R. Thayan, F. M. Kasim, S. Murad, and Z. Saat. 2011. Monitoring of the h275y mutation in pandemic influenza A(H1N1) 2009 strains isolated in Malaysia. *Southeast Asian J.Trop.Med.Public Health* 42:100–104.
1268. Suwannakarn, K., T. Chieochansin, C. Thongmee, J. Makkoch, K. Praianantathavorn, A. Theamboonlers, S. Sreevatsan, and Y. Poovorawan. 2010. Molecular evolution of human H1N1 and H3N2 influenza A virus in Thailand, 2006–2009. *PLoS.One.* 5:e9717. doi:10.1371/journal.pone.0009717 [doi].
1269. Suyani, E., Z. Aki, O. Guzel, S. Altindal, E. Senol, and G. Sucak. 2011. H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving. *Transpl. Infect.Dis.* 13:208–212. doi:10.1111/j.1399-3062.2010.00569.x [doi].



1270. Suzuki, H., K. Wada, T. Koga, H. Nakamura, A. Okada, H. Suzuki, S. Honda, and A. Nakano. 2011. [The Report of 83(rd) JSOH Conference and a Proposal of Pandemic Flu Preparedness & Response Plan for Businesses and Employers, "Suggested Strategy for Management of Antiviral Drugs"]. *Sangyo Eiseigaku Zasshi* 53:39–43. doi:JST.JSTAGE/sangyoeisei/siryu10001 [pii].
1271. Suzuki, T., T. Takahashi, and Y. Suzuki. 2008. [Role of sulfatide on influenza A virus replication]. *Tanpakushitsu Kakusan Koso* 53:1676–1682.
1272. Suzuki, Y., R. Saito, H. Zaraket, C. Dapat, I. Caperig-Dapat, and H. Suzuki. 2010. Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method. *J.Clin.Microbiol.* 48:57–63. doi:JCM.00698-09 [pii];10.1128/JCM.00698-09 [doi].
1273. Suzuki, Y., R. Saito, I. Sato, H. Zaraket, M. Nishikawa, T. Tamura, C. Dapat, I. Caperig-Dapat, T. Baranovich, T. Suzuki, and H. Suzuki. 2011. Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method. *J.Clin.Microbiol.* 49:125–130. doi:JCM.01401-10 [pii];10.1128/JCM.01401-10 [doi].
1274. Svetlikova, D., P. Kabat, A. Ohradnova, J. Pastorek, and T. Betakova. 2010. Influenza A virus replication is inhibited in IFN-lambda2 and IFN-lambda3 transfected or stimulated cells. *Antiviral Res.* 88:329–333. doi:S0166-3542(10)00766-7 [pii];10.1016/j.antiviral.2010.10.005 [doi].
1275. Sy, C. L., S. S. Lee, M. T. Liu, H. C. Tsai, and Y. S. Chen. 2010. Rapid emergence of oseltamivir resistance. *Emerg.Infect.Dis.* 16:723–725. doi:10.3201/eid1604.091706 [doi].
1276. Sym, D., P. N. Patel, and G. M. El-Chaar. 2009. Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities. *Ann.Pharmacother.* 43:2001–2011. doi:aph.1M557 [pii];10.1345/aph.1M557 [doi].
1277. Taha, S. H., M. A. Mehrez, M. Z. Sitohy, A. G. Abou Dawood, M. M. Abd-El Hamid, and W. H. Kilany. 2010. Effectiveness of esterified whey proteins fractions against Egyptian Lethal Avian Influenza A (H5N1). *Viroi.J.* 7:330. doi:1743-422X-7-330 [pii];10.1186/1743-422X-7-330 [doi].
1278. Takagi, M., K. Motohashi, A. Nagai, M. Izumikawa, M. Tanaka, S. Fuse, T. Doi, K. Iwase, A. Kawaguchi, K. Nagata, T. Takahashi, and K. Shin-ya. 2010. Anti-influenza virus compound from *Streptomyces* sp. RI18. *Org.Lett.* 12:4664–4666. doi:10.1021/ol102007d [doi].
1279. Takahashi, E., K. Kataoka, K. Fujii, J. Chida, D. Mizuno, M. Fukui, O. Hiro, K. Fujihashi, and H. Kido. 2010. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. *Microbes.Infect.* 12:778–783. doi:S1286-4579(10)00112-7 [pii];10.1016/j.micinf.2010.04.013 [doi].
1280. Takahashi, T., H. Satoh, M. Takaguchi, S. Takafuji, H. Yokoyama, S. Fujii, and T. Suzuki. 2010. Binding of sulphatide to recombinant haemagglutinin of influenza A virus produced by a baculovirus protein expression system. *J.Biochem.* 147:459–462. doi:mvq013 [pii];10.1093/jb/mvq013 [doi].
1281. Takayama, E., T. Ono, E. Carnero, S. Umemoto, Y. Yamaguchi, A. Kanayama, T. Oguma, Y. Takashima, T. Tadakuma, A. Garcia-Sastre, and Y. Miyahira. 2010. Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against *Trypanosoma cruzi* infection. *Int.J.Parasitol.* 40:1549–1561. doi:S0020-7519(10)00245-6 [pii];10.1016/j.ijpara.2010.05.011 [doi].
1282. Takiyama, A., L. Wang, M. Tanino, T. Kimura, N. Kawagishi, Y. Kunieda, H. Katano, N. Nakajima, H. Hasegawa, T. Takagi, H. Nishihara, T. Sata, and S. Tanaka. 2010. Sudden death of a patient with pandemic influenza (A/H1N1pdm) virus infection by acute respiratory distress syndrome. *Jpn.J.Infect. Dis.* 63:72–74.
1283. Talarek, E., L. Dembinski, A. Radzikowski, K. Smalisz-Skrzypczyk, T. Jackowska, and M. Marczyńska. 2010. [Clinical course of influenza A(H1N1)v in children treated in Warsaw in season 2009/2010]. *Przegl.Epidemiol.* 64:497–501.

1284. Talbird, S. E., A. J. Brogan, and A. P. Winiarski. 2009. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1–12 years in the U.S. *Am.J.Prev.Med.* 37:381–388. doi:S0749-3797(09)00527-3 [pii];10.1016/j.amepre.2009.08.012 [doi].
1285. Tamura, D., N. Sugaya, M. Ozawa, R. Takano, M. Ichikawa, M. Yamazaki, C. Kawakami, H. Shimizu, R. Uehara, M. Kiso, E. Kawakami, K. Mitamura, and Y. Kawaoka. 2011. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. *Clin. Infect.Dis.* 52:432–437. doi:ciq183 [pii];10.1093/cid/ciq183 [doi].
1286. Tanabe, T., K. Hara, M. Nakajima, S. Shimakawa, and H. Tamai. 2010. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. *Brain Dev.* 32:440–444. doi:S0387-7604(08)00303-3 [pii];10.1016/j.braindev.2008.12.018 [doi].
1287. Tang, J. W. 2010. The persistence of influenza infection. *Emerg.Infect.Dis.* 16:1817–1818. doi:10.3201/eid1611.101431 [doi].
1288. Tang, J. W., N. Shetty, and T. T. Lam. 2010. Features of the new pandemic influenza A/H1N1/2009 virus: virology, epidemiology, clinical and public health aspects. *Curr.Opin.Pulm.Med.* 16:235–241. doi:10.1097/MCP.0b013e3283375727 [doi];00063198-201005000-00011 [pii].
1289. Tang, J. W., N. Shetty, T. T. Lam, and K. L. Hon. 2010. Emerging, novel, and known influenza virus infections in humans. *Infect.Dis.Clin.North Am.* 24:603–617. doi:S0891-5520(10)00028-0 [pii];10.1016/j.idc.2010.04.001 [doi].
1290. Tang, S. H., J. X. Chen, G. Li, H. W. Wu, C. Chen, N. Zhang, N. Gao, H. J. Yang, and L. Q. Huang. 2010. Research on component law of Chinese patent medicine for anti-influenza and development of new recipes for anti-influenza by unsupervised data mining methods. *J.Tradit.Chin Med.* 30:288–293.
1291. Tang, X. C., H. R. Lu, and T. M. Ross. 2010. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. *Vaccine* 28:6821–6831. doi:S0264-410X(10)01185-0 [pii];10.1016/j.vaccine.2010.08.040 [doi].
1292. Tang, Y., G. Zhong, L. Zhu, X. Liu, Y. Shan, H. Feng, Z. Bu, H. Chen, and C. Wang. 2010. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. *J.Immunol.* 184:5777–5790. doi:jimmunol.0903588 [pii];10.4049/jimmunol.0903588 [doi].
1293. Tate, M. D., H. C. Schilter, A. G. Brooks, and P. C. Reading. 2011. Responses of mouse airway epithelial cells and alveolar macrophages to virulent and avirulent strains of influenza A virus. *Viral Immunol.* 24:77–88. doi:10.1089/vim.2010.0118 [doi].
1294. Taylor, W. R., E. Burhan, H. Wertheim, P. Z. Soepandi, P. Horby, A. Fox, R. Benamore, S. L. de, T. T. Hien, and F. Chappuis. 2010. Avian influenza – a review for doctors in travel medicine. *Travel.Med. Infect.Dis.* 8:1–12. doi:S1477-8939(09)00162-8 [pii];10.1016/j.tmaid.2009.11.006 [doi].
1295. Tchuente, J. M., S. A. Khamis, F. B. Augusto, and S. C. Mpeshe. 2011. Optimal control and sensitivity analysis of an influenza model with treatment and vaccination. *Acta Biotheor.* 59:1–28. doi:10.1007/s10441-010-9095-8 [doi].
1296. te Beest, D. E., B. M. van, M. E. Bos, A. Stegeman, and M. P. Koopmans. 2010. Effectiveness of personal protective equipment and oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 2003. *Emerg.Infect.Dis.* 16:1562–1568. doi:10.3201/eid1610.091412 [doi].
1297. Tebruegge, M., A. Pantazidou, N. Ritz, T. Connell, P. Bryant, S. Donath, and N. Curtis. 2010. Perception, attitudes and knowledge regarding the 2009 swine-origin influenza A (H1N1) virus pandemic among health-care workers in Australia. *J.Paediatr.Child Health* 46:673–679. doi:JPC1820 [pii];10.1111/j.1440-1754.2010.01820.x [doi].

1298. Teijaro, J. R., D. Verhoeven, C. A. Page, D. Turner, and D. L. Farber. 2010. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. *J.Virol.* 84:9217–9226. doi:JV1.01069-10 [pii];10.1128/JVI.01069-10 [doi].
1299. Teijaro, J. R., K. B. Walsh, S. Cahalan, D. M. Fremgen, E. Roberts, F. Scott, E. Martinborough, R. Peach, M. B. Oldstone, and H. Rosen. 2011. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. *Cell* 146:980–991. doi:S0092-8674(11)00941-X [pii];10.1016/j.cell.2011.08.015 [doi].
1300. Tekgunduz, E., M. K. Yuksel, C. Erbay, B. Aribas, C. Ozdilekcan, H. Arslan, S. Kocubaba, I. Demiriz, A. Tetik, K. Arda, and F. Altuntas. 2010. Pandemic 2009 H1N1 influenza in patients with hematopoietic stem cell transplantation and hematologic malignancy: single center experience. *Oncology* 79:409–414. doi:000320789 [pii];10.1159/000320789 [doi].
1301. Temte, J. L. and J. P. Prunuske. 2010. Seasonal influenza in primary care settings: review for primary care physicians. *WMJ.* 109:193–200.
1302. Thabet, A. A., S. H. Al-Bahlooli, A. Al-Kohlani, and A. Shoja'a. 2010. Oseltamivir-resistant pandemic (H1N1)2009 in Yemen – case report. *Viol.J.* 7:88. doi:1743-422X-7-88 [pii];10.1186/1743-422X-7-88 [doi].
1303. Theocharis, G., E. K. Vouloumanou, P. I. Rafailidis, T. Spiropoulos, S. G. Barbas, and M. E. Falagas. 2010. Evaluation of a direct test for seasonal influenza in outpatients. *Eur.J.Intern.Med.* 21:434–438. doi:S0953-6205(10)00134-2 [pii];10.1016/j.ejim.2010.06.013 [doi].
1304. Thitithanyanont, A., A. Engering, M. Uiprasertkul, P. Ekchariyawat, S. Wiboon-Ut, R. Kraivong, A. Limsalakpetch, U. Kum-Arb, K. Yongvanitchit, N. Sa-Ard-lam, P. Rukeyen, R. Mahanonda, K. Kawkitinarong, P. Auewarakul, P. Utaisinchaoen, S. Sirisinha, C. J. Mason, M. M. Fukuda, and S. Pichyangkul. 2010. Antiviral immune responses in H5N1-infected human lung tissue and possible mechanisms underlying the hyperproduction of interferon-inducible protein IP-10. *Biochem.Biophys. Res.Commun.* 398:752–758. doi:S0006-291X(10)01319-7 [pii];10.1016/j.bbrc.2010.07.017 [doi].
1305. Thomas, B., A. S. Hollister, and K. A. Muczynski. 2010. Peramivir clearance in continuous renal replacement therapy. *Hemodial.Int.* 14:339–340. doi:HDI451 [pii];10.1111/j.1542-4758.2010.00451.x [doi].
1306. Thompson, M. and C. Heneghan. 2010. Antivirals for pandemic influenza: a triumph of policy over evidence? *Trends Pharmacol.Sci.* 31:391–393. doi:S0165-6147(10)00091-X [pii];10.1016/j.tips.2010.05.005 [doi].
1307. Thorlund, K., T. Awad, G. Boivin, and L. Thabane. 2011. Systematic review of influenza resistance to the neuraminidase inhibitors. *BMC.Infect.Dis.* 11:134. doi:1471-2334-11-134 [pii];10.1186/1471-2334-11-134 [doi].
1308. Tisoncik, J. R., R. Billharz, S. Burmakina, S. E. Belisle, S. C. Proll, M. J. Korth, A. Garcia-Sastre, and M. G. Katze. 2011. The NS1 protein of influenza A virus suppresses interferon-regulated activation of antigen-presentation and immune-proteasome pathways. *J.Gen.Virol.* 92:2093–2104. doi:vir.0.032060-0 [pii];10.1099/vir.0.032060-0 [doi].
1309. Toal, M., K. Agyeman-Duah, A. Schwenk, and W. Yoong. 2010. Swine flu and pregnancy. *J.Obstet. Gynaecol.* 30:97–100. doi:10.3109/01443610903502049 [doi].
1310. Tomi, M., T. Nishimura, and E. Nakashima. 2011. Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier. *J.Pharm.Sci.* 100:3708–3718. doi:10.1002/jps.22642 [doi].
1311. Tong, S. Y., F. Dakh, A. C. Hurt, Y. M. Deng, K. Freeman, P. K. Fagan, I. G. Barr, and P. M. Giffard. 2011. Rapid detection of the H275Y oseltamivir resistance mutation in influenza A/H1N1 2009 by single base pair RT-PCR and high-resolution melting. *PLoS.One.* 6:e21446. doi:10.1371/journal.pone.0021446 [doi];PONE-D-11-06394 [pii].

1312. Torres, J. P., M. O’Ryan, B. Herve, R. Espinoza, G. Acuna, J. Manalich, and M. Chomali. 2010. Impact of the novel influenza A (H1N1) during the 2009 autumn–winter season in a large hospital setting in Santiago, Chile. *Clin.Infect.Dis.* 50:860–868. doi:10.1086/650750 [doi].
1313. Torres-Ramirez, A. 2010. [Pandemic influenza caused by A(H1N1) in pregnant women]. *Ginecol. Obstet.Mex.* 78:121–127.
1314. Tosh, C., H. V. Murugkar, S. Nagarajan, S. Tripathi, M. Katare, R. Jain, R. Khandia, Z. Syed, P. Behera, S. Patil, D. D. Kulkarni, and S. C. Dubey. 2011. Emergence of amantadine-resistant avian influenza H5N1 virus in India. *Virus Genes* 42:10–15. doi:10.1007/s11262-010-0534-z [doi].
1315. Tracht, S. M., S. Y. Del Valle, and J. M. Hyman. 2010. Mathematical modeling of the effectiveness of facemasks in reducing the spread of novel influenza A (H1N1). *PLoS.One.* 5:e9018. doi:10.1371/journal.pone.0009018 [doi].
1316. Tramontana, A. R., B. George, A. C. Hurt, J. S. Doyle, K. Langan, A. B. Reid, J. M. Harper, K. Thursky, L. J. Worth, D. E. Dwyer, C. O. Morrissey, P. D. Johnson, K. L. Buising, S. J. Harrison, J. F. Seymour, P. E. Ferguson, B. Wang, J. T. Denholm, A. C. Cheng, and M. Slavin. 2010. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. *Emerg.Infect.Dis.* 16:1068–1075. doi:10.3201/eid1607.091691 [doi].
1317. Tran, N. D., M. Albicker, L. Schneider, and N. Cramer. 2010. Enantioselective assembly of the benzo[d]xanthene tetracyclic core of anti-influenza active natural products. *Org.Biomol.Chem.* 8:1781–1784. doi:10.1039/c002011g [doi].
1318. Tremolieres, F. 2009. [Do we really need antifu virus medication?]. *Med.Mal Infect.* 39 :667–673. doi:S0399-077X(09)00220-0 [pii];10.1016/j.medmal.2009.08.001 [doi].
1319. Triana-Baltzer, G. B., L. V. Gubareva, A. I. Klimov, D. F. Wurtman, R. B. Moss, M. Hedlund, J. L. Larson, R. B. Belshe, and F. Fang. 2009. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. *PLoS.One.* 4:e7838. doi:10.1371/journal.pone.0007838 [doi].
1320. Triana-Baltzer, G. B., L. V. Gubareva, J. M. Nicholls, M. B. Pearce, V. P. Mishin, J. A. Belser, L. M. Chen, R. W. Chan, M. C. Chan, M. Hedlund, J. L. Larson, R. B. Moss, J. M. Katz, T. M. Tumpey, and F. Fang. 2009. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. *PLoS.One.* 4:e7788. doi:10.1371/journal.pone.0007788 [doi].
1321. Triana-Baltzer, G. B., M. Babizki, M. C. Chan, A. C. Wong, L. M. Aschenbrenner, E. R. Campbell, Q. X. Li, R. W. Chan, J. S. Peiris, J. M. Nicholls, and F. Fang. 2010. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. *J.Antimicrob.Chemother.* 65:275–284. doi:dkp421 [pii];10.1093/jac/dkp421 [doi].
1322. Triana-Baltzer, G. B., R. L. Sanders, M. Hedlund, K. A. Jensen, L. M. Aschenbrenner, J. L. Larson, and F. Fang. 2011. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. *J.Antimicrob.Chemother.* 66:15–28. doi:dkq387 [pii];10.1093/jac/dkq387 [doi].
1323. Trost, B. M. and T. Zhang. 2011. Development of a concise synthesis of (-)-oseltamivir (Tamiflu). *Chemistry.* 17:3630–3643. doi:10.1002/chem.201003454 [doi].
1324. Tsalik, E. L., E. F. Hendershot, D. G. Sangvai, H. M. Cunningham, C. K. Cunningham, M. G. Lopez-Marti, W. K. Purdy, C. W. Woods, and L. B. Caram. 2010. Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population. *J.Clin.Virol.* 47:286–288. doi:S1386-6532(09)00603-9 [pii];10.1016/j.jcv.2009.12.012 [doi].
1325. Tsujimoto, K., C. Sakuma, M. Uozaki, H. Yamasaki, H. Utsunomiya, K. Oka, and A. H. Koyama. 2010. Antiviral effect of pyridinium formate, a novel component of coffee extracts. *Int.J.Mol.Med.* 25:459–463.

1326. Tsukahara, Y. 2010. [Change of strategies for novel and seasonal flu during pregnancy]. *Nihon Rinsho* 68:1650–1655.
1327. Tu, W., H. Mao, J. Zheng, Y. Liu, S. S. Chiu, G. Qin, P. L. Chan, K. T. Lam, J. Guan, L. Zhang, Y. Guan, K. Y. Yuen, J. S. Peiris, and Y. L. Lau. 2010. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. *J.Virol.* 84:6527–6535. doi:JV1.00519-10 [pii];10.1128/JVI.00519-10 [doi].
1328. Tu, W., J. Zheng, Y. Liu, S. F. Sia, M. Liu, G. Qin, I. H. Ng, Z. Xiang, K. T. Lam, J. S. Peiris, and Y. L. Lau. 2011. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. *J.Exp.Med.* 208:1511–1522. doi:jem.20110226 [pii];10.1084/jem.20110226 [doi].
1329. Tullu, M. S. 2009. Oseltamivir. *J.Postgrad.Med.* 55:225–230. doi:jpgm\_2009\_55\_3\_225\_57411 [pii];10.4103/0022-3859.57411 [doi].
1330. Tung, N. H., H. J. Kwon, J. H. Kim, J. C. Ra, J. A. Kim, and Y. H. Kim. 2010. An anti-influenza component of the bark of *Alnus japonica*. *Arch.Pharm.Res.* 33:363–367. doi:10.1007/s12272-010-0303-5 [doi].
1331. Tung, N. H., H. J. Kwon, J. H. Kim, J. C. Ra, Y. Ding, J. A. Kim, and Y. H. Kim. 2010. Anti-influenza diarylheptanoids from the bark of *Alnus japonica*. *Bioorg.Med.Chem.Lett.* 20:1000–1003. doi:S0960-894X(09)01780-6 [pii];10.1016/j.bmcl.2009.12.057 [doi].
1332. Turner, D. A., K. J. Rehder, S. L. Peterson-Carmichael, C. P. Ozment, M. S. Al-Hegelan, W. L. Williford, M. A. Peters, P. W. Noble, and I. M. Cheifetz. 2011. Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A. *Respir.Care* 56:941–946. doi:rc01066r2turner [pii];10.4187/respcare.01066 [doi].
1333. Turner, K. B. and M. H. Levy. 2010. Prison outbreak: pandemic (H1N1) 2009 in an Australian prison. *Public Health* 124:119–121. doi:S0033-3506(09)00371-0 [pii];10.1016/j.puhe.2009.12.005 [doi].
1334. Turner, S. J., L. E. Brown, P. C. Doherty, and A. Kelso. 2009. Q&A: What have we found out about the influenza A (H1N1) 2009 pandemic virus? *J.Biol.* 8:69. doi:jbiol179 [pii];10.1186/jbiol179 [doi].
1335. Taylor, W. R., Thinh B. N., Anh G. T., Horby P., Wertheim H., Lindegardh N., de Jong M. D., Stepniewska K., Hanh T. T., Hien N. D., Bien N. M., Chau N. Q., Fox A., Ngoc N. M., Crusat M., Farrar J. J., White N. J., Ha N. H., Lien T. T., Trung N. V., Day N., Binh N. G. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. *PLoS One.* 2008;3(10):e3410 [doi].
1336. Uchida, N. and H. Toyoda. 2011. Antioxidant therapy as a potential approach to severe influenza-associated complications. *Molecules.* 16:2032–2052. doi:molecules16032032 [pii];10.3390/molecules16032032 [doi].
1337. Uchiyama, H., A. Toda, M. Imoto, S. Nishimura, H. Kuroki, S. Soeda, H. Shimeno, S. Watanabe, and R. Eyanagi. 2010. The stimulatory effects of caffeine with oseltamivir (Tamiflu) on light-dark behavior and open-field behavior in mice. *Neurosci.Lett.* 469:184–188. doi:S0304-3940(09)01560-2 [pii];10.1016/j.neulet.2009.11.069 [doi].
1338. Uesawa, Y., E. Motege, Y. Dai, K. Ishii, and K. Mohri. 2010. Prediction models for feverishness developed during interferon therapy of chronic hepatitis C patients. *Pharmazie* 65:114–116.
1339. Ugarte, S., F. Arancibia, and R. Soto. 2010. Influenza A pandemics: clinical and organizational aspects: the experience in Chile. *Crit Care Med.* 38:e133–e137. doi:10.1097/CCM.0b013e3181c87716 [doi].
1340. Ujike, M., K. Shimabukuro, K. Mochizuki, M. Obuchi, T. Kageyama, M. Shirakura, N. Kishida, K. Yamashita, H. Horikawa, Y. Kato, N. Fujita, M. Tashiro, and T. Odagiri. 2010. Oseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, Japan. *Emerg.Infect.Dis.* 16:926–935. doi:10.3201/eid1606.091623 [doi].

1341. Ujike, M., M. Ejima, A. Anraku, K. Shimabukuro, M. Obuchi, N. Kishida, X. Hong, E. Takashita, S. Fujisaki, K. Yamashita, H. Horikawa, Y. Kato, A. Oguchi, N. Fujita, M. Tashiro, and T. Odagiri. 2011. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009–2010. *Emerg.Infect.Dis.* 17:470–479. doi:10.3201/eid1703.101188 [doi].
1342. Ulvestad, E., E. Swensen, G. S. Simonsen, and E. Schei. 2010. [The pandemic – an afterthought]. *Tidsskr.Nor Laegeforen.* 130:169–171. doi:1940463 [pii];10.4045/tidsskr.10.0023 [doi].
1343. Upadhyay, A., J. Chompoo, W. Kishimoto, T. Makise, and S. Tawata. 2011. HIV-1 integrase and neuraminidase inhibitors from *Alpinia zerumbet*. *J.Agric.Food Chem.* 59:2857–2862. doi:10.1021/jf104813k [doi].
1344. Urso, R., N. Bevilacqua, M. Gentile, D. Biagioli, and F. N. Lauria. 2011. Pandemic 2009 H1N1 virus infection associated with purpuric skin lesions: a case report. *J.Med.Case.Reports.* 5:132. doi:1752-1947-5-132 [pii];10.1186/1752-1947-5-132 [doi].
1345. Uyeki, T. 2009. Diagnostic testing for 2009 pandemic influenza A (H1N1) virus infection in hospitalized patients. *N.Engl.J.Med.* 361:e114. doi:NEJMopv0911052 [pii];10.1056/NEJMopv0911052 [doi].
1346. Uyeki, T. M. 2010. 2009 H1N1 virus transmission and outbreaks. *N.Engl.J.Med.* 362:2221–2223. doi:362/23/2221 [pii];10.1056/NEJMe1004468 [doi].
1347. Vabret, A., J. Dina, D. Cuvillon-Nimal, E. Nguyen, S. Gouarin, J. Petitjean, J. Brouard, and F. Freymuth. 2010. [Seasonal flu]. *Pathol.Biol.(Paris)* 58:e51–e57. doi:S0369-8114(10)00030-1 [pii];10.1016/j.patbio.2010.01.009 [doi].
1348. Valinotto, L. E., R. A. Diez, P. R. Barrero, J. A. Farias, E. L. Lopez, and A. S. Mistchenko. 2010. Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. *Antivir.Ther.* 15:923–927. doi:10.3851/IMP1635 [doi].
1349. Valvi, C., R. Kulkarni, A. Kinikar, and S. Khadse. 2010. 2009H1N1 Infection in a 1-day-old neonate. *Indian J.Med.Sci.* 64:549–552. doi:75930 [pii].
1350. van den Dool, C., E. Hak, M. J. Bonten, and J. Wallinga. 2009. A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes. *Emerg.Infect.Dis.* 15:1547–1555. doi:10.3201/eid1510.081129 [doi].
1351. van den Wijngaard, C. C., J. E. van Steenberghe, M. A. van der Sande, and M. P. Koopmans. 2009. [New influenza A (H1N1): advised indication and prescription of antiviral drugs]. *Ned.Tijdschr. Geneeskd.* 153:A1053.
1352. van Dissel, J. T., R. A. Coutinho, and M. A. van der Sande. 2009. [Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations]. *Ned.Tijdschr. Geneeskd.* 153:B486.
1353. van Hoek, A. J., A. Underwood, M. Jit, E. Miller, and W. J. Edmunds. 2011. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. *PLoS.One.* 6:e17030. doi:10.1371/journal.pone.0017030 [doi].
1354. Van Sickels, N. J., V. Mave, R. Zhang, M. Killackey, A. Paramesh, F. Regenstein, and D. Mushatt. 2010. Three organ transplant patients infected with 2009 novel H1N1 influenza in early fall, 2009. *J.La State Med.Soc.* 162:206, 208–206, 213.
1355. van Tuijn, C. F., E. Nur, E. J. van Beers, H. L. Zaaijer, and B. J. Biemond. 2010. Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection. *Am.J.Hematol.* 85:303–304. doi:10.1002/ajh.21638 [doi].

1356. van, B. M., T. Donker, M. van der Lubben, R. B. van Gageldonk-Lafeber, D. E. te Beest, M. Koopmans, A. Meijer, A. Timen, C. Swaan, A. Dalhuijsen, S. Hahne, A. van den Hoek, P. Teunis, M. A. van der Sande, and J. Wallinga. 2010. Transmission of novel influenza A(H1N1) in households with post-exposure antiviral prophylaxis. *PLoS.One.* 5:e11442. doi:10.1371/journal.pone.0011442 [doi].
1357. van, d., V and M. Schutten. 2010. Satisfying the need for rapid diagnosis of new variant influenza A H1N1. *Expert.Rev.Mol.Diagn.* 10:251–253. doi:10.1586/erm.10.18 [doi].
1358. van, d., V, F. F. Stelma, and C. A. Boucher. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. *N.Engl.J.Med.* 363:1381–1382. doi:10.1056/NEJMc1003749 [doi].
1359. van, d., V, M. Jonges, S. Herfst, J. Maaskant, A. Van der Linden, J. Guldemeester, G. I. Aron, T. M. Bestebroer, M. Koopmans, A. Meijer, R. A. Fouchier, A. D. Osterhaus, C. A. Boucher, and M. Schutten. 2010. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. *J.Clin.Virol.* 47:34–37. doi:S1386-6532(09)00478-8 [pii];10.1016/j.jcv.2009.09.030 [doi].
1360. van, M. A., N. Sabarth, H. S. Dacho, P. Bruhl, M. Schwendinger, B. A. Crowe, B. P. Noel, O. Kistner, and H. M. Keith. 2010. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. *Vaccine* 28:1778–1785. doi:S0264-410X(09)01912-4 [pii];10.1016/j.vaccine.2009.12.008 [doi].
1361. van, V. E., S. Hutchinson, G. Penrice, S. Ahmed, and J. McMenamin. 2011. Compliance to oseltamivir and subsequent occurrence of self-reported adverse drug reactions among nursery and primary school children following exposure to Influenza A(H1N1)v. *Scott.Med.J.* 56:120. doi:56/2/120-c [pii];10.1258/smj.2010.010017 [doi].
1362. Vanderlinden, E., F. Goktas, Z. Cesur, M. Froeyen, M. L. Reed, C. J. Russell, N. Cesur, and L. Naesens. 2010. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. *J.Virol.* 84:4277–4288. doi:JVI.02325-09 [pii];10.1128/JVI.02325-09 [doi].
1363. Vasil'ev, A. N. 2010. [Etiotropic drug therapy of widespread and socially significant human viral infections]. *Antibiot.Khimioter.* 55:29–34.
1364. Vasoo, S., C. W. Crank, and K. Singh. 2010. Timely administration of antivirals for pandemic (H1N1) 2009 influenza. *Clin.Infect.Dis.* 50:1428–1429. doi:10.1086/652288 [doi].
1365. Vcev, A. 2009. [Management of side effects during antiviral therapy]. *Acta Med.Croatica* 63:463–467.
1366. Vedula, M. S., S. Jennepalli, R. Aryasomayajula, S. R. Rondla, M. R. Musku, R. R. Kura, and P. R. Bandi. 2010. Novel nucleosides as potent influenza viral inhibitors. *Bioorg.Med.Chem.* 18:6329–6339. doi:S0968-0896(10)00660-7 [pii];10.1016/j.bmc.2010.07.017 [doi].
1367. Vergara Serrano, J. C. 2010. [Infra-usage of oseltamivir in Spain]. *Med.Intensiva.* 34:155. doi:S0210-5691(09)00170-3 [pii];10.1016/j.medin.2009.12.002 [doi].
1368. Viasus, D., J. R. Pano-Pardo, J. Pachon, A. Campins, F. Lopez-Medrano, A. Villoslada, M. C. Farinas, A. Moreno, J. Rodriguez-Bano, J. A. Oteo, J. Martinez-Montauti, J. Torre-Cisneros, F. Segura, F. Gudiol, and J. Carratala. 2011. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. *Clin.Microbiol.Infect.* 17:738–746. doi:CLM3362 [pii];10.1111/j.1469-0691.2010.03362.x [doi].
1369. Vidal, C., L. Kapelusznik, M. Goldberg, C. Halverstam, S. Daefler, D. Calfee, and R. G. Phelps. 2010. The dermatologic manifestation of novel influenza A(H1N1). *Arch.Dermatol.* 146:101–102. doi:146/1/101 [pii];10.1001/archdermatol.2009.344 [doi].

1370. Volmer, C., S. M. Soubies, B. Grenier, J. L. Guerin, and R. Volmer. 2011. Immune response in the duck intestine following infection with low-pathogenic avian influenza viruses or stimulation with a Toll-like receptor 7 agonist administered orally. *J.Gen.Virol.* 92:534–543. doi:vir.0.026443-0 [pii];10.1099/vir.0.026443-0 [doi].
1371. Walker, K. 2009. International society for antiviral research – 22nd international conference. Part 2. *IDrugs.* 12:411–412.
1372. Walkiewicz, M. P., D. Basu, J. J. Jablonski, H. M. Geysen, and D. A. Engel. 2011. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. *J.Gen.Virol.* 92:60–70. doi:vir.0.025015-0 [pii];10.1099/vir.0.025015-0 [doi].
1373. Wallensten, A., M. Salter, S. Bennett, I. Brown, K. Hoschler, and I. Oliver. 2010. No evidence of transmission of H5N1 highly pathogenic avian influenza to humans after unprotected contact with infected wild swans. *Epidemiol.Infect.* 138:210–213. doi:S0950268809990811 [pii];10.1017/S0950268809990811 [doi].
1374. Wallinga, J., B. M. van, and M. Lipsitch. 2010. Optimizing infectious disease interventions during an emerging epidemic. *Proc.Natl.Acad.Sci.U.S.A* 107:923–928. doi:0908491107 [pii];10.1073/pnas.0908491107 [doi].
1375. Walsh, K. B., J. R. Tejjaro, P. R. Wilker, A. Jatzek, D. M. Fremgen, S. C. Das, T. Watanabe, M. Hatta, K. Shinya, M. Suresh, Y. Kawaoka, H. Rosen, and M. B. Oldstone. 2011. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. *Proc.Natl.Acad.Sci.U.S.A* 108:12018–12023. doi:1107024108 [pii];10.1073/pnas.1107024108 [doi].
1376. Walter, S. N., A. Balaus, C. Galvan, P. M. Ana, P. Velez, M. C. Del Carmen, and D. M. Beltramo. 2010. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. *Genet. Test.Mol.Biomarkers* 14:749–751. doi:10.1089/gtmb.2010.0037 [doi].
1377. Wan Po, A. L., P. Farndon, and N. Palmer. 2009. Maximizing the value of drug stockpiles for pandemic influenza. *Emerg.Infect.Dis.* 15:1686–1687. doi:10.3201/eid1510.090844 [doi].
1378. Wan, Y., Z. Zhou, Y. Yang, J. Wang, and T. Hung. 2010. Application of an In-Cell Western assay for measurement of influenza A virus replication. *J.Virol.Methods* 169:359–364. doi:S0166-0934(10)00287-9 [pii];10.1016/j.jviromet.2010.08.005 [doi].
1379. Wang, B. Z., R. Xu, F. S. Quan, S. M. Kang, L. Wang, and R. W. Compans. 2010. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. *PLoS.One.* 5:e13972. doi:10.1371/journal.pone.0013972 [doi].
1380. Wang, B., D. E. Dwyer, C. C. Blyth, M. Soedjono, H. Shi, A. Kesson, M. Ratnamohan, K. McPhie, A. L. Cunningham, and N. K. Saksena. 2010. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. *Antiviral Res.* 87:16–21. doi:S0166-3542(10)00572-3 [pii];10.1016/j.antiviral.2010.04.002 [doi].
1381. Wang, C., B. Cao, Q. Q. Liu, Z. Q. Zou, Z. A. Liang, L. Gu, J. P. Dong, L. R. Liang, X. W. Li, K. Hu, X. S. He, Y. H. Sun, Y. An, T. Yang, Z. X. Cao, Y. M. Guo, X. M. Wen, Y. G. Wang, Y. L. Liu, and L. D. Jiang. 2011. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. *Ann.Intern.Med.* 155:217–225. doi:155/4/217 [pii];10.1059/0003-4819-155-4-201108160-00005 [doi].
1382. Wang, H., X. Jia, L. Yang, L. Sun, H. Wang, and W. Liu. 2008. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha]. *Sheng Wu Gong.Cheng Xue.Bao.* 24:1556–1560.
1383. Wang, J. F. and K. C. Chou. 2010. Insights from studying the mutation-induced allosterity in the M2 proton channel by molecular dynamics. *Protein Eng Des Sel* 23:663–666. doi:gzq040 [pii];10.1093/protein/gzq040 [doi].



1384. Wang, K., S. Xie, and B. Sun. 2011. Viral proteins function as ion channels. *Biochim.Biophys.Acta* 1808:510–515. doi:S0005-2736(10)00155-0 [pii];10.1016/j.bbamem.2010.05.006 [doi].
1385. Wang, M., J. Qi, Y. Liu, C. J. Vavricka, Y. Wu, Q. Li, and G. F. Gao. 2011. Influenza A virus N5 neuraminidase has an extended 150-cavity. *J.Virol.* 85:8431–8435. doi:JVI.00638-11 [pii];10.1128/JVI.00638-11 [doi].
1386. Wang, M., M. V. Larsen, M. Nielsen, M. Harndahl, S. Justesen, M. H. Dziegiel, S. Buus, S. T. Tang, O. Lund, and M. H. Claesson. 2010. HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses. *PLoS.One.* 5:e10533. doi:10.1371/journal.pone.0010533 [doi].
1387. Wang, P. and J. Z. Zhang. 2010. Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase. *J.Phys.Chem.B* 114:12958–12964. doi:10.1021/jp1030224 [doi].
1388. Wang, S. Q., X. C. Cheng, W. L. Dong, R. L. Wang, and K. C. Chou. 2010. Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. *Biochem.Biophys.Res. Commun.* 401:188–191. doi:S0006-291X(10)01695-5 [pii];10.1016/j.bbrc.2010.09.020 [doi].
1389. Wang, S. T., L. S. Chen, L. T. Lee, and H. H. Chen. 2011. Dynamic epidemic model for influenza with clinical complications. *Infect.Control Hosp.Epidemiol.* 32:456–464. doi:10.1086/658945 [doi].
1390. Wang, W., B. Qiu, Q. Li, H. Chen, and W. Xu. 2010. CT onset of influenza A (H1N1) complicated with severe pneumonia in two typical cases. *Panminerva Med.* 52:355–359. doi:R41102480 [pii].
1391. Wang, X., O. Hao, W. Wang, X. Ying, and H. Wang. 2010. Evaluation of the use of different solvents to extract the four main components of Yinqiaosan and their in vitro inhibitory effects on influenza-A virus. *Kaohsiung.J.Med.Sci.* 26:182–191. doi:S1607-551X(10)70027-9 [pii];10.1016/S1607-551X(10)70027-9 [doi].
1392. Wang, Y. G., L. Ni, W. Zhang, H. B. DU, X. W. Li, and R. B. Wang. 2010. [Clinical feature and treatment of 69 Chinese children patients infected with influenza A (H1N1)]. *Zhonghua Er.Ke.Za Zhi.* 48:100–103.
1393. Wang, Y. T., C. H. Chan, Z. Y. Su, and C. L. Chen. 2010. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase. *Biophys. Chem.* 147:74–80. doi:S0301-4622(09)00238-5 [pii];10.1016/j.bpc.2009.12.002 [doi].
1394. Wang, Y., H. Xiao, N. Wu, H. Shi, H. Xu, L. Zhou, X. G. Xi, T. Wang, and X. Wang. 2011. Characterization of the antiviral activity for influenza viruses M1 zinc finger peptides. *Curr.Microbiol.* 62:126–132. doi:10.1007/s00284-010-9682-6 [doi].
1395. Wang, Y., H. Xu, N. Wu, H. Shi, X. Wang, and T. Wang. 2010. Monoclonal antibody, but not synthetic peptide, targeting the ectodomain of influenza B virus M2 proton channel has antiviral activity. *New Microbiol.* 33:311–317.
1396. Warren-Gash, C., L. Smeeth, and A. Hayward. 2010. Influenza and myocardial infarction. *Expert.Rev. Cardiovasc.Ther.* 8:143–146. doi:10.1586/erc.09.188 [doi].
1397. Watanabe, A. 2010. [Present and future in development of new anti-influenza drugs]. *Nihon Rinsho* 68:1685–1689.
1398. Watanabe, A., S. C. Chang, M. J. Kim, D. W. Chu, and Y. Ohashi. 2010. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. *Clin.Infect.Dis.* 51:1167–1175. doi:10.1086/656802 [doi].
1399. Watanabe, K., J. Sakurai, H. Abe, and T. Katoh. 2010. Total synthesis of (+)-stachyflin: a potential anti-influenza A virus agent. *Chem.Commun.(Camb.)* 46:4055–4057. doi:10.1039/c000193g [doi].
1400. Watanabe, N. 2011. Conversion to type 1 diabetes after H1N1 influenza infection: a case report. *J.Diabetes* 3:103. doi:10.1111/j.1753-0407.2010.00110.x [doi].

1401. Watcharananan, S. P., T. Suwatanapongched, P. Wacharawanichkul, W. Chantratitaya, V. Mavichak, and S. B. Mossad. 2010. Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure. *Transpl.Infect.Dis.* 12:127–131. doi:TID493 [pii];10.1111/j.1399-3062.2010.00493.x [doi].
1402. Waterer, G. W., D. S. Hui, and C. R. Jenkins. 2010. Public health management of pandemic (H1N1) 2009 infection in Australia: a failure! *Respirology*. 15:51–56. doi:RES1675 [pii];10.1111/j.1440-1843.2009.01675.x [doi].
1403. Way, A. S., D. N. Durrheim, T. Merritt, and H. Vally. 2010. Antiviral distribution data – a potential syndromic surveillance system to assist pandemic health service operational planning. *Commun.Dis. Intell.* 34:303–309.
1404. Weber, J. T., A. Nicoll, C. B. Bridges, and B. C. Ciancio. 2010. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu. *BMJ* 340:c130.
1405. Webster, D., Y. Li, N. Bastien, R. Garceau, and T. F. Hatchette. 2011. Oseltamivir-resistant pandemic H1N1 influenza. *CMAJ*. 183:E420–E422. doi:cmaj.100313 [pii];10.1503/cmaj.100313 [doi].
1406. Wei, J. Y., F. F. Chen, J. Jin, W. Y. Mai, W. B. Qian, H. T. Meng, L. P. Mao, G. X. Xu, H. F. Wang, Y. J. Lou, and H. Y. Tong. 2010. Novel influenza A (H1N1) in patients with hematologic disease. *Leuk. Lymphoma* 51:2079–2083. doi:10.3109/10428194.2010.508823 [doi].
1407. Wei, J., J. Waithman, R. Lata, N. A. Mifsud, J. Cebon, T. Kay, M. J. Smyth, A. J. Sadler, and W. Chen. 2010. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a. *J.Immunol.* 185:6013–6022. doi:jimmunol.1002129 [pii];10.4049/jimmunol.1002129 [doi].
1408. Wei, Q., G. Q. Peng, M. L. Jin, Y. D. Zhu, H. B. Zhou, H. Y. Guo, and H. C. Chen. 2006. [Cloning, prokaryotic expression of chicken interferon-alpha gene and study on antiviral effect of recombinant chicken interferon-alpha]. *Sheng Wu Gong.Cheng Xue.Bao.* 22:737–743.
1409. Weight, A. K., J. Haldar, C. L. Alvarez de, L. V. Gubareva, T. M. Tumpey, J. Chen, and A. M. Klibanov. 2011. Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus. *J.Pharm.Sci.* 100:831–835. doi:10.1002/jps.22338 [doi].
1410. Weinberg, A., L. Y. Song, T. Fenton, S. A. Nachman, J. S. Read, J. Patterson-Bartlett, and M. J. Levin. 2010. T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. *AIDS Res.Hum.Retroviruses* 26:51–59. doi:10.1089/aid.2009.0163 [doi].
1411. Weiss, I. D., H. Shoham, O. Wald, H. Wald, K. Beider, M. Abraham, N. Barashi, E. Galun, A. Nagler, and A. Peled. 2011. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions. *Cytokine* 54:249–257. doi:S1043-4666(11)00024-X [pii];10.1016/j.cyto.2011.01.011 [doi].
1412. Weiss, I. D., O. Wald, H. Wald, K. Beider, M. Abraham, E. Galun, A. Nagler, and A. Peled. 2010. IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. *J.Interferon Cytokine Res.* 30:439–449. doi:10.1089/jir.2009.0084 [doi].
1413. Wells, Q., B. Hardin, S. R. Raj, and D. Darbar. 2010. Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza. *Heart Rhythm*. 7:1454–1457. doi:S1547-5271(10)00735-6 [pii];10.1016/j.hrthm.2010.07.025 [doi].
1414. Wen, W. H., S. Y. Wang, K. C. Tsai, Y. S. Cheng, A. S. Yang, J. M. Fang, and C. H. Wong. 2010. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. *Bioorg.Med.Chem.* 18:4074–4084. doi:S0968-0896(10)00314-7 [pii];10.1016/j.bmc.2010.04.010 [doi].
1415. Weng, J., Y. B. Li, R. B. Wang, F. Q. Li, C. Liu, A. S. Chan, and G. Lu. 2010. A practical and azide-free synthetic approach to oseltamivir from diethyl D-tartrate. *J.Org.Chem.* 75:3125–3128. doi:10.1021/jo100187m [doi].

1416. Wenger, J. D., L. J. Castrodale, D. L. Bruden, J. W. Keck, T. Zulz, M. G. Bruce, D. A. Fearey, J. McLaughlin, D. Hurlburt, K. B. Hummel, S. Kitka, S. Bentley, T. K. Thomas, R. Singleton, J. T. Redd, L. Layne, J. E. Cheek, and T. W. Hennessy. 2011. 2009 Pandemic influenza A H1N1 in Alaska: temporal and geographic characteristics of spread and increased risk of hospitalization among Alaska Native and Asian/Pacific Islander people. *Clin.Infect.Dis.* 52 Suppl 1:S189–S197. doi:ciq037 [pii];10.1093/cid/ciq037 [doi].
1417. Weston, K. M. and G. Truman. 2010. An influenza prophylaxis clinic in a primary school: 24 hours from notification to protection. *N.S.W.Public Health Bull.* 21:16–18. doi:NB09032 [pii];10.1071/NB09032 [doi].
1418. White, M. R., P. Boland, T. Teclé, D. Gantz, G. Sorenson, I. Tornøe, U. Holmskov, B. McDonald, E. C. Crouch, and K. L. Hartshorn. 2010. Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain. *J.Innate.Immun.* 2:267–279. doi:000272313 [pii];10.1159/000272313 [doi].
1419. WHO guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. [http://www.who.int/csr/resources/publications/swineflu/h1n1\\_use\\_antivirals\\_20090820/en/index.html](http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/index.html)
1420. Widjaja, I., V. E. de, D. M. Tscherne, A. Garcia-Sastre, P. J. Rottier, and C. A. de Haan. 2010. Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step. *J.Virol.* 84:9625–9631. doi:JVI.01048-10 [pii];10.1128/JVI.01048-10 [doi].
1421. Widmer, N., P. Meylan, A. Ivanyuk, M. Aouri, L. A. Decosterd, and T. Buclin. 2010. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. *Clin.Pharmacokinet.* 49:741–765. doi:3 [pii];10.2165/11534730-000000000-00000 [doi].
1422. Wiesener, N., C. Zimmer, N. Jarasch-Althof, P. Wutzler, and A. Henke. 2011. Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate. *Med.Microbiol.Immunol.* 200:115–126. doi:10.1007/s00430-010-0182-x [doi].
1423. Wildschut, E. D., H. M. de, M. J. Ahsman, D. Tibboel, A. D. Osterhaus, and P. L. Fraaij. 2010. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. *PLoS.One.* 5:e10938. doi:10.1371/journal.pone.0010938 [doi].
1424. Wilking, H., S. Buda, L. E. von der, D. Altmann, G. Krause, T. Eckmanns, and W. Haas. 2010. Mortality of 2009 pandemic influenza A(H1N1) in Germany. *Euro.Surveill* 15.
1425. Williams, D. J., M. Hall, T. V. Brogan, R. W. Farris, A. L. Myers, J. G. Newland, and S. S. Shah. 2011. Influenza coinfection and outcomes in children with complicated pneumonia. *Arch.Pediatr.Adolesc. Med.* 165:506–512. doi:archpediatrics.2010.295 [pii];10.1001/archpediatrics.2010.295 [doi].
1426. Winther, B., S. L. Block, K. Reisinger, and R. Dutkowski. 2010. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. *Int.J.Pediatr.Otorhinolaryngol.* 74:684–688. doi:S0165-5876(10)00119-9 [pii];10.1016/j.ijporl.2010.03.024 [doi].
1427. Wiwanitkit, V. 2009. Antiviral drug treatment for emerging swine flu. *Clin.Ter.* 160:243–245.
1428. Wolf, M. C., A. N. Freiberg, T. Zhang, Z. Akyol-Ataman, A. Grock, P. W. Hong, J. Li, N. F. Watson, A. Q. Fang, H. C. Aguilar, M. Porotto, A. N. Honko, R. Damoiseaux, J. P. Miller, S. E. Woodson, S. Chantasirivisal, V. Fontanes, O. A. Negrete, P. Krogstad, A. Dasgupta, A. Moscona, L. E. Hensley, S. P. Whelan, K. F. Faull, M. R. Holbrook, M. E. Jung, and B. Lee. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. *Proc.Natl.Acad.Sci.U.S.A* 107:3157–3162. doi:0909587107 [pii];10.1073/pnas.0909587107 [doi].
1429. Wolfe, C., I. Greenwald, and L. Chen. 2010. Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. *Emerg.Infect.Dis.* 16:1809–1811. doi:10.3201/eid1611.101053 [doi].

1430. Wolff, T. and S. Ludwig. 2009. Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences. *J. Interferon Cytokine Res.* 29:549–557. doi:10.1089/jir.2009.0066 [doi].
1431. Wong, J. P., M. E. Christopher, A. M. Salazar, L. Q. Sun, S. Viswanathan, M. Wang, E. G. Saravolac, and M. J. Cairns. 2010. Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza. *Front Biosci.(Schol.Ed)* 2:791–800. doi:102 [pii].
1432. Wong, J. P., M. E. Christopher, S. Viswanathan, G. Schnell, X. Dai, L. D. Van, and E. R. Stephen. 2010. Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. *Expert.Rev.Respir.Med.* 4:171–177. doi:10.1586/ers.10.15 [doi].
1433. Wong, S. Y., Q. Li, J. Veselinovic, B. S. Kim, A. M. Klibanov, and P. T. Hammond. 2010. Bactericidal and virucidal ultrathin films assembled layer by layer from polycationic N-alkylated polyethylenimines and polyanions. *Biomaterials* 31:4079–4087. doi:S0142-9612(10)00167-5 [pii];10.1016/j.biomaterials.2010.01.119 [doi].
1434. Wong, S., K. Pabbaraju, A. Wong, K. Fonseca, and S. J. Drews. 2011. Development of a real-time RT-PCR assay for detection of resistance to oseltamivir in influenza A pandemic (H1N1) 2009 virus using single nucleotide polymorphism probes. *J. Virol. Methods* 173:259–265. doi:S0166-0934(11)00080-2 [pii];10.1016/j.jviromet.2011.02.014 [doi].
1435. Woo, P. C., E. T. Tung, K. H. Chan, C. C. Lau, S. K. Lau, and K. Y. Yuen. 2010. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. *J. Infect. Dis.* 201:346–353. doi:10.1086/649785 [doi].
1436. Woo, T. M. 2010. 2009 H1N1 influenza pandemic. *J. Pediatr. Health Care* 24:258–266. doi:S0891-5245(10)00113-6 [pii];10.1016/j.pedhc.2010.05.001 [doi].
1437. Woods, C. J., M. Malaisree, S. Hannongbua, and A. J. Mulholland. 2011. A water-swap reaction coordinate for the calculation of absolute protein-ligand binding free energies. *J. Chem. Phys.* 134:054114. doi:10.1063/1.3519057 [doi].
1438. Wozniak, A. L., S. Griffin, D. Rowlands, M. Harris, M. Yi, S. M. Lemon, and S. A. Weinman. 2010. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. *PLoS Pathog.* 6:e1001087. doi:10.1371/journal.ppat.1001087 [doi].
1439. Wu, J. T., S. Riley, and G. M. Leung. 2009. Reducing the impact of the next influenza pandemic using household-based public health interventions. *Hong Kong Med J.* 15 Suppl 9:38–41.
1440. Wu, J., F. Zhang, M. Wang, C. Xu, J. Song, J. Zhou, X. Lin, Y. Zhang, X. Wu, W. Tan, J. Lu, H. Zhao, J. Gao, P. Zhao, J. Lu, and Y. Wang. 2010. Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses. *PLoS One.* 5:e15825. doi:10.1371/journal.pone.0015825 [doi].
1441. Wu, Q., C. Yu, Y. Yan, J. Chen, C. Zhang, and X. Wen. 2010. Antiviral flavonoids from *Mosla scabra*. *Fitoterapia* 81:429–433. doi:S0367-326X(09)00298-6 [pii];10.1016/j.fitote.2009.12.005 [doi].
1442. Wu, S., K. B. Patel, L. J. Booth, J. P. Metcalf, H. K. Lin, and W. Wu. 2010. Protective essential oil attenuates influenza virus infection: an in vitro study in MDCK cells. *BMC Complement Altern Med.* 10:69. doi:1472-6882-10-69 [pii];10.1186/1472-6882-10-69 [doi].
1443. Wu, U. I., M. T. Liu, J. T. Wang, S. M. Hsieh, S. C. Chang, and Y. C. Chen. 2010. Serological response to H1N1 influenza virus infections in adults treated with oseltamivir. *Clin. Infect. Dis.* 51:1223–1225. doi:10.1086/656922 [doi].
1444. Wu, W., K. B. Patel, J. L. Booth, W. Zhang, and J. P. Metcalf. 2011. Cigarette smoke extract suppresses the RIG-I-initiated innate immune response to influenza virus in the human lung. *Am. J. Physiol Lung Cell Mol. Physiol* 300:L821–L830. doi:ajplung.00267.2010 [pii];10.1152/ajplung.00267.2010 [doi].

1445. Wu, Y., J. Q. Li, Y. J. Kim, J. Wu, Q. Wang, and Y. Hao. 2011. In vivo and in vitro antiviral effects of berberine on influenza virus. *Chin J.Integr.Med.* 17:444–452. doi:10.1007/s11655-011-0640-3 [doi].
1446. Wunderink, R. G. 2010. Influenza and bacterial pneumonia – constant companions. *Crit Care* 14:150. doi:cc8974 [pii];10.1186/cc8974 [doi].
1447. Wunderlich, K., D. Mayer, C. Ranadheera, A. S. Holler, B. Manz, A. Martin, G. Chase, W. Tegge, R. Frank, U. Kessler, and M. Schwemmler. 2009. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. *PLoS.One.* 4:e7517. doi:10.1371/journal.pone.0007517 [doi].
1448. Xi, X., Y. Xu, L. Jiang, A. Li, J. Duan, and B. Du. 2010. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. *BMC.Infect.Dis.* 10:256. doi:1471-2334-10-256 [pii];10.1186/1471-2334-10-256 [doi].
1449. Xiao, H., S. H. Lu, Q. Ou, Y. Y. Chen, and S. P. Huang. 2010. Hospitalized patients with novel influenza A (H1N1) virus infection: Shanghai, June–July 2009. *Chin Med.J.(Engl.)* 123:401–405.
1450. Xie, X. B., Q. R. Zhu, Y. L. Ge, Z. L. Wang, G. C. Zhao, and X. H. Wang. 2009. [Analysis of 12 children with novel influenza A (H1N1) virus infection]. *Zhonghua Er.Ke.Za Zhi.* 47:935–938.
1451. Xie, Y., J. Gong, M. Li, H. Fang, and W. Xu. 2011. The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase. *Curr.Med.Chem.* 18:1050–1066. doi:BSP/CMC/E-Pub/2011/062 [pii].
1452. Xu, G., J. Dou, L. Zhang, Q. Guo, and C. Zhou. 2010. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. *Biol.Pharm.Bull.* 33:238–243. doi:JST.JSTAGE/bpb/33.238 [pii].
1453. Yamagishi, T., T. Matsui, N. Nakamura, T. Oyama, K. Taniguchi, T. Aoki, K. Hirakawa, and N. Okabe. 2010. Onset and duration of symptoms and timing of disease transmission of 2009 influenza A (H1N1) in an outbreak in Fukuoka, Japan, June 2009. *Jpn.J.Infect.Dis.* 63:327–331.
1454. Yamashita, M. 2010. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. *Antivir.Chem.Chemother.* 21:71–84. doi:10.3851/IMP1688 [doi].
1455. Yamaya, M., K. Shinya, Y. Hatachi, H. Kubo, M. Asada, H. Yasuda, H. Nishimura, and R. Nagatomi. 2010. Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells. *J.Pharmacol.Exp.Ther.* 333:81–90. doi:jpet.109.162149 [pii];10.1124/jpet.109.162149 [doi].
1456. Yan, Q. 2010. Systems biology of influenza: understanding multidimensional interactions for personalized prevention and treatment. *Methods Mol.Biol.* 662:285–302. doi:10.1007/978-1-60761-800-3\_14 [doi].
1457. Yang, G., M. Wan, Y. Zhang, L. Sun, R. Sun, D. Hu, X. Zhou, L. Wang, X. Wu, L. Wang, and Y. Yu. 2010. Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. *Immunology* 131:501–512. doi:IMM3322 [pii];10.1111/j.1365-2567.2010.03322.x [doi].
1458. Yang, J. R., Y. C. Lin, Y. P. Huang, C. H. Su, J. Lo, Y. L. Ho, C. Y. Yao, L. C. Hsu, H. S. Wu, and M. T. Liu. 2011. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005–2009. *PLoS.One.* 6:e18177. doi:10.1371/journal.pone.0018177 [doi].
1459. Yang, J. R., Y. P. Huang, Y. C. Lin, C. H. Su, C. Y. Kuo, L. C. Hsu, H. S. Wu, and M. T. Liu. 2010. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. *Antiviral Res.* 88:256–262. doi:S0166-3542(10)00736-9 [pii];10.1016/j.antiviral.2010.09.014 [doi].

1460. Yang, M. L., Y. H. Chen, S. W. Wang, Y. J. Huang, C. H. Leu, N. C. Yeh, C. Y. Chu, C. C. Lin, G. S. Shieh, Y. L. Chen, J. R. Wang, C. H. Wang, C. L. Wu, and A. L. Shiau. 2011. Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. *J.Virol.* 85:10010–10020. doi:JV1.00301-11 [pii];10.1128/JVI.00301-11 [doi].
1461. Yang, P., Y. Deng, X. Pang, W. Shi, X. Li, L. Tian, Y. Zhang, X. Wang, F. Huang, M. C. Raina, and Q. Wang. 2010. Severe, critical and fatal cases of 2009 H1N1 influenza in China. *J.Infect.* 61:277–283. doi:S0163-4453(10)00207-0 [pii];10.1016/j.jinf.2010.07.010 [doi].
1462. Yang, S. G., J. E. Wo, M. W. Li, F. F. Mi, C. B. Yu, G. L. Lv, H. C. Cao, H. F. Lu, B. H. Wang, H. Zhu, and L. J. Li. 2009. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). *Vaccine* 27:7451–7458. doi:S0264-410X(09)00715-4 [pii];10.1016/j.vaccine.2009.05.014 [doi].
1463. Yang, Z., Y. Nie, G. Yang, Y. Zu, Y. Fu, and L. Zhou. 2010. Synergistic effects in the designs of neuraminidase ligands: analysis from docking and molecular dynamics studies. *J.Theor.Biol.* 267:363–374. doi:S0022-5193(10)00452-2 [pii];10.1016/j.jtbi.2010.08.029 [doi].
1464. Yasuda, T., M. Yamaki, A. Imura, Y. Shimotai, K. Shimizu, T. Noshita, and S. Funayama. 2010. Anti-influenza virus principles from *Muehlenbeckia hastulata*. *J.Nat.Med.* 64:206–211. doi:10.1007/s11418-009-0386-9 [doi].
1465. Yates, L., M. Pierce, S. Stephens, A. C. Mill, P. Spark, J. J. Kurinczuk, M. Valappil, P. Brocklehurst, S. H. Thomas, and M. Knight. 2010. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. *Health Technol.Assess.* 14:109–182. doi:10.3310/hta14340-02 [doi].
1466. Yavarian, J., T. M. Azad, X. Zheng, V. Gregory, Y. P. Lin, and A. Hay. 2010. Amantadine resistance in relation to the evolution of influenza A(H3N2) viruses in Iran. *Antiviral Res.* 88:193–196. doi:S0166-3542(10)00700-X [pii];10.1016/j.antiviral.2010.08.013 [doi].
1467. Yeh, J. Y., M. S. Coumar, J. T. Horng, H. Y. Shiao, F. M. Kuo, H. L. Lee, I. C. Chen, C. W. Chang, W. F. Tang, S. N. Tseng, C. J. Chen, S. R. Shih, J. T. Hsu, C. C. Liao, Y. S. Chao, and H. P. Hsieh. 2010. Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives. *J.Med.Chem.* 53:1519–1533. doi:10.1021/jm901570x [doi].
1468. Yeh, N., N. L. Glosson, N. Wang, L. Guindon, C. McKinley, H. Hamada, Q. Li, R. W. Dutton, P. Shrikant, B. Zhou, R. R. Brutkiewicz, J. S. Blum, and M. H. Kaplan. 2010. Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. *J.Immunol.* 185:2089–2098. doi:jimmunol.1000818 [pii];10.4049/jimmunol.1000818 [doi].
1469. Yi, H., J. Y. Lee, E. H. Hong, M. S. Kim, D. Kwon, J. H. Choi, W. Y. Choi, K. S. Kim, J. K. Lee, H. B. Oh, and C. Kang. 2010. Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea. *Emerg. Infect.Dis.* 16:1938–1942. doi:10.3201/eid1612.100600 [doi].
1470. Yokoyama, T., K. Tsuchida, A. Ushiki, N. Kobayashi, K. Urushihata, T. Koizumi, and K. Kubo. 2010. Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus. *Intern.Med.* 49:427–430. doi:JST.JSTAGE/internalmedicine/49.3022 [pii].
1471. Yoldascan, E., B. Kurtaran, M. Koyuncu, and E. Koyuncu. 2010. Modeling the economic impact of pandemic influenza: a case study in Turkey. *J.Med.Syst.* 34:139–145.
1472. Yoo, E. S. 2011. Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy. *J.Microbiol.Biotechnol.* 21:449–454. doi:JMB021-05-01 [pii].
1473. Yoo, J. K., D. P. Baker, and E. N. Fish. 2010. Interferon-beta modulates type 1 immunity during influenza virus infection. *Antiviral Res.* 88:64–71. doi:S0166-3542(10)00671-6 [pii];10.1016/j.antiviral.2010.07.006 [doi].

1474. Yoshioka, D., I. Tokimatsu, H. Ishii, and J. Kadota. 2010. [Current anti-influenza virus chemotherapy]. *Nihon Rinsho* 68:1679–1684.
1475. Young, J. A., D. Sermwittayawong, H. J. Kim, S. Nandu, N. An, H. Erdjument-Bromage, P. Tempst, L. Coscoy, and A. Winoto. 2011. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. *J.Biol.Chem.* 286:6521–6531. doi:M110.172288 [pii];10.1074/jbc.M110.172288 [doi].
1476. Yount, J. S., B. Moltedo, Y. Y. Yang, G. Charron, T. M. Moran, C. B. Lopez, and H. C. Hang. 2010. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. *Nat.Chem.Biol.* 6:610–614. doi:nchembio.405 [pii];10.1038/nchembio.405 [doi].
1477. Yu, C., Y. Yan, X. Wu, B. Zhang, W. Wang, and Q. Wu. 2010. Anti-influenza virus effects of the aqueous extract from *Mosla scabra*. *J.Ethnopharmacol.* 127:280–285. doi:S0378-8741(09)00703-X [pii];10.1016/j.jep.2009.11.008 [doi].
1478. Yu, H., Q. Liao, Y. Yuan, L. Zhou, N. Xiang, Y. Huai, X. Guo, Y. Zheng, H. R. van Doorn, J. Farrar, Z. Gao, Z. Feng, Y. Wang, and W. Yang. 2010. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. *BMJ* 341:c4779.
1479. Yu, H., Z. Feng, T. M. Uyeki, Q. Liao, L. Zhou, L. Feng, M. Ye, N. Xiang, Y. Huai, Y. Yuan, H. Jiang, Y. Zheng, P. Gargiullo, Z. Peng, Y. Feng, J. Zheng, C. Xu, Y. Zhang, Y. Shu, Z. Gao, W. Yang, and Y. Wang. 2011. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. *Clin.Infect.Dis.* 52:457–465. doi:ciq144 [pii];10.1093/cid/ciq144 [doi].
1480. Yu, J., B. W. Liu, L. Lan, Y. Yuan, H. Zhang, and C. H. Jia. 2010. [Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of elderly patients with chronic hepatitis C]. *Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue.Za Zhi.* 24:373–375.
1481. Yu, K., C. Luo, G. Qin, Z. Xu, N. Li, H. Liu, X. Shen, J. Ma, Q. Wang, C. Yang, W. Zhu, and H. Jiang. 2009. Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)? *Cell Res.* 19:1221–1224. doi:cr2009111 [pii];10.1038/cr.2009.111 [doi].
1482. Yu, L., L. Sun, Y. Nan, and L. Y. Zhu. 2011. Protection from H1N1 influenza virus infections in mice by supplementation with selenium: a comparison with selenium-deficient mice. *Biol.Trace Elem.Res.* 141:254–261. doi:10.1007/s12011-010-8726-x [doi].
1483. Yu, M., A. Liu, G. Du, L. Naesens, E. Vanderlinden, C. E. De, and X. Liu. 2011. Discovery of dihydro-alkoxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. *Chem.Biol Drug Des* 78:596–602. doi:10.1111/j.1747-0285.2011.01180.x [doi].
1484. Zandvliet, M. L., L. E. van, I. Jedema, S. Kruihof, M. G. Kester, H. J. Guchelaar, J. H. Falkenburg, and P. Meij. 2011. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. *J.Immunother.* 34:307–319. doi:10.1097/CJI.0b013e318213cb90 [doi].
1485. Zanvit, P., A. Tichopad, M. Havlickova, O. Novotna, M. Jirkovska, K. Kolostova, D. Cechova, J. Julak, I. Sterzl, and L. Prokesova. 2010. Adjuvant effect of *Bacillus firmus* on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A. *Immunol.Lett.* 134:26–34. doi:S0165-2478(10)00200-2 [pii];10.1016/j.imlet.2010.08.006 [doi].
1486. Zapata, R., M. Uribe, W. Martinez, A. Andrade, J. L. Leal, and F. Gomez. 2010. Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient. *Liver Transpl.* 16:447–452. doi:10.1002/lt.22013 [doi].
1487. Zaraket, H., H. Kondo, C. Tabet, R. Hanna-Wakim, Y. Suzuki, G. S. Dbaibo, R. Saito, and H. Suzuki. 2011. Genetic diversity and antiviral drug resistance of pandemic H1N1 2009 in Lebanon. *J.Clin.Virol.* 51:170–174. doi:S1386-6532(11)00141-7 [pii];10.1016/j.jcv.2011.04.001 [doi].

1488. Zaraket, H., R. Saito, R. Wakim, C. Tabet, F. Medlej, M. Reda, T. Baranovich, Y. Suzuki, C. Dapat, I. Caperig-Dapat, G. S. Dbaibo, and H. Suzuki. 2010. Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008–09 season. *J.Med.Virol.* 82:1224–1228. doi:10.1002/jmv.21795 [doi].
1489. Zaraket, H., R. Saito, Y. Suzuki, T. Baranovich, C. Dapat, I. Caperig-Dapat, and H. Suzuki. 2010. Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses. *J.Clin.Microbiol.* 48:1085–1092. doi:JCM.01532-09 [pii];10.1128/JCM.01532-09 [doi].
1490. Zaraket, H., R. Saito, Y. Suzuki, Y. Suzuki, I. Caperig-Dapat, C. Dapat, I. I. Shabana, T. Baranovich, and H. Suzuki. 2010. Genomic events contributing to the high prevalence of amantadine-resistant influenza A/H3N2. *Antivir.Ther.* 15:307–319. doi:10.3851/IMP1538 [doi].
1491. Zarubaev, V. V., A. V. Garshinina, N. A. Kalinina, A. A. Shtro, S. V. Beliaevskaia, V. E. Nebol'sin, and O. I. Kiselev. 2010. [Protective activity of Ingavirin in experimental lethal influenza due to pandemic influenza virus A (H1N1)v in albino mice]. *Antibiot.Khimioter.* 55:24–31.
1492. Zarubaev, V. V., A. V. Garshinina, N. A. Kalinina, A. A. Shtro, V. E. Nebol'sin, and O. I. Kiselev. 2010. [Antiviral activity of Ingavirin in experimental lethal influenza due to influenza virus B in albino mice]. *Antibiot.Khimioter.* 55:8–11.
1493. Zarubaev, V. V., E. L. Golod, P. M. Anfimov, A. A. Shtro, V. V. Saraev, A. S. Gavrillov, A. V. Logvinov, and O. I. Kiselev. 2010. Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus. *Bioorg.Med.Chem.* 18:839–848. doi:S0968-0896(09)01065-7 [pii];10.1016/j.bmc.2009.11.047 [doi].
1494. Zarybaev, V. V., O. I. Kiselev, N. A. Kalinina, A. L. Kovalenko, A. V. Garshinina, A. K. Sirotkin, S. V. Beliaevskaia, and M. G. Romantsov. 2011. [Effect of antiviral drugs with various mechanisms of action on morphogenesis of infection caused by extremely pathogenic influenza virus strains in animals]. *Eksp.Klin.Farmakol.* 74:17–21.
1495. Zarychanski, R., T. L. Stuart, A. Kumar, S. Doucette, L. Elliott, J. Kettner, and F. Plummer. 2010. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. *CMAJ.* 182:257–264. doi:cmaj.091884 [pii];10.1503/cmaj.091884 [doi].
1496. Zenciroglu, A., A. A. Kundak, M. Aydin, N. Okumus, A. Dursun, M. S. Ipek, B. S. Karagol, N. Hakan, N. N. Karadag, A. B. Altas, and G. Korukluoglu. 2011. Swine influenza A (H1N1) virus infection in infants. *Eur.J.Pediatr.* 170:333–338. doi:10.1007/s00431-010-1293-5 [doi].
1497. Zeng, H., C. Pappas, J. M. Katz, and T. M. Tumpey. 2011. The 2009 pandemic H1N1 and triple-reassortant swine H1N1 influenza viruses replicate efficiently but elicit an attenuated inflammatory response in polarized human bronchial epithelial cells. *J.Virol.* 85:686–696. doi:JVI.01568-10 [pii];10.1128/JVI.01568-10 [doi].
1498. Zhang, C. J., L. G. Gu, and H. T. Yu. 2011. [Antagonism of baicalin on cell cyclical distribution and cell apoptosis in A549 cells infected with influenza A (H1N1) virus]. *Bing.Du Xue.Bao.* 27:108–116.
1499. Zhang, C., Y. Xu, L. Jia, Y. Yang, Y. Wang, Y. Sun, L. Huang, F. Qiao, S. Tomlinson, X. Liu, Y. Zhou, and H. Song. 2010. A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. *Viol.J.* 7:30. doi:1743-422X-7-30 [pii];10.1186/1743-422X-7-30 [doi].
1500. Zhang, G. B., F. H. Bing, J. Liu, Z. Li, Y. F. Liao, J. Li, and C. Y. Dong. 2010. Effect of total alkaloids from *Commelina communis* L. on lung damage by influenza virus infection. *Microbiol.Immunol.* 54:754–757. doi:10.1111/j.1348-0421.2010.00277.x [doi].
1501. Zhang, G., S. Sun, T. Zhu, Z. Lin, J. Gu, D. Li, and Q. Gu. 2011. Antiviral isoindolone derivatives from an endophytic fungus *Emericella* sp. associated with *Aegiceras corniculatum*. *Phytochemistry* 72:1436–1442. doi:S0031-9422(11)00238-X [pii];10.1016/j.phytochem.2011.04.014 [doi].



1502. Zhang, G., Z. Xia, Y. Liu, X. Li, X. Tan, Y. Tian, L. Liang, G. Nie, and B. Zhou. 2011. Epidemiological and clinical features of 308 hospitalized patients with novel 2009 influenza A (H1N1) virus infection in China during the first pandemic wave. *Intervirology* 54:164–170. doi:000319930 [pii];10.1159/000319930 [doi].
1503. Zhang, H. P., Y. M. Zeng, Z. S. Lin, W. Chen, J. S. Liang, H. Zhang, and W. R. Huang. 2009. [Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi*. 32:356–359.
1504. Zhang, H., J. Song, and J. Shi. 2011. [Screen anti-influenza virus serum marker of *Lonicera japonica* by proteomics technology]. *Zhongguo Zhong.Yao Za Zhi*. 36:1071–1074.
1505. Zhang, J., X. Geng, Y. Ma, S. Ruan, S. Xu, L. Liu, H. Xu, G. Yang, C. Wang, C. Liu, X. Han, Q. Yu, H. Cheng, and Z. Li. 2010. Fatal avian influenza (H5N1) infection in Human, China. *Emerg.Infect.Dis.* 16:1799–1801. doi:10.3201/eid1611.090212 [doi].
1506. Zhang, L., Y. X. Cheng, A. L. Liu, H. D. Wang, Y. L. Wang, and G. H. Du. 2010. Antioxidant, anti-inflammatory and anti-influenza properties of components from *Chaenomeles speciosa*. *Molecules*. 15:8507–8517. doi:molecules15118507 [pii];10.3390/molecules15118507 [doi].
1507. Zhang, Q., Q. J. Zhao, R. S. Xiong, J. F. Li, and J. S. Shen. 2010. [Research progress of anti-influenza virus agents]. *Yao Xue.Xue.Bao*. 45:289–299.
1508. Zhang, Q., Z. Wang, Y. Yuan, Z. Xue, G. Zhai, W. Zuo, S. Zhu, G. Zhu, and X. Xu. 2011. Immunoadjuvant effects of hemagglutinating virus of Japan envelope (HVJ-E) on the inactivated H9 subtype avian influenza virus vaccine. *Vet.Immunol.Immunopathol.* 141:116–123. doi:S0165-2427(11)00080-8 [pii];10.1016/j.vetimm.2011.02.021 [doi].
1509. Zhang, T., C. Y. Wang, Y. W. Gao, S. T. Yang, T. C. Wang, and X. Z. Xia. 2011. [Development of anti-influenza drug]. *Bing.Du Xue.Bao*. 27:475–480.
1510. Zhang, T., P. S. Zhao, W. Zhang, M. Liang, Y. W. Gao, S. T. Yang, T. C. Wang, C. Qin, C. Y. Wang, and X. Z. Xia. 2011. Antisense oligonucleotide inhibits avian influenza virus H5N1 replication by single chain antibody delivery system. *Vaccine* 29:1558–1564. doi:S0264-410X(10)01861-X [pii];10.1016/j.vaccine.2010.12.088 [doi].
1511. Zhao, C., T. Y. Hsiang, R. L. Kuo, and R. M. Krug. 2010. ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. *Proc.Natl.Acad.Sci.U.S.A* 107:2253–2258. doi:0909144107 [pii];10.1073/pnas.0909144107 [doi].
1512. Zhao, S. P., Z. H. Hai, D. M. Tan, G. L. Xiao, Q. H. Gu, M. Li, X. M. Li, and C. P. Hu. 2009. [Clinical experience of successful management of a human case with A/H5N1 infection in Hunan Province]. *Zhonghua Jie.He.He.Hu Xi.Za Zhi*. 32:347–350.
1513. Zhao, X., C. Li, S. Zeng, and W. Hu. 2011. Discovery of highly potent agents against influenza A virus. *Eur.J.Med.Chem.* 46:52–57. doi:S0223-5234(10)00750-6 [pii];10.1016/j.ejmech.2010.10.010 [doi].
1514. Zhiqiang, W., Y. Yaowu, Y. Fan, Y. Jian, H. Yongfeng, Z. Lina, W. Jianwei, and J. Qi. 2010. Effective siRNAs inhibit the replication of novel influenza A (H1N1) virus. *Antiviral Res.* 85:559–561. doi:S0166-3542(10)00003-3 [pii];10.1016/j.antiviral.2009.12.010 [doi].
1515. Zhirnov, O. P. and H. D. Klenk. 2011. [Aprotinin-induced inhibition of pandemic influenza virus A(H1N1) reproduction]. *Vopr.Virusol.* 56:24–28.
1516. Zhirnov, O. P., H. D. Klenk, and P. F. Wright. 2011. Aprotinin and similar protease inhibitors as drugs against influenza. *Antiviral Res.* 92:27–36. doi:S0166-3542(11)00385-8 [pii];10.1016/j.antiviral.2011.07.014 [doi].

1517. Zhirnov, O. P., T. Y. Matrosova, M. N. Matrosova, and H. D. Klenk. 2011. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. *Antivir.Chem. Chemother.* 21:169–174. doi:10.3851/IMP1715 [doi].
1518. Zhou, B. T., Y. M. Fan, T. M. Li, and X. Q. Liu. 2010. Clinical features of initial cases of 2009 pandemic influenza A (H1N1) in Macau, China. *Chin Med.J.(Engl.)* 123:2651–2654.
1519. Zhou, B., Y. Li, J. A. Belser, M. B. Pearce, M. Schmolke, A. X. Subba, Z. Shi, S. R. Zaki, D. M. Blau, A. Garcia-Sastre, T. M. Tumpey, and D. E. Wentworth. 2010. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. *Vaccine* 28:8015–8025. doi:S0264-410X(10)01324-1 [pii];10.1016/j.vaccine.2010.08.106 [doi].
1520. Zhou, H., J. Zhu, J. Tu, W. Zou, Y. Hu, Z. Yu, W. Yin, Y. Li, A. Zhang, Y. Wu, Z. Yu, H. Chen, and M. Jin. 2010. Effect on virulence and pathogenicity of H5N1 influenza A virus through truncations of NS1 eIF4GI binding domain. *J.Infect.Dis.* 202:1338–1346. doi:10.1086/656536 [doi].
1521. Zhou, J., L. Zou, X. Zhang, J. Liao, H. Ni, N. Hou, Y. Wang, H. Li, J. Wu, M. Jonges, A. Meijer, M. Koopmans, and C. Ke. 2011. Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009. *J.Clin.Microbiol.* 49:2651–2655. doi:JCM.00535-11 [pii];10.1128/JCM.00535-11 [doi].
1522. Zhu, Y., L. Lu, L. Xu, H. Yang, S. Jiang, and Y. H. Chen. 2010. Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. *J.Virol.* 84:9359–9368. doi:JVI.00644-10 [pii];10.1128/JVI.00644-10 [doi].
1523. Zielecki, F., I. Semmler, D. Kalthoff, D. Voss, S. Mael, A. D. Gruber, M. Beer, and T. Wolff. 2010. Virulence determinants of avian H5N1 influenza A virus in mammalian and avian hosts: role of the C-terminal ESEV motif in the viral NS1 protein. *J.Virol.* 84:10708–10718. doi:JVI.00610-10 [pii];10.1128/JVI.00610-10 [doi].
1524. Zink, M. C., A. K. Brice, K. M. Kelly, S. E. Queen, L. Gama, M. Li, R. J. Adams, C. Bartizal, J. Varrone, S. A. Rabi, D. R. Graham, P. M. Tarwater, J. L. Mankowski, and J. E. Clements. 2010. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. *J.Infect.Dis.* 202:161–170. doi:10.1086/653213 [doi].
1525. Zohari, S., M. Munir, G. Metreveli, S. Belak, and M. Berg. 2010. Differences in the ability to suppress interferon beta production between allele A and allele B NS1 proteins from H10 influenza A viruses. *Virol.J.* 7:376. doi:1743-422X-7-376 [pii];10.1186/1743-422X-7-376 [doi].
1526. Zoidis, G., N. Kolocouris, J. M. Kelly, S. R. Prathalingam, L. Naesens, and C. E. De. 2010. Design and synthesis of bioactive adamantanolcohols and adamantanamines. *Eur.J.Med.Chem.* 45:5022–5030. doi:S0223-5234(10)00573-8 [pii];10.1016/j.ejmech.2010.08.009 [doi].
1527. Zonis, Z., D. Engelhard, M. Hindiyeh, D. Ram, M. Mandelboim, E. Mendelson, and D. Glikman. 2010. Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. *Emerg.Infect.Dis.* 16:1045–1046. doi:10.3201/eid1606.091875 [doi].